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Abstract 
Acute myeloid leukaemia (AML) is an extremely heterogeneous disease characterised by 
genomic instability, epigenetic changes and a high oxidative stress burden that drives disease 
progression and plays an essential role in prognosis and treatment response. AML treatment is 
challenging and the majority of AML patients suffer relapse, particularly elderly patients. 
Targeting DNA repair mechanisms in cancer is a proven approach that can potentiate the anti-
cancer activity of chemotherapeutic agents to yield better outcomes. The evidence suggests 
that the APE1 and OGG1 components of the base excision DNA repair pathway may be 
essential to cancer cell survival, and based on these reports it is hypothesised that targeting 
APE1 and OGG1 will have therapeutic value in AML. 
In order to test this hypothesis, APE1 and OGG1 gene expression was silenced in several 
AML cell lines using small hairpin RNA (shRNA) interference and cells were investigated for 
effects on proliferation, cloning efficiency, cell cycle, apurinic/apyrimidinic (AP) site 
accumulation and sensitivity to anti-leukaemic chemotherapy. Moreover, wildtype AML cells 
were treated with APE1 inhibitors methoxyamine (MX), E3330 and APE1 inhibitor III 
(APE1-III), and the effect on cell proliferation and cell cycle profile was investigated as 
single agents and in combination with anti-leukaemic chemotherapy. 
APE1 and OGG1 proteins were expressed in all AML cell lines investigated, but protein 
levels were not correlated with mRNA gene expression, suggesting that post-translational 
modification may regulate both proteins.  
APE1 shRNA knockdown slowed cellular proliferation and reduced cloning efficiency of 
AML cell lines HL-60, AML3 and U937. APE1 knockdown did not potentiate the sensitivity 
of AML cell lines to chemotherapeutic agents, including temozolomide, Ara-C, daunorubicin, 
clofarabine, fludarabine and etoposide. In contrast, chemotherapy-induced cell killing induced 
was antagonised by APE1 knockdown in AML cells. APE1 inhibition using MX, E3330 and 
APE1-III showed some single agent activity, with evidence of reduced proliferation and 
clonogenicity, but potentiation of chemotherapy-induced cytotoxicity was not evident. 
APE1 knockdown had no discernible effect on cell cycle kinetics. In contrast, APE1 
inhibition using methoxyamine significantly induced cell cycle blockade in S phase, but no 
alteration in cell cycle profile was evident following APE1 inhibition with E3330 or APE1-
III.  
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RNA sequencing of APE1 knockdown cells identified several genes that were significantly 
upregulated, including many involved in cell cycle regulation and genes that may contribute 
to leukaemogenesis, including PAX5, CDKN1A and FOXO1.  
Targeting OGG1 using shRNA had no effect on proliferation of HL-60 and U937 AML cell 
lines, and only a very modest effect on colony formation in semi-solid soft agar. Furthermore, 
OGG1 silencing had no effect on cellular sensitivity to anti-leukaemic chemotherapy agents, 
and also did not affect cell cycle kinetics. 
In conclusion, the data presented in this thesis indicate that APE1, but not OGG1, may have 
potential therapeutic value as a single agent, but not in combination with established anti-
leukaemic drugs. Additionally, the extensive genetic heterogeneity of AML suggests that 
targeting APE1 may have a utility in some but not all subtypes of AML. OGG1 may provide 
prognostic value in AML, but appears not to be a suitable therapeutic target.  
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PBS     Phosphate buffer saline  
PARP1    Poly ADP-ribose polymerase 1  
PAX5     Paired Box 5 
xx 
 
PCNA     Proliferating cell nuclear antigen 
PCR     polymerase chain reaction 
PI     propidium iodide  
PKC     Protein kinase C 
PMSF     phenylmethanesulfonyl fluoride 
PNKP     polynucleotide kinase/phosphatase 
POL-β     Polymerase beta 
POL-δ     polymerase delta 
POL-ε     Polymerase Epsilon  
PUA     phosphor-α,β-unsaturated aldehyde 
PVDF     polyvinylidene difluoride 
RB     Retinoblastoma  
REF-1     redox factor-1 
RIN     RNA integrity number 
RNA     ribonucleic acid 
ROS     reactive oxygen species 
RAD 51    Radiation sensitivity abnormal 51 
RPMI     Roswell Park Memorial Institute  
RT     room temperature 
RT-PCR    real time PCR 
SDS     Sodium dodecyl sulphate  
shRNA    Short hairpin RNA  
siRNA     Small interfering RNA  
SNP     Single nucleotide polymorphism  
TARDIS    trapped in agarose DNA immunostaining 
xxi 
 
TCGA     The Cancer Genome Atlas 
TDK     tyrosine kinase domain 
TET2     Tet Methylcytosine Dioxygenase 2 
TF      transcription factors 
TMZ     Temozolomide 
TOP2A    Topoisomerase II Alpha 
TOP2B    Topoisomerase II Beta 
Tris     Tris(hydroxymethyl)aminomethane  
UBR3     Ubiquitin protein ligase E3 component   
     N-recognin 3 
v/v      Volume/volume 
w/v      Weight/volume 
WBC     white blood cells  
WHO     World health organisation 
XRCC1    X-ray repair cross-complementing 1 
YB-1     Y box binding protein 1 
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1.1. Acute Myeloid Leukaemia 
Multipotent haematopoietic stem cells (HSC) in bone marrow give rise to all of the different 
type of blood cell. This occurs via a complex molecular cellular process of cell replication and 
differentiation. There are two types of HSC in bone marrow including lymphoid and myeloid 
precursors.   
Acute myeloid leukaemia (AML) is a group of heterogeneous disorders characterised by 
uncontrolled proliferation and blocked differentiation of myeloid lineage cells. Subsequently, 
this leads to accumulation of immature myeloid blast cells in the bone marrow and peripheral 
blood. It is frequently accompanied by decreased numbers and function of other blood cell 
components, including erythrocytes and platelet, which consequently lead to anaemia and 
haemorrhage. Frequent genetic alterations and chromosomal translocations have been 
implicated in AML pathogenesis. The mechanisms by which some of these alterations cause 
the disease is now becoming clearer, although for other alterations there is only a limited 
understanding of causal mechanisms. 
 
1.1.1. AML incidence and epidemiology 
AML occurs in all age groups but the incidence increases with age and the median age at 
diagnosis is 70 years (Figure 1.1). AML is the most frequent leukaemia in neonates but occurs 
at relatively low frequency in childhood and adolescent. AML accounts for about 33% of all 
leukaemia cases in the UK, with higher incidence in men compared to women, with a ratio of 
12:10 (Cancer research UK website). 
 
1.1.2. AML clinical manifestation and diagnosis 
The most common clinical features of AML are anaemia, neutropenia and/or 
thrombocytopaenia. This is predominantly due to infiltration of bone marrow with malignant 
blast cells, which result in inadequate production, differentiation and maturation of all blood 
cells components; white blood cells, red blood cells and thrombocytes. Anaemia is a common 
clinical presentation of AML patients; which leads to fatigue, general weakness, pallor and 
other common symptoms and signs of anaemia. Tendency to bleed is also another common 
clinical feature of AML, caused by the inadequate production and decreased survival of 
platelets.
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Figure 1.1: Incidence of AML in the UK in different age and sex groups. 
This graph shows the average of AML incidence in different age and sex groups in the UK 
between 2011 and 2013. Over 50% of case diagnosed with AML were over 70 years. The 
graph also demonstrate higher incidence rate in males compared to females. (Graph adapted 
from www.cancerresearchuk.org) 
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Organ dysfunction might occur due to infiltration of myeloblasts from peripheral blood to 
systems such as lung, brain and central nervous system (CNS). AML patients are also 
susceptible to infections at the time of presentation, but however, major infections are not 
likely to happen before diagnosis and this might be reflected by high total leukocyte count.  
 
1.1.3. Disease phenotype and classification  
AML is an extremely heterogeneous disease and several systems are used to classify AML 
cases into subgroups. Classification systems predominantly depend on morphological, 
immunological, cytochemical, cytogenetic and molecular features of AML cells. The first 
attempt to classify AML was in 1976 by introducing French-American-British (FAB) 
classification system (Bennett et al., 1976). This was followed by the proposal of a new 
classification system by the World Health Organisation (WHO) in 2001, which was 
subsequently revised in 2008 and 2016 (Vardiman et al., 2002; Vardiman et al., 2009; Arber 
et al., 2016).   
  
1.1.3.1. FAB classification 
The FAB classification system introduced 8 subtypes (M0-M7) of AML depending on 
microscopic morphology and maturation of myeloid cells in peripheral blood and bone 
marrow after routine staining (Table 1.1). The FAB system also attempted to correlate 
cytogenetic alterations (such as translocations, inversions and deletions) with specific 
subtypes, but this was only possible in the M3 subtype (APL: Acute promyelocytic 
leukaemia) which is characterised by the t(15:17) PLM-RARα translocation.  
 
1.1.3.2. WHO classification 
Although the FAB classification is still widely used, it has some limitations which led to 
introducing WHO classification. The WHO classification divides AML into subtypes based 
on cellular morphology, cytogenetics, molecular genetics and immunological biomarkers, to 
generate more informative classification that can also be used for prognostication (Table 1.2) 
(Vardiman et al., 2009). 
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Table 1.1: Overview of French-American-British (FAB) classification of AML. Adapted 
from (Bennett et al., 1976) 
 
Subclass Description
M0 Acute myeloblastic leukaemia minimally differentiated   
M1 Acute myeloblastic leukaemia without maturation   
M2 Acute myeloblastic leukaemia with maturation 
M3 Hypergranular promyelocytic leukaemia 
M4 
• Acute myelomonocytic leukaemia   
• Acute myelomonocytic leukaemia with bone marrow 
eosinophilia (M4 Eo)   
M5  
Acute monocytic leukaemia  
• Undifferentiated monoblastic (M5a)  
• Well-differentiated promonocytic-monocytic (M5b)  
M6 Acute erythroleukaemia   
M7 Acute megakaryocytic leukaemia  
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Table 1.2: AML classification based on the World Health Organisation (WHO) system. 
Adapted from Arber et al., 2016 
 
 
 
Type Description
AML with recurrent 
genetic abnormalities 
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22);CBFB-MYH11 
APL with PML-RARα 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); 
GATA2, MECOM 
AML (megakaryoblastic) with 
t(1;22)(p13.3;q13.3);RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPα 
Provisional entity: AML with mutated RUNX1 
AML with 
myelodysplasia-related 
changes 
Prior history of myelodysplastic syndrome (MDS)  
MDS-related cytogenetic abnormality  
Multilineage dysplasia 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, 
not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations 
related to Down syndrome 
Transient abnormal myelopoiesis (TAM) 
Myeloid leukaemia associated with Down syndrome 
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1.1.4. Genetic mutations and mechanisms of pathogenesis 
AML is an aggressive and extremely heterogeneous disease. Recent developments in 
molecular techniques and whole genome sequencing have improved our understanding of the 
leukaemogenesis process. Chromosomal translocations and other mutations in AML cause 
perturbation in genes involved in regulation of proliferation, differentiation and apoptosis of 
haematopoietic progenitors. Mutations in leukaemia are divided into 3 groups according to 
their anticipated role in leukaemogenesis (Table 1.3). Specifically, mutations that confer a 
proliferative advantage on AML cells were classified as class I mutation, and include 
mutations in FLT3, KIT and RAS (Dombret, 2011). Class II mutations are associated with 
blocked differentiation of myeloid precursors; and include mutations in CEBPα, RUNX1, 
NPM1 and CBFβ (Renneville et al., 2008). Mutations that occur in genes related to epigenetic 
regulation are classified as class III; and are often associated with worse outcome and 
frequently observed in older patients (Dombret, 2011). 
In the next sections (1.1.4.1– 1.1.4.5), common recurrent mutations and molecular alterations 
in AML will be briefly discussed. 
 
1.1.4.1. Acquired somatic alteration 
1.1.4.1.1. Insertion/deletion (Indel) mutations 
FLT3 mutations 
FLT3 (FMS-like tyrosine kinase like receptor 3) mutation is the most frequent mutation 
observed in AML and confers a poor prognosis and increased risk of relapse. FLT3 is 
expressed on immature haematopoietic progenitors (both myeloid and lymphoid) and plays an 
essential role in normal haematopoiesis, regulating haematopoietic cell proliferation and 
differentiation (Small, 2006). FLT3 expression is gradually lost upon differentiation, but 
could be detected in mature dendritic cells (Small, 2006). Two distinct mutations occur in the 
functional domain of the FLT3 receptor and are reported in AML. The first and most frequent 
is internal tandem duplication (FLT3-ITD) and the second type of mutation is caused by 
insertion/deletion or missense mutation in the tyrosine kinase domain (FLT3-TKD).  
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Mutation class Class  I Class II Class II 
Genes FLT3
KIT 
JAK2 
PTPN11 
NRAS 
KRAS
RUNX1
NPM1 
CEBPα 
MLL 
RARα 
CBFβ
TET2 
IDH1/2 
DNMT 
ASXL1 
EZH2 
 
Table 1.3: classification of genetic mutations observed in AML. 
Genetic mutations in AML are classified into three distinct categories. Class I include 
mutations in genes involved in activation of signalling pathways that affect proliferative 
advantage of haematopoietic cells. Class II mutations affect transcription factors that control 
haematopoietic cells differentiation. Class III affect genes involved in epigenetic regulation.  
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1.1.4.2. Acquired point mutations  
NPM1 
Nucleophosmin 1 (NPM1) is a multifunctional protein that functions in the nucleolus and is 
also involved in ribosomal protein assembly and transport, control of centrosome duplication, 
and regulation of the tumour suppressor ARF (Falini and Martelli, 2011). Point mutations in 
exon 12 in NPM1 have been reported primarily in haematological malignancies and ascribed 
as early leukaemogenic event in 35% of AML cases with normal karyotype (Webersinke et 
al., 2014).  
 
IDH1 and IDH2 mutations 
Isocitrate dehydrogenases 1/2 (IDH) are a metabolic enzymes required to catalyse oxidation 
of isocitrate to yield α-ketoglutarate, which is an essential intermediate in the Krebs cycle and 
an important co-substrate for cellular metabolic functions (Levis, 2013). Recurrent somatic 
mutations in cytosolic IDH1 or its mitochondrial homolog IDH2 were primarily identified in 
colorectal cancer, glioblastoma and other brain tumours (Ward et al., 2012; Walker and 
Marcucci, 2015). In AML, IDH1 mutation was first identified following DNA sequencing of 
cytogenetically normal AML and found to be a recurrent event in a small group of patients, 
subsequently confirmed in larger cohort study along with novel mutation in IDH2 (Mardis et 
al., 2009; Marcucci et al., 2010). IDH1/2 mutations occur in approximately 17% of newly 
diagnosed AML cases and they correlate with normal karyotype AML and NPM1 mutations 
(Abbas et al., 2010).  
 
CEBPα 
The CCAAT/enhancer binding protein α (CEBPα) is a transcription factor essential for 
myeloid differentiation and is specifically expressed in myelomonocytic cells (Renneville et 
al., 2008). Mutation in CEBPα usually associated with AML FAB M1, M2 and M4 subtypes 
and is reported in 11-19% of AML cases (Renneville et al., 2008). Two types of mutations are 
frequently observed in AML: frameshift mutation in the N-terminal region of the protein 
results in a truncated form of the CEBPα protein; and insertion/deletion mutations in C-
terminal result in deficient DNA binding. Some AML patients present with a single mutation, 
while others have multiple mutations, including mutation in both the N-terminal and C-
terminal. CEBPα mutations are implicated in leukaemogenesis and function by blocking 
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granulocytic differentiation, activation of proliferation signalling pathways and upregulation 
of genes involved in erythroid linage differentiation (Castilla, 2008; Marcucci et al., 2008).  
 
RAS 
Mutations of RAS oncogene family members frequently occur in variety of cancer types. 
There are three functional RAS genes, including K-RAS (Kirsten), H-RAS (Harvey) and N-
RAS (from neuroblastoma cell line) (Renneville et al., 2008). RAS gene family members 
encode guanine-nucleotide binding proteins crucial in regulation of signalling transduction 
pathways required for proliferation, differentiation and apoptosis (Renneville et al., 2008). 
Mutation in RAS genes activates RAS activity and constitutively activates downstream 
signalling pathways. Mutation in N-RAS occur in 10%-15% of AML cases, whereas K-RAS 
mutation occurs in approximately 5% of AML cases (Renneville et al., 2008).  
 
RUNX1 
RUNX1 (Runt related transcription factor 1) also named AML1 or CBFA2, is a transcription 
factor that plays an essential role in regulation of haematopoietic differentiation. RUNX1 is 
mutated in 12%-16% of AML via either chromosomal translocation, point mutation or gene 
amplification (Renneville et al., 2008). RUNX1 is highly correlated with AML in males, 
older age and M0/M1 FAB subtypes (Tang et al., 2009). Patient with RUNX1 mutations have 
lower complete remission rates with shorter disease free survival (DFS) and overall survival 
compared to patients with wildtype RUNX1 (Walker and Marcucci, 2015).  
 
1.1.4.3. Epigenetic alterations 
Epigenetic alterations are defined as inheritable changes occurring in gene expression without 
an alteration in the DNA coding sequence (Egger et al., 2004). Epigenetic changes occur 
through two mechanisms, including DNA methylation and alterations in histone modification 
pattern, where these play a role in silencing of critical genes involved in normal cellular 
metabolism (Wouters and Delwel, 2016). Epigenetic regulation is a part of physiological 
development and can become dysregulated in some AML cases.  
DNA methylation involves the addition of a methyl group to the carbon at position 5 of 
cytosine in CpG dinucleotides to yield 5-methylcytosine (Wouters and Delwel, 2016). 
Cytosine hypermethylation is associated with silencing of tumour suppressor genes and can 
11 
 
contribute to leukaemogenesis via this mechanism (Wouters and Delwel, 2016). Several 
recurrent mutated genes have been reported in AML and have been associated with epigenetic 
alterations, including TET2, IDH1, IDH2 and DNMT3A (Delhommeau et al., 2009; Schoofs 
et al., 2014). These mutations have some prognostic value and possibly play key roles in 
AML pathogenesis. Certain translocation/genetic mutations in AML, such as AML1-ETO, 
PML-RARα and NPM1, are associated with highly distinctive methylation pattern (Figueroa 
et al., 2010b; 'Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid 
Leukemia,' 2013).  
 
TET2 
The ten-eleven translocation 2 (TET2) is one of three members of TET protein family and it 
plays a critical role in the regulation of demethylation of 5-methylcytosin to 5-
hydroxymethylcytosine in DNA. TET2 is mutated recurrently in a variety of myeloid 
malignancies including myelodysplastic syndrome (MDS), AML and myeloproliferative 
neoplasm (Nakajima and Kunimoto, 2014). TET2 mutation occurs in 7% to 23% of AML 
cases and its impact on prognosis is still controversial (Gaidzik et al., 2012). However, a 
study on 427 patients found that TET2 mutation confers adverse prognosis in patients with 
favourable normal cytogenetic karyotype (Metzeler et al., 2011). TET2 mutation dysregulates 
hydroxylation of 5-methylctosine and leads to hyper-methylation of genes required for normal 
cellular function (Nakajima and Kunimoto, 2014).  
 
1.1.4.4. Dysregulation of miRNA and gene expression 
MicroRNAs (miRNA) are a small noncoding RNAs involved in post-transcriptional 
regulation of gene expression via degradation of mRNA or inhibition of translation by 
binding at the 3’ UTR region (Chuang et al., 2015). Alterations in miRNA expression have 
been associated with AML progression and prognosis (Garzon et al., 2008). Various miRNA 
expression patterns have been reported in different AML cytogenetic groups; hence different 
cytogenetic groups harbour distinct miRNA expression patterns (Jongen-Lavrencic et al., 
2008; Chen et al., 2010). Examples of commonly altered miRNAs in AML include let-7, 
miR-17-92, miR-155, miR-181, miR-191, miR-9 and miR-196a/miR-196b (Chen et al., 2010; 
Marcucci et al., 2011a).  
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The microRNA miR-17-92 cluster is one of the most studied miRNA clusters. This family 
contains seven unique members (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-
19b-1 and miR-92a-1), which are dysregulated in a number of haematological and solid 
cancers (Mogilyansky and Rigoutsos, 2013). miR-17-92 is an important regulator of cell cycle 
and proliferation, and plays a key role in monocytopoiesis and megakaryopoiesis during 
haematopoiesis (Chen et al., 2010). A number of studies have demonstrated overexpression of 
miR-17-92 in mixed-lineage leukaemia (MLL) rearranged leukaemia, which is thought to 
contribute to leukaemogenesis through inhibition of normal haematopoiesis and down-
regulation of target genes promoting cell differentiation and apoptosis (Marcucci et al., 
2011b).  
 
1.1.4.5. Multistage carcinogenesis (Vogelsteins model) 
It is well known that cancer development and progression is driven by mutational events that 
occur in normal cells. Therefore, it is likely that multistage carcinogenesis evolves in cells 
with a mutator phenotype. This theory was first established in colorectal cancer by finding an 
association between hereditary nonpolyposis colorectal cancer and defects in DNA mismatch 
repair conferring a mutator phenotype (Parsons et al., 1993). This observation highlights the 
importance of genome integrity and DNA repair; hence dysregulation of genes involved in the 
DNA damage response or chromosomal stability can lead to increased mutation, genomic 
instability, and eventually cancer transformation.  
In the context of leukaemia, chromosomal translocations play an important role in 
leukaemogenesis (Dohner and Dohner, 2008; Mrozek and Bloomfield, 2008; Chen et al., 
2010). Such chromosomal translocations can lead to the generation of chimeric fusion 
proteins or insertion of genes close to promoter or enhancer elements, which contribute to 
genomic instability and disease progression. The multistage leukaemogenesis theory is widely 
demonstrated in AML, where a series of mutational events lead to proliferation of malignant 
myeloid progenitors with blockage of myeloid differentiation. As such, the presence of single 
mutational events such as FLT3, IDH1/2 or CEBPα is not enough to cause leukaemia, but 
further cooperating mutations are required in order to drive leukemic transition. 
The AML1-ETO fusion protein resulting from the t(8;21) chromosomal translocation was 
shown to block myeloid differentiation and deregulate genes involved in DNA repair and 
stem cell maintenance (Alcalay et al., 2003). Thus, the AML1-ETO oncoprotein induces a 
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mutator phenotype in blast cells and increase the rate of secondary mutations (Forster et al., 
2016).  
 
1.1.5. Prognostication of AML 
Prognostic factors can be divided into two main categories; patient related factors and disease 
related factors. Patient related factors are crucial to predict treatment related early death and 
indicate the ability of patients to tolerate the intensive chemotherapy (Erba, 2007) . Such 
factors include patient age, performance status, comorbidity of other diseases and impaired 
organ function (Erba, 2007). Disease related factors include white blood cells (WBC) count, 
molecular genetic alterations, and previous exposure to cytotoxic therapy or prior 
myelodysplastic syndrome (Döhner et al., 2015). Determination of treatment options and 
predicting resistance to conventional chemotherapy are dependent on both patient and disease 
prognostic factors. However, the European Leukemia Net (ELN) introduced an AML 
prognostication classification system where patients are classified into four categories 
depending on mutational profile and cytogenetic alterations (Dohner et al., 2010). This 
classification include favourable, intermediate-I, intermediate-II, and adverse subgroups 
(Table 1.4).  
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Prognosis Cytogenetic abnormality
Favourable  - t(15;17)(q22;q21)  
- t(8;21)(q22;q22); RUNX1-RUNX1T1 (Regardless of 
additional cytogenetic abnormalities) 
- inv(16)(p13q22) or t(16;16)(p13;q22); CBFB-
MYH11 
- Mutated NPM1 without FLT3-ITD (normal 
karyotype) 
- Biallelic mutated CEBPα (normal karyotype) 
Intermediate I - Mutated NPM1 and FLT3-ITD (normal karyotype) 
- Wild-type NPM1 and FLT3-ITD (normal karyotype) 
- Wild-type NPM1 without FLT3-ITD (normal 
karyotype) 
Intermediate II - t(9;11)(p22;q23); MLLT3-KMT2A 
- Cytogenetic abnormalities not classified as 
favourable or adverse
Adverse  - abn(3q) excluding t(3;5)(q21~25;q31~35) 
- inv(3)(q21q26) or t(3;3)(q21;q26) 
- add(5q), del(5q), −5 
- −7, add(7q)/del(7q), [Excluding cases with 
favourable karyotype] 
- t(6;11)(q27;q23) 
- t(10;11)(p11~13;q23)  
- t(11q23); [excluding t(9;11)(p21~22;q23) and 
t(11;19)(q23;p13)] 
- t(9;22)(q34;q11) 
- −17/abn(17p) 
- Complex (≥ 4 unrelated abnormalities) 
 
Table 1.4: Prognostic classification of AML based on cytogenetic alterations. 
European LeukemiaNet (ELN) Guidelines recommended classification of AML prognostic 
factors into favourable, intermediate I and II, and adverse subgroups depending on 
cytogenetic alterations. Adapted from (Döhner et al., 2015). 
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1.1.6. Treatment of AML 
Treatment of AML is challenging and disease relapse is potential common problem, 
particularly in elderly patients and patients with unfavourable prognosis. Despite the fact that 
AML treatment is difficult, it is curable in 35 to 40% of people younger than 60 years old, and 
5 to 15% of people older than 60 years old (Döhner et al., 2015). Moreover, treatment 
outcome in old patients, who are unable to tolerate chemotherapy without undesirable side 
effect, is still unsatisfactory with only 5-10 month median survival rate (Döhner et al., 2015).  
 
1.1.6.1. Remission induction regimens and consolidation therapy 
AML treatment has not changed significantly for several decades with the exception of acute 
promyelocytic leukaemia (APML) which is treated with all-trans-retinoic acid (ATRA) and 
arsenic trioxide (Coombs et al., 2015). The aim of the treatment is to eliminate blast cells 
below detectable levels by morphological analysis in peripheral blood and less than 5% in 
bone marrow. Remission induction therapy is followed by consolidation therapy to maintain 
complete remission by further cycles of chemotherapy and possibly bone marrow 
transplantation. Newly diagnosed patients are stratified according to the ELN prognostication 
system to determine their eligibility for intensive remission induction chemotherapy and to 
assess treatment options. Remission induction therapy starts with continuous infusion of 
cytarabine (Ara-C) for 7 days (100-200 mg/m2) in combination with 3 days of an 
anthracycline, such as daunorubicin (60 mg/m2) or idarubicin (10-12 mg/m2) (Döhner et al., 
2015). Complete remission is usually achieved in the first cycle for patients aged less than 60 
years (Döhner et al., 2015), however a substantial number of patients will relapse within two 
years with chemoresistant disease. Patients older than 60 years with favourable or 
intermediate prognosis, with no coexisting conditions are likely to benefit from the standard 
induction therapy. Conversely, older patients with adverse cytogenetics with/without 
coexisting conditions may not benefit the standard induction therapy, but may be treated with 
low dose Ara-C, hypomethylating agents or hydroxyurea plus supportive care.   
However, recent clinical studies have attempted to improve and optimise the outcome of 
remission induction therapy by stratifying patient into subgroups according to their age and 
genetic risk, and combining the classical remission induction regimen with targeted therapy. 
A recent key study performed by the Medical Research Council aimed to improve induction 
and consolidation outcome in newly diagnosed younger AML patients (aged 0 – 73 years) by 
comparing conventional treatment course versus new drugs combinations (Burnett et al., 
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2013). The overall rates of remission between different treatment combinations were similar, 
but the combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and 
idarubicin (FLAG-Ida) significantly reduced relapse rate, and improved disease-free survival 
rate (Burnett et al., 2013).  
With the exception of acute promyelocytic leukaemia, current AML treatment still widely 
relies on intensive chemotherapy followed by either consolidation or allogeneic stem cell 
transplantation. However, the field of AML treatment is markedly progressing in terms of 
finding new therapeutic agents and standard dose optimisation. To this end, it seems that the 
most effective treatment approach for AML involves conventional treatment in combination 
with drugs specifically targeting upregulated/activated signal transduction molecules.  
 
1.1.6.2. Nucleoside analogues 
Nucleoside analogues have been used clinically for several decades and their ability to target 
vital cellular mechanisms has made them the cornerstone of AML treatment. Nucleoside 
analogues are chemically modified molecules developed to resemble normal DNA precursor 
nucleosides. Consequently, they are integrated into genomic DNA during DNA replication 
leading to inhibition of DNA synthesis via replication fork collapse. However, the mechanism 
of action of nucleoside analogues is cell cycle specific, where incorporation of fraudulent 
nucleosides into DNA during S phase in actively proliferating cells induces cell cycle 
checkpoint signalling and apoptosis. Nucleoside analogues can inhibit DNA synthesis via 
disruption of ribonucleotide reductase enzymatic activity, which required to catalyse 
formation of deoxyribonucleotide triphosphate (dNTP) (Galmarini et al., 2001). 
Consequently, this result in reduction of dNTP synthesis that is required for DNA synthesis. 
Accumulating evidences suggest another mechanism by which nucleoside analogues induce 
cytotoxicity in leukaemia cells; by inhibition of DNA synthesis during DNA repair. Early 
studies showed that induction of DNA damage by ultraviolet (UV) enhanced incorporation of 
fludarabine into DNA and inhibited ongoing DNA repair performed by nucleotide excision 
repair by causing irreversible damage leading to the activation of PARP or P53 mediated 
apoptosis (Sandoval et al., 1996).  
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1.1.6.2.1. Cytarabine (Ara-C) 
Ara-C is the backbone of AML remission induction treatment. It is a pyrimidine nucleoside 
analogue which resembles the structure of deoxycytidine in DNA, with a unique hydroxyl 
group in a β-D-configuration on the 2’-carbon of the deoxyribose ring (Figure 1.2). There are 
three potential mechanisms by which Ara-C induce cytotoxicity to cancer cells, including 
incorporation into replicating DNA leading to chain termination, inhibition of DNA repair 
and inhibition of topoisomerase I enzymes (Gmeiner et al., 2003) . Ara-C is taken up into 
cells through specific nucleoside transporters and converted through a series of 
phosphorylation events into Ara-C triphosphate (Matsuda and Sasaki, 2004). This is followed 
by incorporation into actively replicating DNA instead of deoxycytidine, which induces 
significant conformational perturbations at the site of incorporation. Consequently, this 
process prevents and inhibits DNA polymerase binding, and induces stalled replication and 
chain termination, leading to activation of intra-S phase checkpoints and apoptosis. Recent 
study have demonstrated that Ara-C is a substrate for polymerase β (an enzyme involved in 
base excision repair (BER)), suggesting that a component of Ara-C-induced cytotoxicity 
might be mediated be BER (Prakasha Gowda et al., 2010). During BER, DNA glycosylases 
recognise and remove damaged base/bases leaving a gap in the DNA backbone; abasic site 
(AP site). AP sites are cleaved by APE1 and with gap filling mediated by polymerase β. The 
resulting nick is sealed by the joint actions of XRCC1 and DNA ligase as described in section 
1.2.1.1. However, during DNA replication and during BER, the fraudulent pyrimidine 
nucleoside bases of Ara-C are incorporated into the DNA by polymerase β, which slows 
ligation by XRCC1 and DNA ligases (Prakasha Gowda et al., 2010), and can eventually lead 
to stalled replication and fork collapse (Ewald et al., 2008; Prakasha Gowda et al., 2010). 
This process triggers the S phase DNA damage checkpoint, blocks DNA synthesis and causes 
cells to accumulate in the S phase of the cell cycle (Ewald et al., 2008; Prakasha Gowda et al., 
2010). 
 
1.1.6.2.2. Clofarabine 
Clofarabine is a next generation nucleoside analogue which was developed on the basis of 
previous experience with other nucleoside analogue such as fludarabine and cladribine to 
achieve higher efficacy and lower toxicity (Figure 1.2) (Zhenchuk et al., 2009). Clofarabine is 
similar to Ara-C in terms of mechanism of action, by which it incorporate into DNA leading 
to termination of chain elongation and inhibition of DNA synthesis. It also reported that 
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clofarabine induces damage to the mitochondrial membrane which triggers apoptosis via 
release of cytochrome c and other pro-apoptotic factors (Zhenchuk et al., 2009). Preclinical 
and clinical data demonstrate that clofarabine has a broad anticancer in haematological and 
solid tumours. Clofarabine is currently used for the treatment of elderly AML patients who 
are unable to tolerate intensive chemotherapy and patients with refractory AML. Recent 
clinical trial data demonstrates that clofarabine in combination with low dose Ara-C increases 
the complete remission rate in elderly patients and those with refractory AML with minimal 
toxicity, but with no significant improvements in overall survival (Buckley et al., 2015).  
 
1.1.6.2.3. Fludarabine 
Fludarabine or 9-β-D-arabinosyl-2-fluoroadenine (Figure 1.2) is an adenosine analogue 
commonly used for the treatment of chronic lymphocytic leukaemia (CLL). Similar to Ara-C 
and Clofarabine, fludarabine inhibits DNA synthesis. Currently its use in combination with 
other drugs such as Ara-C, daunorubicin, clofarabine and/or other drugs is still under 
investigation in clinical trials. The UK AML15 Medical Research Council clinical trial 
showed that fludarabine in combination with Ara-C, granulocyte colony-stimulating factor, 
and idarubicin significantly increase remission rate and reduced the risk of relapse particularly 
in patients with favourable and intermediate risk karyotype (Burnett et al., 2013). 
 
 
 
 
Figure 1.2: Chemical structure of nucleoside analogues commonly used in AML 
treatment. 
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1.1.6.3. Anthracyclines 
Anthracyclines such as daunorubicin, doxorubicin and idarubicin have been used for over 4 
decades as AML remission induction chemotherapy. Anthracycline are administered for 3 
days along with continues infusion of Ara-C for 7 days. Despite the extensive clinical utility 
of anthracyclines in AML treatment, the mechanism of their action is still not fully elusive. 
However, several mechanisms of action were proposed and all of them act through induction 
of DNA damage. Mechanisms of anthracyclines action include: DNA intercalation, 
generation of free radicals to induce DNA damage, DNA alkylation, interfering with DNA 
unwinding during DNA replication by inhibition of topoisomerase II leading to DNA damage 
induction and apoptosis (Gewirtz, 1999; Minotti et al., 2004). Anthracyclines also act on 
cancer cells by lipid peroxidation of cell membrane (Gewirtz, 1999). 
More recent studies investigated the benefit of anthracycline dose adjustment/intensification 
to improve the complete remission rates and overall survival. The UK NCRI AML17 trial was 
initiated to compare the benefit of high dose daunorubicin (90 mg/m2) versus 60 mg/m2 in 
AML induction therapy in 1206 patients. No evidence were found for an overall benefit in 
patients treated with high daunorubicin dose. Furthermore, there was high mortality within 60 
days in the patient group treated with high dose daunorubicin, which eventually lead to 
prematurely termination of this study (Burnett et al., 2015).  
 
1.1.6.4.Topoisomerase II poisons  
Topoisomerase II (TOP2) enzymes are crucial for normal DNA metabolism during DNA 
replication, transcription and recombination, and function primarily by removing knots and 
relaxing supercoiled DNA during replication (Allan and Travis, 2005). Two distinct isoforms 
of TOP2 enzymes are expressed in human cells including TOP2α (TOP2A) and TOP2β 
(TOP2B), which share 70% of their amino acid sequence, but are encoded by two different 
genes on chromosomes 17q21–22 and 3p24, respectively (Pendleton et al., 2014). TOP2 
enzymes are tightly regulated by post-translational modification, which can become 
dysregulated in cancer (Chikamori et al., 2010). However, TOP2 poisons, such as etoposide, 
doxorubicin and mitoxantrone, are widely used useful anticancer treatments, but are 
associated with treatment-related secondary AML, and particularly MLL gene translocation at 
11q23, PML-RARα t(15;17) and AML1-ETO t(8,21) (Cowell and Austin, 2012). Etoposide is 
not routinely used in induction therapy because addition to conventional chemotherapy does 
not significantly improve overall survival (Bishop et al., 1990; Hann et al., 1997; Burnett et 
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al., 2013). However, patients with refractory/relapsed AML can benefit from etoposide 
treatment with good tolerability (Abbi et al., 2015; Thol et al., 2015). Doxorubicin (the 
anthracycline and a TOP2 poison as well) is now not used routinely in AML treatment due to 
its association with cardiotoxicity, and alternative anthracyclines provided better response and 
outcome in AML patients (Minotti et al., 2004). Mitoxantrone is anthracycline that also has 
anti-TOP2 activity. It is commonly used in remission induction regimens, and also as post-
remission therapy in combination with Ara-C or other chemotherapeutic agent.  
 
1.1.6.5. Differentiation therapy (ATRA and ATO) 
ATRA (all-trans-retinoic acid) is the first successful targeted therapy in AML where it is used 
as a differentiation therapy for M3 FAB acute promyelocytic leukaemia (APL) classification 
AML patients. This particular subtype is uniquely characterised by the presence of the 
t(15;17)(q22;q21) translocation that expresses the promyelocytic leukaemia (PML)/retinoic 
acid receptor α (RARα) fusion protein. ATRA specifically disrupts the PML/RARα fusion 
protein and abrogates the cell differentiation blockade and induces terminal differentiation of 
granulocytic cells (Wang and Chen, 2008). Risk of relapse is extremely high when APL is 
treated with ATRA as a single agent, especially in the subgroup of APL patients with 
t(11;17)- associated APL which expresses the promyelocytic leukaemia zinc finger 
(PLZF)/RARα fusion oncoprotein (Petrie et al., 2009). Treatment with a combination of 
ATRA and arsenic trioxide (ATO) significantly abrogates relapse risk and overcomes 
resistance issues, yielding high complete remission rates and improved overall survival (Petrie 
et al., 2009). Furthermore, treatment with a combination of ATRA/ATO with standard 
induction chemotherapy improves the clinical outcome in APL patient with complete 
remission rates of 90% to 95% and 5 years overall survival approaching 100% (Wang and 
Chen, 2008).  
 
1.1.6.6. Hypomethylating agents 
Current treatment regimens for AML include intensive chemotherapy in order to eliminate 
myeloid blasts in the bone marrow and peripheral blood. But there is a large category of 
patients who either do not respond to available treatment due to genetic/epigenetic 
heterogeneity of the disease, and/or due to an inability of those patients to tolerate intensive 
treatment.  
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Hypomethylating agents benefit MDS patients and elderly AML patients who are not eligible 
for intensive chemotherapy or who have refractory AML. There are two mechanisms by 
which hypomethylating agents mediate cytotoxicity. The first mechanism occurs through 
inhibition of methyltransferase activity and preventing further DNA hypermethylation (Ewald 
et al., 2008). The second mechanism is via their function as nucleoside analogues and 
incorporation into DNA, leading to DNA damage which triggers DNA repair pathways, cell 
cycle checkpointing and apoptosis (Jiemjit et al., 2008; Palii et al., 2008). Azacitidine and 
decitabine, for example, are hypomethylating agent as well as acting as nucleoside analogues 
due to their ability to incorporate into DNA and mediate cell death via apoptosis (Ewald et al., 
2008). Both agents were assessed in a number of clinical trial which consistently reported 
improvement in overall survival and tolerability with minimal side effect in elderly AML 
patients > 60 years with blast counts between 20-30%. A recent clinical trial (the international 
phase 3 AZA-AML-001 study) reported that azacitidine increased median overall survival by 
3.8 months compared to current commonly used AML treatments (Dombret et al., 2015).  
 
1.1.6.7. Consolidation Therapy 
Consolidation or post-remission therapy aims to minimise relapse and destroy residual 
remaining blast cells that were not killed during remission induction. Decision making 
regarding consolidation therapy is facilitated by genetic profiling; with a decision to either 
proceed to bone marrow HSC transplantation for high risk AML or conventional 
consolidation chemotherapy for low risk AML patients. 
Consolidation with intensive chemotherapy in patients younger than 60 years constitutes 
intermediate dose Ara-C for 2 to 4 cycles. The optimal dose and number of cycles is still an 
open issue, but doses of 1000 to 1500 mg/m2 are recommended, and could be used in 
combined with mitoxantrone in patients with adverse karyotype (Döhner et al., 2015). 
However, high dose Ara-C did not show benefit for favourable or intermediate-risk disease, 
compared to traditional consolidation (Burnett et al., 2013). Patients with adverse risk who 
are not able to tolerate chemotherapy or have no response (refractory disease) are eligible for 
clinical trials with novel agents. A recent clinical trial showed that combination of amsacrine, 
cytarabine, etoposide, and then mitoxantrone/cytarabine was superior to standard therapy in 
this patient subgroup (Burnett et al., 2013).  
Allogeneic HSC transplantation following complete remission is the best anti-leukaemic 
treatment choice to minimise disease relapse. The relative benefits and risks of HSC vary in 
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different cytogenetic groups defined by the European Leukaemia Net (ELN) (section 1.1.5) 
(Cornelissen et al., 2012). Reports indicate that only intermediate and adverse risk AML 
patients significantly benefit from allogeneic HSC transplantation, but in patients with 
favourable karyotype AML the limited benefits of improved survival and outweighed by the 
increased risk of toxicity and death associated with the transplant conditioning procedure 
(Koreth et al., 2009; Cornelissen and Blaise, 2016).  
 
1.1.7. Targeted therapy in AML 
AML is heterogeneous disease with curable rate of 35 to 40% of people younger than 60 
years old, and 5 to 15% of people older than 60 years old. The backbone of AML treatment is 
combination of Ara-C with anthracycline, has not changed over 40 years. As such, the 
majority of patients experience relapse, which is a particular problem in elderly groups and 
those patients with adverse karyotype. Following complete remission, only a minority of 
AML patients are eligible for allogenic HSC transplantation, which is associated with high 
morbidity and mortality. Moreover, the lack of selectivity of the conventional AML treatment 
is a major disadvantage, and results in undesirable adverse side effects. Owing to such poor 
outcome, it is clear that current conventional AML treatment has significant limitations, 
highlighting the clinical need for new targeted therapies with reduced toxicity that are better 
tolerated in patients with poor performance status. 
The development of targeted therapies for AML is an area of significant investment for the 
research community, with a major shift from focusing on conventional treatment strategies to 
the development of novel therapies that specifically inhibit proteins or pathways essential to 
maintenance of the leukaemic clone, but which are either not present or not essential in non-
leukaemic cells. Theoretically, this targeted approach preserves normal cells and consequently 
minimise adverse side effect caused by intensive chemotherapy, increasing chemotherapy 
efficacy and improves quality of life of AML patients. Identification of targeted therapy relies 
on exploring specific genetic alterations in AML cells that drive disease progression, cell 
survival and/or treatment resistance. This is followed by discovery and development of 
molecularly target drugs that exploit these vulnerabilities. As such, recurrently mutated genes 
in AML, and which are essential for maintenance of the leukaemia, represent potential 
therapeutic targets.  
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1.1.7.1. FLT3 inhibitors 
FLT3 mutation is one of the most prevalent mutation in AML, occurring in approximately 
30% of AML cases, and is associated with poor prognosis and a high risk of relapse 
(Pemmaraju et al., 2014). There are two different groups of FLT3 mutations including FLT3 
with internal tandem duplications (FLT3-ITD) and point mutations in the tyrosine kinase 
domain (FLT3-TKD). Due to the fact that FLT3 protein is frequently mutated in AML and 
confers a poor prognosis, it became a legitimate target for therapy in AML. Several FLT3 
inhibitors have been developed and tested in clinical trials, including sorafenib, lestaurtinib, 
midostaurin, tandutinib and sunitinib. However, the results from clinical trial for the first 
generation of FLT3 inhibitors were unsatisfactory, primarily due to low specificity for FLT3 
and concerns about development of resistance mediated by acquired mutations in FLT3 
(Wander et al., 2014). In addition, single agent treatment was only effective at inducing a 
transient reduction in blast count. Currently, phase III trials are ongoing to test the second 
generation of FLT3 inhibitors which thought to be highly potent and more specific for the 
FLT3 kinase (Döhner et al., 2015). 
 
1.1.7.2.Gemtuzumab ozogamicin (Mylotarg®) 
Gemtuzumab ozogamicin (Mylotarg®) is a treatment for AML patients with CD33 positive 
AML and is used at first relapse in those aged over 60 years and not eligible for further 
intensive chemotherapy. Gemtuzumab is the first approved antibody targeted chemotherapy 
and is composed of anti-CD33 antibody linked to a calicheamicin derivative, which is a 
potent antitumor antibiotic. Data from several randomised clinical trials demonstrated that 
gemtuzumab did not increase the proportion of patients achieving complete remission, but it 
significantly reduced the risk of relapse and increase the overall survival in patient with 
favourable and intermediate prognosis (Burnett et al., 2011b; Hills et al., 2014). Despite 
promising results from initial clinical trials, the drug license was suspended in the United 
States of America due to high treatment-related mortality, including cardiac failure 
(Petersdorf et al., 2013).  
 
1.1.7.3. IDH1 and IDH2 inhibitor 
IDH1 and IDH2 are crucial metabolic enzymes in the Krebs cycle and both are frequently 
mutated in AML and contribute to leukaemogenesis (Abbas et al., 2010; Chaturvedi et al., 
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2013). IDH mutations lead to DNA hypermethylation through disruption of the epigenetic 
regulator TET2 (Figueroa et al., 2010a). Although IDH mutations are considered legitimate 
therapeutic targets in AML, very few IDH inhibitors are available for preclinical evaluation. 
Nevertheless, studies with IDH2 inhibitor AGI-6780 have demonstrated induction of 
differentiation and suppression of leukaemia cell growth (Wang et al., 2013a). Furthermore, 
some IDH inhibitors have undergone clinical evaluation in clinical trials, and preliminary 
results are encouraging (Stein et al., 2014). In early phase I clinical trial, the AG-221 IDH2 
inhibitor induced differentiation of leukemic blasts, had a favourable pharmacokinetic profile 
and led to durable responses with complete remissions of up to 4.5 months when administered 
as a single agent (Stein et al., 2014).  
 
1.1.7.4. Targeting DNA repair/DNA damage response in AML 
It is becoming clearer that chromosomal translocations, genetic aberrations and epigenetic 
events can disrupt genome stability and activate the DNA damage response in AML, and yet 
these same alterations also affect treatment efficacy, confer treatment resistance, and promote 
disease progression. Mutations in genes involved in DNA repair in AML are relatively 
uncommon with the exception of TP53. However, targeting DNA repair in AML is not fully 
established and still under investigation in preclinical studies and some clinical trials, such as 
PARP-1 inhibitors for example.  
 
1.1.7.4.1. PARP-1 
Poly (ADP-ribose) polymerase 1 (PARP-1) inhibition has demonstrated therapeutic efficacy 
in cancers harbouring BRCA1 or BRCA2 mutations, including some breast and ovarian 
cancers. PARP-1 play a crucial role in base excision repair (BER) (see section 1.2.1.1). 
Specifically, PARP-1 inhibition potentiates the anticancer activity of chemotherapeutic agents 
that generate DNA damage repaired by PARP-1 and BER, such as temozolomide, 
topoisomerase I poisons and ionising radiation (Mitchell et al., 2009; Curtin and Szabo, 
2013). Several preclinical studies have demonstrated the potential utility of PARP-1 inhibition 
in AML. One key study demonstrated anti-leukaemic activity of PARP-1 inhibitors, as a 
single agent, on a number of AML and MDS cell lines in addition to primary AML cells 
(Gaymes et al., 2009). The addition of decitabine in combination with PARP-1 inhibitors 
further potentiated cell killing. PARP-1 inhibition led to the accumulation of DNA double 
25 
 
strand breaks which subsequently led to apoptosis (Gaymes et al., 2009). Consistent with this 
observation, a recent preclinical study confirmed the potential utility of PARP-1 inhibition in 
AML, and particularly in cells harbouring the AML1-ETO and PML-RARα fusion 
oncoproteins (Esposito et al., 2015). It appears that sensitivity to PARP-1 inhibition 
correlated with changes in the expression of genes involved in DNA damage repair; 
particularly components of homologous recombination, including RAD51, ATM and 
BRCA1/2 (Aly and Ganesan, 2011; Weil and Chen, 2011). PARP-1 inhibition triggers 
differentiation and senescence in both human and mouse model with AML1-ETO and PML-
RARα; consistent with previous reports that DNA damage induces differentiation in 
haematopoietic cells (Santos et al., 2014). Therefore, PARP-1 inhibition is a potential target 
in AML and its utility is still under exploration in phase I clinical trials both with and without 
temozolomide or carboplatin for the treatment of refractory AML, high-risk myelodysplasia, 
or aggressive myeloproliferative disorders (clinicaltrials.gov website).  
 
1.2. Targeting base excision repair as a therapeutic strategy in AML 
DNA repair systems are important to maintain genomic integrity and prevent ongoing DNA 
mutation caused by endogenous and exogenous DNA damaging agents such as 
chemotherapeutic agents and radiation. Several DNA repair pathways are required to maintain 
genomic integrity, including base excision repair (BER), nucleotide excision repair, mismatch 
repair, homologous recombination repair, non-homologous end joining (NHEJ) and direct 
DNA repair pathway.  
Base excision repair (BER) is an important DNA repair system required to repair DNA 
lesions induced by alkylation, oxidation, ionizing radiation as well as deamination. 
Unrepaired damaged bases can mispair during DNA replication and could become fixed as 
mutation (Kelley et al., 2014). BER operate in all cell cycle phases through two sub-
pathways; short-patch BER and long-patch BER (Branzei and Foiani, 2008). It is not fully 
understood how short and long patch repair are invoked, but the type of damage and the cell 
cycle phase may play a crucial role in this process (Fortini and Dogliotti, 2007; Kim and 
Wilson, 2012). In particular, short-patch pathway is active during the G1 phase to repair 
single base damage, and long-patch BER is utilised in the repair of DNA damage by replacing 
a strand of 2-8 bases, primarily during S and G2 phases of the cell cycle (Fortini and 
Dogliotti, 2007; Branzei and Foiani, 2008). 
26 
 
The potential utility of targeting DNA repair (specifically BER) components has already been 
demonstrated in preclinical and clinical studies. For example, inhibition of PARP1, a key 
modulator enzyme in BER, has shown promise in preclinical and clinical studies of germline 
BRCA1/2 deficient breast and ovarian cancer with dysregulated homologous recombination 
repair. Although PARP inhibition is promising, recent reports have raised some issues, 
including the development of PARP inhibition resistance and enhanced myelosuppression 
(Plummer et al., 2008; Fojo and Bates, 2013). Moreover, the PARP family has 17 members 
raising issues related to drug selectivity which may limit the clinical utility of PARP 
inhibitors (Rouleau et al., 2010). However, targeting other components of BER such as APE1, 
XRCC1 or POLβ also show promise in preclinical studies (Barakat et al., 2012; Li and 
Wilson, 2014). In particular, targeting APE1 has been extensively investigated leading to the 
development of several inhibitors (discussed in section 1.2.1.4).   
The specific importance of BER for AML cell survival is not fully understood. However, 
previous studies have highlighted the importance of BER and other DNA repair systems to 
maintenance of the tumour environment, leading to the hypothesis that BER components 
(particularly APE1 and OGG1) may play an essential role in AML that could be targeted 
through inhibition of function. In the following sections (1.2.1 and 1.2.2), the biological roles 
of APE1 and OGG1 in normal and cancer cells will be discussed, in addition to the potential 
for targeting these components in a therapeutic setting. 
 
1.2.1. Targeting Apurinic/Apyrimidinic endonuclease 1 (APE1) as a therapeutic strategy 
in AML 
APE1 is an abundant protein in eukaryotic cells with approximately 104 – 105 molecules per 
cell and an approximate half-life of 8 hours (Tell et al., 2009). It is a relatively small protein 
(36.5 kDa) and consists of 318 amino acids encoded by ~3 kb gene localised on chromosome 
14 q11.2-12 (Fritz, 2000). The redox function of APE1 resides in the N-terminal region while 
the C-terminal portion is responsible for the DNA repair function (Tell et al., 2009). The first 
33-35 amino acids of the N-terminal region comprises the nuclear localization sequence 
(NLS) which is also essential for protein-protein interaction and RNA binding activity of 
APE1 (Tell et al., 2010a).  
APE1 is a multifunctional protein, crucial for cell survival, proliferation and maintenance of 
genomic stability. It plays a key role in repairing DNA damage induced by oxidative stress 
and alkylating agents through its function as part of BER (Tell and Wilson, 2010). APE1 also 
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has a redox regulatory function, which is mediated through interaction and activation of a 
variety of transcription factors involved in regulation of cell survival and proliferation, 
including NF-кB, AP-1, Egr-1, HIF-1α and TP53 (Tell et al., 2010a). In addition, recent 
studies have revealed more functions of APE1, including RNA quality control, regulation of 
parathyroid hormone through interaction with negative calcium repressing element, 
angiogenesis and other functions (Bhakat et al., 2009). Furthermore, APE1 is essential for 
embryonic development, cell survival and viability; homozygous mutation in APE1 in mice 
induced embryogenic lethality at day 5.5 (Xanthoudakis et al., 1996). 
28 
 
 
 
Figure 1.3: The structure of human APE1 protein. 
(A) APE1 protein (36.5 kDa) consists of 318 amino acids. The redox function of APE1 
resides in the N-terminal region while the C-terminal portion is responsible for the DNA 
repair function. The first 33-35 amino acids of the N-terminal region comprises the nuclear 
localization sequence (NLS) which is also essential for protein-protein interaction and RNA 
binding activity of APE1. Figure adapted from (Dyrkheeva et al., 2016). (B) APE1 tertiary 
structure with illustration of the position of critical redox active cysteines residues C65, C93 
and C99. Figure adapted from (Luo et al., 2012).
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1.2.1.1.APE1 functions 
DNA repair function 
Several DNA base lesions caused by alkylating agents and majority of lesions induced by 
oxidative stress are repaired by BER. The main components of BER include DNA 
glycosylases, APE1, DNA polymerases and DNA ligases. Other factors are important for 
recruiting and coordination of BER. However, APE1 is unique in its role in BER and no other 
enzyme has endonuclease function. Additionally, APE1 also possesses very weak 3’ 
exonuclease activity and 3’ phosphodiesterase activity (Li and Wilson, 2014).  
BER is initiated by recognition and excision of the damaged base/bases by the action of a 
DNA glycosylase to create an abasic site (Apurinic/Apyrimidinic site or AP site). Different 
DNA glycosylases recognise their specific damaged base/bases. There are two types of DNA 
glycosylases including monofunctional and bifunctional glycosylases (Table 1.5) (Kim and 
Wilson, 2012). Monofunctional glycosylases only perform base excision of the damaged base 
and mainly repair alkylated and deaminated bases (Krokan and Bjoras, 2013). Bifunctional 
glycosylases mainly repair oxidized DNA lesions and exhibit glycosylase activity in addition 
to AP lyase activity, which create 3’ incision to AP site in the phosphodiester backbone of the 
DNA by either by β-elimination or by β,δ-elimination (Kim and Wilson, 2012; Krokan and 
Bjoras, 2013).  
However, following removal of the damaged base, processing the DNA damage proceed via 
either short patch or long patch BER depending on the type of damage and glycosylase 
involved (Figure 1.4) (Kim and Wilson, 2012). 
 
- Short patch BER  
Short patch BER is engaged in response to single nucleotide damage and is the predominant 
pathway in proliferating and non-proliferating cells (Akbari et al., 2004; Fortini and Dogliotti, 
2007). If the damaged base removed by monofunctionl glycosylases (Table 1.5), processing 
the DNA damage is processed via short patch BER. Following removal of the damaged 
base/bases, the AP-endonuclease APE1 processes the resulting AP site by creating a 5’ 
incision in the phosphodiester backbone of the DNA (Kim and Wilson, 2012). This incision 
generates hydroxyl group (OH) at 3’ end and deoxy ribose phosphate at the 5’ termini 
(5’dRP). This followed by recruiting β polymerase to removes 5’dRP by its 
phosphodiesterase activity and filling the gap with the correct bases (Kim and Wilson, 2012). 
30 
 
Subsequent to this, DNA ligase III and XRCC1 (X-ray cross-species complementing 1) are 
activated and function to repair the incision and complete the repair process (Figure 1.4) (Kim 
and Wilson, 2012). Although the role of PARP1 (and PARP2) is BER is not clear evidence 
suggests that PARP is essential in activation and recruitment of polymerase β, XRCC1 and 
DNA ligase III (Kelley and Fishel, 2008). In contrast, recent studies suggest that PARP is not 
essential to BER, but complements BER (Strom et al., 2011).  
Incision of the damaged base by the AP lyase activity (β-elimination) of a bifunctional 
glycosylase, including OGG1, MYH and NTH1, creates a blocking DNA nick phosphor-α,β-
unsaturated aldehyde (PUA) at the 3’ end. This lesion is refractory to polymerase activity and 
must be removed by phosphodiesterase activity of APE1 in order to allow polymerase to gap 
fill. Following processing of the PUA, repair can proceed via gap filling mediated by 
polymerase β with nick ligation performed by DNA ligase III and XRCC1 via short patch 
BER.  
 
- Long patch BER 
Long patch BER specifically repair oxidised and reduced damaged bases (Kim and Wilson, 
2012). Removal of damaged bases by bifunctional glycosylases NEIL1/2 or 3 via β,δ-
elimination, creates a blocking 3’ phosphate (PO4), which resists DNA polymerase mediated 
repair and requires further processing by polynucleotide kinase/phosphatase (PNKP). PNKP 
has 3’ phosphatase and 5’ DNA kinase activities that remove 3’PO4 blocking group (Krokan 
and Bjoras, 2013). Proliferating cell nuclear antigen (PCNA) and/or polymerases ε and δ 
subsequently perform strand removal by displacing 3-8 bases (Kim and Wilson, 2012). The 
displaced strand is subsequently resynthesised by FEN1 (flap endonuclease 1). Ultimately, 
DNA ligase I completes the repair process by sealing the DNA nick (Figure 1.4) (Kim and 
Wilson, 2012). 
 
There are several factors that could influence selection of the short or long patch BER 
pathways. The nature of DNA damage determines which glycosylase initiates the repair 
process and therefore determines which sub-pathways could be executed (Fortini et al., 1999). 
For example, the oxidised DNA lesion 2-deoxyribonolactone is refractory to polymerase β 
lyase activity and therefore requires long patch BER (Sung and Demple, 2006). The 
differentiation state and the cell cycle stage of the cell may also contribute to sub-pathway 
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selection. The short patch pathway is executed equally in both dividing and non-dividing cells 
(Akbari et al., 2004). On the other hand, long patch repair pathway is thought to be primarily 
active only in dividing cells (Fortini and Dogliotti, 2007; Narciso et al., 2007). Protein-protein 
interaction that occur during/after excising damaged base may also contribute to pathway 
selection. XRCC1 is a crucial BER component that plays a key role in coordinating the early 
steps of BER as well as its role in ligation of the DNA backbone (Vidal et al., 2001; Moor et 
al., 2015). Cells with mutated XRCC1 exhibit impaired ligation and defective polymerase β-
dependent single nucleotide insertion via the short patch pathway (Cappelli et al., 1997).  
 
- Coordination of BER by APE1 
BER is a tightly regulated process and several factors are involved in the coordination of 
repair. APE1 is involved in coordination of BER by interaction and recruitment of other BER 
components. Several glycosylases and factors are reported to directly interact with APE1 to 
regulate BER, including OGG1, XRCC1, polymerase β, PARP-1 and P53 (Vidal et al., 2001; 
Sidorenko et al., 2007; Parsons and Dianov, 2013; Moor et al., 2015; Poletto et al., 2016). 
APE1 interaction with BER enzymes enhances the efficiency of DNA damage repair as well 
as minimising accumulation of potential cytotoxic DNA repair intermediates. 
After excision of a damaged base, DNA glycosylases, such as OGG1, TDG, UDG and NTH1, 
bind tightly to the created AP site to protect it and the strand break until the recruitment of 
APE1 to the damage site (Donley et al., 2015). Consequently, APE1 displaces the DNA 
glycosylase and activates BER downstream effectors such as polymerases, ligases and 
XRCC1. APE1 also interacts with XRCC1 during processing of AP sites in order to 
accelerate the repair process and prevent formation of 5’ blocking lesions (dirty ends), which 
could be cytotoxic (Vidal et al., 2001). Furthermore, APE1 recruitments polymerase β to the 
AP site in order to accelerate excision of 5′-dRP residues (Bennett et al., 1997). 
 
Although BER is a conserved pathway that maintains genome stability through elimination of 
a number of alkylated, deaminated and oxidised bases, there is evidence that suggest 
redundancy in BER to safeguard DNA against cytotoxic and mutagenic lesions. For example, 
removal of a damaged base by the AP lyase function of bifunctional glycosylases such as 
OGG1 and NEIL-1, 2 creates a 3’PUA that can be processed via PNKP and repair proceeds 
via long-patch BER, therefore bypassing APE1 inhibition (Mokkapati et al., 2004; 
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Wiederhold et al., 2004). Loss of APE1 function could also be compensated by APE2, which 
exhibits strong 3’-5’ exonuclease and 3’phosphodiesterase activities and weak AP 
endonuclease activity (Tsuchimoto et al., 2001; Burkovics et al., 2006; Burkovics et al., 
2009). The status of mismatch DNA repair (MMR) and O6-methylguanine-DNA 
methyltransferase (MGMT) could also backup BER and limit DNA damage if BER is 
disabled. For example, temozolomide (TMZ), a methylating agent, induce O6-methylguanine, 
N3-methyladenine and N7-methylguanine DNA adducts that are collectively repaired by 
MGMT and BER. Specifically, N3-methyladenine and N7-methylguanine DNA adducts are 
removed and processed by BER and considered relatively inert or weakly pro-cytotoxic 
(Fronza and Gold, 2004; Shrivastav et al., 2010; Wirtz et al., 2010). O6-methylguanine 
lesions are rapidly removed by MGMT, but if unrepaired, these can become mismatched with 
thymine during DNA replication. Inefficient removal of mismatched bases leads to the 
accumulation of DNA stand breaks and induction of apoptosis (Zhang et al., 2012). 
Therefore, TMZ-induced DNA adducts are largely removed and excised by MGMT and their 
cytotoxicity is primarily dependant on the MMR status of the cell. MMR can also backup 
BER in removal of mismatch bases such as 5-fluorouracil:G and U:G, which are 
predominantly removed by BER (Fischer et al., 2007; Schanz et al., 2009).” 
 
Redox/transcriptional regulation function of APE1 
In addition to the DNA repair function of APE1, it also functions as a reduction/oxidation 
signalling protein and is therefore referred to as redox effector factor 1 (REF-1). APE1 
reduces functional cysteine (Cys) domains situated in the DNA binding sites of a number of 
transcription factors such as NF-кB, AP-1, Egr-1, HIF-1α, P53 and other transcription factors 
(Bhakat et al., 2009). The exact mechanism by which APE1 reduces and interacts with 
transcription factors has not been fully elucidated. However, there are two functional Cys 
residues (Cys65 and Cys93) implicated in APE1 redox function (Luo et al., 2012). Cys65 is a 
buried residue located in the N-terminus on the first beta strand in the fold of a beta sheet in 
the protein core (Figure 1.3B) (Kelly et al., 2012). Cys93 is also buried inside the protein 
core, but in the opposite beta sheet to that where Cys65 lies (Figure 1.3B)  (Luo et al., 2012). 
It is thought that the redox function is mediated through a thiol-mediated redox reaction (Luo 
et al., 2012). This occurs through interaction of Cys65 on APE1 with the functional Cys 
residues on the target transcription factor to form mixed disulphide bonds which are then 
attacked and resolved by Cys93 (Luo et al., 2012). The formation of a disulphide bond in 
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APE1 means that it becomes oxidized and the target transcription factor becomes reduced 
(Luo et al., 2012).
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Abbreviation Full name Damaged base type Description 
AAG/MPG 
Alkyl adenine 
DNA glycosylase/ 
Methyl purine 
DNA glycosylase 
Alkylated base 
Mono-functional 
glycosylases, i.e. they 
excise the damaged base 
only. 
UNG  
Uracil DNA 
glycosylase  
Deaminated 
base  
TDG  
Thymine DNA 
glycosylase  
Deaminated 
base  
MBD4  
Methyl-CpG-
binding domain 4  
Deaminated 
base  
OGG1  
8-oxo-guanine 
glycosylase 1  
Oxidized base  
Bi-functional 
glycosylases, i.e. they 
excise the damaged base/s 
and have AP lyase activity. 
MYH  MutY homolog  Oxidized base  
NTH1  
Endonuclease 
three homolog 1  
Oxidized base  
NEIL1  
Nei endonuclease 
VIII-like 1  
Oxidized base  
NEIL2  
Nei endonuclease 
VIII-like 2  
Oxidized base  
NEIL3  
Nei endonuclease 
VIII-like 3  
Oxidized base  
 
Table 1.5: List of DNA glycosylases involved in base excision repair pathway. 
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Figure 1.4: Overview of base excision repair (BER) pathway. 
First step in BER begins with recognition of DNA damage and excising damaged base by 
DNA glycosylases. BER process the DNA damage via short or long patch sub-pathways 
depending on the type and cause of damage as well as the glycosylases involved. Removal of 
damaged bases result in creating AP site in the DNA backbone. In short patch BER, APE1 is 
recruited to processes the resulting AP site by creating a 5’ incision in the phosphodiester 
backbone of the DNA. This incision generates hydroxyl group (OH) at 3’ end and deoxy 
ribose phosphate (dRP) or phosphate group at the 5’. This followed by recruiting polymerase 
β to the site of damage to fill the correct base followed by sealing the gap by XRCC1 and 
ligase III. If the damaged base is removed by AP lyase activity of DNA glycosylase, this will 
create phosphor-α,β-unsaturated aldehyde (PUA) at the 3’ end which processed by 
phosphodiesterase activity of A|PE1 followed by filling the gap by polymerase β and sealing 
the DNA backbone by XRCC1 and ligase III via short patch BER. In long patch pathway, 
bifunctional glycosylases creates a blocking 3’ phosphate (PO4), which resists DNA 
polymerase mediated repair and requires further processing by polynucleotide 
kinase/phosphatase (PNKP). The process of DNA repair continue through polymerase β, ε 
and δ, PCNA and FEN1 which displace strand of 3-8 bases and synthesise a new strand. DNA 
ligase I completes the repair process by sealing the DNA nick.
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DNA repair and redox functions are completely independent from each other and inhibiting or 
interrupting one function does not affect the other (Bapat et al., 2009). This is because each 
function is encoded by different structural domains of APE1. The repair function is encoded 
by C-terminal while the redox function is performed by the N-terminal region of the protein 
(Bapat et al., 2009).  
Recent studies have revealed that targeting the redox activity of APE1 (but not repair activity) 
using small molecule inhibitors or by introducing an inactivating mutation, hyper-sensitises 
tumour cells to alkylating agents and radiotherapy (Kelley et al., 2012). Targeting this 
function is thought to inhibit the interaction between APE1 and transcription factors involved 
in driving tumour growth, angiogenesis and proliferation of malignant cells (Kelley et al., 
2012). As such, inhibiting the redox function of APE1 has become a potentially attractive 
target for the development anticancer drugs.  
 
Other APE1 functions 
The DNA repair and redox functions are not the only important functions of APE1. Recent 
studies have revealed unexpected novel function of APE1. For example, APE1 has an RNA 
quality control function mediated through interaction with nucleophosmin 1 (NPM1) 
(Vascotto et al., 2009b) and exerts endoribonuclease activity on c-MYC mRNA (Barnes et 
al., 2009; Kim et al., 2010; Kim et al., 2011).  
NPM1 is one of the hub proteins located in the nucleolus and is a multifunctional protein 
involved in ribosomal protein assembly and transport, control of centrosome duplication, and 
regulation of the tumour suppressor ARF (Falini and Martelli, 2011). The mechanism by 
which NPM1 interacts with APE1 is unclear, but it is thought that NPM1 directly binds to the 
N-terminus of APE1 and inhibits its binding to RNA (Tell et al., 2010b). In addition, NPM1 
binds rRNA and prevents it from binding to APE1. Oxidative stress is thought to decrease the 
binding affinity of NPM1 for both APE1 and rRNA, which releases APE1 to exert its RNA 
function (Tell et al., 2010b). Consequently, after AP site cleavage, the resulting RNA 
fragments are degraded via the activity of an exosome complex and exoribonuclease 1 
(XRN1) (Tell et al., 2010b). Although NPM1 mutation in AML confers relatively favourable 
prognosis, this mutation might not affect APE1 functions as a recent study demonstrated that 
the endonuclease activity of APE1 is consistent regardless of the presence or absence NPM1 
mutation (Vascotto et al., 2013).  
APE1 also possesses a second RNA function, and displays endoribonuclease activity on c-
MYC proto-oncogene mRNA (Barnes et al., 2009; Kim et al., 2010; Kim et al., 2011). 
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Investigations have demonstrated that APE1 has endoribonuclease activity by cleaving 
specific regions of c-MYC mRNA (Kim et al., 2011). The endoribonuclease activity of APE1 
occurs in the absence of Mg+2 ions, which are crucial in the DNA endonuclease function of 
APE1 (Kim et al., 2011). In vitro studies clearly demonstrate a role for APE1 in the 
regulation and stability of c-MYC mRNA; possibly through its endoribonuclease function 
(Barnes et al., 2009; Kim et al., 2010). Specifically, transient knockdown of APE1 in HeLa 
cells using siRNA leads to increased c-MYC mRNA level (2 to 5 fold) and an increase in 
transcript half-life (Barnes et al., 2009). However, the mechanism by which APE1 interacts 
and regulates mRNA expression is not yet understood.  
Dissecting the endoribonuclease function of APE1 has raised many questions surrounding its 
involvement in RNA metabolism. For example, if APE1 is able to regulate c-MYC gene 
expression, is it also able to regulate the expression of other genes, including those proteins 
involved in cancer promotion and progression. Although beyond the scope of this project, it 
might be useful to identify other targets for the endoribonuclease function of APE1, and 
whether targeting this activity of APE1 could be exploited for cancer therapy. 
As APE1 is developed as a target in cancer treatment, its functions have been investigated 
extensively in the literature. APE1 was identified as a transcriptional repressor via its ability 
to bind to negative calcium repressing element and regulate parathyroid hormone gene 
expression and the human renin gene (Bhakat et al., 2003; Bhakat et al., 2009). APE1 also 
has been shown to interact with Y-box binding protein 1 (YB-1), leading to transcriptional 
activation of the multi-drug resistance gene 1 (MDR1) (Sengupta et al., 2011). APE1 also 
inhibits activation of PARP during repair of single strand breaks induced by oxidative stress 
(Peddi et al., 2006). Moreover, APE1 is involved in natural killer cell mediated cell 
cytotoxicity by interaction with granzymes A and K (Guo et al., 2008).  
 
1.2.1.2. Role of APE1 in cancer 
Since APE1 is essential for normal cellular functions, its role has been explored in cancer and 
other human diseases, such as neurodegenerative diseases and cardiovascular diseases (Jeon 
et al., 2004; Gencer et al., 2012; Maynard et al., 2015). The importance of APE1 is 
highlighted by its ability to modulate DNA repair via BER and its redox transcriptional 
regulation of several pathways that are involved in homeostasis of normal cells and survival 
of cancer cells. Consistent with this, several biological and aetiological studies provide 
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evidence that APE1 is dysregulated during cancer progression, and that chemotherapy 
resistance is associated with elevated expression of APE1 in cancer cells.  
Although most studies have ascribed APE1 localisation predominantly to the nucleus, where 
it functions as an endonuclease in BER and as a redox regulator, some tissues shows 
cytoplasmic localisation or both nuclear and cytoplasmic localisation (Tell et al., 2005; Sheng 
et al., 2012; Vascotto et al., 2013). Particularly, the localisation of APE1 to the cytoplasm is 
reported in cell types displaying high metabolic activity such as hepatocytes, spermatocytes 
and lymphocytes (Tell et al., 2005). Furthermore, APE1 localisation to the cytoplasm has 
been well documented in many cancers and correlates with poor prognosis (Di Maso et al., 
2007; Sheng et al., 2012; Sudhakar et al., 2014), highlighting the importance of APE1 extra-
nuclear functions.  
Anti-cancer agents predominantly function by damaging the DNA and targeting signalling 
pathways that otherwise promote cancer cell survival. As such, the efficacy of such agents 
could be reduced in cells with functional APE1-mediated DNA repair and redox regulation. 
Therefore, APE1 could be a potential predictive marker for response to therapy and disease 
progression. Consistent with this hypothesis, APE1 overexpression was significantly 
associated with poor prognosis in breast cancer (Woo et al., 2014). Furthermore, APE1 
expression was also correlated with poor overall survival of patients with ovarian cancer, and 
may predict platinum resistance (Al-Attar et al., 2010). Conversely, low APE1 expression can 
be a potential prognostic marker and sign of aggressive disease as demonstrated in oestrogen 
receptor positive breast cancer (Abdel-Fatah et al., 2014).  
 
1.2.1.3. APE1 genetic polymorphism and susceptibility to cancer 
APE1 is a multifunctional protein and responsible for maintaining genomic stability. As such, 
any DNA sequence polymorphism could impact on protein function, may increase cancer risk 
and also be prognostic. The most frequently reported APE1 polymorphism is an amino acid 
substitution from aspartic acid to glutamic acid in the position 148 (Asp148Glu), encoded by 
a polymorphism in exon 5 (Karahalil et al., 2012). It is carried by approximately 46% of 
western Europeans (Wallace et al., 2012). Although this polymorphism does not appear to 
affect the DNA endonuclease function of APE1, it is thought to confer hypersensitivity to 
radiation and an increased susceptibility to cancer (Wallace et al., 2012). However, reports 
about the Asp148Glu variant are inconsistent; Wang and colleagues report an association 
between Asp148Glu and risk of bladder cancer, while another study reported no significant 
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association with susceptibility to bladder cancer (Liu et al., 2013). Other polymorphisms 
include Gln51His, Ile64Val, Leu104Arg, Glu126Asp, Arg237Ala and Asp283Gly (Fishel and 
Kelley, 2007; Wallace et al., 2012). The latter four polymorphisms are rare and are associated 
with reduced DNA endonuclease activity (Hadi et al., 2000), although further work is 
required to determine whether they affect risk of cancer in humans. 
Genetic polymorphisms in DNA genes may influence leukaemia susceptibility and/or 
treatment outcome. Genetic polymorphisms in DNA repair gene such as XRCC1 and XPD has 
been linked to leukaemia risk and treatment outcome (Allan et al., 2004; Bănescu et al., 
2014). Relatively few studies have investigated associations between genetic variations in 
APE1 and the risk of developing leukaemia or prognosis. Kuptsova and colleagues 
investigated APE1 variants, including Asp148Glu, in primary samples from AML patients, 
and found no effect on DNA repair capacity. In addition, another study found no significant 
associations between the Asp148Glu APE1 variant and event-free survival 320 paediatric 
patients with acute lymphoblastic leukaemia (Krajinovic et al., 2002). However, a study 
investigated 105 Chinese children with AML found that the Asp148Glu APE1 polymorphism 
was associated with increased risk of leukaemia in children exposed to X-ray radiation (Zhu 
et al., 2008).  
Additional studies are essential to clarify the relationship between DNA repair variants and 
leukaemia. Specifically, larger studies are needed in order to clarify the role of these 
polymorphisms as determinants of susceptibility to cancer and prognosis. 
  
1.2.1.4. APE1 inhibitors 
APE1 is essential for maintenance of genomic stability and cell survival, and plays a key role 
in responding to DNA damage under oxidative stress. Even in conditions when exogenous 
DNA damage is very low, silencing APE1 using RNA interference was enough to decrease 
cell proliferation, and led to an accumulation of unrepaired cytotoxic AP sites and increased 
apoptosis (Fung and Demple, 2005). Additionally, increased APE1 expression has been 
linked with cancer chemotherapy resistance (Bapat et al., 2009). Taken together, these data 
strongly suggest that targeting APE1 is an attractive strategy for the development of novel 
cancer treatments. This strategy has been intensively investigated in the last few years. For 
example, reducing APE1 protein levels using RNA interfering techniques or inhibition of its 
functions using specific inhibitors, sensitised cancer cells to radiotherapy and 
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chemotherapeutic agents such as temozolomide (TMZ), methylmethane sulfonate (MMS) and 
bleomycin (Bapat et al., 2009). 
Given the importance of APE1 in both normal and malignant cell function, there is a clear 
need to identify APE1 inhibitors specific to just one of its many functions. In addition, there is 
also a need to develop specific APE1 inhibitors with no off-target effects and which are 
effective in the low micromolar (µM) or nanomolar (nM) concentration range. Recent studies 
have identified a number of promising compounds thought to specifically inhibit APE1 in the 
low µM concentration range, but these need further validation, characterisation and 
optimization before moving forward to clinical use (Al-Safi et al., 2012; Rai et al., 2012; 
Srinivasan et al., 2012; Raia et al., 2013). Furthermore, inhibitors against specific functions of 
APE1 would help to identify which are critical for cancer promotion or chemotherapy 
resistance, as well as identifying which functions might be suitable targets for cancer therapy, 
i.e. targeting DNA repair or redox function.  
Currently, there are two categories of APE1 inhibitors, including DNA repair inhibitors and 
redox functions inhibitors. Of these, the best studied include DNA repair inhibitors 
methoxyamine, lucanthone and CRT0044876, and redox function inhibitors E3330, gossypol, 
soy isoflavones and resveratrol.  
 
1.2.1.4.1. APE1 DNA repair inhibitors  
Methoxyamine 
Methoxyamine (MX) (see Figure 1.5 for chemical structure) is an indirect inhibitor of the 
DNA repair function of APE1 (Wilson and Simeonov, 2010), which irreversibly binds to AP 
sites in damaged DNA and blocks APE1 from binding, and thus interrupts BER (Liu and 
Gerson, 2004; Wilson and Simeonov, 2010). MX reacts with the aldehyde group within the 
AP site that results in the formation of an intermediate adduct refractory to APE1 lyase 
activity (Figure 1.6) (Rosa et al., 1991; Liu and Gerson, 2004). AP site binding by 
methoxyamine leads to an accumulation of AP sites, increasing DNA damage as well as 
generation of cytotoxic single DNA strand breaks. Preclinical studies revealed that 
methoxyamine potentiates fludarabine cytotoxicity in HL60 AML cells, primary CLL 
leukaemia cells and HL-60 xenograft mouse model (Bulgar et al., 2010). Currently, MX in 
combination with fludarabine is in phase I trials to treat patient with relapsed or refractory 
haematological malignancies such as chronic myeloid/lymphoid leukaemia and Hodgkin/non-
Hodgkin lymphoma (clinicaltrials.gov). Methoxyamine is also in phase 1 trials in 
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combination with TMZ to treated patient with advanced solid tumours (clinicaltrials.gov). 
However, MX may have limited clinical utility because it is required in high concentrations, 
depending on cell type, in order to potentiate cytotoxicity when combined with alkylating 
agents.  
 
 
Figure 1.5: Chemical structure of common APE1 inhibitors 
 
 
 
 
Figure 1.6: MX interaction with AP site (adapted from (Zhu et al., 2012))
AP site Methoxyamine (MX) AP site-MX complex 
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APE1 inhibitor III (APE1- III) 
The development of APE1 inhibitors for use in the clinic is reliant on understanding the 
mechanism of action by which they operate (Luo et al., 2008; Tell et al., 2009). Initially, 
however, the identification of compounds with APE1 inhibitory activity requires the use of 
high-throughput screening approaches. First attempt to identify APE1 inhibitors was 
developed and adapted by Madhusudan and colleagues, 2005. This technique is a 
fluorescence-based assay using purified APE1 and an artificial abasic DNA substrate; 
tetrahydrofuran (Madhusudan et al., 2005). However, this approach was utilised to identify 
specific APE1 inhibitor in about 352,498 compounds, which resulted in the identification of a 
potential APE1 inhibitor III molecule (Rai et al., 2012). APE1 inhibitor III (N-(3-
(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)acetamide) 
(APE1-III) (Figure 1.5) and its analogue displayed low µM APE1 inhibition, which resulted 
in significant accumulation of AP sites in treated cells, and potentiation of a number of 
chemotherapeutic agents. This compound demonstrated a low inhibitory concentration 50% 
(IC50) of 2 µM for the endonuclease function of APE1 in whole cell extract and recombinant 
protein (Rai et al, 2012), which was confirmed in an independent study (Poletto et al., 2015). 
The pharmacokinetic features of the APE1-III and its analogue (compound 52) was promising 
with a good cytotoxicity profile. APE1-III crossed the blood-brain barrier more efficiently 
compared to compound 52, but achieved lower maximum plasma levels, and a shorter half-
life time in plasma in a mouse model. However, there has been no further development of 
these compounds and they have not yet entered clinical trial.  
MEF fibroblast cells either wild-type (NPM1+/+) or null (NPM1−/−) for nucleophosmin were 
treated with APE1-III inhibitor and MX as single agents, to determine the role of NPM1 
expression in sensitivity to APE1 inhibition (Vascotto et al., 2013). NPM1−/− cells were 
significantly more sensitive to both inhibitors, compared to NPM1+/+ cells. Similarly, APE1-
III demonstrated promising results in a synthetic lethality screen when used to treat PTEN 
deficient melanoma cell lines (Abbotts et al., 2014). PTEN deficient cells were hypersensitive 
to APE1 inhibition using APE1-III and other APE1 inhibitors (Abbotts et al., 2014). 
Moreover, APE1-III significantly increased the accumulation of uncleaved AP sites, γH2A 
foci phosphorylation, and induced apoptosis.  
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Other Inhibitors 
CRT00044876 or 7-nitro-indol-2-carboxylic acid (NCA) (Figure 1.5) is a first generation 
APE1 endonuclease specific inhibitor. It was described by Madhusudan et al., (2005) as an 
inhibitor of APE1 endonuclease activity and shown to potentiate the cytotoxicity of a number 
of DNA damaging agents including methyl methanesulfonate, temozolomide, H2O2 and 
Zeocin at a non-cytotoxic dose (200 µM), when administered as a single agent. Additionally, 
the authors reported that CRT0044876 did not alter the cytotoxicity of agents that induce 
DNA lesions not commonly repaired by BER, suggesting that CRT0044876 acts specifically 
through inhibition of APE1 endonuclease function. More recent studies demonstrate 
phosphorylation of H2AX and accumulation of AP sites following APE1 inhibition using 
CRT00044876 (Hong et al., 2016). However, several studies failed to demonstrate APE1 
inhibition using this compound, raising questions about the effectiveness of this compound 
(Fishel and Kelley, 2007; Simeonov et al., 2009; Naidu et al., 2010).  
Lucanthone was first recognised as an anti-Schistosoma treatment and also as a topoisomerase 
II inhibitor (Fishel and Kelley, 2007). The molecular structure of luchanthone is more 
complex than MX. It has also been found to inhibit RNA synthesis as well as APE1 DNA 
endonuclease activity (Naidu et al., 2011). Recent studies have demonstrated that lucanthone 
cleaves and degrades APE1 at low µM concentrations (50 – 100 µM) (Naidu et al., 2011). 
Breast cancer cell lines treated with lucanthone exhibited significant AP site accumulation in 
a dose dependant manner, suggesting inhibition of the DNA repair function of APE1 (Mendez 
et al., 2002). Another study found that lucanthone inhibits DNA repair activity and potentiates 
the cytotoxicity of alkylating agents TMZ and MMS in the MDA-MB231 breast cancer cell 
line (Luo and Kelley, 2004). However, it remains to be determined whether these 
observations are because of anti-APE1 activity or anti-topoisomerase activity. Therefore, 
more studies are required in order to elucidate the exact mechanism by which lucanthone acts 
on cancer cells. 
There is considerable effort being applied to the search for APE1 inhibitors capable of 
targeting specific APE1 functions without off-target effects at low µM concentrations. Recent 
reports have revealed a new novel APE1 inhibitor, ML199, which was found to specifically 
inhibit APE1 in the low µM dose range (Raia et al., 2013). This agent also potentiates MMS 
at non-toxic doses in HeLa cells (Raia et al., 2013). However, there are other APE1 inhibitors 
reported in the literature, including reactive blue 2, myricetin, arylstibonic acid, 
aurintricarboxylic acid and other molecules (Wilson and Simeonov, 2010; Mohammed et al., 
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2011; Al-Safi et al., 2012; Srinivasan et al., 2012; Feng et al., 2015). Further work is required 
to characterise these agents and the mechanisms of their interaction with APE1.  
 
1.2.1.4.2. Redox function Inhibitors 
E3330 
APE1 redox inhibitors are limited, and are available for preclinical use only. Efforts aimed at 
the identification of redox inhibitors are restricted by the lack of appropriate high throughput 
screening approaches to identify molecules that inhibit the redox function of APE1 (Li and 
Wilson, 2014). The first APE1 redox inhibitor, E3330, was identified as an inhibitor for TNF-
α secretion from monocytes and macrophages, and exhibited anti-inflammatory properties 
when used to treat hepatitis (Miyamoto et al., 1992; Nagakawa et al., 1992; Goto et al., 
1996).  
E-3-[2-(5,6-dimethoxy-3-methyl-1,4-benzoquinonyl)]-2-nonylpropenoic acid (E3330) (Figure 
1.5) is a potential specific APE1 redox activity inhibitor. It interferes with the interaction 
between APE1 and target transcription factors involved in cancer promotion, such as NF-кB, 
AP-1 (Fos/Jun), HIF-1α and other downstream transcription factors (Kelley et al., 2012). 
E3330 also blocks retinal angiogenesis in vivo as well as functioning in vitro by blocking 
APE1 redox transcriptional activity (Jiang et al., 2011). Additionally, E3330 has been found 
to inhibit macrophage-mediated inflammatory responses through inhibition of APE1, which 
consequently suppresses the transcriptional activity of NF-кB and AP-1 (Jedinak et al., 2011). 
Moreover, E3330 demonstrated inhibition of STAT3 as well as APE1 transcriptional activity 
in pancreatic cancer cells which inhibited their proliferation and migration (Cardoso et al., 
2012). Recent studies have also revealed that high concentrations of E3330 (> 100 µM) also 
inhibit the DNA endonuclease activity of APE1 (Zhang et al., 2013), suggesting that this 
agent is not a specific inhibitor of APE1 redox function. The same authors also derived a 
novel compound from this inhibitor by replacing the carboxyl group on E3330 with an amide 
group, resulting in a compound (E3330 amide) capable of specifically inhibiting APE1 redox 
function at lower concentration relative to E3330 (Zhang et al., 2013). Recently, several 
analogues of E3330 (RN8-51, RN10-52, and RN7-60) were identified using global mass 
spectrometric analysis with lower IC50 against ovarian cell lines relative to E3330.  
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1.2.1.4.3. Naturally occurring inhibitors 
There are a number of naturally occurring compounds reported to inhibit APE1 redox 
function, including soy isoflavons, gossypol, resveratrol, curcumin and ascorbate (Raffoul et 
al., 2012; Qian et al., 2014). Soy isoflavons inhibit APE1 endonuclease and redox functions, 
and sensitise prostate cancer cells and non-small-cell lung cancer cells to radiation, in a dose 
and time dependant manner (Raffoul et al., 2007; Singh-Gupta et al., 2011). The mechanism 
by which soy isoflavons inhibit APE1 is still largely unknown, but it is thought that soy 
isoflavons prevent APE1 from reducing NF-кB, leading to increased cellular sensitivity to 
radiation (Kelley et al., 2012).  
Gossypol is a naturally occurring BCL-2 homology 3–mimetic compound extracted from 
cotton seeds and tropical trees. It inhibits the BCL-2 (B-cell lymphoma 2) anti-apoptotic 
protein and interacts with caspases released from mitochondria during apoptosis induction 
(Qian et al., 2014). The inhibitory effect of gossypol on APE1 was identified following 
reports that BCL-2 directly interacts with APE1 through BCL-2 homology 3 domain (Zhao et 
al., 2008). Gossypol has been shown to inhibit APE1 redox and endonuclease function, and 
demonstrated antitumor activity in both in vivo and xenograft models (Qian et al., 2014). 
Phase III clinical trials are now ongoing to determine if gossypol could improve docetaxel and 
cisplatin in patients with non–small cell lung carcinoma with high levels of APE1 expression 
(clinicaltrials.gov website). 
 Resveratrol is another potential APE1 inhibitor, found in grapes, mulberries and other plants 
(Raffoul et al., 2012). Several epidemiology studies have reported that consumption of this 
agent protects against a number of cancers, including skin cancer, liver cancer, prostate cancer 
and others (Raffoul et al., 2012). It has been shown that resveratrol inhibits APE1 binding to 
AP1 in melanoma cells which sensitised to the alkylating agent dacarbazine. However, a 
recent study revealed that resveratrol protected rat brain neural cells from inflammation by 
increasing APE1 expression (Zaky et al., 2013). One explanation of this finding is that neural 
cells recognise APE1 inhibition caused by this compound and compensate for the deficiency 
by increasing transcription levels to maintain APE1 protein level.  
 
1.2.1.5. APE1 as a therapeutic target in AML 
APE1 is the key protein in the BER pathway and down-regulation/inhibition of this protein 
reduces DNA damage repair capacity and potentiate the cytotoxicity of alkylating agents. 
Overexpression of APE1 has also been reported in several malignancies, such as multiple 
myeloma, ovarian cancer, osteosarcoma and AML (Wang et al., 2004; Casorelli et al., 2006; 
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Abbotts and Madhusudan, 2010; Al-Attar et al., 2010; Xie et al., 2010). Although APE1 
targeting has been investigated extensively in other malignancies, the value of this approach 
has not yet been well established for AML. Nevertheless, the high levels of ROS reported in 
AML, and particularly poor prognosis AML, suggest that targeting APE1 could be of 
therapeutic value, owing to the involvement of APE1 in DNA repair and maintenance of 
genome stability. Consistent with this model, targeting the redox function of APE1 could also 
prove of therapeutic value in AML maintaining a balanced redox system, which is important 
for cellular homeostasis. 
It is becoming clear that epigenetic changes and chromosomal translocations in AML activate 
several signalling pathway, such as STAT3, PI3K and FLT3, which lead to increase ROS 
production and induce DNA damage response. Thus, activation of these pathways can induce 
a mutator phenotype leading to the acquisition of further mutations that can drive disease 
progression. ROS is normally generated in haematopoietic stem cell (HSC), predominantly as 
superoxide, to regulate its quiescence state (Hole et al., 2011). The level of ROS production 
and elimination is tightly regulated via complex pathways including oxidation/reduction 
reactions and enzymatic activities (Hole et al., 2011). Nevertheless, evidence of 
overproduction of ROS has been demonstrated in several pathological and cancer conditions 
such as atherosclerosis, rheumatoid arthritis, diabetes and leukaemia (Sallmyr et al., 2008b; 
Uttara et al., 2009).  
Focusing on AML, increased cellular stress caused by ROS production leads to the induction 
of oxidative DNA damage, double strand breaks, and triggering DNA repair. Any defect in 
the DNA repair pathways, particularly the BER and NHEJ pathways, leads to increased 
genomic instability and chromosomal translocations/deletions (Rassool et al., 2007; Sallmyr 
et al., 2008b; Esposito and So, 2014). Furthermore, ROS can modulate BER directly and 
indirectly, through oxidation/reduction of BER enzymes and through transcriptional 
dysregulation of genes that encode BER enzymes, respectively (Luo et al., 2010). This 
evidence suggests that targeting ROS and/or its regulatory mechanisms might be of 
therapeutic value in AML.  
This led to hypothesis that APE1 would be a potential target in AML treatment, owing to its 
function to maintain genome stability through DNA repair and redox regulation. This 
hypothesis is founded on two critical observations (Figure 1.7). AML cells rely on APE1 
DNA repair function, which repairs DNA damage caused by oxidative stress and 
chemotherapeutic agents. Therefore, APE1 inhibition can lead to accumulation of DNA 
damage and may trigger apoptosis to cancer cells. Secondly, APE1 inhibition would disrupt 
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transcription factors by which AML cells coordinate their survival prior to and following 
treatment. 
Some studies have begun to address the potential of APE1 targeting in human leukaemia. The 
use of methoxyamine in conjunction with fludarabine or manumycin was found to enhance 
cytotoxicity of these drugs in leukaemia cells (She et al., 2005; Bulgar et al., 2010). The 
authors demonstrated that methoxyamine inhibits APE1 endonuclease repair function and 
enhances the cytotoxicity of fludarabine by three fold compared to fludarabine alone in HL60 
AML cells and primary CLL leukaemia cells in vitro and in a mouse xenograft model (Bulgar 
et al., 2010). Furthermore, disruption of BER by methoxyamine enhances manumycin-
induced apoptosis in HL60 and U937 AML cell lines (She et al., 2005). Most recent studies 
have revealed that histone deacetylase inhibitors downregulate APE1. For example, vorinostat 
(a histone deacetylase inhibitor) downregulates APE1 expression in kasumi-1 AML cells and 
the authors concluded that this suggests a new strategy for APE1 inhibition (Petruccelli et al., 
2013). This inhibition might be explained by another study which showed that another histone 
deacetylase inhibitor (trichostatin) induces APE1 extracellular secretion from HEK293 cells 
(Choi et al., 2013), which could lead to decreased intracellular APE1 level. Although these 
studies clearly demonstrate the potential of APE1 inhibition as a therapeutic strategy in AML, 
more work is required to elucidate the role of this molecule in AML and further validate it as 
a therapeutic target.  
There are limited data regarding the use of the redox function inhibitor, such as E3330, in the 
context of leukaemia. Fishel et al (2010) investigated the effects of E3330 on retinoic acid-
induced differentiation in HL60 and PLB acute myeloid leukaemia cells. They found that 
combining E3330 with retinoic acid inhibited NF-кB reduction by APE1 and blocked DNA 
binding of APE1 to retinoic acid receptors, leading to increased apoptosis and growth arrest. 
They also found that single agent E3330 induced growth inhibition of HL60. However, 
further work is required to establish the inhibitory effects of this agent on leukaemia cells. 
However, it is essential to consider the importance of APE1 for normal cellular functions, and 
targeting this protein may trigger backup mechanisms to compensate for its deficiency and 
maintain cell viability. For example, targeting APE1 using E3330 redox function conferred 
protection phenotype driven by upregulation of NRF2 expression, which paly essential role in 
cellular protection against high oxidative stress (Fishel et al., 2015).  
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Figure 1.7: Proposed model of APE1 involvement in AML. 
AML cells are characterised by elevated reactive oxygen species (ROS) that modulate their 
differentiation, proliferation and self-renewal advantages. This occur via modulation 
oncogenes, transcription factors redox status an enzymes. APE1 may play an essential role in 
leukaemogenesis through preserving genome stability under oxidative stress and via redox 
regulation of transcript factors that enhance leukaemia progression. Therefore, targeting 
APE1 functions could increase the efficacy of AML treatment by increasing DNA damage, 
reducing cells proliferation and induction of apoptosis. 
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1.2.1.6.Synthetic lethality studies 
Cancer cells are dependent on multiple DNA repair pathways to maintain their survival and 
any deficiency in one repair pathway can trigger activation of alternative pathways to 
compensate for this deficiency and maintain cell survival. However, targeting activated 
alternative DNA repair pathways can lead to inhibition of cancer cells viability and sensitises 
them to apoptosis; this is what referred to synthetic lethality (Figure 1.8A). The concept of 
synthetic lethality in targeting DNA repair pathways was exploited following successful 
sensitisation of breast and ovarian cancers with mutations in BRCA1 or BRCA2 by inhibition 
of PARP-1. In this model, homologous recombination DNA repair is compromised in some 
breast and ovarian cancers due to mutation in BRCA1 or BRCA2. BRCA-deficient cells are 
dependent on PARP-1 which coordinates single strand break repair operated by BER pathway 
(Shaheen et al., 2011; Curtin and Szabo, 2013). PARP-1 inhibition selectively induces cell 
killing in BRCA-deficient cells through accumulation of double strand breaks resulting from 
unrepaired single strand breaks, which consequently causes collapse of replication forks 
during DNA synthesis (Figure 1.8B).  
The promising results with PARP inhibition in ovarian and breast cancer cells harbouring 
BRCA1/2 mutations led to attempts to exploit this approach in other cancers with defective 
DNA repair. APE1 is absolutely essential in BER and likely to be promising alternative target 
for synthetic lethality in cancer. APE1 inhibition was synthetic lethal in cancer cells 
harbouring mutation/deficiency in BRCA, ATM (ataxia telangiectasia mutated) and PTEN 
(phosphatase and tensin homolog) (Sultana et al., 2012; Abbotts et al., 2014). BRCA/ATM-
deficient Chinese hamster cell lines were more susceptible to APE1 inhibition compared to 
BRCA/ATM proficient cells (Sultana et al., 2012). Notably, APE1 inhibition led to 
significant accumulation of AP sites and double strand breaks, and induced cell cycle arrest at 
the G2/M phase. This evidence indicates that APE1 inhibition is responsible for synthetic 
lethality, similar to PARP inhibition, in a BRCA/ATM deficient background. However, 
further characterisation of APE1 synthetic lethality in other cancer models is required to 
confirm these findings.  
The same research team have conducted further investigation to explore the potential of APE1 
synthetic lethality in different cancer models (Abbotts et al., 2014). Firstly, it was noted that 
melanoma patients showing low PTEN and high APE1 mRNA expression have poor overall 
survival and relapse free survival. This led to questioning the relationship between PTEN and 
APE1. PTEN is transcriptionally regulated by APE1 redox function via EGR-1, and is 
involved in maintenance of genomic stability through regulation of RAD51 (Shen et al., 
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2007; Fantini et al., 2008). In addition, PTEN is important negative regulator of anti-apoptotic 
PI3K/AKT pathway. This study illustrated the utility of synthetic lethality approaches in 
melanoma treatment through inhibition of APE1, which may also apply in other cancer 
models. 
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Figure 1.8: Schematic representation of synthetic lethality principle in cancer. 
(A) Normal cells rely on multiple mechanisms/pathways (gene A and gene B) to maintain 
cells survival and preserve genome stability. In cancer cells, one of the pathways is inactive 
due to mutation (either gene A or gene B) and cells rely on the alternative pathway to support 
their survival. Exploiting this advantage in cancer cells by inhibition of the activated pathway 
can selectively drive cancer cells to apoptosis. (B) PARP-1 inhibition selectively induces cell 
killing in breast and ovarian cancer cells with BRCA1/2 germline mutation through 
accumulation of double strand breaks resulting from unrepaired single strand breaks. SSB; 
single strand breaks, DSB; double strand breaks.  
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1.2.2. Targeting 8-oxoguanine DNA glycosylase (OGG1) as a therapeutic target in AML 
1.2.2.1. OGG1 overview  
Targeting other BER components were explored for therapeutic purposes, specifically DNA 
glycosylases (Speina et al., 2005; Huang et al., 2009; Jacobs et al., 2013; Donley et al., 
2015). DNA glycosylases play essential role in early steps in BER by excising wide range of 
DNA lesions. OGG1 is a critical DNA glycosylase involved in the BER pathway (Figure 1.4– 
long patch pathway) where it catalyses removal of 8-hydroxyguanine (8-OHG), which is a 
pro-mutagenic damaged DNA base induced by oxidative stress. Unrepaired 8-OHG can lead 
to transversion of G:C to T:A by DNA polymerases during DNA replication (Boiteux and 
Radicella, 2000). OGG1 also catalyses removal of formamidopyrimidine DNA adducts 
generated following exposure to ionising radiation or free radicals (Hu et al., 2005a). 
Therefore, OGG1 is involved in preserving genome integrity and supressing tumorigenesis. 
Human OGG1 gene is located on chromosome 3p25-26, which is frequently lost or deleted in 
several tumours including lung, breast, colon, prostate tumours; that suggest loss of OGG1 
function and possible contribution to cancer progression (Boiteux and Radicella, 2000; Hardie 
et al., 2000). 
There are two major isoforms of OGG1 mRNA splice variants, including type 1 and type 2, 
based on their last exons (Boiteux and Radicella, 2000). OGG1 type 1 with exon 7 (variants 
1a and 1b), and OGG1 type 2 with exon 8 (variants 2a to 2e). Variants 1a and 2a are 
predominant in human cells and encode OGG1 1a and OGG1 2a proteins. Both OGG1 protein 
variants share the same N terminal structure of the protein, but however, OGG1 1a protein has 
a unique nuclear localisation signal on its C terminal structure, hence actively localised to the 
nucleus (Nishioka et al., 1999; Boiteux and Radicella, 2000). In contrast, OGG1 2a has 
mitochondrial localisation signal on the C terminal of the protein and exclusively localised to 
mitochondria (Boiteux and Radicella, 2000). 
OGG1 is bifunctional glycosylase enzyme; meaning that it excises specific damaged DNA 
base (referred as mono-functional activity) and also has the ability to create an incision 3’ to 
the AP site on the phosphodiester backbone of the DNA. OGG1 has AP lyase activity on 8-
oxoG:C and AP:C DNA (Bjoras et al., 1997). However, an AP site is created in the DNA 
backbone following removal of the damaged base. The AP site is either recognised and 
processed by the endonuclease function of APE1 to generate 5’-dRP and 3’-OH, or processed 
by the AP lyase of OGG1. AP lyase activity creates a polymerase blocking 3’-phospho-α-β-
unsaturated aldehyde at and a 5’ phosphate (Hill et al., 2001). The resultant product processed 
by the 3’-phosphodiesterase activity of APE1, followed by engagement of polymerase β to 
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incorporate the correct base occurs via the short patch BER pathway. The AP lyase activity is 
regulated and enhanced by APE1 (Saitoh et al., 2001; Sidorenko et al., 2007). 
Since BER consists of two distinct sub-pathways; short patch and long patch pathways 
(section 1.2.1.1), it is not yet known how or whether OGG1 activity influences the pathway 
by which BER is executed. However, XRCC1 is thought to modulate OGG1 activity by 
influencing it to perform as a mono-functional glycosylase then stabilising it following 
removal of damaged bases at AP sites until recruitment of APE1 (Melissa et al., 2013).  
 
1.2.2.2. OGG1 polymorphism  
Single nucleotide polymorphisms and mutations in OGG1 have been reported in a variety of 
cancer cases and linked to increased cancer risk, although their role has not yet been fully 
elucidated. The S326C variant (ref SNP ID: rs1052134) is one of the most commonly studied 
polymorphisms in human OGG1. It is caused by transversion of cytosine to guanine at 
nucleotide 1245, which results in substitution of serine with cysteine at codon 326 located in 
the C terminal domain of the protein (Simonelli et al., 2013). This variant has been linked to 
impaired OGG1 DNA repair activity (Kershaw and Hodges, 2012). 
A reported point mutation in OGG1 leads to functional loss of enzymatic activity in the KG-1 
AML cell line (Hyun et al., 2000). This mutation, encoded by a CGA to CAA base mutation, 
leads to substitution of arginine with glutamine at position 229. More recently, a 
polymorphism was reported in KG-1 which results from substitution of arginine with 
glutamine at position 229 (R229Q) (ref SNP ID: rs1805373) (Hill and Evans, 2007). Earlier 
studies reported that KG-1 AML cells harbouring Arg229Glu variant were more sensitive to 
radiation due to reduced OGG1 activity, accumulation of 8-oxoG lesions and activation of 
apoptosis (Hyun et al., 2002). However, it is important to highlight that possibly multiple 
factors (many of which are cancer-type dependent) can influence the sensitivity of cells to 
either DNA damaging agents or ionising radiation.  
Reports of statistical association between SNPs in OGG1 and leukaemia risk are inconsistent 
and inconclusive. For example, a study was performed on 99 AML patients to evaluate the 
influence of polymorphic variants in BER genes, found that OGG1 S326C variant had no 
significant correlation with cytogenetic group (Saitoh et al., 2013), although this study is 
statistically underpowered. Another study demonstrated that the OGG1 S326C variant may 
contribute to susceptibility to paediatric acute lymphocytic leukaemia (ALL) (Stanczyk et al., 
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2011). Presence of this particular variant in advanced myelodysplastic syndrome (MDS) was 
thought to contribute accumulation of 8-OxoG lesions and disease development (Jankowska 
et al., 2008).   
 
1.2.2.3. Role of OGG1 in leukaemia  
OGG1 expression is constitutively downregulated by the AML1-ETO fusion oncoprotein 
encoded by the t(8;21) chromosomal translocation in haematopoietic cells in AML patients 
(Liddiard et al., 2010; Forster et al., 2016). OGG1 expression down regulation in this AML 
sub-group may contribute to leukaemogenesis via reduction of DNA repair capacity and 
acquisition of cooperating mutations (Liddiard et al., 2010; Forster et al., 2016). A recent 
study confirmed that AML1-ETO fusion oncoprotein binds to the OGG1 gene promoter and 
negatively regulates transcription (Forster et al., 2016). This, leads to loss of OGG1 
expression and the acquisition of a mutator phenotype via the accumulation of G:C to T:A 
transversion mutation.  
Gene expression data from 174 patients representing the full range of FAB AML groups 
(except M3) recruited to MRC AML trials 10-15 was analysed to explore the prognostic value 
of OGG1 expression in AML (Liddiard et al., 2010). This study found that OGG1 was 
downregulated in AML patients with core binding factor (CBF) mutations, including inv(16) 
and t(8;21). Furthermore, high OGG1 expression was correlated with adverse cytogenetic 
patients group, who had significantly shorter overall survival with a higher risk of relapse. 
This study highlighted the importance of OGG1 as a valuable prognostic factor in a particular 
subset of AML patient, who may fail to respond to conventional chemotherapy. Hence, 
because high expression of OGG1 has prognostic value, it is possible that targeting OGG1 
could have clinical utility.  
 
1.2.2.4. OGG1 inhibitors 
Despite the fact that OGG1 is an essential enzyme for the maintenance of genome stability, 
and its dysregulation is associated with a number of cancers, there are few reports about 
specific small molecules inhibitors. Initial attempts to develop inhibitors to glycosylases 
involved in BER pathway, including OGG1, NEIL1 and NTH1, were disappointing (Jacobs et 
al., 2013). A high throughput screen that included 400,000 molecular from the Molecular 
Libraries Small Molecule Repository identified 4 potential purine analogues that exhibited 
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anti-glycosylases activity toward NEIL1, OGG1, and NTH1 with relatively equivalent 
potencies (Jacobs et al., 2013). However, the identified molecules were unselective and 
inhibit multiple DNA glycosylases with equivalent potencies. This is because several DNA 
lesions can be excised by more than one DNA glycosylase. Such redundancy may hamper 
efforts to find clinically efficacious inhibitors.  
Donley and colleagues recently identified 5 small hydrazide molecules that exhibit anti-
OGG1 activity. However, this study did not characterise the exact mechanism by which 
OGG1 glycosylase/lyase activity is inhibited, and this need further investigation. 
Nevertheless, the identified molecules did not show any inhibitory effect on OGG1 substrate 
interaction and had limited reactivity with DNA. The prevailing evidence suggests that these 
molecules function through inhibition of Schiff base formation during OGG1 catalysis 
(Donley et al., 2015). Schiff base is an important intermediate, and transient complex formed 
between glycosylases and AP site following removal of damaged base, and function as 
stabiliser for the enzyme until APE1 recruitment (Hill et al., 2001).  
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1.3. Hypothesis and Aims 
1.3.2. Hypothesis  
Inhibition of the repair and/or redox functions of APE1 or the glycosylase activity of OGG1 
will sensitise acute myeloid leukaemia cells to standard induction chemotherapy, improving 
the efficacy of these agents. 
 
1.3.3. Aims 
1. Generate AML cell lines with stable expression of shRNA constructs specifically 
targeting APE1/OGG1 using lentiviral transduction system. 
2. Determine the effect of APE1/OGG1 shRNA targeting on cell phenotype, including 
growth characteristics, clonogenicity and cell cycle. 
3. Determine the effects of APE1/OGG1 shRNA targeting on cellular sensitivity to 
standard induction chemotherapy used in AML, including temozolomide 
daunorubicin, cytarabine, etoposide, clofarabine and fludarabine. 
4. Determine the effect of APE1 small molecule inhibitors on AML cell phenotype as 
single agents, including growth characteristics, clonogenicity, cell cycle, AP site 
accumulation and gene expression. 
5. Determine the effect of APE1 inhibition using small molecule inhibitors on cellular 
sensitivity to standard induction chemotherapy used in AML, including 
temozolomide, daunorubicin, cytarabine, etoposide, clofarabine and fludarabine. 
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Chapter 2. Materials and Methods 
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2.1. AML cell lines 
All acute myeloid leukaemia (AML) cell lines used in this work are detailed in  
Table 2.1, along with their corresponding media and morphology. All AML cell lines used in 
this project were originally purchase from Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures, (DSMZ, Germany) and kept in liquid nitrogen. Specific 
features of each cell line are described in detail in the relevant results chapters.  
 
2.2. Chemicals and Reagents 
All chemical and reagents used were Analar grade and were purchased from Sigma Aldrich 
Co LTD (Dorset – UK) unless otherwise stated. Phosphate buffered saline (PBS) was 
prepared from PBS tablets (Life technologies – Paisley – UK). Each tablet was dissolved in 
500 ml of deionised distilled water and autoclaved prior to use. All other chemicals and 
reagents prepared for use in specific experiments are described in this chapter in relevant 
sections below.  
 
2.3. General Cell Culture Methods 
2.3.1. Routine Cell Culture 
Fetal bovine serum (FBS) supplement for cell culture media was purchased from Gibco, 
Thermo Fisher scientific. Tissue culture RPMI media (Roswell Park Memorial Institute 1640) 
and reagents were purchased from Sigma Aldrich Co Ltd (Dorset – UK). Tissue culture 
plasticware was from Corning and Costar (VWR International Ltd., Leicestershire, UK). All 
tissue culture work was performed in a class II microbiological safety cabinet (BIOMAT-2, 
Medical Air Technology Ltd., Oldham, UK). All cell lines were routinely maintained in 
suspension in 10 ml of RPMI media supplemented with 10-20 % (V/V) of FBS, 50 µg/ml 
Penicillin/streptomycin in T25 sterile tissue culture flasks. Cultures were incubated at 37 °C 
in a humidified 5% CO2 incubator (Heraeus Equipment Ltd., Essex, UK).  
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Cell line Description TP53 and MGMT status 
HL-60 
 Acute 
Promyelocytic 
leukaemia cells (M2 
FAB classification).  
- Proficient MGMT gene expression *  
- TP53 gene deletion (Wolf and Rotter, 1985) 
U937  Promonocytic leukaemia M4 
- Absent MGMT gene expression *  
- TP53 deletion (46 base deletion ending 
exactly at the 3' end of exon 5) (Sugimoto et 
al., 1992)  
THP-1 
 AML M5 with 
t(9;11)(p21;q23) and 
MLL-AF9 fusion 
gene.  
- TP53 deletion (Sugimoto et al., 1992) 
NB4 
 AML M3 with 
t(15;17)(q22;q11) 
and PML-RARα 
fusion gene 
- Proficient MGMT gene expression * 
- TP53 missense mutation (Kojima et al., 
2005) 
MV4-11 
 AML M5 with 
t(4;11)(q21;q23) and 
MLL-AF4 fusion 
gene  
- TP53 point mutations at codon 344 exon 9 
(Fleckenstein et al., 2002) 
OCI-
AML2  AML M4 ‐ Proficient MGMT gene expression * 
OCI-
AML3 
 AML M4 with 
NPM1 mutation and 
hemizygous for RB1.
‐ Proficient MGMT gene expression * 
 
- TP53 wildtype (Kojima et al., 2005) 
Kasumi1 
 AML with t(8;21) 
and AML1-ETO 
fusion protein 
 
 
Table 2.1: List of AML cell used in this project. 
* Gene expression was determined by RT² PCR Array – Personal communication – Professor 
James Allan – Newcastle University.
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2.3.2. Cell Counting and determination of cell density 
All cell counting was performed using either a Neubauer haemocytometer (VWR 
international Ltd) and/or a TC20 automated cell counter (Bio-Rad Laboratories Ltd., 
Hertfordshire, UK). TC20 automated cell counter results were validated by comparing cell 
counts using a Neubauer haemocytometer prior to routine use. For quality purposes, a 
verification slide system was used to validate the cell counter every time the cell counter was 
turned on and prior to taking results. The verification slide system contains two sides (A and 
B) with a well-defined number of micro wells that could be recognised and counted by the 
cell counter. To perform a cell count, an aliquot of cell suspension was mixed with an equal 
volume of 0.4% Trypan blue solution (Sigma Aldrich Co Ltd. Dorset – UK) and 10 µl of the 
mixture was loaded onto a haemocytometer or a TC20 cell counter counting slide.   
 
2.3.3. Cryopreservation of Cells in Liquid Nitrogen 
After determination of cell count, an appropriate volume of cell suspension containing 5x106 
cells was dispensed into a sterile BD Falcon tube and centrifuged at 300 g for 5 minutes at 
room temperature. The supernatant was discarded and cells pellets were resuspended in 1 ml 
of freezing media consisting of FBS supplemented with 10% v/v Dimethyl sulfoxide 
(DMSO). Cells suspensions were transferred into sterile cell culture cryogenic tubes (Thermo 
scientific) and frozen slowly in Mr. Frosty™ Freezing Container (Thermo scientific) in a -
80 °C freezer, then transferred into liquid nitrogen for long term storage.  
 
2.3.4. Resuscitation of Frozen Cells 
Deeply frozen cryogenic tubes were brought out of liquid nitrogen and thawed quickly by 
incubation in warm water. Cells suspensions were transferred into sterile Falcon tubes 
containing 5 ml of pre-warmed culture media and centrifuged at 300 g for 5 minutes. The 
supernatant was completely removed and cells pellets were re-suspended in 5 ml of 
appropriate cell culture media, after which cell suspensions were transferred to T25 sterile 
culture flask and incubated at 37 °C in 5% CO2. Cell cultures were monitored daily for 
growth and were not used in any experiment until cells achieved exponential growth kinetics.  
 
61 
 
2.4. Gene Expression Analysis Using Quantitative Real-Time Polymerase Chain 
Reaction (RT-PCR) 
2.4.1. Preparation of Cell Pellets 
Five to seven million cells were dispensed into a sterile Falcon tube and centrifuged at room 
temperature for 5 minutes at 300 g. The supernatant was discarded and the cell pellet was 
washed in 5 ml of cold PBS. Cells were centrifuged at 300 g at room temperature for 5 
minutes. The supernatant was discarded and the cell pellet was resuspended in 1 ml of cold 
PBS and transferred to a sterile 1.5 ml eppendorf tube and centrifuged at 300 g at room 
temperature for 5 minutes. Supernatant was discarded and cell pellets were kept at -80 °C 
until required.  
 
2.4.2. RNA Extraction and Quantitation 
Total RNA was extracted from frozen cell pellets consisting of 7x106 cells using the RNeasy 
Mini Kit (Qiagen, Crawley, UK). Cells pellets were thawed on ice and RNA extracted 
following protocols provided by the manufacturer. Briefly, cells were lysed in lysis buffer 
supplemented by the manufacturer and homogenised using a 21 gauge needle. Lysed cells 
were transferred into an RNeasy mini spin column containing a silica gel membrane where 
RNA binds to the membrane and contaminants are removed using washing buffers provided 
in the kit. RNA was eluted in 50 µl nuclease-free deionised water and quantified using a 
NanoDrop® ND-1000 spectrophotometer (Thermo Scientific, DE, USA). NanoDrop® 
measures the absorbance at 260 nm, and performs the necessary calculations according to the 
Beer Lambert Law to provide an estimate of the RNA concentration. RNA samples were 
adjusted to a concentration of 200 ng/µl in 15 µl of nuclease-free distilled H2O and used in the 
next step of the reaction (section 2.4.3). Any remaining RNA was stored at -80 °C. 
 
2.4.3. Reverse Transcription of RNA into complementary DNA (cDNA) 
A High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Warrington, UK) 
was used to prepare cDNA. This kit utilises the random primer method for initiating reverse 
transcriptase mediated cDNA synthesis of RNA molecules present in the sample. Reverse 
transcriptase master mix was prepared according to manufacturer’s protocol as shown in 
Table 2.2 and 10 µl of the prepared master mix was dispensed into appropriate number of 0.2 
ml MicroAmp® Reaction Tubes (Applied Biosystems). In each well, 10 µl of 200 ng/µl total 
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RNA was added. A negative control was prepared using nuclease free water instead of RNA, 
to confirm that reagents were not contaminated. Reaction tubes were covered with a thick 
adhesive film to prevent overheating and evaporation of the reaction mixture. A GeneAmp® 
PCR System 9700 (Applied Biosystems) was used to perform single cycle cDNA 
amplification as follows: 
Step 1  25°C    10 min 
Step 2  37°C    120 min 
Step 3  85°C  5 seconds 
Step 4  4  °C  Hold 
 
This reaction yield 100 ng/µl cDNA which was then diluted to 5 ng/µl using nuclease free 
distilled H2O and stored at 4 °C until required. 
 
 
Reagent name Required volume 
RT Buffer (10x) 2 µl  
dNTP mix (100 mM) 0.8 µl 
RT Random Primers (10x) 2 µl  
MultiScribe® Reverse Transcriptase 1 µl  
RNase inhibitor 1 µl  
Nuclease-free H2O 3.2 µl  
Total volume per reaction 10 µl  
 
Table 2.2: Components of reverse transcriptase master mix used for cDNA synthesis. 
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2.4.4. Real-Time PCR Setup 
Inventoried and validated TaqMan® Gene Expression Assays for human APE1, OGG1 and β-
ACTIN were purchased form Applied Biosystems. Each assay contains oligonucleotide probe 
with fluorophore (FAM = 6-carboxyfluorescein) covalently attached to the 5’ end and a 
quencher (NFQ/MGB = non-fluorescent quencher/Minor groove binder) at the 3’ end. Assays 
were received as 20x concentrated stock, which was aliquoted to minimize freeze-thaw cycles 
and stored at -20 °C.  
An appropriate amount of TaqMan® Gene Expression Assay was mixed with TaqMan® 
Universal PCR Master Mix (Applied Biosystems), according to manufacturer protocols. 
Eleven microlitres of each master mix was dispensed into an appropriate number of wells of a 
96-well Optical PCR Plate (Applied Biosystems). Nine microlitres of 5 ng/µl cDNA was 
added to each well. A negative control was prepared using the negative control prepared in 
the previous section (2.4.3) to ensure that reagents used are not contaminated. Q-PCR 
reactions for each gene for each cell line and controls were set-up in quadruplicate. PCR 
plates were sealed appropriately, mixed gently using a plate shaker and placed in a 7300 Real 
time PCR system (Applied Biosystems).   
The RT-PCR system was programmed to cycle as follows: 
- 50 °C  2 minutes 
- 95 °C  10 minutes 
- 95 °C  15 second 
- 60 °C  1 minutes 
 
2.4.5. Data Analysis 
The 2-ΔΔCt method was used to quantify relative gene expression as described in Livak and 
Schmittgen, 2001. Briefly, cycle threshold (Ct) values for each reaction were obtained 
following fluorescence detection by the RT-PCR system and saved in a file compatible with 
SDS version 1.4 (Applied Biosystems) software. Ct values refer to the number of cycles 
required for the fluorescent signal to exceed background level. Data were copied into an excel 
data sheet and all calculations after this step were performed Microsoft excel. The means of 
quadruplicate Ct values were calculated for each gene in each cell line and used for 
quantification of gene expression. APE1 and OGG1 gene expression in each cell line was 
normalised to the β-ACTIN housekeeping gene. Normalised expression levels were compared 
40 cycles 
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to expression of APE1 and OGG1 in NB4 cell line. This result generated values representing 
fold change in expression for APE1 and OGG1. Gene expression data are displayed on a bar 
chart showing the mean fold change in gene expression for each AML cell line relative to 
expression in NB4 cells, and error bars shown are the standard error of the mean. Two 
independent experiments using 2 independent RNA/cDNA samples were performed to 
generated gene expression data.  
 
2.5. Generation of Stable APE1 Deficient AML Cell Lines Using Short Hairpin RNA 
(shRNA) Mediated Gene Knockdown 
Stable APE1 and OGG1 deficient subclones of AML cell lines were generated using short 
hairpin RNA (shRNA) mediated gene knockdown. This method uses lentiviral particle to 
carry shRNA constructs (Figure 2.1) into cells for incorporation into the host genome. A 
permanent blockage of the expression of the target genes occurs through expression of 
integrated constructs by RNA polymerase III which result in constitutive production of a 
shRNA molecule. ShRNA molecules are cleaved by DICER to generate a small interfering 
RNA (siRNA), which then becomes integrated in the active RNA Interference Specificity 
Complex (RISC). Integrated siRNA guides RISC to bind and degrade mRNA of the target 
gene.  
 
2.5.1. shRNA constructs, Control and Reagents 
Verified and prepacked MISSION® shRNA lentiviral constructs targeting APE1 (Table 2.3), 
OGG1 (Table 2.4) and empty pLKO.1 plasmid vector (off target control) were purchased 
from Sigma-Aldrich, UK. All lentiviral particles were received as frozen stocks, and aliquoted 
to avoid freezing/thaw cycles that may reduce functional viral titre. Hexadimethrine bromide 
stock was prepared by dissolving 800 μg hexadimethrine bromide in 1 ml sterile distilled H2O 
to yield 800 μg/ml stock. This stock solution was then sterilised by passage through a 0.2 μm 
filter (VWR International Ltd.) and stored at 4°C. 
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Figure 2.1: pLKO.1-puro Lentiviral TRC1.5 Vector Map 
PLKO.1-puro vector allow for transduction of the shRNA as packaged in lentiviral particle. 
The vector length is 7,086 bp including shRNA insert, and 7,052 bp without an shRNA insert. 
The pLKO.1 puro plasmid vectors carry a puromycin resistance (puroR) cassette which can 
be used as selection marker and to enable stable gene silencing. Figure adapted from 
www.sigmaaldrich.com  
 
 
Cppt: Central polypurine tract 
hPGK: Human phosphoglycerate kinase eukaryotic promoter 
puroR: Puromycin resistance gene for mammalian selection 
SIN/LTR: 3' self inactivating long terminal repeat 
f1 ori: f1 origin of replication 
ampR: Ampicillin resistance gene for bacterial selection 
pUC ori: pUC origin of replication 
5' LTR: 5' long terminal repeat 
Psi: RNA packaging signal 
RRE: Rev response element 
 
66 
 
 
 
 
 
C
lo
ne
 ID
 
C
lo
ne
 N
am
e 
Ve
ct
or
 
M
at
ch
 
R
eg
io
n 
Ta
rg
et
 S
eq
ue
nc
e 
T
R
C
N
00
00
00
79
58
 
(C
1)
 
N
M
_0
80
64
9.
1-
13
05
s1
c1
 
pL
K
O
.1
 
3U
TR
 
C
A
G
A
G
A
A
AT
C
TG
C
AT
TC
TA
TT
 
T
R
C
N
00
00
00
79
59
 
(C
2)
 
N
M
_0
80
64
9.
1-
60
9s
1c
1 
pL
K
O
.1
 
C
D
S 
G
C
C
TG
G
A
C
TC
TC
TC
AT
C
A
AT
A
 
T
R
C
N
00
00
00
79
61
 
(C
3)
 
N
M
_0
80
64
9.
1-
49
7s
1c
1 
pL
K
O
.1
 
C
D
S 
C
C
TG
G
AT
TA
A
G
A
A
G
A
A
A
G
G
AT
 
T
R
C
N
00
00
01
12
14
 
(C
4)
 
N
M
_0
80
64
9.
1-
74
0s
1c
1 
pL
K
O
.1
 
C
D
S 
G
C
C
G
G
G
TG
AT
TG
TG
G
C
TG
A
AT
 
T
R
C
N
00
00
34
26
86
 
(C
5)
 
N
M
_0
80
64
9.
1-
60
9s
21
c1
 
pL
K
O
_T
R
C
00
5 
C
D
S 
G
C
C
TG
G
A
C
TC
TC
TC
AT
C
A
AT
A
 
 
T
ab
le
 2
.3
: l
is
t o
f s
hR
N
A
 c
on
st
ru
ct
 u
se
d 
to
 k
no
ck
do
w
n 
A
PE
1 
in
 A
M
L
 c
el
ls
. 
 
67 
 
 
 
 
 
C
lo
ne
 ID
 
C
lo
ne
 N
am
e 
Ve
ct
or
 
M
at
ch
 
R
eg
io
n 
Ta
rg
et
 S
eq
ue
nc
e 
T
R
C
N
00
00
00
49
13
  
(G
1)
 
N
M
_0
02
54
2.
4-
15
55
s1
c1
 
pL
K
O
.1
 
C
D
S 
C
G
C
A
A
G
TA
C
TT
C
C
A
G
C
TA
G
AT
  
T
R
C
N
00
00
00
49
15
  
(G
2)
 
N
M
_0
02
54
2.
4-
17
71
s1
c1
 
pL
K
O
.1
 
C
D
S 
C
G
G
C
TC
AT
C
C
A
G
C
TT
G
AT
G
AT
 
T
R
C
N
00
00
00
49
16
 
(G
3)
 
N
M
_0
02
54
2.
4-
14
45
s1
c1
 
pL
K
O
.1
 
C
D
S 
C
G
G
AT
C
A
A
G
TA
TG
G
A
C
A
C
TG
A
 
T
R
C
N
00
00
31
46
72
 
(G
4)
 
N
M
_0
02
54
2.
5-
11
35
s2
1c
1 
pL
K
O
_T
R
C
00
5 
C
D
S 
TG
TG
C
C
C
G
TG
G
AT
G
TC
C
AT
AT
 
T
R
C
N
00
00
31
47
40
 
(G
5)
 
N
M
_0
02
54
2.
5-
84
8s
21
c1
 
pL
K
O
_T
R
C
00
5 
C
D
S 
C
G
G
C
TC
AT
C
C
A
G
C
TT
G
AT
G
AT
 
 
T
ab
le
 2
.4
: l
is
t o
f s
hR
N
A
 c
on
st
ru
ct
 u
se
d 
to
 k
no
ck
do
w
n 
O
G
G
1 
in
 A
M
L
 c
el
ls
. 
68 
 
2.5.2. Assessment of Puromycin Sensitivity and Hexadimethrine Bromide  
Puromycin is an antibiotic that inhibits protein synthesis and is toxic to eukaryotic cells. The 
pLKO.1 puro/ pLKO_TRC005 plasmid vectors used in this project carry a puromycin 
resistance cassette which can be used as selection marker; cells successfully transduced with 
shRNA are insensitive to puromycin. Assessment of puromycin sensitivity was performed to 
determine the minimum concentration of puromycin required to kill all non-transduced cells. 
Briefly, a cell suspension at a density of 2x104 cells/ml and in a final volume of 2 ml in 6 
wells plate was established. Cells were treated with escalating doses of puromycin including 
0, 2, 4, 6, 8 and 10 µg/ml. Cells were monitored microscopically and counted every 24 hours 
for 3 days.  
All cell lines tested in this project were dead after 3 days of treatment with 2 µg/ml 
puromycin. This was confirmed by morphological examination following microscopic 
examination and trypan blue exclusion. To confirm this as the optimal concentration, the 
assay was repeated but with lower puromycin; i.e. 0, 1 and 2 µg/ml puromycin. It was 
observed that 1 µg/ml puromycin reduced the viability of cells up to approximately 89%, but 
did not induce 100% cytotoxicity. Therefore, 2 µg/ml puromycin concentration was used as 
standard concentration for all shRNA selection media.  
 
2.5.3. Assessment of Hexadimethrine Bromide sensitivity 
Hexadimethrine bromide is used to enhance the transduction efficiency of mammalian cell 
lines. Some cells are sensitive to cytotoxicity induced by hexadimethrine bromide and it is 
important to examine this prior performing transduction. Sigma-Aldrich, the manufacturer of 
transduction shRNA constructs, recommended supplementing the transduction media with 8 
µg/ml hexadimethrine bromide.  
To assess the sensitivity of AML cells to hexadimethrine bromide, a cell suspension at a 
density of 2x104 cells/ml and in a final volume of 2 ml in 6 wells plate was established. Cells 
were treated with 8 µg/ml hexadimethrine bromide. Untreated control were setup in each plate 
and plates were incubated at 37 °C / 5% CO2 for 3 days. 
After 3 days, cell growth and viability were assessed microscopically and by counting cells 
using a haemocytometer and trypan blue dye exclusion. If cell growth and viability were not 
affected by 8 µg/ml of hexadimethrine bromide compared to untreated control, this 
concentration of hexadimethrine bromide was used in transductions.  
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2.5.4.  Lentiviral Transduction 
Exponentially growing cells were counted using a TC20 cell counter and seeded at a final 
density of 5x104 cell/ml in 10 ml of full media, supplemented with 8 µg/ml hexadimethrine 
bromide. A 1 ml aliquot of cell suspension was transferred into a sterile 15 ml Falcon tube 
and an appropriate volume of thawed shRNA lentiviral particles was added directly to the cell 
suspension. The required volume of lentiviral was calculated prior to use to give the required 
MOI as follows: 
ܸ݋݈ݑ݉݁	ݎ݁ݍݑ݅ݎ݁݀	ሺ݈݉ሻ ൌ ݎ݁ݍݑ݅ݎ݁݀	ܯܱܫ	ݔ	ݐ݋ݐ݈ܽ	݊ݑܾ݉݁ݎ	݋݂	݈݈ܿ݁ݏݒ݅ݎ݈ܽ	ݐ݅ݐ݁ݎ	ሺܷܶ/݈݉ሻ 	 
Viral titer is the concentration of viruses and expressed as titer unit/ml (TU/ml). Viral titer 
was supplied by the manufacturer for each lentiviral particles. MOI used = 2 in all shRNA 
knockdown experiments performed during this project, to minimise multiple integration of 
shRNA into the cell genome, and to reduce the probability of insertional mutagenesis.  
After the addition of the shRNA lentiviral particles, cells were centrifuged for 30 minutes at 
800 g at 32°C. Following centrifugation, the supernatant was carefully discarded and cells 
were resuspended in 2 ml of full media and transferred to a 6 well plate. Plates were incubated 
for 4 days in a humidified, 5% CO2 incubator at 37°C. Parallel with this experiment, the same 
procedure was performed for controls, but without adding lentiviral particles.  
 
2.5.5. Puromycin Selection of Transduced Cells 
After 4 days incubation, all lentiviral transduced cells and control cells were transferred into 
sterile universal tubes and centrifuged at 300 g to remove media. Cells were resuspended in 
fresh full media supplemented with 2 µg/ml puromycin, transferred to new 6 well plates and 
incubated for 3 days in humidified, 5% CO2 incubator at 37°C. Cells were monitored every 
day and media replaced every 3 days until they resumed exponential growth, which usually 
takes up to 3 weeks post-transduction. At this stage, all cell populations consist only of cells 
with shRNA construct integrated into their genome, while non-transduced cells were killed by 
puromycin selecting media.  
Following expansion of transduced populations, single cell subclones with stable target 
protein knockdown were generated by plating at low density in semi-solid soft agar 
(described later in section 2.8.2). 
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2.5.6. Assessment of Knockdown Efficiency 
The efficiency of APE1 and OGG1 knockdown was assessed by determining cellular protein 
levels using western blotting (described in section 2.6).  
 
2.5.7. Routine culture of knockdown cell lines 
All transduced cells were maintained in full media and passaged regularly as described in 
section 2.3. All transduced cells were passaged as required in full media supplemented with 2 
µg/ml puromycin. 
 
2.6. Western blotting 
Western blot analysis was performed to determine protein expression of APE1 and OGG1 and 
the expression of housekeeping genes α-tubulin and/or GAPDH. This technique involves a 
number of steps including extraction of cytosolic protein, separation of proteins depending on 
their size using electrophoresis, transfer of separated proteins onto a membrane and 
visualisation of proteins using specific antibodies. All reagents and solutions used in western 
blotting are described in detail in Table 2.5. 
2.6.1. Preparation of cell lysate 
A previously prepared frozen cell pellet (described in section 2.4.1) containing 5 million cells 
was thawed on ice and resuspended in 150 µl sodium dodecyl sulphate (SDS) sample buffer. 
The cells suspension was homogenised using a 21 gauge needle attached to a 1 ml syringe to 
disrupt and lyse the cells. The cell lysate was heated on at 100 °C for 5 minutes and 
centrifuged at 14,000 g for 10 minutes to precipitate cells debris. Protein concentration was 
determined using the Pierce BCA assay kit (described in section 2.6.2). 
After determination of protein concentration, this was adjusted to 1 mg/ml in a final volume 
of 0.5 ml. Briefly, 500 µg of protein was transferred to a 1.5 ml eppendorf tube and made up 
to 450 µl using SDS sample buffer. Then, β-mercaptoethanol was added to a final 
concentration of 20% v/v and bromophenol blue was added to a final concentration of 0.01% 
v/v. The resultant protein extract was aliquoted and stored at -20°C until required.  
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Reagent Description
SDS sample buffer 
Tris-HCl
SDS 
glycerol  
pH 6.8
62.5 M 
2% (w/v) 
20% (v/v)   
SDS electrode buffer 
Tris-HCl 
Glycine 
SDS 
pH 6.8
41.2 mM 
192 mM  
0.1% (w/v)  
transfer buffer 
CAPS-NaOH 
methanol 
pH 11 
10 mM  
10% (v/v)  
TBS/Tween  
(washing buffer) 
Tris-HCl 
NaCl,  
Tween-20  
pH 7.5
0.01 M  
0.1 M  
0.05% (v/v)  
Blocking buffer 
TBS-Tween 
Non-fat skimmed milk 
powder 
5% (w/v)  
 
Table 2.5: Buffer solutions used in western blotting. 
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2.6.2. Determination of protein concentration by Pierce BCA assay 
Protein concentration was determined using the Pierce® BCA Protein Assay Kit manufactured 
by Fisher Scientific UK Ltd Leicestershire, UK. The principle of this assay is based on 
colorimetric detection following reduction of copper cations (Cu+2 to Cu+1) by protein with 
bicinchoninic acid (BCA) in an alkaline medium. This results in the generation of a purple 
coloured complex with absorbance that can be measured at 562 nm and which is linearly 
related to protein concentration. The assay was performed according to manufacturer 
instructions which are summarised as follows: 
Samples were diluted in distilled water, i.e. 10 µl of each protein extract was diluted in 90 µl 
of distilled H2O. This step is crucial to bring the protein concentrations within the detection 
range of 0.2 to 1.2 mg/ml. Protein standards were prepared by diluting 2 mg/ml albumin 
standard provided with the kit using distilled H2O to a final concentration of 1.2, 1.0, 0.8, 0.6, 
0.4 and 0.2 mg/ml. For each standard and diluted extract, 10 µl was dispensed into a 96 well 
plate (VWR International Ltd) in quadruplicate. For blank wells, 10 µl of distilled H2O was 
added. Then, 190 µls of BCA working reagent was dispensed quickly into each well using a 
multichannel pipette and mixed gently using a plate shaker. The plate was then incubated at 
37°C for 30 minutes. 
Immediately after incubation, a Spectromax® 250 Microplate Spectrophotometer System 
(Molecular Devices Corporation, Crawley, UK) was used to read the absorbance at 570 nm. 
Protein concentrations were calculated from corrected mean absorbance values using 
Microsoft Excel, via generation of a standard curve using absorbance values of albumin 
standards. The standard curve was used to calculate protein concentration in each protein 
extract.  
 
2.6.3. SDS PAGE and electrophoretic transfer 
Separation of proteins was performed using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Bio-Rad 4–20% Mini-PROTEAN® TGX™ precast protein gels 
(Bio-Rad Laboratories Ltd., Hertfordshire, UK) were used for separation of proteins and were 
placed in a Mini-PROTEAN® Vertical Electrophoresis Cell system (Bio-Rad Laboratories 
Ltd., Hertfordshire, UK) filled with SDS electrode buffer. For each cell line, 15 µl of pre-
warmed protein extract (15 µg of protein) was loaded into each well. For every gel, 5 µl of 
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PageRuler™ pre-stained protein ladder was loaded into the last lane. Using a constant voltage 
at 150V, samples were electrophoresed for approximately 45 minutes.  
After electrophoresis, separated proteins were transferred from the gel onto a 
polyvinylidenefluoride (PVDF) membrane (GE Healthcare Ltd, Buckinghamshire, UK) by 
electrophoresis. PVDF membranes were soaked in 100% ethanol prior to use and placed in 
transfer buffer. Also, 2 transfer sponges and 2x 3 mM Whatman® chromatography paper 
(supplied by VWR International Ltd) were pre-soaked in transfer buffer prior to use. Gels 
were transferred into transfer cassettes with a PVDF membrane inserted between Whatman 
papers and transfer sponges. Transfer cassettes were placed in the electrophoresis system 
filled with transfer buffer and electrophoresed for 45 minutes at 100v. Ice pack was placed in 
the transfer tank to prevent overheating.  
 
2.6.4. Antibody detection and visualisation of bound proteins 
After transferring proteins onto PVDF membranes, the membranes were removed from the 
transfer cassette and soaked in 5% blocking buffer (Table 2.5) for 1 hour at room temperature 
on a roller mixer. PVDF membranes were then transferred into a 50 ml BD Falcon™ tube 
containing 5 ml blocking buffer with primary antibody (Table 2.6) and incubated overnight at 
4°C on a roller mixer. Following incubation with primary antibodies, PVDF membranes were 
washed with 10 ml TBS/Tween 3 times at room temperature for 10 minutes each. Membranes 
were transferred into a 50 ml BD Falcon™ tube containing 5 ml of appropriate secondary 
antibody conjugated to horseradish peroxidase and incubated for 1 hour at room temperature 
on a roller mixer. Membranes were then transferred into new Falcon tubes and washed with 
10 ml TBS/Tween for 10 minutes 3 times at room temperature.  
Bound antibodies were detected by Amersham™ ECL™ Prime Western Blotting Detection 
Reagent (GE Healthcare Ltd, Buckinghamshire, UK) according to the manufacturer 
instructions. Chemiluminescence signals emitted by bounded antibodies were visualised by 
exposing the membrane to Carestream® Kodak® BioMax® light film (Sigma Aldrich Co Ltd, 
Dorset, UK). Exposure times varied form 2 seconds to 10 minutes depending on target 
protein. Films were developed using Mediphot 937 X-Ray Filmprocessor (Colenta 
Lobortechnik, Austria).  
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APE1 and OGG1 antibodies were examined prior to use in further experiments to identify 
optimal concentration and to determine their specificity for APE1 and OGG1 by using 
knockdown cells (Appendix A). 
In order to quantify western blot protein bands, developed films were analysed by FujiFilm 
Intelligent Dark Box, LAS‐3000, (Luminescent Image Analyser System, USA). The 
generated data was analysed by the LAS 3000 Image Reader software and Microsoft Excel 
software. To determine the extent of knockdown, proteins were quantified and normalised 
firstly to protein level in the loading control and then normalised to protein level of parental 
control cells.  
 
 
Antibody Source and type Supplier 
catalogue 
number Dilution 
Pr
im
ar
y 
an
tib
od
ie
s 
APE1 Mouse , Monoclonal Abcam plc AB194 1:2500 
OGG1 Rabbit,  polyclonal Abcam plc AB91421 1:10000 
α-tubulin Mouse , Monoclonal Sigma-Aldrich T6074 1:80000 
P21 Mouse , Monoclonal Calbiochem OP64 1:100 
PAX5 Mouse , Monoclonal 
Santa Cruz 
Biotechnology SC55515 1:400 
GAPDH Rabbit,  polyclonal 
Santa Cruz 
Biotechnology SC25778 1:400 
Se
co
nd
ar
y 
an
tib
od
ie
s Anti-
mouse Ab 
Goat,  
Polyclonal Dako P0447 1:5000 
Anti-
rabbit Ab 
Goat,  
Polyclonal Dako P0448 1:5000 
 
Table 2.6: Primary and secondary antibodies used in western blotting. 
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2.7.RNA sequencing 
RNA was extracted from APE1 and control shRNA transduced cell clones as described in 
section 2.4.2. RNA integrity number (RIN) was determined by using the Agilent RNA 6000 
Nano Kit (Agilent Technologies, UK) on the Agilent 2100 Bioanalyzer.  
The RIN was determined according to the manufacturer protocol. Briefly, 65 µl of pre-filtered 
gel was mixed with 1 µl RNA 6000 Nano dye concentrate and vortexed, and centrifuged at 
13,000 g for 10 minutes at room temperature. The gel/dye mixture was loaded into wells 
marked G in the RNA 6000 Nano chip and compressed using a plunger, followed by adding 5 
μl of RNA 6000 Nano marker to all wells. All RNA samples were denatured by incubation at 
70°C for 2 minutes prior to loading 1 µl into each well. RNA was loaded into its 
corresponding well. The Nano chip was vortexed at 2400 rpm for 1 minute on IKA mixer and 
placed into Agilent 2100 Bioanalyzer analysed by the Eukaryote Total RNA Nano series II 
programme. Samples with a RIN of 7 or higher were considered suitable for RNA 
sequencing. 
RNA samples were sequenced using the Illumina HiSeq 2500 platform by AROS Applied 
Biotechnology, Denmark. RNA sequencing data was analysed by DESeq2 software V 3.2.  
 
2.8. Cytotoxicity assessment assays 
The purpose of cytotoxicity assays was to assess the sensitivity of knockdown cells to 
different chemotherapeutic agents compared to control parental cells. These assays were also 
used to investigate the efficacy of APE1 inhibitors as a single agent and in combination with 
other chemotherapeutic agents. Two methods were used to determine cell cytotoxicity in 
response to anti-leukaemia treatment including growth inhibition assay using trypan blue dye 
exclusion with cell counting, and the colony formation assay.  
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2.8.1. Growth inhibition assay using trypan blue and cell counter 
2.8.1.1. Drugs and exposure 
Chemotherapeutic agents and APE1 inhibitors used throughout this project are listed in Table 
2.7. Drugs were dissolved using an appropriate solvent, aliquoted and stored in the dark at -
20°C (or at -80°C for the E3330 APE1 inhibitor). Working solutions were prepared shortly 
prior to use by diluting concentrated drug stocks using FBS-free RPMI culture medium.  
 
 
Drug name Provider Solvent 
Stock 
concentration 
Dose range 
used 
Cytarabin (Ara-C) Sigma-Aldrich DMSO 50 mM 5 – 40 nM 
Daunorubicin  Sigma-Aldrich DMSO 10 mM 4 – 16 nM 
Etoposide  Sigma-Aldrich DMSO 50 mM 50 – 600 nM 
Temozolomide  Sigma-Aldrich DMSO 100 mM 5 – 300 nM 
Clofarabine Sigma-Aldrich DMSO 50 mM 2.5 – 100 nM
Fludarabine Sigma-Aldrich DMSO 50 mM 0.1 – 50 µM 
Methoxyamine  Sigma-Aldrich PBS 0.5 M 0.5 – 18 mM 
E3330 
Novus 
Biologicals 
DMSO 40 mM 5 – 60 µM 
APE1 inhibitor III Calbiochem DMSO 10 mM 0.2 – 10 µM 
 
Table 2.7: Cytotoxic agents and APE1 inhibitors used in growth inhibition and 
cytotoxicity assays. 
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2.8.1.2. Growth inhibition assay setup, cell counting and data analysis 
To test drug sensitivity, exponentially growing cells were counted using the TC20 cell counter 
and seeded at a final density of 2x104 cells/ml in an appropriate volume of culture media. For 
each drug dose, a 5 ml aliquot of cell suspension was transferred to a 6 well plate (or a T25 
culture flask for methoxyamine treatment), and supplemented with an appropriate volume of 
drug to give the required final dose. A vehicle control was performed with appropriate solvent 
(mainly DMSO) but without drug. Plates/Flasks were incubated for 4 days in a humidified 
CO2 incubator at 37°C. 
After 4 days incubation, the number viable cells in each culture was counted using the TC20 
cell counter and trypan blue dye exclusion. For shRNA knockdown cells or single drug 
treatment, the percentage of viable cells for each treated cell culture was determined by 
calculating the percentage of viable cells compared to the vehicle control of the same cell 
line/subclone. For cells treated with a combination of chemotherapy and APE1 inhibitor, the 
percentage of viable cells for each treated cell culture was determined by calculating the 
percentage of viable cells in treated cultures to viable cells treated with APE1 inhibitor as a 
single agent. Microsoft excel was used to perform all calculations. Data were processed using 
GraphPad Prism V6 software to generate cytotoxicity curve. Error bars on kill curves 
represent the standard error of three independent experiments. 
  
2.8.2. Colony formation assay 
Colony formation assay (CFA) was performed to determine the effect of inhibition or 
knockdown of APE1 or OGG1 on cloning efficiency and the ability of AML cells to form 
colonies from single cells in semi-solid soft agar. It was also used to investigate the sensitivity 
of AML cells to chemotherapy alone or in combination with APE1 inhibitors or after APE1 
knockdown using shRNA. Furthermore, CFA was performed to generated single cell clones 
from shRNA transduced cell populations to generate sub-clones with stable knockdown of the 
gene of interest. 
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2.8.2.1. Drugs and exposure 
Drugs used in the CFA are described in section 2.8.1.1. In order to study the effect of APE1 
inhibitors as a single agent or in combination with chemotherapy, exponentially growing cells 
were counted using a TC20 cell counter and seeded to a final density of 1x105 cells/ml in an 
appropriate amount of complete culture media. Cell suspensions were incubated for 24 hours 
before drug addition to allow exit out of lag phase and the establishment of exponential 
growth. After 24 hours, cell suspensions were aliquoted into 5 ml into T25 culture flasks, and 
supplemented with an appropriate volume of drug to give the required final dose. A vehicle 
control was performed with appropriate solvent but without drug. Each experiment was 
performed on 3 independent occasions. Cells were exposed to drug for 24 hours and 
incubated in a humidified 5% CO2 incubator at 37°C. For generating sub-clones from shRNA 
transduced cells, the same process was performed except that cells were not treated with drug. 
 
2.8.2.2. Cell preparation after treatment 
Following 24 hours incubation all treated and control cells were transferred into sterile 
universal tubes (VWR International Ltd) and centrifuged at 250 g at room temperature to 
remove culture media. After centrifugation, supernatant was discarded and cell pellets were 
resuspended in sterile pre-warmed PBS and centrifuged to remove any remaining drug. Cells 
were then resuspended in full culture media and cell counts were performed using the TC20 
cell counter. Cells were counted in triplicate for accurate estimation of cell density and 
transferred to a new flacon tube at a density of 1x104 cell/ml. Serial dilution was performed to 
give final density of 40 cells/ml for drug sensitivity experiment or 10 cells/ml for generating 
subclones from shRNA transduced populations. Following serial dilution, 5 ml or 1 ml of 
diluted cells were transferred into 10 cm petri dishes or 6 well plates prior to the addition of 
soft agar.  
 
2.8.2.3. Preparation of semi-solid soft agar 
Semi-solid soft agar was prepared by adding 5 ml of sterile PBS to 200 mg of SeaKem ME 
Agarose (Lonza – supplied by VWR International Ltd) in a Falcon tube. Agarose was 
dissolved by microwaving to give a final agarose concentration of 40 mg/ml. An appropriate 
volume of molten agarose was quickly added to an appropriate volume of pre-warmed full 
media to give 4 mg/ml agarose. Then, 5 ml or 1 ml of prepared agarose media was transferred 
79 
 
to a 10 cm petri dishes or 6 well plate and mixed gently to give 2 mg/ml (or 0.2 %) semi-
solid-soft agar. This protocol results in 200 cell/plate in 10 cm dishes and 10 cells/well in 6 
wells plates. Plates were incubated in humidified incubator at 37°C with 5% CO2 for 2-3 
weeks depending on cell line.  
 
2.8.2.4. Colony expansion, visualisation, counting and data analysis 
For generating sub-clones from shRNA transduced cells population, single colonies were 
picked using a pipette and transferred to 0.5 ml of complete media in 24 well plates and 
incubated for 2-3 days. Cells were then expanded and used in several experiments. For drug 
sensitivity and cloning efficiency experiments, colonies were counted after visualised using 
0.05% thiazolyl blue tetrazolium bromide (MTT) stain. 
For shRNA knockdown cells or single drug treatments, the percentage of viable cells for each 
treated cell culture was determined by calculating the percentage of colonies in treated 
cultures compared to vehicle control treated cells of the same line or clone. For cells treated 
with a combination of chemotherapy and APE1 inhibitors, cloning efficiency for each treated 
cell culture was determined by calculating the percentage of colonies in treated cultures 
compared to colonies treated with APE1 inhibitor as a single agent. Microsoft excel was used 
to perform all calculations. Data were processed using GraphPad Prism V6 software to 
generate cytotoxicity curve. Error bars on kill curves represent the standard error of three 
independent experiments. 
 
2.9. Cell cycle analysis using flow cytometer 
Propidium Iodide (PI) stain was used to determine the cell cycle distribution of cells after 
APE1 or OGG1 knockdown and/or after treatment with APE1 inhibitors. PI is a fluorescent 
dye, which can bind to both DNA and RNA and can be detected in either the FL-2 or FL-3 
channels on a FACS Calibur instrument. Viable cells do not take up PI and need to be 
artificially permeabilised to allow PI entry, which can be achieved by fixation in 70% ethanol. 
Cell cycle analysis depends on measuring the amount of DNA in each single cell. Cells going 
through S phase undergo DNA replication and have more DNA compared to cells in G0/G1 
(2N), therefore take up more PI and have a stronger fluorescent signal. Cells in G2/M phase 
have double the DNA content (4N) compared to cells in G0/G1, until they undergo mitosis. 
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2.9.1. Cell preparation, fixation and staining with propidium iodide (PI) 
To study the effects of APE1 inhibitors on cell cycle, cells were counted using a TC20 cell 
counter and seeded to a final density of 1x105 cells/ml and treated with APE1 inhibitors. Cells 
were incubated for 24, 48 or 72 hours and harvested for cell cycle analysis. After treatment, 
cells were counted using a TC20 cell counter and 5x105 cells were washed as described in 
section 2.4.1. Cells then were fixed using 70% ethanol and vortexed to prevent cell clumping 
and kept at -20°C prior to PI staining. The same process was performed to prepare 
APE1/OGG1 shRNA transduced cells for cell cycle analysis but without treatment. 
Ethanol was removed by centrifugation at 300 g for 15 minutes at room temperature and cell 
pellets were resuspended in 100 µl of citrate buffer (0.25 M Sucrose, 40 mM sodium citrate, 
pH 7.6) and transferred into FACS tubes. Cells were then stained with 400 µl PI (20 µg/ml 
propidium iodide, 0.5% NP-40, 0.5 mM EDTA) and treated with 1 µl of RNase A to 
eliminate RNA. Tubes were kept at 4°C protected from light for 1 hour prior to cytometric 
analysis.  
After incubation, cell cycle analysis was performed on a FACSCalibur flow cytometer with 
BD Cell Quest Pro software (BD Biosciences) and PI detected in the FL-2 channel. 
Instrument settings were optimised for each cell line using control untreated cells/shRNA 
cells. A dot plot of FL-2 area versus FL-2 width was created to identify target cells and gating 
was setup around G0/G1/G2/M populations to exclude cell aggregates and doublets. Gated 
cells were plotted on a histogram of event count versus linear FL-2 area. G0/G1 peak was 
adjusted to 200 on the FL-2 area linear axis and 10,000 events were collected for each sample.  
 
2.9.2. Data analysis 
Data was analysed using Cell Quest Pro software (BD Biosciences) to determine the 
percentage of cells in each cell cycle phase. Data in histograms generated during data 
collection (described in previous section 2.9.1) were used to determine the proportion of cells 
in each cell cycle phase. Different phases in the cell cycle were marked and a table of 
statistics identifying the percentage of cells in each phase was generated from the histogram. 
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2.10. Abasic (AP) site quantification 
Abasic sites or Apurinic/Apyrimidinic (AP) sites are one of the most frequent spontaneous 
DNA lesions and it is estimated that high ROS could generate about 50,000 to 200,000 AP 
site per cell per day in the genome and that brain cells contain the most AP sites (Martin et al 
2008). AP sites are potentially mutagenic and also potentially lethal via the ability to block 
DNA replication. Primarily, the majority of AP sites are recognised and repaired by the BER 
system and any malfunction in BER components would lead an accumulation of unrepaired 
AP sites. AP site accumulation was determined, after APE1 inhibition or knockdown using 
shRNA, by a colorimetric assay kit supplied by Abcam, UK (cat# ab65353). In this assay, 
Aldehyde reactive probe (ARP) reacts specifically with an aldehyde group on the open ring 
form of AP sites. After ARP and AP site reaction, the resulting compound can be tagged with 
biotin, which can then be quantified via the avidin-biotin assay followed by colourimetric 
detection of peroxidase conjugated to avidin. 
 
2.10.1. Cells treatment and extraction of genomic DNA 
For shRNA transduced cells, cells were treated with 50 µM H2O2 for 1 hour and washed with 
pre-warmed sterile PBS and transferred to complete media. For cells to be treated with APE1 
inhibitors, cells were treated with 50 µM H2O2 for 1 hour and washed with pre-warmed PBS 
and centrifuged at 300 g for 5 minutes at room temperature. Supernatant was discarded and 
cells were transferred to complete RPMI media supplemented with the required dose of APE1 
inhibitor. Cell pellets were prepared prior to treatment and after 2, 4 and 8 hours of H2O2 
treatment (as described in section 2.4.1) and kept at -80°C until required.  
Genomic DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen, 
Crawley, UK) according to manufacturer protocols. Briefly, cells were lysed and 
homogenised using the provided buffers, then dispensed into spin column containing a 
QIAamp® silica gel membrane. DNA binds to the silica membrane and other contaminants 
were removed by washing with provided buffers. DNA was eluted in 200μl buffer AE (10 
mM Tris-HCl, 0.5 mM EDTA, pH 9.0) and quantified using a NanoDrop® ND-1000 
spectrophotometer. Extracted DNA was aliquoted and stored at -20°C until required. 
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2.10.2. Quantification of AP site using the Aldehyde Reactive Probe base kit 
AP site quantification was performed according to manufacturer protocols. Briefly, extracted 
DNA was diluted to 0.1 μg/μl in TE buffer and then tagged with ARP. Tagged DNA was 
precipitated by centrifugation at 14000 g and washed 3 times with 70% ethanol. TE buffer 
was added to ARP tagged DNA. ARP-DNA standards were prepared by diluting the ARP-
DNA standard (containing 40 ARP sites per 105 base pair (bp)) provided with the kit to 
generate standards of 0, 8, 16, 24, 32 and 40 ARP sites per 105 bp. For each ARP standard and 
test sample, 60 µl was dispensed in triplicate into a 96 well plate and 100 µl of DNA binding 
solution was added to each well. Plates were sealed to avoid any evaporation and incubated at 
room temperature overnight to allow DNA to bind to the plate surface. After incubation, DNA 
binding solution was discarded and plates were washed 5 times with 250 µl washing buffer. 
HRP-Streptavidin solution was added to each well and incubated at room temperature for 1 
hour with gentle agitation. HRP-Streptavidin solution was discarded and plates were washed 
5 times with 250 µl washing buffer. After washing, HRP Developer was added to each well, 
and incubated at 37°C for 1 hour. Following incubation, absorbance was determined at 650 
nm using a Spectromax® 250 Microplate Spectrophotometer System. 
Absorbance values of ARP-DNA standards were used to generate a standard curve and to 
generate an equation used to calculate AP sites in each sample. All calculations were 
performed using Microsoft excel and data are shown in graph bars.  
 
2.11. TARDIS assay 
The trapped in agarose DNA immunostaining (TARDIS) assay was originally developed to 
detect and quantify melphalan and cisplatin DNA adducts, but later adapted to quantify 
topoisomerase-DNA complexes (Tilby et al., 1987; Cowell et al., 2011). This assay was 
performed to assess the ability of APE1 to remove TOP2 α and β complexes after treatment 
with etoposide.  
 
2.11.1. Cell treatment and staining 
The TARDIS assay was performed as previously described (Mariani et al., 2015). Briefly, 
TOP2 DNA adducts were generated by treating exponentially growing cells with 100 µM 
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etoposide for 1 hour. Following treatment, 5x105 cells were washed twice with cold PBS, re-
suspended in 50 µl of cold PBS, then pre-warmed at 37 °C for 30 seconds and embedded in 
an equal volume of pre-warmed molten 2% W/V agarose in PBS (SeaPrep ultra low gelling 
agaros - Lonza, US). The mixture was spread consistently on microscopic slides pre-coated 
with 0.5% agarose, and placed on a cold surface to solidify the cell-agarose mixture. Slides 
were then dipped for 30 minutes at room temperature in lysis buffer [1% SDS, 20 mM Na 
phosphate pH 6.5 and 10 mM EDTA] in the presence of protease inhibitors [1% 
Benzamidine, 1% phenylmethanesulfonyl fluoride, 0.1% Leupeptin, 0.1% Pepstatin and 0.1% 
DTT] obtained from Sigma-Aldrich UK. Following cell lysis, slides were incubated for 30 
minutes in 1 M NaCl + protease inhibitors followed by washing with PBS+ protease 
inhibitors 3 times (5 minutes per wash) at room temperature. After washing with PBS and 
protease inhibitors, slides were exposed to primary specific antibodies directed against 
TOP2A and TOP2B for 1.5 hours at room temperature. Primary antibodies used were rabbit 
anti-TOP2 polyclonal antibodies raised and purified in Professor Caroline Austin’s laboratory 
at Newcastle University, and were used at 1:400 dilution in BSA-PBS-Tween [PBS, 0.1% 
(v/v) Tween-20 and 1% (w/v) bovine serum albumin (BSA)]. Following incubation with 
primary antibodies, slides were washed 3 times with PBST [PBS and 0.1% (v/v) Tween-20] + 
protease inhibitors, and incubated with secondary antibodies Alexa488 [1:250 dilution in 
BSA-PBS-Tween] (Life Technologies) for 1.5 hours protected from light. Slides were then 
washed as previously described and stained with 1 ml of 2 μg/ml Hoechst 33258 (Invitrogen) 
in PBS for 5 minutes. Finally, after staining, excess Hoechst was drained, mounting media 
Vectashield (without DAPI) was applied to the slide, and appropriate coverslips were placed 
and secured with a sealant. Slides were examined immediately or kept at 4 °C until required.  
 
2.11.2. Microscopy and data analysis 
Slides were examined using epifluorescence microscope Olympus IX-81 and images were 
recorded for each treatment and each cell line. Two different optical filters were used to 
separately capture the florescent signal emitted by Hoechst (exited at 352 nm and emit at 461 
nm) and Alexa 488 (exited at 495 nm and emit at 519 nm). On average, 6 pairs of images 
were recorded for each slide to give approximately 300 cells/slide. Images were merged and 
their background was corrected and analysed using Volocity software version 1.0.0 (Perkin 
Elmer). Integrated fluorescence values were processed using GraphPad Prism to calculate 
mean values which were plotted on a volcano graph plot. 
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Chapter 3: The prognostic value of APE1 and OGG1 expression and 
Evaluation of their gene expression and protein levels in AML 
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3.1. Introduction 
AML is heterogeneous disease characterised by high oxidative stress burden, DNA damage 
and genome instability, which is predicted to contribute to leukaemogenesis. It is important to 
stress that the DNA damage response mechanisms are essential in normal cells and their 
dysregulation may contribute to malignant transformation. Upregulation of DNA damage 
response pathways in AML cells may confer protection against DNA damaging agents, and 
consequently promote chemoresistance and cell survival. Accumulating evidence indicates 
that APE1 and OGG1 expression is upregulated in cancer and may be used as a prognostic 
marker for disease progression and chemotherapy resistance (Al-Attar et al., 2010; Liddiard et 
al., 2010; Abdel-Fatah et al., 2014). However, the prognostic value of APE1 in AML has not 
yet been established. OGG1 has been suggested as a prognostic indicator in AML (Liddiard et 
al., 2010). 
  
3.1.1. APE1 as a prognostic marker in AML 
Although APE1 expression has been well characterised in several cancer types (Wang et al., 
2004; Di Maso et al., 2007; Wang et al., 2009a; Al-Attar et al., 2010; Woo et al., 2014), its 
expression and role in AML pathogenesis, prognosis and treatment response is still unknown. 
Published studies report heterogeneous APE1 mRNA expression in AML, but have not 
characterised its prognostic value. High APE1 mRNA expression has been reported in a 
single case of acute promyelocytic leukaemia (APL) occurring as a second therapy-induced 
malignancy (Casorelli et al., 2006). In contrast, another study showed that APL-associated 
fusion proteins PLZF-RARα and PML-RARα are linked to reduced APE1 mRNA and protein 
expression (Petruccelli et al., 2013). Furthermore, this study demonstrated that PLZF-RARα 
and PML-RARα-expression cells are more sensitive to vorinostat histone deacetylase 
inhibitor compared to fusion negative cells, due to reduced BER capacity. Regardless of its 
role in determining sensitivity to chemotherapy, APE1 is essential component of BER 
pathway and it is important to maintain balanced expression. APE1 upregulation or 
downregulation may drive dysregulated activity of BER and contribute to genome instability.  
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3.1.2. OGG1 expression as prognostic marker in leukaemia 
The OGG1 DNA glycosylase is an important enzyme that removes oxidised DNA lesions in 
DNA, including primarily 8-oxoguanine. Failure to remove such lesions can result in 
mutagenic transversion of G:C to T:A (Forster et al., 2016). High expression of OGG1 is 
shown to confer poor prognosis in AML (Liddiard et al., 2010). Specifically, patients with 
high OGG1 expression were more likely to relapse and have shorter overall survival and 
shorter relapse-free survival compared to patients with high OGG1 expression (Liddiard et 
al., 2010). Moreover, high OGG1 expression is associated with adverse cytogenetics which is 
an independent marker of poor prognosis. Conversely, low OGG1 expression is reported in 
AML with the t(8;21) translocation and AML1/ETO fusion protein, which may contribute to 
the better outcome in this patient group.  
 
3.1.3. APE1 and OGG1 are regulated by post-translational modification  
Post-translational modifications are important mechanisms by which proteins are controlled 
and regulated in respect of their protein-protein interactions, protein function, cellular protein 
levels, enzymatic activities and cellular localisation. Several reports demonstrate that both 
APE1 and OGG1 are regulated by post-translational modification, via ubiquitination, 
phosphorylation and acetylation (Bhakat et al., 2009; Hegde et al., 2012; Carter and Parsons, 
2016).  
 
APE1 regulation by post-translational modifications 
APE1 is regulated at the transcriptional and post-translational levels. It has been reported that 
mouse double minute 2 (MDM2) and Cyclin-dependent kinase 5 (Cdk5) modulates APE1 
ubiquitination (Busso et al., 2009; Busso et al., 2011). APE1 ubiquitination occur at lysine 
residues K24, K25 and K27, which are located in the N-terminus. MDM2 inhibition using 
nutlin-3 (MDM2-P53 inhibitor) resulted in enhanced APE1 ubiquitination (Fantini et al., 
2010). Furthermore, mutant MDM2 was not able to ubiquitinate APE1 (Fantini et al., 2010). 
Ubiquitin protein ligase E3 component N-recognin 3 (UBR3) also is also reported to 
ubiquitinate and regulate APE1 protein levels (Meisenberg et al., 2012). 
Several studies have reported APE1 phosphorylation and demonstrated effect on both DNA 
repair and redox functions (Yacoub et al., 1997; Hsieh et al., 2001; Huang et al., 2010). Cdk5 
and P35 complex interact with APE1 and induce phosphorylation at Thr232 in the C-terminus 
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of the protein (Huang et al., 2010). Cdk5/P35 mediated phosphorylation resulted in a 
reduction of APE1 endonuclease activity and led to accumulation of AP sites and cell death in 
a neuronal cell model (Huang et al., 2010). APE1 redox function has also been shown to be 
stimulated via protein kinase C (PKC) phosphorylation following treatment with DNA 
damaging agents (Hsieh et al., 2001), although the mechanism remains unclear.  
Acetylation of APE1 at lysine residues 6 and 7 by the transcriptional co-activator p300 
enhances binding of APE1 to negative calcium response elements in response to elevated 
calcium level (Bhakat et al., 2003). APE1 acetylation in this context acts as repressor for 
parathyroid hormone promoter. Acetylation of APE1 at lysine residues 6 and 7 was shown to 
enhance its binding to Y-box binding protein 1 (YB-1), which resulted in activation of the 
YB-1-dependent multidrug resistance gene 1 (MDR1) (Chattopadhyay et al., 2008). Further 
investigation to delineate the mechanism by which APE1 acetylation controls YB-1-mediated 
activation of MDR1 gene found that APE1 is stably associated with RNA polymerase II 
transcription factor on MDR1 gene promoter (Sengupta et al., 2011). Thus, APE1 acetylation 
is required to recruit and activate YB-1/p300 complex to enhance MDR1 expression. 
However, sirtuin1 (SIRT1) has been found to control the acetylation status of lysine residues 
6 and 7 (Yamamori et al., 2010). SIRT1 deacetylates these residues following DNA damage 
and promotes APE1 interaction with XRCC1 to induce BER. Furthermore, the APE1-NPM1 
interaction is modulated by acetylation of lysine residues 27, 31, 32 and 35 which located in 
the N-terminal of APE1 (Fantini et al., 2010). 
 
OGG1 regulation by post-translational modifications 
Like APE1, OGG1 also is regulated by post-translational modification as well as 
transcriptional regulation. OGG1 ubiquitination has only been reported in one limited study. 
Under hypothermic condition, OGG1 ubiquitination was shown to be catalysed by C-terminus 
of HSC70-interacting protein (CHIP) E3 ligase (Fantini et al., 2013). Thermal inactivation of 
OGG1 resulted in loss of glycosylase function, followed by ubiquitination and proteasomal 
degradation (Fantini et al., 2013). Furthermore, undegraded remnants of OGG1 translocate 
from the nucleus into the perinuclear region to further decrease OGG1 DNA repair activity 
(Fantini et al., 2013). 
OGG1 is phosphorylated in vivo by protein kinase c (PKC) (Dantzer et al., 2002). In this 
study, OGG1 was bound to chromatin and phosphorylation reported at several serine residues 
of OGG1. Luna and colleagues studied the subcellular localisation and expression of OGG1 
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and its polymorphic variant OGG1- S326C, and reported that phosphorylation of serine 
residue 326 governs OGG1 translocation to the nucleus (Luna et al., 2005). OGG1 
phosphorylation can be mediated by two different tyrosine kinases c-Abl and cyclin 
dependant kinase 4 (Cdk4) (Hu et al., 2005b). C-Abl mediated phosphorylation had no effect 
of OGG1 glycosylase activity, whereas Cdk4 mediated phosphorylation increased OGG1 
glycosylase activity up to 2.5 fold (Hu et al., 2005b).  
P300 catalyses OGG1 acetylation at lysine 338 and 341, and enhances its glycosylase activity 
by reducing its affinity for AP sites generated during oxidative stress (Bhakat et al., 2006). 
Furthermore, the OGG1 acetylation rate increased 2.5 fold following glucose oxidase-induced 
oxidative stress, which suggests DNA damage dependent activation of OGG1 repair activity 
(Bhakat et al., 2006). 
 
3.2. Aims of this chapter  
The general and specific aims of the work in this chapter are as follow: 
- To explore APE1 gene expression and protein expression in AML cells and relate this 
to disease progression and prognosis. To achieve this target: 
o Study prognostic impact of APE1 and OGG1 expression in AML using 
available data in the public domain. 
o Evaluate APE1 and OGG1 mRNA gene expression in AML cell lines using 
real time PCR. 
o Evaluate APE1 and OGG1 protein expression in AML cell lines using western 
blot assay.  
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3.3.Results 
3.3.1. Prognostic impact of APE1 and OGG1 expression in AML 
In order to evaluate the prognostic value of APE1 and OGG1 in AML patients, gene 
expression data from several public databases were evaluated. In particular, all data presented 
in this section was evaluated using PROGgeneV2 – the Pan Cancer Prognostics Database 
hosted by the Centre for Computational Biology and Bioinformatics at Indiana University and 
Purdue University in Indianapolis, USA 
(http://watson.compbio.iupui.edu/chirayu/proggene/database/index.php). This database 
provides comprehensive survival analysis based on mRNA expression, and presents data as a 
Kaplan Meier survival plot. Datasets used to evaluate the prognostic value of APE1 and 
OGG1 include The Cancer Genome Atlas (TCGA) acute myeloid leukaemia dataset (The 
Cancer Genome Atlas Research, 2013; Papaemmanuil et al., 2016) (N=157) and the 
Prognostic gene signature for normal karyotype AML dataset (GSE12417) (N=163) (Metzeler 
et al., 2008). Both APE1 and OGG1 gene expression was determined in all datasets using the 
Affymetrix U133 microarray. Data analysis was performed on gene level only, i.e. databases 
did not show information about probes of APE1 and OGG1 that has been used in the analysis.  
Neither AML dataset provided evidence that APE1 expression associates with overall survival 
in AML (Figure 3.1). Specifically, when categorised into two major groups by the median 
expression level, APE1 did not significantly associate with overall survival in either the 
TCGA or GSE12417 datasets (P= 0.3 for both datasets). In the TCGA dataset, OGG1 
expression did not associate with survival in AML when categorised into two groups by the 
median (p=0.89) (Figure 3.2). However, in the GSE12417 dataset, low OGG1 expression was 
significantly associated with shorter overall survival (p=0.0049) (Figure 3.2).  
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3.3.2. Determination of APE1 mRNA expression in AML cell lines by Quantitative RT-
PCR 
APE1 mRNA gene expression was assessed by real time polymerase chain reaction (RT-PCR) 
in 8 AML cell lines including HL-60, AML2, AML3, U937, MV4-11, NB4, Kasumi1 and 
THP-1. Data were expressed as fold change and were normalised to NB4 APE1 gene 
expression. NB4 was selected because it represents M3 FAB classification AML, which is 
characterised by repressed DNA repair activity due to the presence of the PML-RARα fusion 
(Casorelli et al., 2006; Esposito and So, 2014).  
RT-PCR demonstrated a modest variation, but not significant according to p value calculated 
by an unpaired t-test, in APE1 mRNA gene expression in the AML cell lines investigated 
(Figure 3.3A). HL-60 cells had the highest APE1 mRNA expression with mean of 1.33 fold 
compared to NB4 APE1 mRNA transcripts. Other cell lines showed minimal variation in 
APE1 expression. 
 
3.3.3. APE1 protein expression in AML cell lines determined by western immunoblotting 
Western blotting was performed to investigate APE1 protein level in AML cell lines 
including HL-60, AML2, AML3, U937, MV4-11, NB4, Kasumi1 and THP-1. APE1 protein 
levels were consistently expressed in the majority of AML cell lines used (Figure 3.3B), 
demonstrating lack of correlation between APE1 mRNA and protein level and suggesting that 
APE1 protein levels are tightly regulated.  
To further quantify APE1 protein levels, western blots were assessed by densitometry using 
Fuji Film Intelligent Dark Box, LAS‐3000, Luminescent Image Analyser System and the data 
were analysed using LAS 3000 Image Reader software (Fujifilm Medical Systems U.S.A., 
Inc). APE1 protein levels were normalised to α-tubulin loading control, and then normalised 
to NB4 protein expression. Result showed consistent APE1 protein levels in the majority of 
investigated AML cell lines (Figure 3.3C). Highest APE1 protein expression was observed in 
MV4-11 (165%) and U937 (130%). 
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Figure 3.3: APE1 expression in AML cell lines. 
(A) APE1 mRNA expression determined in population of asynchronous AML cells using real 
time PCR. Data represent the mean of two independent experiments and error bars of standard 
deviation. There was no significant variation in APE1 gene expression between cell lines 
according to the p values calculated by unpaired parametric t test. 
(B) Western blot showing protein expression of APE1 in several AML cell lines.                 
(C) Representative quantification of APE1 protein from western blot, quantified by 
densitometer. There was no significant variation in APE1 protein expression between cell 
lines according to p values calculated by unpaired parametric t test. 
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3.3.4. OGG1 mRNA transcript expression in AML cell lines determined by Quantitative 
RT-PCR 
RT-PCR was used to assess the expression of OGG1 in AML cell lines including HL-60, 
AML2, AML3, U937, MV4-11, NB4, Kasumi1 and THP-1. OGG1 mRNA gene expression 
data were expressed as fold change and normalised to NB4 OGG1 gene expression.  
As expected and consistent with previous reports, Kasumi-1 cells demonstrated the lowest 
OGG1 mRNA expression, due to presence of the AML1-ETO1 t(8;21) chromosomal 
translocation, which represses OGG1 expression (Figure 3.4A) (Liddiard et al., 2010; Forster 
et al., 2016; Li et al., 2016). THP-1 cells demonstrated highest OGG1 expression compared to 
other cell lines, which was 3.57 fold higher than NB4 at the mRNA level. Other AML cell 
lines demonstrated comparable OGG1 gene expression. 
 
3.3.5. OGG1 protein expression in AML cell lines determined by western immunoblotting 
Western blotting was performed to assess OGG1 protein expression in AML cells previously 
tested for mRNA expression. Surprisingly results showed stable OGG1 expression in all 
AML cell lines tested regardless of mRNA transcript levels (Figure 3.4B). In particular, 
Kasumi-1 cells were expected to have low OGG1 protein due to low mRNA transcript level. 
However, quantified OGG1 western blot result using densitometer showed slight consistency 
with mRNA levels, where kasumi1 cells expressed the lowest OGG1 protein (84% compared 
to NB4) (Figure 3.4C). Furthermore, THP1 and U937 demonstrated higher OGG1 protein 
expression compared to all other cell lines.  
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Figure 3.4: OGG1 expression in AML cell lines. 
(A) OGG1 mRNA expression determined in population of asynchronous AML cells using 
real time PCR. Data represent the mean of 2 independent experiments and error bars of 
standard deviation. Unpaired parametric t test was used to calculate p values. p < 0.05 (*), p < 
0.01 (**), p < 0.001 (***) 
(B) Western blot showing protein expression of OGG1 in several AML cell lines.                
(C) Representative quantification of OGG1 protein from western blot, quantified by 
densitometer. There was no significant variation in OGG1 protein expression between cell 
lines according to p values calculated by unpaired parametric t test.
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3.4. Discussion  
The current prognostication system for AML patients includes only cytogenetic abnormalities 
caused by chromosomal translocations/deletions and recurrent somatic mutations, but does 
not include any somatic alterations in DNA repair genes (Grimwade et al., 2010). However, it 
is becoming clearer now how DNA repair dysregulation and genetic variation in DNA genes 
may influence AML prognosis/risk and determine treatment outcome following 
chemotherapy (Allan et al., 2004; Kuptsova et al., 2007; Saitoh et al., 2013; Esposito and So, 
2014). Despite these advances, relatively little is known about the utility of APE1 and OGG1 
as prognostic markers in AML. 
Although altered APE1 expression correlates with prognosis and overall survival in several 
solid tumours (Wang et al., 2009a; Al-Attar et al., 2010; Abdel-Fatah et al., 2014; Woo et al., 
2014), there was no association between APE1 expression and overall survival in AML. In 
addition, OGG1 prognostic utility is inconclusive, despite previous report indicating its 
prognostic value in AML (Liddiard et al., 2010). However, this is explained by extreme 
cytogenetic heterogeneity of AML and the presence of oncogenic fusion proteins that may 
limit any effect of altered APE1/OGG1 expression. APE1 and OGG1 are sensitive biomarkers 
for oxidative stress induced DNA damage and their upregulation or downregulation is 
dependent on the type of DNA damage and possibly the molecular basis of AML (Li and 
Wilson, 2014; Thakur et al., 2014). Accumulating evidence has associated oncogenic fusion 
proteins (such as AML1-ETO and PML-RARα) with defects in DNA repair, which result in 
further genomic instability that may drive disease progression (Alcalay et al., 2003; Boehrer 
et al., 2009; Petruccelli et al., 2013; Cheng et al., 2015; Forster et al., 2016). On the other 
hand, high oxidative stress in AML may induce DNA damage and activate DNA damage 
response pathways (Seedhouse et al., 2006; Cavelier et al., 2009). Therefore, it is likely that 
the application of APE1 and OGG1 as independent prognostic markers in AML would be 
challenging, but could be feasible if combined with other AML prognostic markers such as 
FLT3, NPM1, N-RAS. Larger scale studies would be required to fully evaluate the prognostic 
value of APE1 and OGG1, taking into consideration other prognostic factors in AML and the 
extreme heterogeneity of the disease.  
APE1 and OGG1 gene expression was determined in several AML cell lines using RT-PCR 
and results were normalised to APE1 and OGG1 expression of NB4 cells. Although the 
expression of both genes in AML cells should be normalised to its relevant expression in 
normal haematopoietic cells such as +CD34 cells, this was difficult due to inability to obtain 
these cells. However, APE1 and OGG1 mRNA was differentially expressed in 8 AML cell 
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lines including HL-60, AML2, AML3, U937, MV4-11, NB4, Kasumi-1and THP-1. Notably, 
kasumi-1 cells showed highest APE1 expression and lowest OGG1 expression. APE1 and 
OGG1 protein was expressed in all AML cell lines investigated, but was not completely 
correlated with mRNA expression. The disparity between mRNA and protein expression of 
both APE1 and OGG1 suggests the presence of mechanisms that regulate protein levels, 
possibly through post-translational modifications, which can affect stability as well as 
function. Such mechanisms have been well demonstrated for both OGG1 and APE1 and 
include phosphorylation, acetylation and ubiquitination (Yacoub et al., 1997; Dantzer et al., 
2002; Bhakat et al., 2003; Bhakat et al., 2006; Busso et al., 2009) (see section 3.1.3 for more 
details about regulation of APE1 and OGG1 by post-translational modification). 
OGG1 mRNA expression was consistent with its protein level in kasumi-1 cell line. Kasumi-1 
cells carry the AML1-ETO fusion protein, which is known to negatively regulate OGG1 and 
suppress its transcription resulting in reduced protein levels (Alcalay et al., 2003; Liddiard et 
al., 2010; Forster et al., 2016). Despite this, it is not clear whether this has biological effect on 
the protein function.   
 
 
3.5. Summary of chapter 
In summary, the results described in this chapter demonstrate: 
 APE1 expression in AML has no correlation with overall survival and may has no 
prognostic value. 
 Prognostic impact of OGG1 is not conclusive in AML and require further study. 
 APE1 and OGG1 mRNA expression vary between different cell lines 
 Both APE1 and OGG1 are ubiquitously expressed on protein level in all investigated 
AML cell lines.  
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Chapter 4: Targeting APE1 in AML cells using short hairpin RNA 
(shRNA) interference. 
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4.1. Introduction  
Treatment of AML is challenging and disease relapse is a major clinical problem, particularly 
in elderly patients and patients with unfavourable prognosis. Treatment outcome with current 
AML conventional chemotherapeutic regimens is still unsatisfactory, and finding new 
targeted therapies is certainly required. Identification of new targeted therapies essentially 
relies on exploring specific genetic alteration in AML cells that drive disease progression, cell 
survival and/or treatment resistance. Dysregulation of DNA repair pathways has been linked 
to AML promotion and treatment response (Rassool et al., 2007; Fordham et al., 2011; 
Esposito and So, 2014). Therefore, targeting dysregulated DNA repair pathways may be of 
therapeutic value for AML patients, and may increase efficacy of current treatments and 
minimise chemoresistance.  
The value of targeting DNA repair components has been already demonstrated in preclinical 
and clinical studies. Focusing on the BER pathway, several components of this pathway have 
been extensively exploited for therapeutic purposes, including PARP-1, APE1, XRCC1 and 
polymerase β (Barakat et al., 2012; Curtin and Szabo, 2013; Sultana et al., 2013). However, 
only a few DNA repair inhibitors have been investigated in clinical trials, particularly PARP-
1 inhibitors and methoxyamine, both inhibitors of the BER pathway. However, APE1 has 
been scrutinised as a therapeutic target in cancer. In particular, there is no known backup 
mechanism for its function in base excision repair as it is the only recognised protein 
responsible for cleaving abasic sites generated following removal damaged bases by DNA 
glycosylases.  
APE1 is a key protein in the BER pathway and silencing/inhibition of this protein has been 
shown to reduce DNA damage repair capacity and potentiate the cytotoxicity of 
chemotherapeutic agents (Bapat et al., 2010; Bulgar et al., 2010; Fishel et al., 2010; 
Mohammed et al., 2011; Cun et al., 2013). However, despite the promising reports that 
showed the utility of APE1 in cancer, only limited studies have attempted to characterise its 
therapeutic benefit in AML (She et al., 2005; Bulgar et al., 2010; Fishel et al., 2010; Vascotto 
et al., 2013). Nevertheless, these studies are interesting and should be confirmed using other 
techniques including siRNA/shRNA that would validate the findings. Furthermore, these 
studies did not demonstrate the effect of APE1 inhibition/knockdown on the cellular response 
to cytotoxic chemotherapy agents essential in AML treatment such as Ara-C, daunorubicin, 
clofarabine and etoposide. 
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Colleagues in the Institute for Cell and Molecular Biosciences at Newcastle University 
demonstrated that APE1 inhibition using CRT0044876 (Calbiochem, UK) led to an 
accumulation of alpha and beta topoisomerase 2 complexes (TOP2A and TOP2B) in K562 
AML cell line. This was investigated using the Trapped in Agarose DNA Immunostaining 
(TARDIS) assay. Rescue experiments after APE1 inhibition were performed by addition of 
25 unit of recombinant APE1 (New England Biolabs, UK) to K562 cells, which resulted in 
removal of approximately 30% of the TOP2A adducts and 15% of the TOP2B adducts (data 
not shown). However, this led to the hypothesis that APE1 knockdown may result in 
accumulation of TOP2A and TOP2B complexes in AML cells. Thus, APE1 knockdown cells 
generated in this work were used to investigate this hypothesis. 
 
4.1.1. RNA interference and genome editing techniques as tool to silence gene expression 
RNA interference (RNAi) refers to a process by which double stranded RNA (dsRNA) 
interferes and silences mRNA expression of a target gene. This is achieved by either 
degradation of mRNA of the target gene by siRNA (small interfering RNA) or shRNA (short 
hairpin RNA), or via suppression of translation of specific mRNA, which could be achieved 
by miRNA (microRNA). Furthermore, recent advances in CRISPR/cas9 genome editing have 
been developed providing a tool to knockout specific genes more efficiently. RNAi and 
genome editing techniques are an important tool in biomolecular studies which can be used to 
identify gene function in normal cells, and their role in disease phenotype. 
 
4.1.1.1. siRNA 
Small interference RNA (siRNA) is a commonly used RNAi technique to induce transient and 
short-term silencing of gene expression. It consists of double RNA strands, sense (passenger) 
and antisense (guide) strands which constitute 21-23 base pair nucleotides with a dinucleotide 
overhang at the 3’ end (Whitehead et al., 2009). This method utilises either electroporation by 
electrical pulse, or transfection using cationic liposomes or polymer based transfection 
method to deliver siRNA molecules to the cell (Whitehead et al., 2009). Upon siRNA 
delivery to the cell cytoplasm, it is incorporated into the RNA induced silencing complex 
(RISC), which is consequently cleaved by Argonaute-2 to separate dsRNA. This results in 
activation of the RISC complex to guide the antisense siRNA strand to bind to its 
complementary mRNA and induce it degradation (Figure 4.1). Although this method provide 
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simple, fast and satisfactory knockdown of protein of interest, the disadvantage of transient 
knockdown and off-target issues limit the benefit of its use. Additionally, delivery methods of 
siRNA may have an effect on cellular phenotype.  
 
4.1.1.2. shRNA 
Unlike siRNA, shRNA induces long term, stable and more efficient knockdown of target gene 
mRNA expression. It consists of a 21-23 base double-stranded molecule with a loop region 
and dinucleotide overhang at the 3’ end (Figure 4.1). However, shRNA expression can be 
driven from a vector following transduction into host cells using viral particles. Viral particles 
are able to penetrate the target cell and the shRNA expression vector is able to integrate into 
the host genome where it is constitutively transcribed to generate pre-shRNA. Pre-shRNA is 
then processed and cleaved by the dicer/TRBP (Tat–RNA-binding protein) complex to further 
generate mature shRNA. The resulting shRNA complex is exported to cell cytoplasm by 
exportin-5. The shRNA- dicer/TRBP complex associates with Argonaute-2-RISC complex 
generating siRNA molecules that cleave and degrade mRNA of the target gene (Rao et al., 
2009). A selection marker encoded into the shRNA allows for selection of cells that have 
been successfully transduced. Furthermore, recent developments in shRNA based technology 
have improved and modified this system to allow for transient or stable shRNA expression by 
a tetracycline inducible expression vector.  
 
4.1.1.3. microRNA  
MicroRNAs (miRNA) can be used to regulate mRNA gene expression, but which do not 
necessarily target and cleave mRNA unless there is a complete match of mRNA and miRNA. 
miRNA consists of single stranded 19-25 mer fragments which do not exactly match the 
specific target mRNA; hence could non-specifically targets several mRNAs. miRNAs are 
endogenously transcribed by the host cell genome as pre-miRNA, and are then exported to the 
cell cytoplasm where they become associated with an enzyme called Drosha. The dicer-
RISK- Argonaute-2 complex then cleaves the miRNA molecule to induce transcriptional 
repression of protein production (Mack, 2007). Inhibition of translation occur when miRNA is 
partially complementary at the 3’ UTR (untranslated region) region of the mRNA. However, 
cleavage and degradation of mRNA can occur if the miRNA is completely complementary to 
the target mRNA nucleotide sequence.  
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4.1.1.4. CRISPR/ cas9  
Clustered regularly interspaced short palindrome repeats associated nuclease Cas9 
(CRISPR/cas9) is a newly introduced technology that allows genome editing and knock-out 
of specific genes more efficiently compared to siRNA and shRNA. It consist mainly of two 
components; guide RNA (gRNA) and cas9 which has endonuclease activity. gRNA includes 
the sequence required for Cas9 binding and a sequence of approximately 20 nucleotides of 
target gene or spacer. Similar to shRNA, CRISPR/cas9 expression can be encoded into a 
vector and packaged inside viral particles for target cell transduction. Cas9 guided by gRNA 
induces DNA double strand breaks at specific genomic loci, which can be repaired by either 
non-homologous end joining (NHEJ) or homology direct repair systems. Both systems can 
imprecisely repair double strand breaks by introducing frameshift, insertion or deletion 
mutations at coding regions of target genes, which can result in a loss of function (Sander and 
Joung, 2014).  
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Figure 4.1: Schematic representation of gene silencing by siRNA and shRNA. 
siRNA molecule is transfected into target cell using electroporation, or by transfection using 
cationic liposomes or polymer based transfection method. In the cytoplasm of target cell, 
siRNA incorporate into the RNA induced silencing complex (RISC) and cleaved by Argonaute-
2 to separate double strand siRNA. This results in activation of the RISC complex to guide the 
antisense siRNA strand to bind to its complementary mRNA and induce its degradation. shRNA 
molecule is incorporated into a plasmid vector and packaged into viral particles. Viral particles 
are able to penetrate the target cell and the shRNA expression vector is able to integrate into 
the host genome where it is transcribed to pre-shRNA. Pre-shRNA is then processed and 
cleaved by the dicer/TRBP complex to mature shRNA. The shRNA- dicer/TRBP 
(Transactivating response –RNA-binding protein) complex associates with Argonaute-2-RISC 
complex generating siRNA molecules that cleave and degrade mRNA of the target gene. 
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4.2. Aims of this chapter  
Despite the promising reports about targeting APE1 in cancer, this area of research is still 
unexplored in leukaemia, including AML. The aims of the studies described in this chapter 
were to determine whether APE1 silencing using shRNA sensitises AML cells to 
chemotherapy-induced cytotoxicity. 
Specific experimental aims of this chapter were as follows: 
 Generate stable APE1 deficient cells using shRNA and determine the phenotype effect 
of APE1 deficiency on AML cell proliferation and cloning efficiency. 
 Determine the sensitivity of AML cells to different chemotherapeutic agents following 
APE1 knockdown.  
 Determine AP site accumulation subsequent to APE1 silencing. 
 Study the effect of APE1 knockdown on cell cycle kinetics. 
 Determine accumulation of topoisomerase II α and β complexes following APE1 
silencing. 
 Study global gene expression changes following APE1 knockdown.  
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4.3. Results 
4.3.1. TC20™ cell counter validation 
The TC20™ cell counter (Bio-Rad – UK) is an automated cell counter used for cells counting 
during this project. Manual cell counting using the Neubauer haemocytometer is time 
consuming and cell counting is prone to user variability. In order to standardise cell counting 
and minimise variability, the TC20™ automated cell counter was used to provide fast, accurate 
and reproducible cell counts. Validation of the TC20™ automated cell counter was achieved 
by comparing manual cell counts using a Neubauer haemocytometer with the automated cell 
count for every cell line used in this project.  
TC20™ cell counter generated reproducible cell counting with minimal variation compared to 
manual counting with haemocytometer (Figure and table in appendices B and C). Some 
variability in results was observed when cell counts fell below 1x105 cell/ml, which is also a 
recognised problem with manual cell counting.  
 
 
4.3.2. Generation of AML cell lines with stable APE1 knockdown using small hairpin 
RNA (shRNA) 
Five different lentiviral particles carrying APE1 shRNA target sequence (Table 2.3) were 
used to knockdown APE1 in 3 AML cell lines including HL-60, AML3 and U937. Control 
shRNA, which contains non-human off -target shRNA sequence, was used alongside APE1 
shRNA. AML3, U937 and HL-60 were selected as models for AML in experimental work 
during this project for general and specific reasons, as follows: these cell lines have a 
relatively short cell cycle (24-30 hours) and have good cloning efficiency in semi-solid soft 
agar. AML3 cells were specifically selected because it is the only AML cell line with a 
nucleophosmin-1 (NPM1) gene mutation, which is frequently mutated in AML, and its 
inclusion in this work may reflect the effect of APE1 inhibition on AML with NPM1 
mutation. 
Several lentiviral shRNA constructs were able to efficiently silence APE1. Western blotting 
showed that shRNA constructs C1, C2 and C5 achieved 67% to 92% APE1 knockdown at the 
protein level (Figure 4.2), with the C5 construct the most efficient at inducing knockdown. As 
such, construct 5 (C5) was used in the work presented in this chapter. C5 was designed to 
target the GCCTGGACTCTCTCATCAATA sequence in of APE1. The C5 construct uses 
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pLKO_TRC005 backbone vector, which is a modified and improved version of pLKO.1 
vector.  
ShRNA knockdown work used a multiplicity of infection of 2 to minimise multiple 
integration events of the shRNA constructs into cell genome. Multiplicity of infection is the 
ratio of shRNA lentiviral particle to cells. Following shRNA transduction, transduced cell 
populations were exposed to puromycin to selectively kill non-transduced cells; cells carrying 
transduced puromycin resistance genes are not killed by puromycin. Transduced cells were 
then maintained indefinitely in puromycin selection RPMI media. 
It was expected that cell populations knocked down for APE1 would express variable levels 
of APE1 protein on single cell level. Therefore, cells were seeded at low density and colony 
formation assay was performed to generate cell clones originated from single cell with stable 
APE1 knockdown. Cells were grown on semi-solid soft agar for 14 days, then isolated and 
expanded for further characterisation of APE1 expression. 
APE1 protein level in AML cell clones was determined using western blotting and quantified 
using Fuji densitometry. As expected, APE1 protein expression varied between different 
clones and different cell lines (Figures 4.3 and 4.4). Some clones showed negligible protein 
levels. For example, AML3 clones C and D express very low APE1 protein level at 20% and 
15% of APE1 protein, respectively, compared to normal control cells. However, some clones 
showed no reduction in APE1 protein level despite being puromycin resistant. This was 
possibly caused by incomplete integration of shRNA particle into the cell genome and failure 
to achieve sufficient knockdown. Complete knockdown of APE1 was not initially observed in 
AML3, U937 or HL-60 AML cell clones, but this was achieved in subsequent experiments.  
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Figure 4.2: APE1 protein expression in AML cell lines following APE1 knockdown. 
Five lentiviral shRNA constructs (C1 – C5) were used to knockdown APE1 in 3 AML cell 
lines; AML3, U937 and HL-60. APE1 knockdown was investigated using western blotting to 
determine APE1 protein level. Only constructs C1, C2 and C5 generated considerable APE1 
knockdown in all cell lines. Alpha tubulin was used as a loading control. Each blot is 
representative of two independent experiments. 
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Figure 4.3: APE1 protein expression in AML3, U937 and HL-60 subclones generated 
following APE1 knockdown.  
Cell clones were generated on semi-solid soft agar, from AML3, U937 and HL-60 cells 
populations transduced with shRNA C5. APE1 protein expression was determined by western 
blotting following APE1 knockdown. APE1 protein levels vary between different clones. 
Non-target shRNA (control shRNA) was used as control for effects of the transduction 
process on protein expression. Subclones highlighted in red box were used later in growth 
inhibition assay investigations. Alpha tubulin was used as a loading control for AML3 and 
HL-60 cell lines. GAPDH was used loading control for U937 cells. 
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Figure 4.4: Quantification of APE1 protein after APE1 knockdown in AML cells. 
APE1 protein bands and α-tubulin loading controls were quantified from western blots in 
figure 4.3 using Fuji densitometer. APE1 protein levels were firstly normalised to α-tubulin 
loading control for each cell line/clone. Normalised APE1 protein levels were relatively 
normalised to the level of APE1 protein in respective parental control cells. Data presented as 
the percentage of APE1 protein level relative to control cells. 
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4.3.3. Effects of APE1 knockdown on AML cell proliferation and cloning efficiency 
Cell proliferation and colony formation assay survival experiments were performed to 
determine the effect of APE1 knockdown on AML cell growth and viability. Proliferation was 
determined using absolute cell count performed by the TC-20 cell counter and trypan blue 
exclusion dye. All AML cell lines were counted on the first day and seeded at an initial 
density of 5x104 cells/ml and counted every 24 hours for 5 days.  
ShRNA mediated APE1 silencing significantly slowed cell proliferation in HL-60, AML3 and 
U937, which was relatively correlated with APE1 knockdown level in the majority of cases 
(Figure 4.5). For example, HL-60 (clones C and D), U937 (clones C and D), and AML3 
(clones B, C and D) had significantly slower proliferation rates compared to their respective 
controls and compared to clones with APE1 expression. HL-60 clone F, U937 clone B and 
AML3 clone A expressed relatively higher APE1 protein levels and proliferation was 
comparable to controls. These data are consistent with previous reports that APE1 is required 
for normal cell proliferation, and RNAi mediated silencing or inhibition of APE1 reduces 
cells proliferation (Bapat et al., 2010; Zheng et al., 2015).  
Colony formation assays (CFA) were also performed to investigate the effect of APE1 
knockdown on the ability of AML cells to survive in semi-solid soft agar. 
APE1 silencing was associated with a significant reduction of cloning efficiency in AML3, 
U937 and HL-60 (Figure 4.6). In particular, AML3 cell line was particularly hypersensitive to 
APE1 knockdown. AML3 clone C were not able to form colonies and had a very slow cell 
proliferation rate.  
To confirm whether APE1 protein level significantly correlate with proliferation and cloning 
efficiency, APE1 protein levels in AML cells (measured by densitometer in figure 4.4) were 
plotted against normalised proliferation rates and cloning efficiency for each cell line/clone to 
generate linear regression plot. Result showed significant correlation between APE1 protein 
level and cell proliferation and cloning efficiency in the majority of cases (Figure 4.7).  
 
 
 
111 
 
 
 
Figure 4.5: Effect of APE1 shRNA mediated knockdown on AML cells proliferation. 
APE1 knocked down (APE1-KO) clones and off-target shRNA control cells were seeded at 
the density of 2x104 cells/ml and cell count was performed every 24 hours for 5 days. APE1 
knockdown significantly reduced cell proliferation of (A) AML3 (B) U937 and (C) HL-60 
cells. Reduction of cell proliferation is consistent with APE1 knockdown level. All data 
presented are the mean and standard deviation of 3 independent experiments.  
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Figure 4.6: Effect of APE1 shRNA mediated knockdown on AML cells cloning 
efficiency. 
APE knockdown in (A) AML3, (B) U937 and (C) HL-60 reduced their cloning efficiency. 
Data represent the mean of 3 independent experiment and error bar of standard deviation. 
Unpaired parametric t test was used to calculate p values. p < 0.05 (*), p < 0.01 (**), p < 
0.001 (***) or p < 0.0001 (****). 
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Figure 4.7: Correlation between APE1 protein level in AML cells, and proliferation rate 
and cloning efficiency. 
APE1 protein levels were plotted against (A) proliferation rate (relative to controls) and (B) 
absolute cloning efficiency of AML3, U937 and HL-60 cells/clones. Linear regression plot 
was generated and analysis showed significant correlation between APE1 protein level and 
proliferation rate and cloning efficiency. P value < 0.05 were considered significant. 
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4.3.4. APE1 re-expression in AML enhanced cell proliferation 
APE1 protein expression was assessed in APE1 knockdown clones at 4, 8 and 12 weeks of 
shRNA transduction by western blotting (APE1 knockdown levels after 4 weeks are shown in 
Figure 4.5). APE1 protein expression was stably knockdown in all investigated AML cells, 
however, it was re-expressed after 12 weeks in continuous culture for all three AML cell lines 
investigated. Furthermore, APE1 re-expression was associated with an increase in 
proliferation rate comparable to that seen in control cells (Figures 4.8 and 4.9). For example, 
AML3 APE1-KO clones B and C, which had a very low proliferation rate and low APE1 
expression immediately post-transduction (Figure 4.5), retained their normal growth rate upon 
APE1 re-expression. This result provides further evidence that APE1 expression is directly 
associated with AML cell proliferation.  
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Figure 4.8: APE1 protein re-expression in APE1 knockdown cells after 12 week of 
shRNA transduction. 
APE1 protein expression in APE1 knockdown cells was investigate every for 4 weeks after 
shRNA knockdown. APE1 protein was re-expressed after 12 weeks of knockdown.  
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Figure 4.9: Effect of APE1 re-expression on cell proliferation of AML cells with APE1 
knockdown. 
AML cells with APE1 knockdown retain normal proliferation after simultaneous APE1 re-
expression after 12 weeks of APE1 knockdown with shRNA. 
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4.3.5. Effect of APE1 knockdown on AML cell cycle 
APE1 knockdown significantly reduced cell proliferation of AML cell lines AML, U937 and 
HL-60 as demonstrated in section 4.3.3. This may suggest a possible role for APE1 in the 
regulation of the cell cycle and induction of cell cycle arrest. To investigate this hypothesis, 
cell cycle distribution was investigated, and performed on unsynchronised APE1 knockdown 
cell clones and shRNA control cells. Propidium iodide (PI) was used to stain cellular DNA as 
described in section 2.9. Intriguingly, however, no alteration in cell cycle distribution was 
observed in APE1 knockdown cells (Figure 4.10). Further quantitation of cell cycle 
distribution using CellQuest software showed no significant alteration in APE1 knockdown 
cell clones compared to control clones (Table 4.1 and Figure 4.11). 
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Figure 4.10: The effect of APE1 knockdown on AML cell cycle distribution. 
Cell cycle analysis was performed on flow cytometer to investigate the effect of APE1 
knockdown on cell cycle kinetics in (A) AML3, (B) U937 and (C) HL-60. Figures in the left 
panel represent shRNA off-target control cells and figures at the right panel represents APE1 
knockdown (APE1-KO) cells. Cell cycle analysis was performed on 3 independent 
experiments. No alteration in cell cycle distribution was observed following APE1 
knockdown in AML cells.   
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Cells SubG1 % G1/G0 % S % G2/M % 
AML3 control 2.6 60.7 21.5 15.3 
AML3 APE1-KO 2.5 59.7 23.4 14.5 
U937 Control 0.4 58.9 29.7 11.8 
U937 APE1-KO 4.7 54.5 26.6 14.0 
HL-60 control 1.5 52.7 33.8 12.5 
HL-60 APE1-KO 3.6 49.0 32.2 15.2 
 
Table 4.1: Distribution of AML cells in different cell cycle phases after APE1 shRNA 
knockdown. 
Cell cycle analysis was performed on unsynchronized APE1 knockdown (APE1-KO) cells 
and control cells. Quantification of cell cycle distribution was performed using CellQuest 
software. Values presented are the means 3 independent experiments. Percentage of cells in 
each phase of the cell cycle may not add up to exactly 100% in total for each sample. 
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Figure 4.11: Distribution of AML cells in cell cycle phases after APE1 knockdown. 
Cell cycle analysis was performed on flow cytometer to determine AML cell cycle kinetics 
after APE1 knockdown. Graphs shows that APE1 knockdown did not alter cell cycle kinetics. 
Some clones showed relatively less, but not significant, cells in s phase compared to control 
cells. Percentages of cells in each cell cycle phase are summarised in table 4.1. Data represent 
the mean of 3 independent experiments for 3 independent APE1-KO clones and the error bars 
of standard deviation.
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4.3.6. Cytotoxicity in APE1 Knockdown Cell Lines Following Treatment with cytotoxic 
DNA damaging agents 
It has been reported that APE1 silencing sensitises cancer cells to chemotherapy induced 
cytotoxicity (Wang et al., 2004; Montaldi et al., 2015; Zheng et al., 2015). The aim of this 
section was to investigate the sensitivity of APE1 knockdown cells to chemotherapy induced 
cytotoxicity. This was achieved by two methods including growth inhibition assay using 
trypan blue exclusion dye and cell counter, and colony formation assay in semi-solid soft 
agar. Cytotoxic agents including temozolomide (TMZ), Ara-C, daunorubicin, etoposide, 
clofarabine and fludarabine, were used to assess sensitivity of AML cells to anti-leukaemic 
chemotherapy. These agents have different mechanisms of action and mainly operate in S 
phase of the cell cycle. TMZ was used as a positive control drug because it induces DNA 
damage repaired by BER, including N3-methyladenine (9%) and N7-methylguanine (70%) 
(Zhang et al., 2012). Thus, APE1 knockdown is predicted to potentiate TMZ mediated 
cytotoxicity.  
To investigate sensitivity of AML cells to APE1 knockdown using growth inhibition assay 
method, several independent APE1 deficient clones of AML3, U937 and HL-60 (APE1 
protein knockdown represented in Figure 4.3) were treated with several cytotoxic 
chemotherapeutic agents. Results are presented as the percentage of viable cells in the treated 
cell suspension compared to viable cells in the vehicle control treated cell suspension.  
APE1 knockdown AML cells showed either no or reduced sensitivity to all chemotherapy 
agents investigated, compared to their respective control cells. As such, APE1 knockdown 
was occasionally antagonistic. For example, AML3 APE1 knockdown clones were modestly 
sensitive to Ara-C, clofarabine and fludarabine, but sensitivity to TMZ, daunorubicin and 
etoposide was unaffected (Figure 4.12 left). U937 APE1 knockdown cell clones were not 
differentially sensitive to temozolomide, daunorubicin clofarabine or fludarabine, relative to 
their respective control (Figure 4.13 left). However, APE1 knockdown was associated with 
modest antagonism of Ara-C and etoposide-induced growth inhibition, and particularly so at 
high levels of growth inhibition. APE1 knockdown in HL-60 cells conferred slight sensitivity 
to etoposide, but antagonised fludarabine-induced growth inhibition (Figure 4.13 left).  
Antagonism of chemotherapy-induced growth inhibition is likely to be influenced, at least, by 
slow proliferation of APE1 knockdown cells. To illustrate this point, growth inhibition curves 
were modified to show absolute cell count for each cell line/treatment. Consistent with the 
cell proliferation results described in section 4.3.3, APE1-deficient cells had significantly 
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slower proliferation compared to controls (Figures 4.12, 4.13 and 4.14 – right panel figures). 
Therefore, slow proliferation may reduce the efficacy of cytotoxic drugs that target rapidly 
proliferating cells.  
It was noted that AML3 and HL-60 cell clones, irrespective of APE1 status, were relatively 
insensitive to TMZ-induced cytotoxicity (Figures 4.12A and 4.14A). This is potentially 
explained by high methylguanine DNA methyltransferase (MGMT) expression in these cell 
lines, which repairs TMZ induced DNA lesion O6-methylguanine lesions. In contrast, U937 
are MGMT-deficient and were hypersensitive to TMZ induced cytotoxicity. Moreover, U937 
cells are proficient in DNA mismatch repair, which mediates cell death signalling in response 
to DNA methylating agents in cells with deficient MGMT expression (Horton et al., 2009a).  
Moreover, colony formation assay consistently confirmed the phenotype observed in the 
growth inhibition assay described above in this section. Two independent APE1 deficient HL-
60, AML3 and U937 clones (Figure 4.15) and their counterpart control clones were exposed 
to TMZ, Ara-C or daunorubicin for 24 hours, prior to plating in soft agar for colony formation 
as described in section 2.8.2.  
APE1 knockdown antagonised the inhibitory effects of TMZ, Ara-c and daunorubicin in all 
three cell lines tested, and particularly so for TMZ and daunorubicin (Figure 4.16).  
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Figure 4.12: Growth inhibition in response to anti-AML treatment in APE1 knockdown 
AML3 cell line. (Continued on next page). 
Cytotoxicity was assessed by growth inhibition assay. Two independent APE1 knockdown 
(APE1-KO) clones with off-target shRNA control cells were treated with temozolomide 
(TMZ), Ara-C and daunorubicin. Data in left panel figures represent the number of viable 
cells form each treatment as a percentage of the number of viable cells from vehicle only 
treated cells. Right panel figures shows the absolute cell count for each cell line/drug dose. 
(A) Cytotoxicity in response to TMZ. (B) Cytotoxicity in response to Ara-C (C) Cytotoxicity 
in response to daunorubicin. In each case, results represent the mean and standard deviation of 
three independent experiments. 
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Figure 4.12: Growth inhibition in response to anti-AML treatment in APE1 knockdown 
AML3 cell line (Continued from previous page). 
Cytotoxicity was assessed by growth inhibition assay. Two independent APE1 knockdown 
(APE1-KO) clones with off-target shRNA control cells were treated with clofarabine, 
fludarabine and etoposide. Data in left panel figures represent the number of viable cells form 
each treatment as a percentage of the number of viable cells from vehicle only treated cells. 
Right panel figures shows the absolute cell count for each cell line/drug dose. (D) 
Cytotoxicity in response to clofarabine (E) Cytotoxicity in response to fludarabine and (F) 
Cytotoxicity in response to etoposide. In each case, results represent the mean and standard 
deviation of three independent experiments. 
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Figure 4.13: Growth inhibition in response to anti-AML treatment in APE1 knockdown 
U937 cell line. (Continued on next page). 
Cytotoxicity was assessed by growth inhibition assay. Two independent APE1 knockdown 
(APE1-KO) clones with off-target shRNA control cells were treated with temozolomide 
(TMZ), Ara-C and daunorubicin. Data in left panel figures represent the number of viable 
cells form each treatment as a percentage of the number of viable cells from vehicle only 
treated cells. Right panel figures shows the absolute cell count for each cell line/drug dose. 
(A) Cytotoxicity in response to TMZ. (B) Cytotoxicity in response to Ara-C (C) Cytotoxicity 
in response to daunorubicin. In each case, results represent the mean and standard deviation of 
three independent experiments. 
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Figure 4.13: Growth inhibition in response to anti-AML treatment in APE1 knockdown 
U937 cell line (Continued from previous page). 
Cytotoxicity was assessed by growth inhibition assay. Two independent APE1 knockdown 
(APE1-KO) clones with off-target shRNA control cells were treated with clofarabine, 
fludarabine and etoposide. Data in left panel figures represent the number of viable cells form 
each treatment as a percentage of the number of viable cells from vehicle only treated cells. 
Right panel figures shows the absolute cell count for each cell line/drug dose. (D) 
Cytotoxicity in response to clofarabine (E) Cytotoxicity in response to fludarabine and (F) 
Cytotoxicity in response to etoposide. In each case, results represent the mean and standard 
deviation of three independent experiments.
127 
 
 
 
Figure 4.14: Growth inhibition in response to anti-AML treatment in APE1 knockdown 
HL-60 cell line. (Continued on next page). 
Cytotoxicity was assessed by growth inhibition assay. Three independent APE1 knockdown 
(APE1-KO) clones with off-target shRNA control cells were treated with temozolomide 
(TMZ), Ara-C and daunorubicin. Data in left panel figures represent the number of viable 
cells form each treatment as a percentage of the number of viable cells from vehicle only 
treated cells. Right panel figures shows the absolute cell count for each cell line/drug dose. 
(A) Cytotoxicity in response to TMZ. (B) Cytotoxicity in response to Ara-C (C) Cytotoxicity 
in response to daunorubicin. In each case, results represent the mean and standard deviation of 
three independent experiments.
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Figure 4.14: Growth inhibition in response to anti-AML treatment in APE1 knockdown 
HL-60 cells. (Continued from previous page). 
Cytotoxicity was assessed by growth inhibition assay. Three independent APE1 knockdown 
(APE1-KO) clones with off-target shRNA control cells were treated with clofarabine, 
fludarabine and etoposide. Data in left panel figures represent the number of viable cells form 
each treatment as a percentage of the number of viable cells from vehicle only treated cells. 
Right panel figures shows the absolute cell count for each cell line/drug dose. (D) 
Cytotoxicity in response to clofarabine (E) Cytotoxicity in response to fludarabine and (F) 
Cytotoxicity in response to etoposide. In each case, results represent the mean and standard 
deviation of three independent experiments. 
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Figure 4.15: APE1 protein expression in AML cells following APE1 knockdown using 
shRNA. 
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4.3.7. Effect of APE1 knockdown on AP sites accumulation 
AP site quantification, using the aldehyde reactive probe (ARP) assay, was undertaken to 
determine the ability of APE1 deficient cell clones to resolve AP sites after induction of DNA 
damage by hydrogen peroxide (H2O2). ARP reacts specifically with the aldehyde group that 
present on the open ring form of AP site. After treating DNA with ARP, AP sites are tagged 
with biotin residues, and can then be quantified by colorimetric detection via the biotin/avidin 
reaction. 
HL-60, AML3 and U937 APE1 knockdown cells and their respective controls were treated 
with 50 µM H2O2 for one hour to induce DNA damage, and then prepared for AP site assay as 
described in section 2.10.  
The ARP assay was performed using two independent AP site assay kits supplied by Abcam, 
UK and Cell Biolabs, Inc, UK. These kits share the same assay principle discussed in 
section 2.10, and utilise the same reagents and controls. AP sites were determined in 3 
technical replicate for each sample with each assay kit. There was no difference in AP site 
frequency between untreated APE1 proficient and deficient cell clones. AP sites were 
detectable at low levels in all cell lines prior to H2O2 treatment, indicating that these AP sites 
normally exist in cellular DNA. Induction of AP sites was observed 2 hours following 
treatment with H2O2 in all cell lines, with decreasing numbers of AP sites thereafter (Figure 
4.17). Based on a single replicate experiment APE-1 knockdown cells appeared to display 
higher accumulation of AP sites after two hours, but this would need to be confirmed by 
further repeat experiments. Intriguingly, the AP site frequency returned to control background 
levels very rapidly (within 4 hours of H2O2 treatment) in all APE1 deficient cell clones. 
Again, this observation is from a single replicate and requires additional work for 
confirmation. 
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Figure 4.17: AP sites quantification after APE1 silencing in AML cells. 
AP sites determination in AML3, U937 and HL-60. Control cells and APE1 knockdown cells 
(APE1 KO) were pre-treated with 50 µM of hydrogen peroxide (H2O2) for 1 hour. AP sites 
were quantified using aldehyde reactive probe (ARP) based assay prior treatment and after 2, 
4 and 8 hours after treatment. AP sites were quantified using two independent AP site kit 
assay from two independent suppliers. Data represent single experiment. 
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4.3.8. Determination of TOP2 complexes following exposure to Etoposide using TARDIS 
assay (Trapped in agarose DNA immunostaining) 
The aim of this section was to investigate whether APE1 knockdown contribute to 
accumulation of TOP2A and TOP2B complexes in AML cells following treatment with 
etoposide, a topoisomerase poison.  
APE1 knockdown in HL-60 and U937 was confirmed by western blot analysis (Figure 4.18). 
Two independent clones from each cell line and their appropriate controls were used in the 
TARDIS assay. U937 (clones E and H) and HL-60 (clones D and H) were exposed to 100 µM 
of etoposide (topoisomerase II poison) for 1 hour. Cells were then harvested to perform 
TARDIS as described in section 2.11. GraphPad prism software was used to analyse data and 
to calculate P values. Unpaired parametric t test was used to calculate p values. P values less 
than 0.05 were considered significant. 
HL-60 and U937 APE1 knockdown cell clones had lower TOP2A complex accumulation 
following etoposide treatment compared to APE1 proficient control cell clones. For example, 
APE1 deficient HL-60 clones D and H showed significant lower TOP2A complexes (22% 
and 15%, respectively) following incubation with etoposide (Figure 4.19). Similarly, U937 
clones E and H also demonstrated 22% and 19%, respectively, less TOP2A complexes 
compared to controls (Figure 4.19). When combining all data of HL-60 and U937, APE1 
deficient cells showed 18.84±3.514 STD (P value = 0.002) less TOP2A complexes compared 
to APE1 proficient control cells. Although inconsistent with the observation by colleagues in 
the Institute for Cell and Molecular Biosciences, these data are consistent with the result 
described in section 4.3.6 demonstrating reduced sensitivity of APE1 knockdown cells to 
etoposide induced cytotoxicity.  
Stabilisation of TOP2B complexes was observed in APE1 knockdown cells which led to an 
increased accumulation of these complexes compared to APE1 proficient control cell clones. 
Generally, APE1 knockdown in HL-60 and U937 increased TOP2B complex accumulation, 
but this was not true in HL-60 clone D which showed less complex accumulation compared to 
control cells (Figure 4.20). When combining all data for HL-60 and U937, TOP2B complex 
accumulation in AML cells was not statistically significant (P value = 0.06) when stratified by 
APE1 status, even after excluding the HL-60 clone D result as an outlier.  
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Figure 4.18: APE1 knockdown in AML cells used in TARDIS assay. 
Western blots shows the level of APE1 knockdown in (A) HL-60 and (B) U937 cells used in 
TARDIS assay. Clones highlighted in red boxes were used in TARDIS experiments.  
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Figure 4.19: Effect of APE1 knockdown on cellular TOP2A levels. 
The TARDIS assay was performed to investigate the role of APE1 knockdown on etoposide 
induced TOP2A-DNA complex formation.  
(A) Dot blot represent TARDIS fluorescence intensity measurement on single cell level 
in HL-60 (left) and U937 (right). Data are normalised to control cells treated with etoposide. 
Red line represent the median of fluorescence intensity.  
(B) Mean of integrated FITC of HL-60 (left) and U937 (right) treated APE1-KO cells and 
control cells of as percentage of mean of integrated FITC of etoposide treated control cells. 
This result represent the mean of the median of three independent experiments. Unpaired 
parametric t test was used to calculate P values. **** indicate P value < 0.00005. 
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Figure 4.20: Effect of APE1 knockdown on cellular TOP2B levels. 
The TARDIS assay was performed to investigate the role of APE1 knockdown on etoposide 
induced TOP2A-DNA complex formation.  
(A) Dot blot represent TARDIS fluorescence intensity measurement on single cell level 
in HL-60 (left) and U937 (right). Data are normalised to control cells treated with etoposide. 
Red line represent the median of fluorescence intensity.  
(B) Mean of integrated FITC of HL-60 (left) and U937 (right) treated APE1-KO cells and 
control cells of as percentage of mean of integrated FITC of etoposide treated control cells. 
This result represent the mean of the median of three independent experiments. Unpaired 
parametric t test was used to calculate P values. **** indicate P value < 0.00005. 
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4.3.9. RNA sequencing reveals upregulation of genes involved in cell cycle control and 
leukaemia pathogenesis  
RNA sequencing using Illumina HiSeq 2500 was performed to explore the effect of APE1 
knockdown in AML cells, as well as potentially identifying possible mechanism of 
antagonism in APE1 knockdown cells following exposure to anti-leukaemic chemotherapy 
agents. 
Two AML cell lines were used in this experiment HL-60 and AML3. APE1 knockdown was 
confirmed in APE1 shRNA transduced cells and expression confirmed in their respective 
control cells by assessment of protein level using western blotting (Figure 4.21). APE1 
deficient cells, including AML3 clone 5 and HL-60 clone 7, were chosen for RNA sequence 
analysis. RNA quality was assessed using the Agilent RNA 6000 Nano Kit (Agilent 
Technologies, UK) and the Agilent 2100 Bioanalyzer, as described in section 2.7. The results 
represent the average of 3 technical replicates for two cell lines. To exclude cell-type-specific 
effects of APE1 knockdown, upregulated/downregulated genes common to both cell lines are 
reported and discussed here, and p value < 0.05 was deemed to be statistically significant. P 
values were calculated using Wald parametric test, and adjusted for multiple testing using the 
Benjamini-Hochberg algorithm. RNA sequencing data were analysed using DESeq2 software 
V 3.2. This analysis was kindly performed by Dr Yaobo Xu, (Institute of Genetic Medicine, 
Newcastle University). 
APE1 knockdown significantly upregulated 176 genes and downregulated 191 genes in both 
cell lines (listed in tables in appendices D and E). APE1 knockdown was confirmed by RNA 
sequencing in both AML cell lines, HL-60 and AML3, by 12.6 and 8.6 folds respectively, and 
with a p value < 0.0001 in both cell lines. Interestingly, no significant differences in gene 
expression were found in those genes involved in the BER pathway, with the exception of 
NEIL2 that was significantly downregulated approximately 2 fold in APE1 deficient HL-60 
cells compared to control cell clones. Furthermore, there was no significant alteration in the 
expression of the majority of genes involved in cellular DNA repair, with the exception that 
GTF2H1, GTF2H2C and GTF2H3, which encode protein products involved in nucleotide 
excision repair, was significantly downregulated in APE1 deficient cell clones. In addition, 
XRCC6, which plays a role in DNA non-homologous end joining (NHEJ) required for double-
strand break repair, was significantly downregulated in APE1 deficient cells.  
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Figure 4.21: APE1 knockdown in AML3 and HL-60 cells used for RNA sequencing. 
Cell clones were generated on semi-solid soft agar from AML3 and HL-60 cells populations 
transduced with shRNA C5. APE1 knockdown was confirmed on protein level in (A) AML3 
and (B) HL-60 cells, which were used for RNA sequencing. AML3 clone C and HL-60 clone 
E were used for RNA sequencing. 
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Several genes identified as being indirectly transcriptionally regulated byAPE1 were not 
changed following APE1 knockdown, including NF-κB, JUN, FOS, TP53, YBX1, HIF1α, 
SIRT1, GAPDH, STAT3, CBP/p300, HDAC1 and NRF2. 
The EGR1 transcription factor that has previously been reported to interact with APE1 was 
significantly upregulated 2.3 and 1.8 fold in AML3 and HL-60, respectively (P values 
<0.0001 for AML3 and p=0.002 for HL-60). Furthermore, PAX5 transcription factor and 
CDKN1A (p21) cell cycle regulator were differentially overexpressed 2 to 3 fold in both cell 
lines. Western blotting was performed to confirm PAX5 and CDKN1A upregulation on 
protein level. PAX5 protein level upregulation was confirmed in APE1-deficient HL-60 cells. 
However, CDKN1A was undetectable at the protein level in AML3 cells (Figure 4.22A), 
which is explained by low RNA transcripts reads in this cell line (Figure 4.22B). 
Additionally, CDKN1A protein was upregulated in AML3 (Figure 4.22A). HL-60 cell 
showed negligible CDKN1A protein due to low RNA transcripts read (Figure 4.22C). 
Notably, two BCL2 family genes, BCL2A1 and BCL2L11, were differentially upregulated in 
APE1 knockdown cells. The BCL2 gene family plays an essential role in cell survival via 
anti-apoptotic function and impairment of the G0/G1 transition (Zhao et al., 2008). In 
addition, ALDH3B1, which is thought to be involved in the defence against oxidative stress 
and lipid peroxidation (Marchitti et al., 2007), was overexpressed in APE1 deficient cells. 
Collectively, BCL2 and ALDH3B1 activation may support AML cells survival advantage 
after APE1 knockdown and may explain the tolerance/resistance observed when exposed to 
cytotoxic therapy. 
Some transcription factors and tumour suppressor genes that have been previously linked to 
AML pathogenesis, such as FOXO1, CUX1, NPM1, and DNMT3B, were also altered 
following APE1 knockdown. The FOXO1 (Forkhead Box O1) transcription factor, that has 
been reported to enhance AML transformation and progression (Sykes et al., 2011; Kode et 
al., 2016), was upregulated 2 fold in HL-60 and AML3 cell lines. APE1 knockdown also led 
to upregulation of the CUX1 (Cut-Like Homeobox 1) transcription factor. NPM1 and 
DNMT3B were significantly downregulated in both cell lines. NPM1 has previously been 
shown to interact with APE1 and modulate its function (Vascotto et al., 2013; Poletto et al., 
2014). However, NPM1 downregulation following APE1 knockdown may provide further 
evidence of direct interaction with NPM1. 
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Figure 4.22: PAX5 and CDKN1A protein and transcripts levels in HL-60 and AML3 
cells. 
RNA sequencing data showed upregulation of PAX5 and CDKN1A expression after APE1 
knockdown in HL-60 and AML3 cell lines. (A) Determination of PAX5 protein expression by 
western blotting showed upregulation of protein level in HL-60 only. CDKN1A was 
upregulated on protein level in AML3 cells only. (B) PAX5 normalised transcripts reads were 
relatively low in AML3 cells compared to HL-60, therefore were undetectable by western 
blotting. (C) Normalised transcripts reads of CDKN1A in HL-60 cells were also relatively low 
compared to AML3, thus corresponding with undetectable protein levels shown in western 
blotting result. 
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Intriguingly, FLT3 was significantly downregulated 1.7 fold in APE1 deficient AML3 cell 
clones compared to APE1 proficient control clones (p value <0.00001). In contrast, FLT3 
expression was upregulated 2 fold in APE1 deficient HL-60 cell clones, but was not 
statistically significant due to very low RNA transcript levels (P value = 0.4). Furthermore, 
APE1 knockdown led to significantly down regulated Bruton's tyrosine kinase (BTK) 
expression. BTK plays an important role in normal B-cell differentiation and hematopoietic 
signalling and is a potential targets for AML therapy (Rushworth et al., 2014; Pillinger et al., 
2015). 
Etoposide treatment had no effect on AML cells following APE1 knockdown as shown in 
section 4.3.6. Furthermore, the TARDIS assay revealed a significant reduction in TOP2A 
complex formation, but not TOP2A, following etoposide treatment (section 4.3.8). These 
result suggest downregulation of TOP2A and no alteration in TOP2B expression in APE1 
knockdown cells. Consistent with this notion, APE1 knockdown was associated with 
downregulation of TOP2A expression in both cell lines but this was not statistically 
significant. Moreover, TOP2B was also downregulated 1.1 to 1.3 fold in both cell lines but 
this was not statistically significant.  
Interestingly, APE1 knockdown was associated with reduced bleomycin hydrolase (BLMH) 
expression, which encodes a protein that catalyses inactivation of bleomycin and reduces its 
cytotoxicity. This result supports the observation that APE1 overexpression confers 
bleomycin resistance and APE1 silencing enhances bleomycin induced cytotoxicity (Schild et 
al., 1999; Robertson et al., 2001; Fung and Demple, 2011). 
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4.4. Discussion 
4.4.1. APE1 knockdown impairs AML cell growth 
APE1 knockdown has previously been demonstrated to reduce cell proliferation in several 
cancer models (Fung and Demple, 2005; Vascotto et al., 2009b; Jiang et al., 2010; Cun et al., 
2013). Herein, it was clearly evident that shRNA-mediated APE1 knockdown significantly 
impaired cell proliferation and cloning efficiency of AML cell lines HL-60, AML3 and U937. 
Moreover, the reduction in cell proliferation approximately correlated with APE1 protein 
levels. Furthermore, spontaneous re-expression of APE1 led to restoration of normal 
proliferation in AML cells, confirming that the reduction in proliferation was due to loss of 
APE1 expression. 
RNA sequencing data demonstrated significant reduction of MAPK3 expression after APE1 
knockdown in AML cells. MAPK3 play vital role in a variety of cellular processes such as 
proliferation, differentiation and transcription regulation. Consistently, downregulation of 
MAPK3 has been reported previously following APE1 knockdown (Juliana et al., 2012; 
Wang et al., 2013b). It has been demonstrated that APE1 overexpression enhances cell 
proliferation via activation of IL-21 induced MAPK3/1 (Juliana et al., 2012). APE1 
knockdown dramatically reduced IL-21 induced MAPK3/1 and impaired cell proliferation 
and enhanced cell death, but these effects were reversible by APE1 re-expression (Juliana et 
al., 2012). In addition, it is highly possible that upregulation of CUX1 (Cut-Like Homeobox 
1) expression inhibits proliferation following APE1 knockdown. CUX1 is thought to 
negatively regulate hematopoietic cells proliferation and its knockdown induced over-
proliferation of haemocytes in a Drosophila model and enhanced engraftment of human 
haematopoietic cells in immunodeficient mice (McNerney et al., 2013). A putative role for 
CUX1 and other genes as regulators of AML cell proliferation is discussed in more detail in 
section 4.4.5.  
APE1 is essential for embryonic development, cell survival and cell viability; Ape1 
loss/mutation in mouse models induces embryogenic lethality at day 5 to 9 (Xanthoudakis et 
al., 1996; Ludwig et al., 1998; Meira et al., 2001). Intriguingly however, complete loss of 
APE1 protein by shRNA mediated knockdown was not lethal to some AML clones shown in 
Figures 4.15 and 4.21. It is feasible that APE1 expression was not completely abolished and 
was below the detection level of western blotting. RNA sequencing data showed that APE1 
transcript was very low but detectable in APE1 knockdown cells. More likely, APE1 
expression is essential for cell viability in an embryonic context, but not in transformed fully 
differentiated AML cells. Consistent with this notion, a recent study demonstrated no effect 
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on survival or growth in a mouse B cell line (CH12F3) following APE1 gene deletion 
(Masani et al., 2013). However, the mechanism by which APE1 loss induces embryonic 
lethality remains to be fully delineated.  
These findings therefore add to a growing body of evidence that APE1 is an important 
modulator for cell proliferation and provide protection against DNA damage and oxidative 
stress. Since shRNA is not a specific tool to inhibit a particular protein function, it was not 
possible to differentiate between the contribution of different APE1 functions (namely DNA 
repair and redox functions) on cell phenotype. Although both functions are critically 
important to cellular physiology, the precise mechanisms by which APE1 perform its vital 
functions are still not fully understood. Nevertheless, APE1 downregulation reduces DNA 
repair capacity as well as impairing redox regulation function, and may trigger activation of 
alternative mechanisms to allow cells to repair accumulating damage and circumvent cell 
death.  
 
4.4.2. APE1 and cell cycle regulation 
Despite impaired cell proliferation and dysregulation of several genes involved in cell cycle 
modulation such as CDKN1A, E2F7 and CDC42 in APE1 knockdown cells, this seems not 
sufficient to induce cell cycle arrest in AML cells, where there was no clear alteration in cell 
cycle distribution shown by cell cycle analysis. In addition, there was no evidence of 
increased cells in subG1 phase, as indication of apoptosis, in cell cycle analysis. Given that 
APE1 is highly expressed in the early and middle S phase (Fung et al., 2001) and maintains 
the integrity of DNA by preventing mutagenic events during DNA synthesis. It is plausible 
that APE1 downregulation triggers cell cycle modulators such as CDKN1A and other cell 
cycle checkpoints to prevent cell transition into S phase, thus slowing proliferation of cells 
that harbour pro-mutagenic DNA lesions. However, activation of G1 checkpoints by 
CDKN1A is predicted to result in G1 arrest but this was not observed in APE1 knockdown 
cells. Alternatively, reduced DNA repair capacity and higher DNA damage could 
simultaneously activate G1, S and G2/M checkpoints, result in slower transit through all 
phases of the cell cycle. As such, cell cycle analysis using propidium iodide would not be 
sufficiently sensitive to identify such an effect. Rather cell cycle analysis using 
bromodeoxyuridine (BrdU) could be used to track the transit of cells through the different cell 
cycle stages. Alternatively, the DNA fibre assay (Nieminuszczy et al., 2016), which provides 
a direct measure of replication fork speed, could also be used to investigate this phenomenon. 
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However, APE1 involvement in cell cycle control has been well established in several studies 
(Fung et al., 2001; Zou et al., 2007; Jiang et al., 2010), but the exact mechanism by which it 
modulate cell cycle is yet to be defined (Fishel et al., 2008). Available evidence is conflicting 
and inconclusive regarding the influence of APE1 on cell cycle kinetics. APE1 knockdown in 
ovarian cell line SKOV-3X altered several components of cell cycle, including S phase 
progression, S phase exit and transition to G1 (Fishel et al., 2008). In addition, APE1 thought 
to regulate the G0/G1-S cell cycle transition in embryonic stem cells, where APE1 
knockdown compromised transition of cells from G0 to S phase (Zou et al., 2007; Fishel et 
al., 2008). Other studies reported cell cycle arrest at G2/M in HEK-293T cells (Sengupta et 
al., 2011) or impaired S to G2M transition in HeLa cells after APE1 knockdown (Vascotto et 
al., 2009b). In contrast, APE1knockdown did not affect cell cycle kinetics in T98G and 
U87MG glioblastoma cell lines (Montaldi et al., 2015). These conflicting reports possibly 
suggest tissue specificity in terms of APE1 function and its role in regulating the cell cycle.  
 
4.4.3. Cytotoxic effect of AML chemotherapy was not enhanced in APE1 knockdown cells 
Sensitivity of APE1 knockdown cells to chemotherapy induced cytotoxicity was not evident 
in this study. This suggests that APE1 and BER do not play a major role in the repair of 
chemotherapy-induced DNA damage, despite some of these agents inducing base damage 
known to be repaired by BER, specifically TMZ. Alternatively, there are possible backup 
mechanisms that could bypass APE1 knockdown.  
The finding that APE1 knockdown confers tolerance/resistance to TMZ is in contrast to 
published evidence that APE1 loss sensitises cancer cells to TMZ (Silber et al., 2002; Luo and 
Kelley, 2004; Montaldi et al., 2015). TMZ was included here as a positive control drug. The 
adducts that are generated by TMZ are mainly repaired by two mechanisms, including direct 
reversal via the activity of O6-methylguanine-DNA methyltransferase (MGMT) and also BER 
via the action of the alkyl adenine DNA glycosylase/methyl purine DNA glycosylase. TMZ 
induces O6-methylguanine DNA adducts, which are mainly repaired by MGMT. TMZ also 
induces N3-methyladenine and N7-methylguanine DNA adducts that are mainly repaired by 
the BER pathway (Zhang et al., 2012). N3-methyladenine is cytotoxic via DNA replication 
inhibition, whereas N7-methylguanine is relatively inert (Fronza and Gold, 2004; Shrivastav 
et al., 2010). Indeed, inappropriate initiation of N7-methylguanine repair may convert this 
inert lesion to a pro-cytotoxic AP site or strand break (Shrivastav et al., 2010; Wirtz et al., 
2010). Unrepaired O6-methylguanine due to MGMT deficiency leads to mismatching of O6-
methylguanine with thymine during DNA replication, which are recognised by MMR (Zhang 
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et al., 2012). MMR activity leads to repeated attempted cycles of repair which ultimately lead 
to the accumulation of DNA double strand breaks and apoptosis (Zhang et al., 2012). 
Therefore, TMZ-induced DNA adducts are largely removed and excised by MGMT and their 
cytotoxicity is primarily dependant on the MMR status of the cells. Thus, APE1 function 
could be bypassed by MGMT and MMR after TMZ treatment. Consistent with this 
conclusion, AML3 cells, which have high MGMT levels, were less sensitive to TMZ-induced 
growth inhibition. In contrast to AML3, U937 cells are MGMT deficient and showed 
corresponding hypersensitivity to TMZ. Furthermore and consistent with this result, early 
clinical trials indicated that TMZ has greater anti-leukaemic efficacy in patients with low 
MGMT expression (Brandwein et al., 2007; Brandwein et al., 2014). 
Daunorubicin is an essential AML treatment and acts on cancer cells through various 
mechanisms including inhibition of DNA synthesis by DNA intercalation, induction of 
oxidative DNA damage through free radical formation, topoisomerase II inhibition and direct 
damage to cellular structures such as the cell membrane (Agrawal, 2007). However, the exact 
mechanisms by which daunorubicin induces cell killing in AML remain unclear. Based on the 
ability of APE1 to act through BER to remove oxidised DNA bases and its involvement in 
regulation of transcription factors under oxidative stress, it was hypothesised that oxidative 
DNA damage induced by free radicals following daunorubicin treatment will be particularly 
damaging to APE1 deficient AML cells. Unexpectedly, APE1 knockdown did not sensitise 
AML cells to daunorubicin, but conferred tolerance/resistance to the cytotoxic effect of this 
anthracycline. This observation suggests that APE1 does not play a major role is mediating 
cellular response to the DNA damage and oxidative stress induced by daunorubicin. More 
likely, the primary mechanism of daunorubicin cytotoxicity is not via induction of oxidative 
DNA damage and the DNA damage resulted from daunorubicin action is not a substrate for 
BER. Furthermore, redox regulation of transcription factors in response to oxidative stress 
induced by daunorubicin is not only modulated by APE1, but can be regulated by multiple 
and complex signalling transduction network (Trachootham et al., 2008; Mikhed et al., 2015). 
HL-60, AML3 and U937 APE1 deficient cells and their relevant controls did not differ in 
sensitivity to the cytotoxic effects of Ara-C, clofarabine or fludarabine. This could be due to 
the nature of DNA damage induced by these agents and the ability of BER, particularly 
APE1, to recognise and remove that damage. Consistent with this notion APE1 inhibition did 
not sensitise cancer cells to Ara-C (Lam et al., 2006; McNeill and Wilson, 2007; McNeill et 
al., 2009). A mutated form of APE1 protein, which lacks the endonuclease function but 
possesses higher AP-DNA binding affinity, was used to inhibit APE1 endonuclease function 
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in vitro and to identify APE1 biological substrates (McNeill and Wilson, 2007; McNeill et al., 
2009). Mutant APE1 expression in Chinese hamster ovary cells enhanced the cytotoxicity of 
methyl methanesulfonate and dideoxycytidine, but not Ara-C, etoposide or cisplatin (McNeill 
and Wilson, 2007; McNeill et al., 2009). This may possibly be due to low APE1 efficiency in 
removing Ara-C nucleotides (Chou et al., 2000; Lam et al., 2006). Furthermore, fludarabine 
nucleotide has been shown to be substrate for uracil-DNA glycosylase (UDG) (Bulgar et al., 
2010), but no evidence was found to suggest APE1 involvement in fludarabine nucleotide 
removal. The growth inhibitory effects of the topoisomerase II inhibitor etoposide were also 
diminished in APE1 knockdown HL-60, AML3 and U937 cell clones. Moreover, an inability 
of etoposide to sensitise APE1 knockdown cells is partially explained by efficient resolution 
of TOP2A complexes in HL-60 and U937 APE1 deficient cell clones following etoposide 
treatment. Moreover, nucleoside analogues and topoisomerase poisons operate more 
efficiently in exponentially proliferating cells, and their efficacy is compromised in cells with 
a low proliferative index, as seen in APE1 knockdown cell clones.  
Taken together, these data strongly suggest that APE1 is not involved in the recognition and 
removal of DNA damage induced by TMZ, Ara-C, daunorubicin, fludarabine, clofarabine and 
etoposide. However, further investigation is required to interrogate this hypothesis. 
Furthermore, targeting APE1 in cancer cells could be challenging in some circumstances 
because of potential redundancy of APE1 function where backup mechanisms are present to 
maintain genome stability and bypass APE1 inhibition. For example, removal of a damaged 
base by the AP lyase function of bifunctional glycosylases such as OGG1 and NEIL-1 creates 
a 3’PUA that can be processed via PNKP and repair via long-patch BER (Figure 1.4), 
therefore bypassing APE1 function (Wiederhold et al., 2004). Moreover, loss of APE1 
function in AML cells following APE1 knockdown might be compensated by APE2, which 
exhibits strong 3’-5’ exonuclease and 3’phosphodiesterase activities and a weak AP 
endonuclease activity (Tsuchimoto et al., 2001; Burkovics et al., 2006; Burkovics et al., 
2009). Tsuchimoto and colleagues (2001) demonstrated that APE2 is mainly localised in 
nuclei and mitochondria and interacts with PCNA in vitro and possibly participates in long 
patch BER. In addition, impaired BER could also be compensated for by an alternative 
pathway. For example, mismatched 5-fluorouracil:G and U:G, which are predominantly 
removed by BER could also be efficiently removed by MMR (Fischer et al., 2007; Schanz et 
al., 2009). Collectively, these observations indicate redundancy in BER to maintain genome 
stability and could explain the lack of sensitivity of AML cells to chemotherapeutic agents 
following APE1 knockdown.  
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Given that APE1 has a role in redox regulation, it is difficult to delineate the exact 
contribution this function makes to determining cellular response to any given agent. 
Nevertheless, alterations in gene expression revealed by RNA sequencing may prove useful in 
this regard.  
 
4.4.4. Effects of APE1 on AP site accumulation 
AP sites are intermediate repair products generated after excision and removal of damaged 
bases by DNA glycosylases. It is estimated that around 10,000 AP sites/cell/day are 
spontaneously generated under normal physiological conditions (Abbotts and Madhusudan, 
2010). AP sites are mutagenic and cytotoxic if unrepaired, and are primarily cleaved and 
removed by APE1. However, targeting APE1 using RNAi or small molecule inhibitors has 
been reported to enhance chemotherapy induced cytotoxicity by promoting AP site 
accumulation and apoptosis activation (Fung and Demple, 2005; Sultana et al., 2012; Abbotts 
et al., 2014). 
Enhanced AP site accumulation was consistently observed in APE1 knockdown cells relative 
to controls following 2 hours of H2O2 treatment. Furthermore, the evidence from these limited 
experiments suggests that AP sites are rapidly resolved in APE1 knockdown to basal level 
within 4 hours of treatment, whereas this process was delayed in control cells, taking up to 8 
hours post-treatment. This unexpected observation suggests two possible mechanisms by 
which AML cells may respond to APE1 depletion. Although unlikely, AP sites may be 
efficiently removed by alternative mechanisms. Alternatively, AP sites may be rapidly 
converted to single strand or double-strand breaks in APE1 deficient AML cells and repaired 
through NHEJ or homology directed repair.  
It should be noted, however, that the AP site assays undertaken in this project were limited in 
scope and scale. As such, additional experiments are required to further confirm whether 
these mechanisms may be operating. Specifically, the comet assay (alkaline and neutral) 
could be performed to detect the nature of strand breaks induced after APE1 
knockdown/inhibition and after treatment with cytotoxic agents. Detection of phosphorylated 
gamma-H2AX by western blotting could also be a useful biomarker for DNA damage and 
double strand breaks after APE1 knockdown/inhibition and after treatment with cytotoxic 
agents. 
Widespread upregulation of alternative DNA repair mechanisms to compensate for APE1 
deficiency was not supported by RNA sequencing data. Specifically, there was no significant 
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alteration in expression of the majority of genes involved in DNA repair pathways. Rather, a 
small number of genes constituting the core element of TFIIF transcription factor involved in 
nucleotide excision repair were significantly downregulated. These genes include GTF2H1, 
GTF2H2C and GTF2H3. In addition, XRCC6, that plays a crucial role in non-homologous 
end joining (NHEJ) required for double-strand break repair, was significantly downregulated. 
 
4.4.5. Gene expression analysis after APE1 knockdown 
APE1 is an essential modulator and coordinator of the BER pathway, as well as playing a key 
role as a redox regulator for several transcription factors involved in cell proliferation, 
survival and cell cycle. APE1 downregulation reduces DNA repair capacity and is predicted 
to trigger gene expression changes to circumvent accumulating DNA damage and promote 
cell survival. RNA sequencing analysis of APE1 knockdown cells revealed alterations in the 
expression of specific genes involved in cell proliferation, cell cycle, tumour suppression, cell 
survival, RNA metabolism, DNA methylation and tumour invasion, including BCL2, 
ALDH3B1, PAX5, CDKN1A, E2F7, EGR1, FOXO1, CUX1, NPM1, DNMT3B, and VEGFB. 
As APE1 knockdown was associated with differential expression of numerous genes in AML 
cells, only those genes putatively involved in AML pathogenesis/prognosis, DNA repair, cell 
proliferation, survival, differentiation and apoptosis will be discussed. Also, it should be noted 
that the data and discussion presented in this section require further validation, because the 
RNA sequencing analysis undertaken in this thesis was relatively limited in scope. 
Upregulation of anti-apoptotic genes BCL2A1 and BCL2L11 in APE1 knockdown cells may 
explain the lack of sensitivity to anti-leukaemic agents. Furthermore, ALDH3B1 upregulation, 
which is involved in protection against oxidative stress and lipid peroxidation (Jin et al., 
2015), may contribute to the resistance of APE1 knockdown cells to daunorubicin induced 
cytotoxicity. Daunorubicin induced cytotoxicity occurs via induction of oxidative stress, lipid 
peroxidation and other mechanisms discussed in section 1.1.6.3.  
 
CDKN1A 
CDKN1A is an essential protein that plays a key role in regulating cell cycle, DNA 
replication, apoptosis and transcription (Cazzalini et al., 2010). Transcriptional activity of 
CDKN1A is primarily regulated by p53, but is also regulated in a p53 independent manner 
(Abbas and Dutta, 2009; Cazzalini et al., 2010). APE1 has dual regulatory roles in CDKN1A-
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mediated transcriptional activation in a p53 dependent manner (Gaiddon et al., 1999; 
Sengupta et al., 2013). It has also been reported that APE1 down regulation leads to 
upregulation of CDKN1A transcript and protein levels in several cancer cell models (Vascotto 
et al., 2009a; Jiang et al., 2010). Consistent with these reports, APE1 knockdown in AML 
cells upregulates CDKN1A expression at both the transcript and protein level. CDKN1A 
upregulation the AML cell lines used in this study may be p53 independent given that the HL-
60 cell line is deleted for the TP53 gene and that AML3 is dysfunctional for p53 function 
(mediated via over-expression of MDM2) despite being wild-type for TP53 (Sutcliffe et al., 
1998; Drexler et al., 2000). It is possible that activation of CDKN1A transcriptional activity 
following APE1 knockdown is mediated by DHRS2 (HEP27), which was significantly 
upregulated after APE1 knockdown. Limited studies have demonstrated that DHRS2 
expression stabilises p53 by attenuation of MDM2-mediated ubiquitination and degradation, 
therefore leading to an accumulation of MDM2 and CDKN1A (Deisenroth et al., 2010).  
 
EGR1 
Early growth response protein 1 (EGR1) transcription factor was upregulated following APE1 
knockdown in HL-60 and AML3 APE1 knockdown cell clones. APE1-EGR1 interaction has 
been demonstrated in vitro in limited studies and thought to stimulate APE1 expression under 
oxidative stress to induce PTEN tumour suppressor gene activation (Pines et al., 2005; Fantini 
et al., 2008). Interestingly, EGR1 acts as tumour suppressor gene in leukaemia and 
haploinsufficiency in murine mice model enhances AML transformation (Joslin et al., 2007; 
Stoddart et al., 2014). Therefore, upregulation of EGR1 after APE1 knockdown may be a 
protective mechanism for AML cells in response to elevated oxidative stress and DNA 
damage.  
 
FOXO1 
Forkhead box protein O1 (FOXO1) transcription factor was upregulated in APE1 knockdown 
AML cell clones and possibly contributed, at least partly, to attenuated cell proliferation and 
resistance/tolerance to chemotherapeutic agents. FOXO1 has been implicated in cancer as 
both an oncogene and tumour suppressor gene (Fu and Tindall, 2008; Sykes et al., 2011; Lin 
et al., 2014; Zhu, 2014; Kode et al., 2016). It is normally required for maintenance of 
haematopoietic stem cells (HPSC) and protects cells against oxidative stress (Tothova et al., 
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2007). Elevated FOXO1 expression is thought to be a pro-leukaemic event and was shown to 
enhance leukaemic transformation through its interaction with components of the β-catenin 
signalling pathway (Kode et al., 2016). In addition, FOXO1 is upregulated in AML1-ETO 
primary AML samples and is thought to contribute to AML progression (Lin et al., 2014). 
Furthermore, FOXO1 inhibition enhances myeloid maturation, differentiation and 
consequently induces apoptosis in human AML cells (Sykes et al., 2011). Collectively, these 
data suggest that FOXO1 upregulation after APE1 knockdown enhances AML cells survival 
and resistance to cytotoxic treatment. However, APE1 and FOXO1 interaction is not yet fully 
characterised and any role in AML pathogenesis would require extensive further 
investigation.  
 
CUX1 
Cut-Like Homeobox 1 (CUX1) transcription factor has tumour suppressor properties as well as 
oncogenic properties (Ripka et al., 2010; Boultwood, 2013; McNerney et al., 2013; Ramdzan 
and Nepveu, 2014; Wong et al., 2014). It is highly expressed in multipotent hematopoietic 
stem cells, but reduced expression is commonly observed in myeloid progenitors (McNerney 
et al., 2013; Ramdzan and Nepveu, 2014). CUX1 is thought to negatively regulate 
hematopoietic stem cell proliferation and its knockdown induced haemocyte over-
proliferation in Drosophila model and enhanced engraftment of human haematopoietic cells 
in immunodeficient mice (McNerney et al., 2013). In contrast, CUX1 overexpression is 
associated with shorter relapse-free survival and plays an important role in tumour 
progression in breast and pancreatic cancer (Michl et al., 2005; Ripka et al., 2010). However, 
a limited study demonstrated enhancement of OGG1 DNA glycosylase activity in vitro by 
CUX1 to accelerate DNA repair following oxidative DNA damage (Ramdzan et al., 2014), 
although no evidence was found indicating an effect of CUX1 expression on APE1 function. 
Taken together, CUX1 overexpression in AML cells following APE1 depletion seems to 
protect cells from oxidative DNA damage by reducing cell proliferation via modulation of 
cell cycle proteins. 
 
LAIR1 
LAIR1 (Leukocyte-Associated Immunoglobulin-Like Receptor 1) expression, which was 
recently ascribed to have a role in AML development, was differentially elevated in APE1 
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deficient cell clones. LAIR1 plays an essential role in development of AML and ALL using 
both in vitro and in vivo approaches (Poggi et al., 2000; Zocchi et al., 2001; Chen et al., 2015; 
Kang et al., 2015). It is expressed in CD34+ hematopoietic stem cell progenitors and seems to 
be expendable for normal haematopoiesis (Chen et al., 2015; Kang et al., 2015). LAIR1 
expression enhanced engraftment of AML cells in a mouse model as well as induced 
leukemic transformation (Kang et al., 2015). Furthermore, LAIR1 knockdown/knockout 
blocked xenograft of AML and B-ALL cells in a mouse model and induced apoptosis of 
AML cells (Chen et al., 2015; Kang et al., 2015). In addition, deletion of LAIR1 in a 
leukaemia mouse model was associated with rapid remission and longer survival time (Chen 
et al., 2015). These data clearly demonstrated the pro-leukaemic role of LAIR1 and suggest a 
potential role for LAIR1 in mediating resistance of APE1 knockdown cells to 
chemotherapeutic agents. It is also possible that APE1 acts as repressor for LAIR1 
expression, thus investigation of the mechanistic interaction between APE1 and LAIR1 may 
help delineate the contribution of both proteins to AML pathogenesis and resistance to 
chemotherapy. 
 
In addition to the upregulation of several tumour suppressor genes/oncogenes that 
conceivably play a role in AML tolerance/resistance to chemotherapeutic agents, intriguingly, 
APE1 knockdown was also associated with downregulation of several genes that contribute to 
AML pathogenesis, prognosis and tumours invasion such as NPM1, DNMT3B and VEGFB. 
NPM1 modulates and stabilises BER proteins, specifically APE1, and is thought to 
orchestrate BER through regulation of protein translocation to the nucleoplasm under 
conditions of oxidative stress (Vascotto et al., 2009b; Vascotto et al., 2013; Poletto et al., 
2014). APE1/NPM1 protein-protein interaction regulate APE1 DNA endonuclease activity as 
well as RNA riboendonuclease activity (Vascotto et al., 2009b; Poletto et al., 2014). A 
reduction of NPM1 expression in APE1 depleted AML cell clones supports the fact that 
NPM1 interact with APE1 and modulates BER. It appears that APE1 directly interacts with 
NPM1 to recruit other BER proteins components to sites of DNA damage. APE1 depletion is 
predicted to reduce APE1-NPM1 protein interactions potentially leading to de-stabilisation of 
NPM1 protein. However, further validation of NPM1 protein levels in APE1 knockdown cells 
is essential to confirm this notion.  
Interestingly, APE1 knockdown in AML cells resulted in significant downregulation of 
DNMT3B gene expression, which implies that APE1 could play a role in regulating DNA 
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methylation. DNMT3B functions in de novo methylation and is responsible for introducing 
cytosine methylation at CpG sites. However, the role of APE1 in DNA 
methylation/demethylation is still unclear, and reports in this regard are contrasting. For 
example, it was reported that APE1 depletion in conjunction with TDG (thymine DNA 
glycosylase) loss enhances global DNA demethylation in HEK293T cells (Jin et al., 2015). In 
contrast, it is thought that APE1 and TDG are required to activate RNF4 (RING finger protein 
4)-induced DNA demethylation. However, it must be noted that apparent DNMT3B 
upregulation in APE1 knockdown clones as determined from the RNA sequencing data 
obtained here requires further validation at the protein level. It can be expected that APE1 is 
required for demethylation, rather than enhancing methylation, and is required to stimulate 
TDG activation which specifically excises and removes G:T mispairs resulting from 
deamination of 5-methylcytosine residues (Fitzgerald and Drohat, 2008; Schuermann et al., 
2016; Weber et al., 2016). Nevertheless, the role of APE1 in methylation/demethylation is 
beyond the scope of this thesis and further investigation is required to delineate the role of 
APE1 in this process. 
4.5. Summary of this chapter 
In conclusion, despite the cellular and molecular heterogeneity of the AML cell lines models 
used in this work, the outcome of experimental investigations are consistent across all cell 
lines. This implies that targeting APE1 in AML would not be expected to have significant 
improvement in AML treatment, in terms of combination therapy. However, there may be 
some clinical value in using APE1 inhibitors as monotherapy, with evidence that this 
approach may potentially be used to control the proliferation of leukaemic cells. 
In summary, this chapter has demonstrated the following: 
- APE1 knockdown reduces AML cells proliferation and cloning efficiency.  
- Despite reduced cell proliferation, there no evidence of significant alteration in cell 
cycle kinetics. 
- No potentiation of cytotoxic induced chemotherapy was evident following APE1 
knockdown in AML cells. Rather, loss of APE1 antagonised the cytotoxicity of 
several anti-leukaemic agents. 
- Genomic AP sites were rapidly removed in APE1 deficient cells compared to control 
APE1 proficient cells. RNA sequencing revealed no obvious alternative mechanism 
by which APE1 deficient AML cells remove AP sites.  
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- Upregulation of several genes involved in cycle progression, cell proliferation, and 
tumour suppressor genes may provide protection for AML cells from accumulating 
oxidative DNA damage, and likely contribute to the chemotherapy tolerant phenotype 
observed in APE1 deficient AML cells. 
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Chapter 5: Targeting APE1 in AML using small molecule inhibitors 
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5.1. Introduction 
The ability of cancer cells to recognise and repair chemotherapy-induced DNA damage could 
contribute to treatment resistance and relapse. Therefore, inhibition of particular DNA repair 
proteins using small specific inhibitors can efficiently enhance chemotherapy -induced 
cytotoxicity. Chapter 4 demonstrated the utility of targeting APE1 in AML cell line models 
using RNA interference. However, although targeting APE1 using RNAi did not sensitise 
AML cells to conventional chemotherapy, using pharmaceutical inhibitors may additionally 
function by trapping APE1 in situ, which could prove cytotoxic independent of loss of 
function via down-regulation of transcript levels. Furthermore, small molecule inhibitors 
often inhibit their target rapidly and effectively and do not require selection or further cloning 
to observe a phenotype, which is often required when using RNAi. Finally, delivery of RNAi 
to some cells can be inefficient and problematic. In contrast, many small molecule inhibitors 
are readily taken up by cells. 
Since RNAi techniques do not differentially inhibit specific APE1 functions, it is important to 
target specific APE1 functions independently in order to address their individual 
contributions. To this end, several function-specific inhibitors have been explored and 
investigated in preclinical settings and categorised into two major subclasses; DNA repair 
function inhibitors and redox functions inhibitors. More details about specific APE1 inhibitors 
can be found in section 1.2.1.4. 
 
5.1.1. DNA repair function inhibitors 
Targeting DNA repair in leukaemia is a promising approach but has not been extensively 
investigated, in particular base excision repair. Preclinical studies have investigated the 
potential utility of PARP-1 inhibition in leukaemia and generated encouraging results 
(Gaymes et al., 2009; Gaymes et al., 2013; Esposito et al., 2015; Wang et al., 2015). 
However, targeting APE1 as a therapeutic strategy in AML has yet to be investigated. This 
might be due to the lack of potent and specific inhibitors for APE1 functions. Furthermore, 
the exact molecular participation of APE1 in AML pathogenesis and its regulator mechanisms 
remain elusive.  
Several studies have identified a number of potential APE1 inhibitors (Madhusudan et al., 
2005; Simeonov et al., 2009; Bapat et al., 2010; Rai et al., 2010; Mohammed et al., 2011; 
Dorjsuren et al., 2012; Rai et al., 2012; Srinivasan et al., 2012; Raia et al., 2013; Qian et al., 
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2014). However, none of the endonuclease function inhibitors have been investigated in pre-
clinical animal models or clinical trials in humans, presumably due to a lack of specificity, 
undesirable toxicity or poor drug-like properties and cellular membrane permeability (Wilson 
and Simeonov, 2010; Al-Safi et al., 2012; Li and Wilson, 2014). 
Several studies have investigated the efficacy of targeting APE1 in leukaemia in a limited 
context using the non-specific APE1 inhibitor methoxyamine (She et al., 2005; Bulgar et al., 
2010; Caimi et al., 2014).  
Methoxyamine (MX), tradename TRC102, is non-specific inhibitor of APE1 endonuclease 
activity, which functions by inhibiting APE1 lyase activity on AP sites following removal of 
damaged DNA bases by glycosylases. MX reacts with the aldehyde group within the AP site 
that results in the formation of an intermediate adduct refractory to APE1 lyase activity (Rosa 
et al., 1991; Liu and Gerson, 2004). Pre-clinical studies demonstrated enhancement of 
manumycin and fludarabine induced cytotoxicity in AML cells and murine xenograft models 
when used in combination with MX (She et al., 2005; Bulgar et al., 2010). Furthermore, a 
phase I clinical trial of MX in combination with fludarabine for treatment relapsed/refractory 
chronic lymphocytic leukaemia (CLL) and lymphoid malignancies revealed good tolerability 
with no dose limiting toxicities (Caimi et al., 2014). Furthermore, this trial also reported that 
MX increased the activity of fludarabine with limited additional toxicity (Caimi et al., 2014). 
These encouraging results led to speculation that MX may be efficacious in combination with 
standard therapy for AML.  
 
5.1.2. Redox function inhibitors 
Unlike DNA repair inhibitors, the development of APE1 redox inhibitors has been more 
limited, presumably due to the lack of robust screening methods to identify such inhibitors. 
Nevertheless, several redox inhibitors are now under investigation in pre-clinical settings, 
including E3330 and its derivative analogues RN8-51, 10-52, and 7-60. Although the ability 
of E3330 to specifically impair APE1 activity and inhibit downstream target transcription 
factors has been well demonstrated in several studies (Miyamoto et al., 1992; Goto et al., 
1996; Zou and Maitra, 2008; Fishel et al., 2010; Cardoso et al., 2012), the exact mechanism 
of action is still inconclusive (Manvilla et al., 2011; Zhang et al., 2013). Inhibition of APE1 
redox function in AML cells using E3330 in combination with all-trans retinoic acid induced 
cell differentiation and apoptosis (Fishel et al., 2010). Despite promising reports of the 
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potential utility of this molecule in cancer treatment, characterisation of its activity in 
leukaemia is still very limited. 
 
5.2.Aims of this chapter 
The overall aim of the work presented in this chapter was to investigate whether APE1 
inhibition using small molecule inhibitors affects AML cell line growth and sensitivity to 
cytotoxic agents used in the treatment of AML. This aim was addressed by the following 
specific objectives:  
- To treat AML cell lines AML3, U937 and HL-60 with APE1 inhibitors 
methoxyamine, APE1 inhibitor III and E3330 and investigate their single agent 
cytotoxic effects. 
- To investigate effects of APE1 inhibitors as single agents on cell cycle kinetics and 
AP sites accumulation 
- To determine AML cell line sensitivity to APE1 inhibitors in combination with 
temozolomide, Ara-C, daunorubicin, clofarabine, fludarabine and etoposide.  
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5.3. Results 
5.3.1. Evaluating the anti-leukaemic activity of methoxyamine 
5.3.1.1. Methoxyamine single agent cytotoxicity 
The aim of this section was to evaluate the cytotoxic effect of MX as a single agent on AML 
cell lines. Assessment of MX single agent cytotoxicity was measured by two methods growth 
inhibition /trypan blue dye exclusion, and colony formation assay. Prior to performing MX 
dosing, MX was dissolved in PBS and its pH was adjusted to 7±0.02 using sterile 1 N sodium 
hydroxide. 
BER inhibition by MX appears to have only modest cytotoxic effects at doses less than 1 mM 
on AML3, U927 and HL-60 cells (Figure 5.1A). GI50, which refers to the concentration of 
drug that inhibit 50% of cells growth, was determined using GraphPad Prism software 6.0. 
GI50 concentrations for MX in AML3, U937 and HL-60 cells were 1.59 mM, 1.42 mM and 
1.47 mM, respectively. 
In contrast to the phenotype demonstrated by growth inhibition using trypan blue exclusion, 
colony formation assay demonstrated low cytotoxicity of MX at high doses and induced a 
cytostatic phenotype (Figure 5.1B). For example, 20 mM of MX inhibited approximately 47% 
of AML3 colony formation, whereas this dose reduced cell proliferation to below10% of 
controls when investigated using the trypan blue exclusion method.  
It must be noted that most of the growth inhibition based investigations in this study were 
performed in 6well plates, with exception of MX based experiments. It was observed that MX 
may evaporate at 37 °C and reduce cell growth of vehicle control treated cells in adjacent 
wells (data not shown). Therefore, all MX related experiments were performed in T25 culture 
flasks instead of 6 well plates. 
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Figure 5.1: Single agent activity of methoxyamine (MX) on AML cells. 
(A) Assessment of MX growth inhibition as single agent on AML3, U937 and HL-60 using 
trypan blue exclusion and cell counting method.  
(B) Cytotoxicity of MX as single agent on AML3, U937 and HL-60 using colony formation 
assay. 
In each case, data presented shows the number of viable cells/colonies form each treatment as 
a percentage of the number of viable cells/colonies from vehicle only treated cells. Results 
represent the mean and standard deviation of three independent experiments. 
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5.3.1.2.Optimisation of MX dose for AP site measurement, cell cycle assay and combination 
with AML treatment. 
The aim of this section was to find the optimal biologically effective MX dose that can be 
used in the assessment of AP site quantification, cell cycle kinetics and in combination with 
cytotoxic therapies.  
It was noted that MX is required in high concentrations (millimolar (mM) levels) to generate 
a biological effect on cells growth, with a GI50 of approximately 1.5 mM. A concentration of 
500 µM had no discernible effect on AML cell phenotype and did not alter their growth 
(Figure 5.1). In addition, low concentration of MX (0.5 mM and 1 mM) did not affect TMZ or 
fludarabine-induced cytotoxicity (data not shown). Furthermore, several previous reports 
demonstrated potentiation of MX cytotoxicity at 3 to 6 mM in combination with cytotoxic 
drugs (She et al., 2005; Yan et al., 2006; Bulgar et al., 2010; Bulgar et al., 2012). Therefore, a 
dose of 3 mM MX was deemed suitable for studying the effects of this agent on cell cycle, AP 
site kinetics and enhancement of cytotoxic agent-induced chemotherapy.  
 
5.3.1.3. MX blocks BER by competitive binding to AP sites 
MX is not a specific inhibitor for APE1 function, but competitively binds to AP sites 
generated following the excision of damaged bases by DNA glycosylases. The aim of this 
section was to investigate the effect of MX treatment on AP sites induction. AML3, U937 and 
HL-60 cells were pre-treated for 1 hour with 50 µM H2O2, then washed with PBS and 
transferred into RMPI growth media supplemented with 3 mM MX. Control vehicle-treated 
cells were transferred into RPMI media without MX. Cells were isolated prior to treatment 
with H2O2 (0 hour) and 2, 4 and 8 hours after treatment with H2O2. It must be noted that this 
assay was performed once but with triplicates for each sample, therefore statistical analysis 
cannot be performed.  
Results demonstrated an apparent reduction in AP site frequency in MX/ H2O2 treated cells 
compared to cells treated with H2O2 only, implying that MX blocks AP site and prevents 
aldehyde reactive probe (ARP) reagent from tagging AP sites, thus reducing AP site detection 
(Figure 5.2). This effects was consistent for all three AML cell lines investigated.  
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Figure 5.2: AP sites quantification following treatment of AML cells with methoxyamine 
(MX). 
AP sites were quantified following using Aldehyde reactive probe (ARP) assay. AML3, U937 
and HL-60 cells were pre-treated with 50 µM of H2O2 for 1 hour, to induce DNA damage. 
Then, cells were washed and treated with 3 mM of MX. Cells were isolated for AP site 
quantification after prior H2O2 treatment (0 hour) and 2, 4, and 8 hours of MX treatment. MX 
treated cells displayed reduced AP site quantification compared to vehicle control (PBS) 
treated cells. Data represent single experiment.  
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5.3.1.4. MX induces cell cycle blockade in S phase 
Cell cycle analysis was performed to investigate the effect of MX on AML3, U937 and HL-
60AML cells. AML cells were treated with 1 mM and 3 mM MX and isolated at 0, 4, 8, 12, 
24, 48 and 72 hours and fixed in 70% ethanol. Cells were stained with propidium iodide (PI) 
and cell cycle analysis was performed as described in section 2.9.  
Three mM MX treatment induced cell cycle blockade in S phase in a concentration and time 
dependent manner that was apparent between 24 and 72 hours post-treatment (Figures 5.3 and 
5.4), but which was not discernible in the first 12 hours post-treatment (data not shown). In 
contrast, 1 mM MX had no discernible effect on cell cycle kinetics in any of the three cell 
lines investigated (data not shown).  
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Figure 5.3: Effect of methoxyamine (MX) on cell cycle kinetics of AML cells. 
AML3, U937 and HL-60 were treated with 3 mM of MX and cell cycle analysis measured by 
flow cytometer after 24, 48 and 72 hours of MX treatment. Cell cycle analysis was performed 
using BD CellQuest Pro software.  
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Figure 5.4: Representative quantification of cell cycle distribution following treatment of 
AML cells with methoxyamine (MX). 
Cell cycle analysis was performed on flow cytometer to investigate the effect of 
methoxyamine (MX) on cell cycle distribution of (A) AML3, (B) U937 and (C) HL-60 cells. 
Cells were treated with 3 mM of MX and cell cycle was examined after 24, 48 and 72 hours 
of MX treatment. In each case, results represent the mean and standard deviation of three 
independent experiments.  
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5.3.1.5. Cytotoxic effect of MX in combination with cytotoxic chemotherapy 
Trypan blue exclusion dye and colony formation were performed to investigate whether 
inhibition of BER by MX can potentiate the cytotoxicity induced by temozolomide (TMZ), 
Ara-C, daunorubicin, clofarabine, fludarabine and etoposide. TMZ is not used in AML 
treatment but is used in this investigation as a control agent because it induces DNA damage 
that is a substrate for BER (Zhang et al., 2012). In addition, MX is demonstrated to enhance 
TMZ induced cytotoxicity in several published studies (Fishel et al., 2007; Yan et al., 2007; 
Reed et al., 2009).  
AML3, U937 and HL-60 cells were treated for 4 days with anti-leukaemic agents as single 
treatment and in combination with 3 mM of MX. Cells were counted using trypan blue 
exclusion and a TC20 cell counter. For single agent treatments, data are presented as the 
number of viable cells from each treatment as a percentage of the number of viable cells from 
vehicle control treated cells. For MX-chemotherapy combinations, data are presented as the 
number of viable cells form each treatment as a percentage of the number of viable cells from 
MX only treated cells.  
AML3 cells are less sensitive than U937 and HL-60 to TMZ induced cytotoxicity as 
described in previous chapter. AML3 cells were relatively insensitive to TMZ up to a 
concentration of 300 µM. A combination of TMZ and 3 mM MX had no effect on TMZ 
induced cytotoxicity in AML3 cells (Figure 5.5A). Likewise, the addition of 3 mM MX had 
no effect on the cytotoxic effects of etoposide in AML3 (Figure 5.5F) and MX was 
antagonistic in combination with daunorubicin in AML3 (Figure 5.5C). In contrast, AML3 
cells were sensitised to the cytotoxic effects of nucleoside analogues Ara-C, clofarabine and 
fludarabine when combined with MX, but that was not statistically significant (Figures 5.5 B, 
D and E).   
MX antagonised the cytotoxic effects of TMZ, Ara-C, clofarabine and particularly 
daunorubicin in U937 (Figures 5.6 A, B and C). In contrast, MX had no effect on cellular 
response to fludarabine and etoposide in U937 (Figures 5.6 E and F).  
MX had no discernible effect in the cytotoxicity of TMZ, daunorubicin, Ara-C, clofarabine or 
fludarabine in HL-60, but was significantly antagonistic in combination with etoposide 
(Figure 5.7). 
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It has been reported that MX potentiates fludarabine induced cytotoxicity in HL-60 cells 
(Bulgar et al., 2010). However, attempts to replicate this finding were unsuccessful in HL-60, 
as well as AML3 and U937.  
When investigated using the colony formation assay, MX consistently antagonised the 
cytotoxicity of TMZ, Ara-C and daunorubicin (Figure 5.8), which was observed in AML3, 
U937 and HL-60.  
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Figure 5.5: Growth inhibition of methoxyamine (MX) in combination with cytotoxic 
chemotherapy on AML3 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with MX (3 mM). Drug alone 
cytotoxicity represent the number of viable cells form each treatment as a percentage of the 
number of viable cells from vehicle only treated cells. For combination treatment, data was 
normalised to MX single agent cytotoxicity instead of vehicle treated cells. In each case, 
results represent the mean and standard deviation of three independent experiments. P values 
were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****).
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Figure 5.6: Growth inhibition of methoxyamine (MX) in combination with cytotoxic 
chemotherapy on U937 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with MX (3 mM). Drug alone 
cytotoxicity represent the number of viable cells form each treatment as a percentage of the 
number of viable cells from vehicle only treated cells. For combination treatment, data was 
normalised to MX single agent cytotoxicity instead of vehicle treated cells. In each case, 
results represent the mean and standard deviation of three independent experiments. P values 
were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****). 
170 
 
 
 
Figure 5.7: Growth inhibition of methoxyamine (MX) in combination with cytotoxic 
chemotherapy on HL-60 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with MX (3 mM). Drug alone 
cytotoxicity represent the number of viable cells form each treatment as a percentage of the 
number of viable cells from vehicle only treated cells. For combination treatment, data was 
normalised to MX single agent cytotoxicity instead of vehicle treated cells. In each case, 
results represent the mean and standard deviation of three independent experiments. P values 
were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****). 
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5.3.2. Inhibition of AP endonuclease function of APE1 using APE1 inhibitor III (APE1-
III) 
5.3.2.1. Single agent activity of APE1-III in AML cells 
Growth inhibition assay using trypan blue exclusion and colony formation assay was 
performed to measure the cytotoxic effects of the APE1-III inhibitor as a single agent in 
AML3, U937 and HL-60 cells. Both methods consistently demonstrated the potent cytotoxic 
effect of APE1-III inhibitor with a GI50 of 0.9-1.1 µM in all cell lines (Figure 5.9). APE1-III 
was used at concentration of 0.7 µM and 0.4 µM to investigate the effects on cell cycle 
kinetics and AP site formation. 
 
5.3.2.2. Cell cycle effect of APE1-III 
Cell cycle analysis was performed to determine effect of APE1-III on cell cycle kinetics. 
Treatment of AML3, U937 and HL-60 with APE1-III at 0.7 µM had no discernible effect on 
cell cycle kinetics at 24, 48 and 72 hours post-treatment (Figure 5.10).  
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Figure 5.9: Cytotoxicity of APE1 inhibitor III (APE-III) on AML cells. 
 (A) Assessment of APE1-III growth inhibition as single agent on AML3, U937 and HL-60 
using trypan blue exclusion and cell counting method.  
(B) Cytotoxicity of APE1-III as single agent on AML3, U937 and HL-60 using colony 
formation assay. 
In each case, data presented shows the number of viable cells/colonies form each treatment as 
a percentage of the number of viable cells/colonies from vehicle only treated cells. Results 
represent the mean and standard deviation of three independent experiments. 
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Figure 5.10: Effect of APE1 inhibitor III (APE1-III) on cell cycle kinetics of AML cells. 
Cell cycle kinetics for AML3, U937 and HL-60 cells was determined after 24, 48 and 72 
hours of treatment with 700 nM of APE1-III. Cell cycle analysis was performed using 
BD CellQuest Pro software. Cell cycle kinetics for all control cells was performed at 24, 48 
and 72 hours (data not shown). APE1-III showed no effect on AML cells cycle distribution.  
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5.3.2.3. Cytotoxic effect of APE1-III in combination with cytotoxic chemotherapy 
The aim of the section was to investigate whether co-incubation of AML cells with APE1-III 
affects the anti-leukaemic activity of cytotoxic chemotherapy. AML3, U937 and HL-60 cells 
were treated with TMZ, Ara-C, daunorubicin, clofarabine, fludarabine or etoposide as 
monotherapy and in combination with 700 nM APE1-III. Monotherapy data are presented as 
the number of viable cells/colonies form each treatment as a percentage of the number of 
viable cells/colonies from vehicle only treated cells. For APE1-III-chemotherapy combination 
treatments, data are presented as the number of viable cells form each treatment as a 
percentage of the number of viable cells/colonies from APE1-III inhibitor only treated 
cells/colonies.  
Using the growth inhibition assay with trypan blue and cell counting, a low concentration of 
APE1-III (400 nM) did not affect growth inhibition by any of the chemotherapeutic agents on 
AML cells (data not shown). However, a combination of 700 nM APE1-III had no added 
cytotoxicity, but was occasionally antagonistic (Figures 5.11, 5.12 and 5.13).  
Consistent with the phenotype observed in the growth inhibition assay above, data derived 
from the colony formation assay demonstrated antagonism of TMZ, Ara-C and daunorubicin 
in AML3, U937 and HL-60 in combination with the APE1 inhibition APE1-III (at 700 nM) 
(Figure 5.14).   
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Figure 5.11: Growth inhibition of APE1 inhibitor III (APE1-III) in combination with 
cytotoxic chemotherapy on AML3 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with APE1-III (700 nM). Drug 
alone cytotoxicity represent the number of viable cells form each treatment as a percentage of 
the number of viable cells from vehicle only treated cells. For combination treatment, data 
was normalised to APE1-III single agent cytotoxicity instead of vehicle treated cells. In each 
case, results represent the mean and standard deviation of three independent experiments. P 
values were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) 
or p < 0.0001 (****). 
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Figure 5.12: Growth inhibition of APE1 inhibitor III (APE1-III) in combination with 
cytotoxic chemotherapy on U937 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with APE1-III (700 nM). Drug 
alone cytotoxicity represent the number of viable cells form each treatment as a percentage of 
the number of viable cells from vehicle only treated cells. For combination treatment, data 
was normalised to APE1-III single agent cytotoxicity instead of vehicle treated cells. In each 
case, results represent the mean and standard deviation of three independent experiments. P 
values were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) 
or p < 0.0001 (****). 
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Figure 5.13: Growth inhibition of APE1 inhibitor III (APE1-III) in combination with 
cytotoxic chemotherapy on HL-60 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with APE1-III (700 nM). Drug 
alone cytotoxicity represent the number of viable cells form each treatment as a percentage of 
the number of viable cells from vehicle only treated cells. For combination treatment, data 
was normalised to APE1-III single agent cytotoxicity instead of vehicle treated cells. In each 
case, results represent the mean and standard deviation of three independent experiments. P 
values were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) 
or p < 0.0001 (****). 
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5.3.3. Redox function inhibition using E3330 
5.3.3.1. Single agent activity of E3330 
Growth inhibition assay and colony formation assay were performed to investigate cytotoxic 
effect of E3330 alone on AML cells.  
It was noted that E3330-induced growth inhibition was attenuated by the addition of FBS in 
cell culture media (data not shown). Therefore, all experiments described in this section were 
performed using 5% FBS supplemented cell culture media instead of 10% FBS, which was 
routinely used in all other experiments. 
AML3, U937 and HL-60 cells were treated with E3330 for 4 days and data presented as 
growth inhibition curves showing the number of viable cells form each treatment as a 
percentage of the number of viable cells from vehicle only treated cells. E3330 was cytotoxic 
as a single agent to AML3, U937 and HL-60 cells (Figure 5.15A) with GI50 values of 59.4 
µM, 65.8 µM and 40.2 µM, respectively. 
Similarly, single agent E3330 was cytotoxic effect to AML cells when investigated using the 
colony formation assay (Figure 5.15B). However, AML3 cells were more sensitive to this 
APE1 redox function inhibitor compared to U937 and HL-60. 
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Figure 5.15: Single agent cytotoxicity of E3330 on AML cells. 
(A) Assessment of E3330 cytotoxicity as single agent on AML3, U937 and HL-60 using 
trypan blue exclusion and cell counting method.  
(B) Cytotoxicity of E3330 as single agent on AML3, U937 and HL-60 using colony 
formation assay. 
In each case, data presented shows the number of viable cells/colonies form each treatment as 
a percentage of the number of viable cells/colonies from vehicle only treated cells. Results 
represent the mean and standard deviation of three independent experiments. 
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5.3.3.2. E3330 effect on AP sites accumulation 
Treatment AML cells with the E3330 inhibitor is not expected to result in AP site 
accumulation as it only inhibits the redox function of APE1. In order to confirm this, AML 
cells were pre-treated for 1 hour with 50 µM H2O2 to induce DNA damage. Cells were 
washed and transferred into fresh media supplemented with 2% of FBS and then treated with 
40 µM E3330 and AP sites were quantified after 2, 4 and 8 hours of treatment. Again, this 
was a limited experiment performed only once and the result described here is considered 
preliminary. Nevertheless, AP sites quantification did not differ in response to E3330 
treatment, compared to vehicle control (Figure 5.16). There was a clear increase in AP site 
levels following treatment with H2O2, which then returned to background 8 hours post-
treatment. 
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Figure 5.16: AP sites quantification following E3330 treatment.  
AP sites were quantified following using Aldehyde reactive probe (ARP) assay. AML3, U937 
and HL-60 cells were pre-treated with 50 µM of H2O2 for 1 hour, to induce DNA damage. 
Then, cells were washed and treated with 40 µM of E3330. Cells were isolated for AP site 
quantification after prior H2O2 treatment (0 hour) and 2, 4, and 8 hours of E3330 treatment. 
E3330 treated cells displayed reduced AP site quantification compared to vehicle control 
(DMSO) treated cells. Data represent single experiment.  
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5.3.3.3. Effect of E3330 on cell cycle 
The impact of E3330 on cell cycle kinetics is not conclusive with some studies demonstrating 
no effect on cell cycle profile of pancreatic cells (Zou and Maitra, 2008), and other studies 
demonstrating impaired transition from G1 to S phase in pancreatic cancer cells after E3330 
treatment (Jiang et al., 2010; Fishel et al., 2011). In order to assess the impact of E3330 on 
AML cells, AML3, U937 and HL-60 were treated with 40 µM E3330, and cell cycle was 
investigated by flow cytometry 24, 48 and 72 hours after treatment as described in section 2.9. 
Exposure to E3330 had no discernible effect on cell cycle kinetics of any of the three cell 
lines investigated (Figure 5.17).  
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Figure 5.17: effect of E3330 on cell cycle kinetics of AML cells. 
Cell cycle kinetics for AML3, U937 and HL-60 cells was determined after 24, 48 and 72 
hours of treatment with 40 µM of E3330. Cell cycle analysis was performed using 
BD CellQuest Pro software. Cell cycle kinetics for all control cells was performed at 24, 48 
and 72 hours (data not shown). E3330 showed no effect on AML cells cycle distribution.  
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5.3.3.4. Cytotoxic effect of E3330 in combination with AML chemotherapy 
A limited study demonstrated that inhibition of APE1 redox function using E3330 hyper-
sensitised AML cells to retinoic acid induced differentiation and induced apoptosis (Fishel et 
al., 2010). Growth inhibition and colony formation assays were performed to explore whether 
E3330 potentiated inhibition of AML cell proliferation in response to cytotoxic 
chemotherapy.  
In order to investigate the effect of E3330 in combination with cytotoxic chemotherapy, cells 
were treated with chemotherapy alone or in combination with 40 µM E3330. Monotherapy 
data are expressed as the number of viable cells/colonies form each treatment as a percentage 
of the number of viable cells/colonies from vehicle only treated cells. For E3330-
chemotherapy combination treatments, data are expressed relative to E3330 single agent 
instead of vehicle-treated control. 
Using the growth inhibition assay, treatment with E3330 in combination with several 
chemotherapeutic agents had no discernible effect on cytotoxicity in most cases (Figures 5.18, 
5.19 and 5.20). In some cases, however, E3330 was antagonistic. For example, E3330 
displayed no cytotoxicity on AML3 cells when combined with TMZ, clofarabine and 
fludarabine (Figures 5.18 A, D and E). In contrast, E3330 was antagonistic in combination 
with daunorubicin and etoposide in AML3 cells (Figures 5.18 C and F).  
Data derived from the colony formation assay did not suggest any consistent effect of E3330 
in combination with TMZ on AML3 and U937 compared to TMZ alone, but was antagonistic 
in HL-60 cells (Figure 5.21). Moreover, E3330 in combination with Ara-C or daunorubicin 
was antagonistic in AML3 and U937 cells (Figures 5.21 A and B). 
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Figure 5.18: Growth inhibition of E3330 in combination with cytotoxic chemotherapy on 
AML3 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with E3330 (40 µM). Drug alone 
cytotoxicity represent the number of viable cells form each treatment as a percentage of the 
number of viable cells from vehicle only treated cells. For combination treatment, data was 
normalised to E3330 single agent cytotoxicity instead of vehicle treated cells. In each case, 
results represent the mean and standard deviation of three independent experiments. P values 
were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****). 
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Figure 5.19: Growth inhibition of E3330 in combination with cytotoxic chemotherapy on 
U937 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with E3330 (40 µM). Drug alone 
cytotoxicity represent the number of viable cells form each treatment as a percentage of the 
number of viable cells from vehicle only treated cells. For combination treatment, data was 
normalised to E3330 single agent cytotoxicity instead of vehicle treated cells. In each case, 
results represent the mean and standard deviation of three independent experiments. P values 
were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****). 
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Figure 5.20: Growth inhibition of E3330 in combination with cytotoxic chemotherapy on 
HL-60 cells. 
Growth inhibition assay was performed to measure the cytotoxicity of (A) temozolomide 
(TMZ) (B) Ara-C (C) Daunorubicin (Dauno) (D) Clofarabine (Clof) (E) Fludarabine (Flud) 
and (F) Etoposide (Eto) as single agents and in combination with E3330 (40 µM). Drug alone 
cytotoxicity represent the number of viable cells form each treatment as a percentage of the 
number of viable cells from vehicle only treated cells. For combination treatment, data was 
normalised to E3330 single agent cytotoxicity instead of vehicle treated cells. In each case, 
results represent the mean and standard deviation of three independent experiments. P values 
were calculated using two-way ANOVA. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 
0.0001 (****). 
192 
 
 
Fi
gu
re
 5
.2
1:
 C
yt
ot
ox
ic
ity
 o
f A
PE
1 
re
do
x 
in
hi
bi
to
r 
E
33
30
 in
 c
om
bi
na
tio
n 
w
ith
 a
nt
i-l
eu
ka
em
ia
 c
he
m
ot
he
ra
py
 u
si
ng
 c
ol
on
y 
fo
rm
at
io
n 
as
sa
y 
(c
on
tin
ue
d 
on
 n
ex
t p
ag
e)
. 
193 
 
 F
ig
ur
e 
5.
21
: C
yt
ot
ox
ic
ity
 o
f A
PE
1 
re
do
x 
in
hi
bi
to
r 
E
33
30
 in
 c
om
bi
na
tio
n 
w
ith
 a
nt
i-l
eu
ka
em
ia
 c
he
m
ot
he
ra
py
 u
sin
g 
co
lo
ny
 fo
rm
at
io
n 
as
sa
y 
(c
on
tin
ue
d 
fr
om
 p
re
vi
ou
s p
ag
e)
. 
C
ol
on
y 
fo
rm
at
io
n 
as
sa
y 
w
as
 p
er
fo
rm
ed
 to
 in
ve
st
ig
at
e 
th
e 
cy
to
to
xi
c 
ef
fe
ct
 o
f E
33
30
 (6
00
 n
M
) i
n 
co
m
bi
na
tio
n 
w
ith
 T
M
Z,
 A
ra
-C
 a
nd
 
da
un
or
ub
ic
in
 o
n 
(A
) A
M
L3
 (B
) U
93
7 
an
d 
(C
) H
L-
60
. D
at
a 
pr
es
en
te
d 
fo
r c
he
m
ot
he
ra
py
 w
ith
ou
t M
X
 sh
ow
s t
he
 n
um
be
r o
f v
ia
bl
e 
co
lo
ni
es
 fo
rm
 
ea
ch
 tr
ea
tm
en
t a
s a
 p
er
ce
nt
ag
e 
of
 th
e 
nu
m
be
r o
f v
ia
bl
e 
co
lo
ni
es
 fr
om
 v
eh
ic
le
 o
nl
y 
tre
at
ed
 c
el
ls
. F
or
 c
om
bi
na
tio
n 
tre
at
m
en
t, 
da
ta
 w
as
 
no
rm
al
is
ed
 to
 si
ng
le
 a
ge
nt
 c
yt
ot
ox
ic
ity
 e
ff
ec
t o
f 4
0 
µM
 o
f E
33
30
 in
st
ea
d 
of
 v
eh
ic
le
 tr
ea
te
d 
ce
lls
. I
n 
ea
ch
 c
as
e,
 re
su
lts
 re
pr
es
en
t t
he
 m
ea
n 
an
d 
st
an
da
rd
 d
ev
ia
tio
n 
of
 tw
o 
in
de
pe
nd
en
t e
xp
er
im
en
ts
. P
 v
al
ue
s w
er
e 
ca
lc
ul
at
ed
 u
si
ng
 tw
o-
w
ay
 A
N
O
V
A
. p
 <
 0
.0
5 
(*
), 
p 
< 
0.
01
 (*
*)
, p
 <
 0
.0
01
 
(*
**
) o
r p
 <
 0
.0
00
1 
(*
**
*)
. 
 
194 
 
5.4. Discussion 
The aim of this chapter was to investigate whether targeting APE1 using inhibitors of its 
endonuclease activity or its redox capacity would enhance the cytotoxic effects of anti-
leukaemic chemotherapy. In order to explore the utility of targeting APE1 functions in AML, 
three APE1 inhibitors were investigated as single agents or in combination with cytotoxic 
chemotherapy in different AML cell lines. In addition, cell cycle profile and AP sites 
accumulation were determined following APE1 inhibition. 
Modulation of BER using small molecule inhibitors has generated promising results in several 
cancer models. Several pre-clinical and clinical studies have shown that targeting APE1 or 
BER pathway elements as a therapeutic strategy may have clinical utility and may benefit 
particular subsets of AML patients (She et al., 2005; Gaymes et al., 2009; Horton et al., 
2009b; Bulgar et al., 2010; D'Andrea, 2010; Fishel et al., 2010; Vascotto et al., 2013; Caimi 
et al., 2014; Orta et al., 2014; Esposito et al., 2015; Wang et al., 2015). However, previous 
studies have focused only on targeting PARP-1 or interruption of BER processing by 
blocking AP site access using methoxyamine (MX). In contrast, approaches targeting APE1 
in AML using RNA silencing techniques and using specific small molecule inhibitors are still 
relatively undeveloped. 
Non-specific inhibition of APE1 by interruption of BER using MX has been demonstrated to 
enhance fludarabine and manumycin cytotoxic chemotherapy in AML cells (She et al., 2005; 
Bulgar et al., 2010). In order to investigate MX cytotoxicity, AML3, U937 and HL-60 were 
treated with MX as a single agent and in combination with anti-leukaemic chemotherapy. MX 
showed weak single agent activity with a GI50 of approximately 1.5 mM. MX in combination 
with TMZ or fludarabine did not potentiate cytotoxicity, but was occasionally antagonistic, 
which is contrary to previous studies (Fishel et al., 2007; Bulgar et al., 2010; Caimi et al., 
2014). Similarly, MX did not potentiate the cytotoxic effects of Ara-C, daunorubicin, 
clofarabine or etoposide, but occasionally displayed antagonism. These contrasting data may 
explained by the molecular and genetic heterogeneity of AML as well as activation of distinct 
molecular pathways in AML that may change cellular response to APE1 inhibition or BER 
interruption. In addition, the cell cycle arrest at S phase caused by MX may possibly explain, 
at least partly, tolerance of AML cells to cytotoxic chemotherapy, which are particularly 
active against exponentially dividing cells. Furthermore, the different experimental methods 
used to assess cytotoxicity may contribute to these apparently contradictory results. Attempts 
to replicate the results presented by Bulgar and colleagues demonstrated no discernible effect 
of MX on AML cells at 3 mM and also no evidence of fludarabine potentiation. 
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APE1-III has not been extensively investigated as an anti-cancer agent, despite suggestions 
that it may be a promising and potent APE1 inhibitor (Vascotto et al., 2013; Poletto et al., 
2015). APE1-III was cytotoxic to AML cells as a single agent, and particularly to AML3 
cells, which harbour NPM1 mutation. Consistently, APE1-III displayed single agent 
cytotoxicity against Hela cells and mouse embryonic fibroblasts (MEFs) cells (Rai et al., 
2012; Vascotto et al., 2013). Moreover, MEFs with NPM1−/− allele showed hypersensitivity 
to APE1-III compared to MEFs cells with NPM1+/+. However, there was no potentiation of 
anti-leukaemic chemotherapy in combination with APE1-III in all cell lines investigated in 
this project. Rather, there was evidence that APE1-III antagonised anti-AML treatment in 
some cases. Although TMZ is anticipated to induce DNA damage which is recognised by 
BER, the induced DNA damage is not limited to lesions recognised by BER and which is 
repaired by other DNA repair pathways (see section 4.4.3 for more details about TMZ 
cytotoxicity) (Brandwein et al., 2007; Horton et al., 2009b; Zhang et al., 2012). In addition, 
there are potentially several mechanisms that suggest redundant mechanisms that in principle 
could compensate for the inhibition of APE1 and explain the resistance/tolerance phenotype 
demonstrated in cells with APE1 inhibition. These include the AP lyase function of 
bifunctional glycosylases, which could execute APE1-independent BER. In addition, APE2 
could bypasses APE1 function through its exonuclease and phosphodiesterase functions (see 
section 4.4.3 for more details). Furthermore, APE1 has low affinity to DNA damage induced 
by Ara-C and etoposide, which may explain the resistant phenotype with APE1 inhibition in 
AML cells (see section 4.4.3 for more details) (Lam et al., 2006; McNeill and Wilson, 2007; 
McNeill et al., 2009). 
Although the role of APE1 redox function is not yet fully understood in leukaemia, it was 
hypothesised that specific targeting of this function using E3330 would enhance the 
cytotoxicity of anti-leukaemic therapy through interruption of survival mechanisms and 
maintenance of oxidative stress in AML cells. The redox inhibitor E3330 displayed single 
agent cytotoxicity in AML3, U937 and HL-60 cells, and reduced cells growth. Of note, redox 
inhibition of APE1 using E3330 mainly had no effect on the cytotoxic effects of anti-
leukaemia chemotherapy, but there was some evidence of antagonism rather than potentiation 
of the chemotherapy as illustrated by colony formation assay in figure 5.21. However, E3330 
drug activity was affected by FBS concentration in cell culture media and possibly also 
affected by oxygen level tension (Rohrabaugh et al., 2011), which may limit its use. A 
previous study demonstrated that E3330 enhances retinoic acid (RA) induced differentiation 
and apoptosis in HL-60 AML cells (Fishel et al., 2010). E3330 is thought to potentiate RA 
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induced differentiation via enhancement of BLR1 expression (a target gene of RA) and 
inhibition of NF-κB anti-apoptotic pathway activation (Fishel et al., 2010). However, this 
study did not characterise the impact of E3330 on the cytotoxicity of commonly used anti-
leukaemia therapies, specifically Ara-C, daunorubicin, clofarabine and etoposide. 
Nevertheless, one possible explanation for the resistance phenotype observed in response to 
E3330 in combination with chemotherapy may be due to, at least in part, to activation of 
defence mechanisms in order to regulate drug induced oxidative stress and prevent further 
DNA damage. A recent study showed that inhibition of APE1 redox function induces NRF2 
expression at both the protein and transcript level in a dose dependant manner (Fishel et al., 
2015). NRF2 is thought to regulate cellular defence in response to oxidative stress (Fishel et 
al., 2015). Furthermore, siRNA mediated knockdown of APE1 consistently upregulated 
NRF2 transcriptional activity (Fishel et al., 2015). However, there was no evidence of 
upregulation of NRF2 following APE1 shRNA silencing in RNA sequencing data discussed 
in chapter 4. This may imply that upregulation of NRF2 was tissue specific. It is possible that 
other factors may be involved in the resistance phenotype reported in this study, such as 
CDKN1A, PAX5, EGR1, FOXO1 or CUX1. 
It should be noted that two other APE1 inhibitors were assessed in terms of their cytotoxicity 
as single agents, but they were excluded from further investigation due to poor solubility in 
aqueous solution. These inhibitors include CRT0044876 and N-(4-fluorophenyl)-2-(2-phenyl-
4-phenylsulfonyl-oxazol-5-yl)sulfanyl-acetamide.  
The impact of APE1 inhibition on cell cycle is inconclusive and dependent on the inhibitor 
used and the targeted tissue. However, previous data discussed in chapter 4 revealed no 
alteration in cell cycle kinetics of AML cells following APE1 silencing using shRNA. 
Consistent with this observation, specific inhibition of APE1 endonuclease function by APE1-
III or redox function inhibition using E3330 revealed no alteration in cell cycle profile over 
72 hours. Previous reports of E3330 on cell cycle profile are inconclusive, with studies of 
pancreatic and ovarian cancer cells reporting impaired G1/S transition and induced G2 cell 
cycle arrest in response to E3330 (Jiang et al., 2010; Fishel et al., 2011). In contrast, another 
study revealed no effect on cell cycle kinetics of pancreatic cancer cell lines PANC1 by 
E3330 (Zou and Maitra, 2008).  
However, monitoring AML cells for 72 hours after MX treatment showed significant cell 
cycle blockade at S phase. This result may explain the cytostatic effect of single agent MX on 
AML cells when examined using the colony formation assay, with cells arrested in S phase 
unable to form colonies (Figure 5.1B). As MX irreversibly blocks AP site and prevents 
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resolution of BER, cell cycle arrest in S phase may have occurred to prevent replication of 
possible pro-mutagenic lesions caused by MX incorporation into cellular DNA. However, a 
previous study has shown that MX treatment alone does not alter cell cycle kinetics of human 
colorectal cell lines (Yan et al., 2006). MX combination with iododeoxyuridine, slowed cell 
cycle progression from G1 phase and sensitised cells to radiotherapy (Yan et al., 2006). 
BER is initiated following detection of DNA damage and removal of damaged bases by DNA 
glycosylases. The resulting AP sites are the main substrate for APE1 endonuclease function. 
Therefore, quantification of AP sites following APE1 inhibition would provide further 
evidence for inhibition of APE1 endonuclease function. As previously discussed, MX binds to 
AP sites and interrupts BER, and likely interferes with AP site detection. Preliminary data 
presented in this study suggests reduced AP site frequency in MX treated cells compared to 
vehicle control treated cells. This result is in agreement with the fact that MX blocks AP site 
consistent with reported studies (Liu and Gerson, 2004; Wang et al., 2009b; Bulgar et al., 
2012). Determination of AP site frequency following inhibition of APE1 endonuclease 
function using APE1-III was unsuccessful, which was possibly was due to a technical error 
during sample preparation and tagging AP sites with the ARP reagent. However, it is 
expected that APE1 inhibition with APE1-III would lead to increased AP sites accumulation. 
In contrast, the E3330 redox inhibitor is not expected to impair APE1 endonuclease function, 
or have an effect on AP site accumulation. Consistent with this hypothesis, there was no 
alteration in AP site frequency in E3330 exposed cells compared to vehicle control treated 
cells. It should be noted, however, that the AP sites quantification assays undertaken in this 
project were limited in scope and scale. As such, additional experiments are warranted to 
further test whether these mechanisms may be operating. 
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5.5. Summary of this chapter 
APE1 inhibition might not be a suitable generic approach for the treatment of AML, in 
particularly in combination with anti-leukaemia treatment, given the heterogeneity of genetics 
and molecular background of this disease. In addition, targeting APE1 may activate signalling 
pathways that reduce AML cells proliferation in order to prevent further DNA damage. 
Taking this advantage can be clinically useful by controlling AML blast proliferation and then 
controlling the disease progression. Furthermore, lack of appropriate and potent APE1 
inhibitors may slow the progress of this filed of research.  
In summary, this chapter has demonstrated the following: 
- APE1 inhibitors are cytotoxic to AML cells as single agents, but in combination with 
anti-leukaemic cytotoxic chemotherapy either have no effect or are antagonistic. 
- MX induced cell cycle blockade at S phase in AML3, U937 and HL-60 cells 
-  There was no evidence of alteration of cell cycle distribution following APE1-III and 
E3330 treatment. 
- MX prevents resolution of BER via binding to AP sites. 
- The E3330 APE1 redox inhibitor has no discernible effect on AP sites induction or 
resolution following exposure to hydrogen peroxide. 
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Chapter 6: Targeting 8-oxoguanin DNA glycosylase (OGG1) in AML cells using 
shRNA interference. 
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6.1. Introduction  
AML is characterised by excessive production of reactive oxygen species (ROS) resulting in 
high oxidative stress and which can contribute to disease progression and relapse (Zhou et al., 
2010; Hole et al., 2011; Udensi and Tchounwou, 2014). Evidence indicates that high 
oxidative stress induces various forms of DNA damage, which can cause mutations if 
unrepaired (Sallmyr et al., 2008b; Hole et al., 2011). Therefore, DNA repair systems are 
important defence mechanisms against genotoxic DNA damage caused by oxidative stress. In 
particular, base excision repair (BER) is a critical system that mostly repairs oxidised DNA 
bases generated under high oxidative stress (Figure 1.4). However, one of the most abundant 
and deleterious oxidative DNA lesions is 8-oxoguanine (8-oxoG), which results from 
oxidation of guanine, and which is primarily repaired by BER. Specifically, two DNA 
glycosylases in BER are responsible for excising this base, including 8-oxoguanine DNA 
glycosylase (OGG1) and MutY DNA Glycosylase (MUTYH) (Cooke et al., 2003; Scott et al., 
2014). 
OGG1 has been demonstrated previously as a potential prognostic marker in AML (Liddiard 
et al., 2010). Specifically, OGG1 expression, determined using Affymetrix expression 
microarray analysis, correlated with overall survival in AML (Liddiard et al., 2010)(discussed 
in detail in sections 1.2.2). Patients with high OGG1 expression were more likely to have 
adverse cytogenetics risks and significantly reduced overall survival (Liddiard et al., 2010). 
Conversely, patients with low OGG1 expression were more likely to have favourable 
cytogenetics, including t(8;21) (Liddiard et al., 2010). Based on these data it is possible that 
high OGG1 expression may confer enhanced BER activity and inhibition of OGG1 activity 
may enhance chemotherapy efficacy in particular subset of AML patients.  
Several OGG1 polymorphic variants have been reported (Hyun et al., 2000; Hill and Evans, 
2007; Saitoh et al., 2013), some of which have been linked to reduced OGG1 activity as well 
as better response to DNA damaging agents (Hyun et al., 2000; Hill and Evans, 2007) 
(Further details are discussed in section 1.2.2). Therefore, the prevailing evidence implies that 
OGG1 could be a legitimate therapeutic target in AML. However, OGG1 has yet to be 
validated as a viable therapeutic target in cancer, possibly due to the current lack of specific 
inhibitors against OGG1. 
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6.2. Aims of this chapter 
The aim of this chapter was to investigate whether OGG1 knockdown sensitises AML cells to 
conventional genotoxic anti-leukaemic chemotherapy. In order to investigate this hypothesis, 
the following specific objectives were defined: 
- To silence OGG1 using shRNA and to generate of AML cells with stable OGG1 
knockdown. 
- To investigate the impact of OGG1 silencing on AML cell proliferation and cloning 
efficiency. 
- To evaluate the impact of OGG1 knockdown on cell cycle kinetics. 
- To determine the sensitivity of OGG1 knockdown cells to anti-leukemic DNA 
damaging agents. 
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6.3. Results 
Part of the results described in the sections below were performed by undergraduate student 
Ahpa Sae Yeoh, who performed this as part of her undergraduate project under supervision of 
Professor James Allan. Specifically, Ahpa studied the effect of OGG1 knockdown on 
proliferation and cloning efficiency of U937 cells. In addition, she investigated the effect of 
OGG knockdown in U937 cells on cell cycle profile and sensitivity to the anti-proliferative 
effects of DNA damaging agents. 
   
6.3.1. Generation of AML cell lines with stable OGG1 knockdown using small hairpin 
RNA (shRNA) 
Five shRNA lentiviral constructs (table 2.4) targeting different regions of the OGG1 transcript 
were used to knockdown OGG1 in AML cell lines including AML3, U937, HL-60 and 
kasumi-1. Only construct TRCN0000314740 (G5) generated measurable OGG1 knockdown 
at the protein level, which was observed in U937 and HL-60 cells only (data not shown), and 
there was no evidence of OGG1 knockdown in AML3 and kasumi-1 cells (data not shown). 
G5 targets the sequence CGGCTCATCCAGCTTGATGAT of the OGG1 transcript. This 
region is common between the majority of OGG1 splice transcript variants, specifically 
isoforms 1a and 2a, which encode nuclear and mitochondrial OGG1 proteins, respectively.  
Transduced HL-60 and U937 cell populations are expected to be heterogeneous with respect 
to the extent of OGG1 knockdown. This is partly due to heterogeneity in terms shRNA 
integrations per single cell, in addition to differences in shRNA promoter activity due to in the 
site of integration in the host cell genome. In order to obtain cells with stable OGG1 
knockdown, U937 and HL-60 transduced populations were cloned in semi-solid soft agar. 
Western blotting demonstrated considerable variation in OGG1 protein knockdown in 
different cell clones with some clones showing minor reductions in OGG1 expression with 
others showing almost complete loss of OGG1 expression (Figure 6.1). 
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Figure 6.1: OGG1 shRNA induced knockdown in U937 and HL-60 clones. 
(A) U937 and (B) HL-60 cells were transduced with shRNA to knockdown OGG1. Several 
independent clones showed variable OGG1 knockdown on protein levels. Alpha tubulin was 
used as loading control. 
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6.3.2. Effects of OGG1 knockdown on AML cell proliferation and cloning efficiency 
6.3.2.1.Assessment of U937 and HL-60 cell proliferation 
In order to assess the impact of OGG1 knockdown on AML cells, OGG1 proficient and 
deficient U937 and HL-60 cell clones were seeded at a density of 2x104 cells/ml and cell 
density was measured using trypan blue exclusion and cell counter every 24 hours for 5 days.  
U937 and HL-60 cell clones with OGG1 knockdown showed no significant alteration in their 
proliferation kinetics compared to control shRNA-transduced cells with the exception of HL-
60 clones A, C and E (Figure 6.2). Interestingly, HL-60 clone C, which has relatively modest 
OGG1 knockdown (Figure 6.1), had a slow proliferation rate compared to control and other 
OGG1 deficient clones. This is possibly due to integration of the shRNA into a critical region 
in the cells genome which affected proliferation.  
 
6.3.2.2.Assessment of cloning efficiency 
Colony formation assay was performed in order to determine the effect of OGG1 knockdown 
on the ability of U937 and HL-60 cell clones to grow in semi-solid soft agar. U937 clones 
with OGG1 knockdown displayed a similar cloning efficiency to control cell clones (Figure 
6.3 A). In contrast, OGG1 knockdown in HL-60 cells was associated with a modest but 
significant reduction in cloning efficiency compared to control cells (Figure 6.3B). HL-60 
clone C, which had the lowest proliferation rate, also had the lowest cloning efficiency. 
Likewise, HL60 clone E demonstrated low proliferation rate and low cloning efficiency. 
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Figure 6.2: Effect of OGG1 knockdown on AML cells proliferation. 
Proliferation of (A) U937 and (B) HL-60 cells after OGG1 knockdown was assessed by 
monitoring cell density by trypan blue and cell counting every 24 hours for 5 days. Data 
presented are the mean and standard deviation of 3 experiments. 
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Figure 6.3: Effect of OGG1 knockdown on cloning efficiency of AML cells. 
U937 (A) and HL-60 (B) clones with OGG1 knockdown alongside with their respective 
controls were grown on semi-solid soft agar to assess the impact of OGG1 knockdown on 
cloning efficiency. P values were calculated using unpaired t test (*p <0.05) 
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6.3.3. Effect of OGG1 knockdown on AML cell cycle 
Propidium iodide (PI) staining and flow cytometry was performed in order to determine the 
effect of OGG1 knockdown on cell cycle profile of unsynchronised U937 and HL-60 cells. 
Flow cytometry demonstrated no alteration in cell cycle distribution in OGG1 knockdown cell 
clones compared to control cells (Figure 6.4). There was no indication of apoptosis following 
OGG1 knockdown as the proportion of cells in subG1 was not changed in OGG1 deficient 
cells compared to their relevant controls. 
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Figure 6.4: Effect of OGG1 knockdown on cell cycle kinetics of AML cells. 
Cell cycle analysis measured by flow cytometer for to determine the impact of OGG1 
knockdown in U937 and HL-60 cells. 
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6.3.4. Cytotoxicity of OGG1 deficient cells following treatment with cytotoxic DNA 
damaging agents 
OGG1 knockdown cells and their relevant controls were treated with different DNA 
damaging agents in order to determine cytotoxicity in response to anti-leukaemic agents. 
Cells were treated with DNA damaging agents, Ara-C, daunorubicin, clofarabine, fludarabine 
and etoposide, and cell numbers were determined after 4 days using trypan blue exclusion dye 
and cell counting. Results are presented as the number of viable cells from each treatment as a 
percentage of the number of viable cells from vehicle only treated cell populations.  
OGG1 knockdown in U937 cell clones did not affect their sensitivity in response to anti-
leukaemic agents (Figure 6.5). Similarly, OGG1 deficient and proficient HL-60 showed no 
significant differential response to anti-leukaemia treatment (Figure 6.6), with the exception 
that HL-60 clone C, which was moderately tolerant to the anti-proliferative effects of 
genotoxic anti-leukaemia treatment compared to controls. This may be due to the low 
proliferation rate of this clone, and concomitant reduction in sensitivity to genotoxic 
chemotherapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 
 
 
Figure 6.5: Growth inhibition in response to DNA damaging chemotherapy in U937 cells 
with OGG1 knockdown. 
Cytotoxicity assay was performed using growth inhibition assay. Several independent U937 
clones with variable OGG1 knockdown and their relevant control were treated for 4 days with 
Ara-C, daunorubicin, clofarabine, fludarabine and etoposide. Data presented shows the 
number of viable cells form each treatment as a percentage of the number of viable cells from 
vehicle only treated cells. In each case, data represent one experiment. 
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Figure 6.6: Growth inhibition in response to DNA damaging chemotherapy in HL-60 
cells with OGG1 knockdown. 
Cytotoxicity assay was performed using growth inhibition assay. Several independent HL-60 
clones with variable OGG1 knockdown and their relevant control were treated for 4 days with 
Ara-C, daunorubicin, clofarabine, fludarabine and etoposide. Data presented shows the 
number of viable cells form each treatment as a percentage of the number of viable cells from 
vehicle only treated cells. In each case, results represent the mean and standard deviation of 
three independent experiments. 
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6.4. Discussion 
BER is a highly conserved pathway involved in repairing DNA lesions resulting from 
oxidation, alkylation and deamination. The OGG1 DNA glycosylase, which is involved in the 
early steps of BER, removes 8-oxoguanine oxidised DNA bases. High OGG1 expression has 
been associated with worse prognosis and low overall survival in AML (Liddiard et al., 
2010). Thus, OGG1 might be an attractive target in AML and inhibition of its activity could 
potentially enhance the efficacy of AML chemotherapy. 
Targeting OGG1 in AML using shRNA was relatively difficult. AML3, U937, HL-60, 
Kasumi1 cell lines were transduced with 5 different OGG1 lentiviral constructs, but only one 
construct generated measurable OGG1 knockdown in U937 and HL-60, as shown in Figure 
6.1. One possible explanation for this observation is that AML3 and Kasumi1 cells have 
relatively lower mRNA OGG1 transcripts as illustrated in figure 3.4 in chapter 3. OGG1 has 
several alternative splice variant transcripts which may contribute to difficulty in its silencing. 
Two predominant mRNA splice variants are exist in human cells including OGG1 1a and 2a 
(Nishioka et al., 1999). These variants encode OGG1 1a protein, which localised to the 
nucleus and OGG1 2a protein which localised to the mitochondria (Nishioka et al., 1999). 
However, the main shRNA construct (G5) used in this project targets a common sequence on 
OGG1 mRNA transcript variants including 1a and 2a. 
OGG1 is crucial for removing the pro-mutagenic oxidised DNA lesion 8-oxoguanine and 
silencing OGG1 could possibly activate cell signalling pathways to prevent the fixation of 
damage to mutation and to initiate repair with accumulating 8-oxoguanine lesions. However, 
shRNA induced silencing of OGG1 had no effect on AML cell growth kinetics and cloning 
efficiency compared to control cells. Furthermore, OGG1 deficient and proficient cells 
exhibited similar cell cycle kinetics regardless of OGG1 level. These results imply that OGG1 
is not involved in the regulation of cell cycle progression or proliferation.  
It was hypothesised that knocking down OGG1 in AML cells would increase 8-oxoguanine 
DNA lesion levels and sensitise to conventional anti-leukaemic chemotherapy. However, 
knocking down OGG1 in U937 and HL-60 cells appears to have no differential effect on 
response to cytotoxic DNA damaging agents. Although 8-oxoG lesions were not measured 
following OGG1 knockdown, this result suggest presence of alternative mechanism by which 
cells were able to minimise the level of 8-oxoG deleterious lesion, such as MUTYH (Cooke et 
al., 2003; Russo et al., 2004; Russo et al., 2007; Scott et al., 2014). Ogg1 Knockout mice 
showed considerable increase in 8-oxoG lesions (Klungland et al., 1999; Minowa et al., 
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2000). Ogg1 knockout mice also showed tendency to develop lung adenoma/carcinoma 
spontaneously, but however, Ogg1 and Muthy double knockout mice showed no development 
of tumours, regardless of 8-oxoG accumulation (Sakumi et al., 2003). Therefore, it might be 
useful to disable/inhibit the alternative 8-oxoG removal mechanisms in order to efficiently 
enhance accumulation of 8-oxoG and to determine therapeutic utility and biological effect of 
OGG1 depletion/inhibition on cancer cells. Consistent with this suggestion, mouse embryonic 
fibroblasts with Ogg1-/- or Mutyh-/- alone were not sensitive to hydrogen peroxide and tert-
Butyl hydroperoxide induced cytotoxicity (Xie et al., 2008). However, double defective Ogg1 
and Mutyh mouse fibroblast cells were hypersensitive to the cytotoxic effects of hydrogen 
peroxide and tert-Butyl hydroperoxide (Xie et al., 2008).  
Tolerance/resistance of OGG1 deficient AML cells to cytotoxicity of anti-leukaemia therapy 
can also be explained by involvement of OGG1 in biological functions that might be required 
to facilitate the cytotoxicity of DNA damaging agents. In agreement with this notion, a recent 
study demonstrated that OGG1 is essential in oxidative stress induced DNA demethylation 
(Zhou et al., 2016). Knocking down Ogg1 in mouse embryonic fibroblasts cells conferred 
resistance to oxidative stress-induced DNA demethylation, but however, restoring Ogg1 
expression enhanced DNA demethylation induced by H2O2 (Zhou et al., 2016). 
 
6.5. Summary of this chapter 
Although OGG1 is a prognostic marker in AML, the evidence presented in this thesis 
suggests that loss of OGG1 function does not sensitise cells to anti-leukaemic chemotherapy. 
OGG1 knockdown in AML cells did not impair cell proliferation, cell cloning efficiency or 
affect cell cycle kinetics. More importantly, OGG1 knockdown in U937 and HL-60 cells did 
not enhance the cytotoxic effects of several DNA damaging agents. 
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Chapter 7: Concluding discussion 
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7.1. General discussion  
AML is a challenging disease to effectively treat with high mortality rates, particularly in 
elderly patients. The treatment of AML has not changed significantly for several decades and 
remains primarily dependent on Ara-C and anthracycline containing intensive chemotherapy, 
which is not generally well tolerated and potentially life threatening for elderly patients. 
Moreover, the majority of AML patients suffer from disease relapse and develop 
chemotherapy resistant disease. Nevertheless, combination chemotherapy treatment regimens 
allow specific targeting of dysregulated molecular pathways in AML which can facilitate the 
eradication of AML cells. Combination chemotherapy incorporating Ara-C, daunorubicin and 
other established anti-leukaemia treatment, including FLT3 inhibitors, kinase inhibitors and 
histone deacetylase inhibitors for example, has led to improvements in disease outcome for 
some patient groups, but have limited efficacy in other AML subtypes (Burnett et al., 2011a; 
Swords et al., 2012; Montalban-Bravo and Garcia-Manero, 2014). Therefore it is crucial to 
explore alternative well tolerated drugs with low cytotoxicity to normal cells as well as 
minimal side effects. 
AML is characterised by elevated levels of reactive oxygen species and oxidative stress, 
which tightly regulate and support survival of AML cells through a complex network of 
signalling pathways (Rassool et al., 2007; Dohner and Dohner, 2008; Sallmyr et al., 2008b; 
Hole et al., 2011; Zhou et al., 2013). AML is a challenging disease with heterogeneous 
somatic genetic aberrations, which can include the formation of oncogenic fusion genes that 
contribute to the upregulation/activation of pro-survival signalling pathways. These factors 
collectively participate in disease progression, relapse and treatment resistance. Of note, some 
of these oncogenic alterations reportedly induce high oxidative stress and impaired DNA 
repair mechanisms, which can result in accumulation of DNA damage (Alcalay et al., 2003; 
Takacova et al., 2012; Yeung et al., 2012; Esposito and So, 2014). Conversely, upregulation 
of DNA damage response pathways can confer AML cells with protective mechanism to 
circumvent the cytotoxic effects of DNA damaging agents, and ultimately contribute to 
treatment resistance (Bagrintseva et al., 2005; Seedhouse et al., 2006; Cavelier et al., 2009). 
Although DNA repair is compromised in a large subset of AML patients due to acquired 
genetic alterations and resultant fusion proteins, the opportunities for taking advantage of 
compromised DNA repair as a therapeutic strategy is being extensively investigating, 
primarily via synthetic lethal approaches. For example, PARP inhibition is synthetically lethal 
to AML cells expressing the PML-RARα oncogenic fusion protein, which is thought to 
impair the DNA damage response (Esposito et al., 2015). Furthermore, targeting DNA 
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mismatch repair deficient AML cells with PARP inhibitor and temozolomide was 
successfully identified as a synthetic lethal approach (Gaymes et al., 2009; Horton et al., 
2009b; Gaymes et al., 2013). Therefore, targeting DNA repair mechanisms and associated 
regulatory pathways are, in fact, a promising treatment approach in AML. 
Targeting BER pathway proteins, specifically APE1, in cancer has been successfully 
demonstrated in several cancer models and appears to be a promising target in other cancer 
settings (Fishel and Kelley, 2007; Abbotts and Madhusudan, 2010; Dorjsuren et al., 2012; 
Abbotts et al., 2014). Since APE1 has distinct roles in DNA repair, the regulation of several 
transcription factors (redox function), RNA metabolism and other biological functions, 
targeting these functions could prove efficacious and could enhance the cytotoxicity of 
established anti-leukaemia therapy.  
OGG1 is another component of the BER pathway that may represent a viable therapeutic 
target in AML. High OGG1 expression is associated with an adverse prognosis and its 
downregulation may increase AML cell sensitivity to DNA damaging agents (Liddiard et al., 
2010). 
 
7.1.1. Targeting APE1 as therapeutic strategy in AML 
Compelling evidence from clinical data strongly links alterations in DNA repair in cancer 
with prognosis, which can help to determine treatment plans and predict outcome. APE1 
over-expression has been associated with adverse prognosis in several cancers including 
ovarian cancer, breast cancer, pancreatic cancer, lung cancer and multiple myeloma (Yang et 
al., 2007; Wang et al., 2009a; Al-Attar et al., 2010; Sheng et al., 2012; Woo et al., 2014; 
Abdel-Fatah et al., 2015). However, APE1 overexpression and its role as a prognostic marker 
in AML has not yet been established. Evidence presented in this study indicates that APE1 is 
ubiquitously expressed in AML cell lines and its expression (at the transcript level) does not 
significantly correlate with overall survival in AML. It is possible that the molecular genetic 
heterogeneity in AML and activation of multiple oncogenic pathways as well as chromosomal 
translocations may mask any effect of APE1 as a prognostic marker in AML. Furthermore, 
the data presented in this study is statistically underpowered to detect anything other than a 
strong association between APE1 expression and prognosis in AML. It remains possible that 
APE1 expression may be prognostic in some AML sub-groups but not others, and the accrual 
of large datasets will be required to test this hypothesis. Furthermore, should APE1 
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expression have prognostic value, it will be essential to use this in conjunction with other 
established AML prognostic markers in the clinical setting. 
It is becoming clearer that chromosomal translocations, genetic aberrations and epigenetic 
events can disrupt genome stability and activate DNA damage response pathways, and yet 
these same alterations also affect treatment efficacy, confer treatment resistance, and promote 
disease progression. Although mutations in genes involved in DNA damage response are 
relatively uncommon in AML, with the exception of TP53, evidence suggests that DNA 
damage response dysregulation in AML is caused by two possible mechanisms; disruption of 
transcriptional regulation and polymorphic variation (Alcalay et al., 2003; Allan et al., 2004; 
Seedhouse et al., 2004; Rollinson et al., 2007; Voso et al., 2007). The importance of 
maintaining a balanced DNA damage response is underscored by the observed dysregulation 
of DNA repair systems in several human cancers. Failure of cells to recognise and 
proficiently repair DNA damage is a potential cause of cancer initiation and progression. 
Accumulating evidence demonstrates that loss of DNA repair function in AML increases 
susceptibility to the acquisition of potentially mutagenic DNA base lesions, genome 
instability, and may contribute to disease initiation, evolution and relapse (Jankowska et al., 
2008; Sallmyr et al., 2008a; Sallmyr et al., 2008b; Schnerch et al., 2012; Stanczyk et al., 
2012; Olipitz et al., 2014). Likewise, dysregulated DNA repair in leukaemia could lead to 
over-activity and low repair fidelity, inducing genome instability and treatment resistance 
(Bagrintseva et al., 2005; Seedhouse et al., 2006; Fan et al., 2010). Therefore, it is important 
to consider the wider effects of targeting specific DDR components and impact on the whole 
pathway, and that targeting the DDR might not be suitable treatment approach in some cases, 
and particularly where DNA repair is already impaired or not highly upregulated compared to 
non-leukaemic cells.  
One of the major conclusions arising from the study reported here is that APE1 is critical for 
AML cell proliferation and growth. APE1 knockdown or inhibition significantly impaired cell 
proliferation and reduced cloning efficiency. Despite impaired proliferation, cell cycle 
analysis showed no alterations in cell cycle profile of AML cells. However, the exact role of 
APE1 in cell cycle control and progression is not completely understood. A previous study 
has demonstrated that APE1 expression is cell cycle dependent, where it is highly expressed 
in early to mid S phase, possibly to ensure that replicating DNA is free of pro-mutagenic 
DNA damage (Fung et al., 2001). However, proliferation of AML cells after APE1 
knockdown was reduced by affecting all stages of the cell cycle equally, with gene expression 
data suggesting that this may be primarily due to upregulation of CDKN1A, but upregulation 
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of other genes could also be a contributing factor. CDKN1A upregulation is associated with 
cell cycle arrest primarily in the G0/G1 phase, but can induce cell cycle arrest in other phases. 
CDKN1A is also involved in cell senescence, but there was no indication, from cell cycle 
analysis and gene expression data, of cell senescence after APE1 knockdown/inhibition. Cells 
undergoing senescence arrest in the G0 phase, but there was no evidence of G0 cell cycle 
arrest after APE1 inhibition/knockdown. Furthermore, the gene expression did not show 
general features characteristic of senescent cells, such as upregulation of CDKN2A (p16), 
retinoblastoma, PCNA and other factors (Campisi and d'Adda di Fagagna, 2007). 
Furthermore, CUX1, which thought to prevent cells senescence was significantly upregulated 
in APE1 knockdown cells (Ramdzan et al., 2015). However, determination of senescence 
biomarker beta-galactosidase activity is required to further confirm AML cells were not 
senescent after APE1 inhibition/knockdown.  
Although AML cells displayed impaired growth after APE1 knockdown or inhibition, these 
cells were not differentially sensitive to the cytotoxic and anti-proliferative effects of several 
anti-leukaemic chemotherapy agents. Rather, there was some evidence of antagonism. This 
phenotype could be explained by the fact that the drugs used in this study are mainly 
cytotoxic to exponentially proliferating cells and some drugs utilised here do not generate 
DNA damage that is recognised and repaired by BER. Furthermore, RNA sequencing analysis 
of APE1 knockdown AML cells demonstrated upregulation of several genes involved in 
regulating cell proliferation and cell cycle, in addition to genes previously linked to 
leukaemogenesis, cell survival and regulation of oxidative stress, such as CDKN1A, PAX5, 
BCL-2, FOXO1, CUX1, LAIR1 and EGR-1. Of note, RNA sequencing data analysis is 
preliminary and requires further validation at the protein level. However, impaired cellular 
proliferation following APE1 knockdown was not due to alteration in cell cycle kinetics but 
likely due to upregulation of CDKN1A expression and other factors such as PAX5, EGR-1 
and CUX1. These factors are collectively involved in sophisticated networks of signal 
transduction that maintain several cellular functions including cell proliferation and cell 
survival (see section 4.4.5 for more details). 
Impairment of critical DNA repair components reduces cell proliferation and may restrict cell 
cycle progression to allow DNA damage repair (Viale et al., 2009). As such, this may explain 
the low levels of DNA damage (AP sites) and topoisomerase II alpha and beta complexes in 
APE1 knockdown cell clones as determined by the AP site quantification and trapped in 
agarose DNA immunostaining (TARDIS) assays. However, determination of AP sites using 
ARP colorimetric assay has been limited in this study and the assay technique may not be 
219 
 
reliable. This is due to potential loss of DNA during tagging with ARP and during washing 
processes. Such limitations could be avoided by using cell based AP site quantification 
methods. In addition, further investigation of the nature of DNA damage induced after APE1 
knockdown/inhibition is required, which could includedetermining single and double DNA 
strand breaks using comet assay. 
These findings therefore add to a growing body of evidence that APE1 is an important 
modulator for cell proliferation and provides protection against DNA damage and oxidative 
stress. Since shRNA is not a tool that can be used to specifically target a specific protein 
function, it was not possible to differentiate between the contribution of different APE1 
functions (namely DNA repair and redox regulation) on cell phenotype. Although both 
functions are critically important to cellular physiology, the precise mechanisms by which 
APE1 performs these functions are still not fully understood. Nevertheless, APE1 
downregulation reduces DNA repair capacity as well as impairing redox regulation function, 
and may trigger activation of alternative mechanisms to allow cells to repair accumulating 
damage and circumvent cell death. 
In terms of clinical application, although not explored in this thesis, targeting APE1 in AML 
may have limited curative potential, based on the observation that cell death is not directly 
elicited and also that there is no evidence of potentiation of genotoxic anti-leukemic 
chemotherapy. Rather, APE1 downregulation and inhibition appear to be cytostatic. As such, 
APE1 inhibition in a clinical setting may slow disease progression via reduction of blast cell 
proliferation and therefore control disease symptoms, which is a clinically feasible and 
legitimate treatment approach. 
Targeting APE1 in AML may also have adverse effects on normal haematopoietic stem cells 
and therefore impair haematopoiesis. Although the exact role of APE1 in normal 
haematopoiesis is still elusive, an early report demonstrated that APE1 is involved in 
regulation of differentiation of haematopoietic stem cells (Zou et al., 2007). Silencing APE1 
expression in embryonic stem cells reduced haemangioblast precursors and resulted in 
diminished haematopoiesis (Zou et al., 2007). Furthermore, blocking the redox function of 
APE by E3330, impaired haematopoiesis by inhibition of CD34+ stem cells differentiation 
down the erythroid and myeloid lineages (Zou et al., 2007). AML patients suffer from 
anaemia, pancytopenia and thrombocytopenia as a result of infiltration of bone marrow with 
myeloid progenitors with impaired differentiation, leading eventually to haematopoiesis 
failure. Therefore, targeting APE1 in AML patients could be challenging and may contribute 
to the prevailing anaemia by blocking myeloid differentiation. Clinically, one possible 
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solution to overcome this issue is to co-administer enhancers for haematopoiesis in 
conjunction with APE1 inhibitors. Therefore, these data suggest that not only cancer cells are 
dependent on APE1 function, but normal cells (CD34+ cells) are also dependent on APE1 
functions. Therefore, targeting APE1 can be cytostatic, or potentially cytotoxic to non-cancer 
non-target normal cells and it remains to be determined whether there is a potential 
therapeutic window. However, it should be noted that the presence of a therapeutic window 
was not directly explored in this work, as such, further investigation using normal CD34+ 
cells is required to discern this.  
In summary, APE1 remains a potential therapeutic target in AML as monotherapy, but not in 
combination with the established anti-leukaemia therapy. In addition, limited specificity and 
potency of APE1 inhibitors is currently a major challenge in this particular area of research. 
 
7.1.2. Targeting OGG1 as therapeutic strategy in AML 
The BER pathway initiates DNA repair by recognition, excising and removing damaged bases 
via the action of multiple DNA glycosylases, which have unique DNA lesion specificities. 
However, one of the key DNA glycosylases involved in this process is the 8-oxoguanine 
DNA glycosylase (OGG1), which recognises oxidised guanine bases 8-oxoguanine. High 
OGG1 expression in AML has recently been associated with poor prognosis and identified as 
a prognostic marker in AML (Liddiard et al., 2010). In addition, AML with the t(8;21) 
chromosomal translocation is characterised by the AML1-ETO fusion protein, which 
represses OGG1 expression (Krejci et al., 2008; Forster et al., 2016). Patients with the 
AML1-ETO fusion protein have a better response to DNA damaging agents and a relatively 
favourable prognosis, possibly due to low OGG1 activity (Cho et al., 2003; Krejci et al., 
2008; Liddiard et al., 2010). Moreover, some polymorphic variants of OGG1, such as S326C 
and R229Q, are characterised by low OGG1 enzymatic activity and may confer cellular 
sensitivity to DNA damaging agents (Hyun et al., 2000; Hill and Evans, 2007). This 
compelling evidence, added to high oxidative burden in AML, strongly supports the 
hypothesis that targeting OGG1 activity in AML cells may lead to an accumulation of 
unrepaired 8-oxoG lesions in AML blasts and enhance cells killing in response to DNA 
damaging agents that generate oxidative stress, such as daunorubicin.  
The data presented in this thesis demonstrates that OGG1 is ubiquitously expressed in AML 
cell lines and its prognostic value in a clinical setting is inconclusive and warrants further 
investigation. However, given that AML is characterised by a high oxidative burden added to 
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the oxidative stress caused by external sources, such as anti-leukaemia treatment, these factors 
collectively contribute to oxidative DNA damage and upregulation of DNA damage response, 
including BER, which is a normal cellular response. Therefore, upregulation of OGG1 could 
also be used as a biomarker for high oxidative stress as well as a prognostic marker in AML. 
Including established AML prognostic markers such as chromosomal translocations, FLT3, 
RAS or NPM1 in conjunction with OGG1 may provide better prognostic information. 
However, validation of OGG1 as an independent prognostic marker in other datasets is 
required before its inclusion can be justified.  
OGG1 shRNA knockdown studies undertaken here provide evidence that OGG1 might not be 
a promising therapeutic target in AML. The prevailing evidence suggests that OGG1 
knockdown has no or negligible effect on cell proliferation and clonogenicity. Furthermore, 
no evidence was found suggesting potentiation of cytotoxicity induced by genotoxic 
chemotherapy agents by OGG1 knockdown in AML cell lines. Taken together, these data 
suggest that OGG1 has no role in modulation of AML cell proliferation and has no role in 
affecting response to DNA damaging anti-leukaemic agents.  
Although 8-oxoG lesions were not directly measured in this work, these data imply that 8-
oxoG lesions were either not lethal to AML cells and/or alternative mechanisms were 
involved in removing the damage that would otherwise have been repaired by OGG1-
mediated BER. 8-oxoG lesions can be excised by other DNA glycosylases, including 
MUTYH and MTH1, which support the notion that alternative mechanisms are involved in 
their removal (Cooke et al., 2003; Russo et al., 2004; Russo et al., 2007; Scott et al., 2014). 
Therefore, targeting OGG1 and the alternative enzymes that deal with 8-oxoG lesions may 
sensitise AML cells to DNA damaging agents.  
The AML1-ETO fusion oncoprotein confers a relatively favourable prognosis (Cho et al., 
2003; Krejci et al., 2008; Liddiard et al., 2010). The favourable outcome is primarily 
attributed to the t(8;21) chromosomal translocation and reduced DNA damage response, as 
demonstrated by repressed OGG1 expression in this particular patient subgroup (Krejci et al., 
2008; Liddiard et al., 2010). Despite these reports, knocking down OGG1 in AML cells did 
not sensitise them to DNA damaging agents. It is possible that other factors may be 
responsible for the good prognosis and better treatment response in patients with the AML1-
ETO fusion protein. For example, coexistence of other cytogenetic and molecular alterations 
could possibly contribute to favourable outcome of patients with the t(8;21) translocation 
(Hartmann et al., 2016). Similarly, several studies demonstrated that other factors, such as 
KIT and FLT3-ITD mutations, may contribute to adverse prognosis in t(8;21) AML, 
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regardless of OGG1 expression (Baer et al., 1997; Nishii et al., 2003; Gustafson et al., 2009; 
Krauth et al., 2014). Furthermore, OGG1 downregulation in AML1-ETO positive cells 
confers a mutator phenotype by predisposing to G:C to T:A transversions, which may drive 
the acquisition of further mutations that are required for disease relapse. As such, complete 
elimination of subclones carrying this oncogenic fusion protein is essential to prevent disease 
relapse (Forster et al., 2016). Therefore, targeting OGG1 might not be a suitable approach for 
AML treatment, but rather still a potential prognostic marker if confirmed in larger scale 
studies.  
 
7.2. Conclusion 
APE1 knockdown and inhibition has demonstrated limited benefit in AML. Specifically, the 
evidence suggests that there is no value in targeting APE1 as a mechanism to potentiate the 
cytotoxicity of established anti-leukaemic therapies. However, there may be some clinical 
value in using APE1 targeting strategies as monotherapy, with evidence that this approach 
may potentially be used to control the proliferation of leukaemic blast cells. However, this 
approach may be compromised by the engagement of pro-survival mechanisms. Specifically, 
APE1 is essential for normal cellular functions and any disruption of its function could induce 
compensatory mechanisms to maintain cell protection, survival and to efficiently repair 
mutagenic oxidative DNA damage. The involvement of BCL2, CDKN1A, EGR1, PAX5, 
FOXO1 and other components appear to support AML cell survival under oxidative stress 
and may delay cell proliferation in order to allow sufficient DNA damage repair. 
In contrast, OGG1 knockdown had no discernible effect on AML cells and it therapeutic 
targeting may be compromised by the presence of alternative 8-oxoG repair mechanisms. 
Nevertheless, OGG1 may have value as a prognostic marker in AML. 
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7.3. Future directions 
This study was limited to only three AML cell lines. Given that AML is heterogeneous 
disease, including additional AML cell lines representing other genetic and molecular 
characteristics may further clarify the potential value of targeting APE1 in AML. Although 
challenging, including CD34+ cells as positive control to confirm the presence of a 
therapeutic window would be essential. Furthermore, including primary AML cells is 
essential to assess APE1 expression and to determine sensitivity to APE1 inhibitor alone or in 
combination with anti-leukaemia chemotherapy.  
Investigating the effects of double strand break inducing drugs, such as Mylotarg®, and 
differentiating therapies, such as ATRA, after APE1 knockdown/inhibition is also important. 
Data from RNA sequencing showed upregulation of XRCC6, which binds DNA double 
strand breaks and recruits /activates DNA protein kinases, which govern the response to DNA 
damage. APE1 knockdown/inhibition (in particular inhibition of redox function) may also 
enhance ATRA-induced differentiation and apoptosis (Fishel et al., 2010). The current study 
used constitutively expressed shRNA to knockdown APE1 and OGG1 in AML cells. This 
system has some limitations including re-expression of target protein after 10 to 14 weeks of 
transduction, and the inability to resuscitate the majority of knockdown cell clones after 
cryopreservation in liquid nitrogen. As both enzymes are critical for DNA repair, it could be 
possible that DNA damage induced during the freezing/thawing process was beyond repair 
and triggered apoptosis. Therefore, it would be prudent to explore the use of inducible shRNA 
transduction systems, which enable switching the target gene on/off in a controllable manner.  
AP site quantification studies in APE1 knockdown and APE1 inhibited cells (chapters 4 and 
5) were limited in this thesis. Further quantification and validation of the initial results 
presented here are warranted in order to draw strong conclusions from these data. 
Furthermore, the use of assays for specific structural types of DNA damage following APE1 
knockdown or inhibition using comet assay will help determine the type of the DNA damage 
induced. 
The results of RNA sequencing analysis of APE1 knockdown cells are promising and 
provided evidence of the mechanisms that may be responsible for the observed phenotype 
(attenuated cell proliferation) in APE1 knockdown cell clones. Nevertheless, further 
validation of these results at the protein levels is required. Furthermore, studying a possible 
role for APE1 in the regulation of FOXO1, CUX1 and LAIR1 may help to further elucidate 
these mechanisms. 
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Having demonstrated that APE1 knockdown or inhibition antagonises the anti-proliferative 
effects of cytotoxic chemotherapy, it will be useful to explore the mechanisms responsible for 
mediating this phenotype, and whether this is entirely mediated by the compromised 
proliferation of APE1 knockdown cells or whether other mechanisms may be involved. 
CDKN1A and other transcription factors may have a putative role in the observed phenotype.  
As OGG1 is a potential prognostic marker in AML, it is important to demonstrate the 
regulatory mechanisms of this protein and study its exact role in AML. 
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Appendix A 
 
Figure shows AML3 cells with APE1 knockdown. The APE1 antibody used in this project 
was a mouse monoclonal (clone 13B8E5C2) specific to human APE/ref-1 protein with a 
molecular weight of approximately 37 kDa according to manufacturer. 
 
Figure shows AML3 cells with OGG1 knockdown using 3 different shRNA particles (G2, G4 
and G5). The OGG1 antibody used in this project was a rabbit IgG polyclonal reactive to 
mouse and human OGG1 protein with a molecular weight of approximately 39 kDa according 
to manufacturer. The antibody was raised against a synthetic peptide corresponding to aa 318-
345 of the C terminal of human OGG1 protein  
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Appendix B 
Comparison between cell count using TC20 automated cell counter and manual counting 
using haemocytometer to validate using TC20 for routine cell counting. AML3, U937 and 
HL-60 cells were seeded into cell density of 5x104 cells/ml in the first day and counted every 
24 hours for 5 days using TC20 cell counter and haemocytometer. Data presented in each case 
represent the mean of three independent experiments and error bars of standard deviation  
 
 
 
227 
 
Appendix C 
Comparison between counting using TC20 automated cell counter and manual counting using 
haemocytometer. AML3, U937 and HL-60 cells were seeded into cell density of 5x104 in the 
first day and counted every 24 hours for 5 days using TC20 cell counter and haemocytometer. 
Cell count represent the mean of three independent experiments.  
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Appendix D 
Commonly upregulated genes in AML3 and HL-60 cells following APE1 knockdown 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
01 ABCA1 2.55 1.01E-003 2.16 1.29E-002 
02 AC003090.1 2.46 2.13E-003 4.19 2.63E-002 
03 ACOT11 1.91 1.49E-004 1.80 1.73E-003 
04 ACPP 1.83 8.26E-007 1.98 3.72E-004 
05 ADCY1 3.23 6.71E-005 5.07 1.24E-003 
06 AGBL3 1.76 2.27E-002 1.78 5.42E-003 
07 ALDH3B1 1.52 5.24E-004 1.70 4.22E-005 
08 ANPEP 2.30 8.82E-006 1.59 2.29E-002 
09 AOAH 1.81 1.72E-002 2.08 1.35E-003 
10 AP5B1 1.58 4.86E-004 1.58 4.82E-004 
11 APOBR 1.54 4.83E-002 1.75 1.47E-002 
12 APOLD1 1.54 4.61E-004 1.66 1.13E-003 
13 ARHGAP10 5.70 7.84E-003 37.85 5.65E-009 
14 ATP10D 1.88 9.45E-010 4.63 6.87E-011 
15 ATP8B4 1.78 9.64E-004 1.50 4.58E-002 
16 ATXN1 1.60 1.99E-003 1.50 1.17E-002 
17 BARX1 2.48 3.39E-007 3.22 2.59E-002 
18 BCL2A1 2.30 2.53E-005 1.54 4.66E-002 
19 BCL2L11 1.78 3.38E-003 1.67 1.52E-002 
20 BEST1 1.79 2.10E-002 2.20 1.90E-002 
21 BMX 2.30 1.12E-003 8.07 2.18E-026 
22 BTG2 1.93 2.54E-004 3.28 1.67E-010 
23 C1orf186 3.75 6.20E-041 1.39 8.09E-003 
24 C1RL 1.39 6.68E-005 1.77 1.10E-009 
25 C5 1.39 2.49E-002 1.75 1.41E-002 
26 CARD6 1.30 1.73E-002 1.32 4.38E-002 
27 CASP8 1.26 1.45E-003 1.27 8.82E-004 
28 CD38 1.54 9.72E-004 1.42 1.38E-002 
29 CD47 1.19 1.25E-002 1.21 2.03E-003 
30 CDKN1A 2.89 1.31E-006 2.17 8.59E-003 
31 CFAP44 1.67 9.68E-003 1.89 7.14E-004 
32 CLTCL1 1.23 4.67E-002 1.82 7.31E-011 
33 CNTRL 1.32 4.52E-004 1.25 7.23E-003 
34 COL4A1 2.55 2.25E-002 2.31 1.80E-003 
35 CPNE4 5.07 3.12E-007 2.53 1.70E-002 
36 CPQ 1.76 7.28E-004 3.21 1.48E-005 
37 CRISPLD2 1.71 6.20E-003 2.98 6.20E-003 
38 CRTC1 1.62 2.37E-002 1.59 3.45E-002 
39 CST3 1.50 8.53E-005 1.54 6.72E-003 
40 CTD-2231E14.8 1.69 1.85E-009 2.59 1.37E-003 
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Appendix D 
Continue: Commonly upregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
41 CTD-2542L18.1 3.92 1.59E-003 2.28 4.52E-002 
42 CTSK 2.25 2.04E-003 2.04 9.33E-003 
43 CUX1 1.40 4.14E-002 1.46 2.39E-002 
44 CYP4V2 1.33 4.15E-002 2.42 1.50E-007 
45 CYTIP 2.31 5.29E-005 2.78 9.40E-010 
46 DENND1B 1.39 7.63E-004 1.25 4.19E-002 
47 DGKG 1.87 3.04E-005 1.65 1.17E-003 
48 DHRS2 7.45 9.26E-003 4.07 2.06E-003 
49 DNASE1 1.35 5.00E-003 1.55 2.24E-005 
50 DPY19L4 1.27 4.89E-003 1.24 2.50E-002 
51 DSE 1.67 1.77E-002 1.68 1.63E-002 
52 DTX3L 1.75 4.59E-004 1.74 2.29E-003 
53 E2F7 2.21 4.81E-006 2.62 2.94E-009 
54 EGR1 2.29 6.14E-006 1.81 2.41E-003 
55 EMR4P 1.95 1.82E-002 2.31 2.74E-003 
56 EOGT 1.28 1.82E-002 1.56 2.72E-004 
57 EPHB6 30.30 7.64E-034 1.93 1.50E-003 
58 ERAP1 1.47 1.89E-003 1.34 2.99E-002 
59 EXOC6B 1.93 3.46E-003 1.77 4.83E-002 
60 FAM110B 2.04 9.01E-003 2.23 1.13E-002 
61 FAM20C 1.40 8.97E-003 4.67 6.26E-004 
62 FAM65B 3.34 9.62E-004 12.01 3.11E-004 
63 FBP1 1.35 2.05E-002 2.33 4.94E-014 
64 FBXL17 1.61 8.46E-005 1.54 1.11E-003 
65 FNDC3B 1.65 1.12E-005 1.66 1.03E-005 
66 FOXO1 2.05 1.72E-003 2.03 4.40E-003 
67 FRS2 1.37 3.12E-002 1.47 1.00E-002 
68 GALNS 1.26 3.20E-002 1.30 2.72E-002 
69 GATA2-AS1 3.92 1.17E-007 1.77 1.12E-002 
70 GFI1 1.39 7.55E-010 1.22 8.82E-004 
71 GLCE 1.59 6.75E-004 2.64 3.81E-012 
72 GPR137B 1.33 2.30E-002 2.22 1.20E-009 
73 GTF2IRD2B 1.48 4.44E-002 2.03 2.14E-004 
74 HGSNAT 1.35 3.60E-002 1.88 6.29E-005 
75 IGIP 2.11 2.78E-006 1.71 5.82E-003 
76 ITGB2 1.62 1.52E-006 1.34 1.10E-002 
77 ITGB2-AS1 1.65 4.91E-005 2.11 1.83E-005 
78 KANK1 1.40 1.19E-002 1.53 8.22E-004 
79 KIAA0825 1.80 3.08E-002 2.19 3.12E-002 
80 KIAA1211L 1.87 2.56E-002 3.53 1.28E-003 
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Appendix D 
Continue: Commonly upregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
81 KITLG 5.52 6.09E-005 11.27 1.26E-003 
82 LAIR1 1.22 4.15E-002 1.54 4.69E-007 
83 LAMB3 1.59 2.06E-002 3.92 5.11E-003 
84 LINC00638 1.75 3.62E-002 2.35 6.49E-003 
85 LMO7 1.61 9.21E-006 1.38 1.26E-002 
86 LPP 2.39 2.76E-009 2.41 3.46E-009 
87 LRCH3 1.36 1.75E-002 1.34 2.98E-002 
88 LRPAP1 1.27 1.24E-002 1.42 5.44E-005 
89 MAN2B2 1.69 1.46E-006 1.40 4.11E-003 
90 MAPRE3 2.31 1.61E-003 2.60 1.76E-002 
91 MB21D2 2.43 3.27E-004 9.72 1.02E-007 
92 MED12L 2.87 4.78E-002 5.30 4.11E-006 
93 MFSD6 1.42 4.01E-002 3.64 3.78E-011 
94 MR1 1.34 1.19E-002 1.45 2.13E-003 
95 MVB12B 1.71 3.83E-003 2.20 2.38E-008 
96 MYO10 1.95 5.70E-004 2.20 1.44E-002 
97 NCEH1 1.75 1.26E-002 1.79 1.12E-002 
98 NCF1 1.64 6.49E-004 2.50 3.13E-012 
99 NCF1C 1.62 3.26E-004 2.99 3.71E-019 
100 NEB 3.68 5.39E-004 3.61 6.99E-006 
101 NEDD9 2.00 7.25E-006 2.99 4.49E-010 
102 NIPAL2 1.69 4.54E-006 1.66 1.38E-003 
103 NPL 1.79 3.50E-003 1.88 6.24E-004 
104 ODF2L 1.31 7.64E-003 1.28 1.93E-002 
105 OSTM1 1.29 7.15E-004 1.43 4.10E-007 
106 P2RX1 1.47 1.79E-002 1.94 1.09E-005 
107 PAX5 3.61 2.80E-004 2.48 1.91E-004 
108 PCGF5 1.71 2.08E-007 4.07 4.05E-041 
109 PCSK6 1.77 1.68E-005 1.60 9.15E-004 
110 PDE4B 3.00 3.38E-009 1.99 6.99E-005 
111 PFN2 2.04 2.82E-002 2.17 1.60E-002 
112 PHC3 1.55 1.95E-003 1.62 5.35E-004 
113 PHLDA1 1.31 2.84E-002 1.99 4.71E-011 
114 PHTF1 1.24 4.54E-002 1.27 2.61E-002 
115 PILRA 2.24 4.52E-004 2.02 1.59E-002 
116 PIWIL4 1.71 4.19E-006 1.81 2.67E-006 
117 PPM1H 1.77 3.69E-003 5.93 2.66E-019 
118 PRKCE 2.24 6.31E-005 3.01 5.31E-007 
119 PTAFR 1.94 3.72E-003 1.95 3.02E-003 
120 PTGFRN 1.38 1.25E-002 48.29 1.47E-056 
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Continue: Commonly upregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
121 PTPRC 1.38 2.70E-002 1.52 2.99E-003 
122 RAB37 1.41 1.44E-003 1.53 2.10E-004 
123 RAB7B 3.02 8.11E-018 1.62 1.37E-003 
124 RAC2 1.51 1.42E-003 1.47 4.98E-003 
125 RASAL2 2.47 4.91E-008 2.21 5.54E-003 
126 RN7SL141P 3.58 3.46E-003 2.28 2.50E-002 
127 RNASEL 1.41 4.88E-004 1.46 4.26E-003 
128 RNF165 1.90 6.54E-003 2.24 5.59E-004 
129 RP11-37B2.1 2.16 5.40E-004 1.71 3.78E-002 
130 RP11-443B7.1 1.51 2.59E-002 2.42 8.18E-006 
131 RP11-53B2.2 2.34 3.24E-002 4.72 4.29E-002 
132 RP11-556H2.3 2.24 2.45E-002 4.64 4.93E-002 
133 SCAMP2 1.42 3.32E-005 1.28 1.17E-002 
134 SERPINA1 2.17 3.11E-002 5.28 3.62E-007 
135 SESN3 2.20 6.06E-004 11.71 9.19E-027 
136 SIPA1L2 1.72 4.28E-002 4.47 1.39E-005 
137 SIRPB2 1.36 4.08E-002 2.58 1.40E-002 
138 SKOR1 3.88 1.79E-002 1.76 2.57E-002 
139 SLC38A10 1.90 1.00E-008 1.56 3.02E-004 
140 SLC46A3 1.74 2.98E-003 2.62 3.55E-006 
141 SLFN5 2.01 4.88E-002 3.32 4.30E-003 
142 SPPL2A 1.30 2.70E-003 1.44 1.48E-005 
143 SQSTM1 1.45 1.33E-003 1.32 3.00E-002 
144 SRGN 1.63 9.74E-005 2.15 6.72E-011 
145 ST7L 1.31 3.48E-003 1.28 2.91E-002 
146 STK17B 1.17 3.32E-002 1.40 1.41E-007 
147 STXBP5 1.22 3.51E-002 1.77 4.04E-022 
148 STXBP5-AS1 4.02 2.58E-002 2.75 1.03E-002 
149 SUCNR1 3.72 1.47E-011 1.92 1.36E-009 
150 SYNE1 2.57 8.33E-005 5.23 2.59E-006 
151 SYTL2 2.44 1.95E-002 2.58 1.56E-002 
152 TBCEL 1.34 7.39E-003 0.84 1.30E-002 
153 TGFA 3.52 2.57E-005 3.88 1.65E-003 
154 THBS4 1.33 7.17E-003 1.22 1.51E-003 
155 TLR1 2.27 7.97E-004 3.50 8.92E-006 
156 TLR2 1.52 1.18E-002 1.82 3.14E-003 
157 TNFRSF14 1.65 4.55E-003 2.28 8.44E-005 
158 TRGC1 2.66 3.37E-005 4.41 6.19E-014 
159 TRGC2 2.29 1.72E-002 4.81 6.47E-010 
160 TSPAN5 3.32 2.76E-009 4.52 7.08E-007 
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Continue: Commonly upregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
161 TTC14 1.50 1.63E-003 0.91 2.97E-002 
162 TTLL7 2.26 3.85E-003 2.76 5.82E-006 
163 TXNIP 1.49 6.28E-003 1.46 3.06E-004 
164 TYROBP 2.28 5.63E-004 2.15 3.39E-003 
165 UACA 1.85 1.28E-002 6.14 4.03E-005 
166 UBA7 1.70 1.02E-003 1.51 5.91E-003 
167 USP18 1.64 3.46E-002 2.02 1.57E-002 
168 VPS8 1.75 4.08E-012 0.92 3.12E-004 
169 WAS 1.56 1.12E-002 1.26 1.49E-002 
170 WSB2 1.33 4.59E-004 0.80 4.43E-003 
171 WWOX 1.68 4.17E-005 1.05 1.57E-002 
172 ZCWPW1 1.37 4.16E-002 1.45 2.12E-002 
173 ZMAT3 2.39 1.65E-025 1.09 7.12E-005 
174 ZNF438 1.44 9.08E-003 1.16 1.63E-002 
175 ZNF641 1.29 4.47E-002 1.06 5.09E-003 
176 ZNF75D 1.48 1.52E-003 1.38 2.21E-002 
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Appendix E 
Commonly downregulated genes in AML3 and HL-60 following APE1 knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
01 ABCA3 -1.9 3.81E-006 -1.4 9.83E-003 
02 ABCF1 -1.6 1.52E-005 -1.3 9.86E-003 
03 ACP1 -1.3 5.21E-003 -1.3 4.37E-002 
04 ALDH18A1 -1.4 2.02E-004 -1.5 1.40E-006 
05 ALKBH2 -1.5 1.26E-002 -1.5 6.44E-003 
06 APEX1 -8.6 6.33E-162 -12.6 1.40E-233 
07 ARF4 -1.2 1.87E-002 -1.3 3.68E-003 
08 ARMCX5 -16.7 3.92E-045 -1.3 1.55E-002 
09 ASCC2 -2.1 3.33E-022 -2.1 3.33E-022 
10 ASF1A -1.3 8.22E-003 -1.2 2.71E-002 
11 ATF5 -1.4 3.22E-002 -1.5 1.09E-002 
12 ATP5G2 -1.4 1.45E-002 -1.4 8.69E-003 
13 BCAT1 -1.5 7.42E-004 -1.8 3.96E-007 
14 BFAR -1.4 9.42E-004 -1.3 9.40E-003 
15 BIVM -1.8 4.36E-004 -1.6 1.15E-005 
16 BLMH -1.3 1.63E-002 -1.3 1.39E-002 
17 BTK -1.2 7.79E-003 -1.2 1.16E-002 
18 BZRAP1 -1.3 4.88E-002 -1.4 3.23E-003 
19 C12orf75 -2.9 1.60E-025 -2.0 1.81E-008 
20 CACNB1 -2.0 1.88E-005 -2.9 1.31E-012 
21 CAMSAP2 -1.4 3.41E-004 -1.4 1.41E-002 
22 CCBL2 -1.3 6.60E-003 -1.6 8.72E-009 
23 CDC42 -1.6 9.02E-005 -1.6 9.37E-005 
24 CDK16 -1.5 2.29E-003 -1.4 8.07E-003 
25 CENPV -1.4 1.57E-002 -1.4 1.48E-002 
26 CFDP1 -1.5 1.70E-002 -1.7 9.66E-004 
27 CGN -4.1 2.93E-002 -2.3 3.49E-003 
28 CIAPIN1 -1.3 7.17E-004 -1.2 3.64E-002 
29 CNNM4 -1.5 7.77E-004 -1.6 1.73E-004 
30 CPOX -1.7 3.70E-005 -1.5 1.45E-003 
31 CSE1L -1.4 2.26E-006 -1.3 3.81E-004 
32 CUTC -1.4 6.65E-005 -1.3 1.82E-003 
33 DANCR -1.7 6.25E-008 -1.7 2.16E-007 
34 DDN -5.5 8.11E-033 -1.7 2.64E-007 
35 DDX21 -1.3 8.68E-007 -1.2 3.38E-002 
36 DFFA -1.4 4.72E-003 -1.4 1.28E-002 
37 DNAJC24 -1.5 1.28E-002 -1.8 2.14E-005 
38 DNMT3B -1.6 1.03E-003 -1.5 6.03E-003 
39 EFCAB2 -1.4 1.17E-002 -1.4 9.27E-003 
40 EIF4B -1.4 1.88E-002 -1.5 6.89E-003 
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Continue: Commonly downregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
41 EIF4E -1.4 6.39E-003 -1.3 4.56E-002 
42 ELP5 -1.4 3.90E-004 -1.4 5.76E-004 
43 FARP2 -2.0 1.38E-019 -2.1 7.32E-021 
44 FDXACB1 -1.5 2.09E-002 -1.7 1.26E-003 
45 FIRRE -4.6 1.15E-016 -121.4 2.62E-023 
46 FSD1 -2.1 2.91E-004 -1.9 4.97E-002 
47 G3BP1 -1.3 2.94E-005 -1.2 9.13E-004 
48 G3BP2 -1.2 3.47E-002 -1.4 9.19E-010 
49 GJA3 -5.1 5.75E-015 -2.6 1.25E-012 
50 GPD1L -1.4 3.19E-002 -1.4 2.32E-002 
51 GPR63 -2.5 1.68E-007 -3.1 1.45E-014 
52 GRSF1 -1.2 7.22E-003 -1.2 1.53E-002 
53 GSTP1 -1.6 1.88E-005 -1.4 6.52E-003 
54 GTF2H1 -1.2 4.79E-002 -1.5 1.18E-005 
55 GTF2H2C -1.2 4.24E-002 -1.2 4.01E-002 
56 GTF2H3 -1.3 7.64E-003 -1.4 6.20E-004 
57 GTSF1 -1.4 3.15E-003 -1.5 4.72E-005 
58 HMMR -2.0 1.04E-004 -2.3 3.84E-006 
59 HN1L -1.6 2.05E-004 -1.4 2.20E-002 
60 HNRNPDL -1.4 1.35E-004 -1.3 2.08E-002 
61 HNRNPH3 -1.2 3.79E-002 -1.3 1.41E-002 
62 ILF2 -1.2 1.87E-002 -1.2 4.24E-002 
63 IMPA1 -1.8 7.37E-015 -2.2 4.93E-025 
64 IMPDH2 -1.3 1.44E-004 -1.3 5.06E-004 
65 IPO5 -1.3 1.59E-002 -1.5 5.95E-005 
66 ITGB1BP1 -1.4 8.28E-004 -1.3 3.87E-002 
67 JOSD1 -1.7 8.88E-008 -1.6 5.57E-005 
68 KCTD3 -1.4 9.64E-003 -1.4 7.66E-003 
69 KIF3C -1.9 2.93E-006 -2.4 9.47E-006 
70 LEPREL2 -1.6 3.46E-003 -6.6 2.03E-048 
71 LMO4 -1.4 3.90E-002 -1.4 2.46E-002 
72 LPPR2 -2.5 1.86E-022 -3.0 6.28E-018 
73 LRRC8B -1.8 4.72E-006 -1.4 1.40E-002 
74 LRRC8C -1.5 1.52E-002 -1.5 4.33E-002 
75 MAK16 -1.3 1.12E-002 -1.3 6.89E-003 
76 MAP4K1 -1.9 4.04E-006 -2.7 1.31E-014 
77 MAPK3 -1.3 2.92E-002 -1.5 2.05E-003 
78 MAPK6 -1.5 2.12E-014 -1.5 1.79E-015 
79 MARCKS -1.6 2.67E-002 -3.5 7.04E-005 
80 MARS -1.2 1.45E-002 -1.5 1.62E-010 
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Continue: Commonly downregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
81 MCCC2 -1.3 3.21E-002 -1.7 1.91E-007 
82 ME1 -1.5 6.11E-003 -2.4 2.05E-018 
83 ME2 -1.2 3.03E-002 -1.3 3.02E-003 
84 MED6 -1.8 1.25E-009 -1.6 5.00E-007 
85 METTL2A -1.2 2.00E-002 -1.2 2.58E-002 
86 METTL8 -1.3 7.06E-003 -1.2 4.88E-002 
87 MOGS -1.3 4.47E-002 -1.3 4.21E-002 
88 MPZL1 -1.8 5.64E-007 -1.4 3.35E-003 
89 MRPL9 -1.9 2.41E-018 -2.0 2.40E-023 
90 MRPS2 -1.4 1.73E-003 -1.4 1.28E-002 
91 MRPS27 -1.2 2.48E-002 -1.2 1.39E-002 
92 MTCH2 -1.4 1.59E-003 -1.7 8.11E-009 
93 MTHFD1 -2.4 8.64E-050 -2.1 8.64E-038 
94 MTOR -1.3 2.01E-002 -1.3 3.02E-003 
95 NAP1L1 -1.3 1.58E-002 -1.3 2.24E-002 
96 NAP1L4 -1.1 3.00E-002 -1.3 1.15E-005 
97 NARS2 -1.2 2.63E-002 -1.2 4.50E-002 
98 NCR3LG1 -1.5 8.70E-003 -1.7 2.65E-004 
99 NIPA2 -1.5 2.17E-005 -1.4 2.67E-003 
100 NLE1 -1.3 4.52E-003 -1.2 4.68E-002 
101 NPM1 -1.4 7.11E-004 -1.3 1.12E-002 
102 NPM3 -1.5 4.61E-002 -1.8 6.10E-004 
103 NRARP -3.1 9.44E-003 -1.5 4.28E-002 
104 NUP54 -1.2 2.27E-002 -1.2 1.73E-003 
105 PALD1 -1.8 3.21E-005 -1.8 5.58E-005 
106 PBX2 -1.5 6.87E-004 -1.4 1.56E-002 
107 PCID2 -1.2 2.35E-002 -1.4 6.89E-005 
108 PFAS -1.4 1.15E-004 -1.3 1.73E-002 
109 PFKM -2.2 9.12E-020 -1.8 5.65E-013 
110 POLE4 -1.6 8.88E-004 -1.4 3.22E-002 
111 PPFIA3 -1.5 1.05E-002 -1.4 2.23E-002 
112 PTK7 -1.7 6.76E-003 -16.5 8.84E-022 
113 RAB29 -1.2 4.86E-003 -1.4 9.20E-007 
114 RAB31 -1.4 1.53E-002 -1.9 7.70E-007 
115 RAB4A -1.4 3.81E-006 -1.5 2.84E-009 
116 RABEP1 -1.6 2.29E-006 -1.5 1.49E-004 
117 RAP2A -2.1 2.67E-011 -1.5 1.25E-003 
118 RASSF3 -1.3 5.87E-004 -1.3 1.07E-003 
119 RBM12 -1.2 4.10E-002 -1.2 8.16E-003 
120 RBM19 -1.4 2.15E-002 -1.3 3.93E-002 
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Continue: Commonly downregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
121 RCC1 -1.9 9.86E-007 -1.7 1.39E-004 
122 RDH11 -1.3 2.34E-002 -1.4 2.22E-002 
123 RENBP -3.0 7.99E-004 -2.7 1.56E-002 
124 RHOF -1.4 1.18E-003 -1.3 6.00E-003 
125 RHOQ -1.3 3.04E-002 -1.7 8.83E-008 
126 RHPN2 -1.9 7.51E-007 -1.5 7.28E-003 
127 RIC8A -1.2 4.61E-002 -1.5 6.43E-005 
128 RNU12 -1.5 4.22E-002 -1.8 1.21E-003 
129 RP11-1082L8.4 -2.4 3.49E-004 -3.1 4.20E-003 
130 RP11-253E3.3 -2.0 4.36E-003 -12.5 2.01E-006 
131 RP11-391M1.4 -1.9 3.54E-003 -1.6 3.79E-002 
132 RP1-239B22.5 -1.9 1.13E-005 -1.7 2.23E-004 
133 RPL14 -1.3 3.73E-002 -1.3 3.78E-002 
134 RPL19 -1.3 1.58E-002 -1.4 4.98E-003 
135 RPLP0P6 -1.8 1.08E-003 -1.5 5.00E-002 
136 RRM1 -1.4 1.12E-004 -1.3 1.26E-003 
137 RUVBL1 -1.3 3.48E-002 -1.3 1.43E-002 
138 RWDD4 -1.5 4.53E-004 -1.5 6.26E-004 
139 SAAL1 -1.3 4.16E-002 -1.5 6.29E-005 
140 SEC13 -1.2 2.21E-002 -1.3 1.49E-003 
141 SERP1 -1.3 1.89E-003 -1.4 5.55E-005 
142 SLC19A2 -1.4 1.71E-003 -1.3 2.96E-002 
143 SLC25A15 -1.4 4.09E-003 -1.5 2.96E-004 
144 SLC25A17 -1.3 2.16E-003 -1.3 3.25E-003 
145 SLC37A4 -1.3 3.47E-002 -1.6 1.54E-004 
146 SLC7A2 -1.4 2.12E-003 -1.8 1.51E-011 
147 SNHG16 -1.5 1.88E-008 -1.3 4.32E-003 
148 SNHG8 -1.4 3.90E-002 -1.6 9.23E-004 
149 SNORD12C -1.7 3.28E-003 -1.6 2.05E-002 
150 SNRNP48 -1.5 2.07E-006 -1.2 2.51E-002 
151 SNRPA -1.3 3.54E-002 -1.4 2.91E-002 
152 SOBP -1.4 1.99E-002 -1.5 1.07E-002 
153 SORT1 -4.6 1.31E-033 -1.4 1.13E-002 
154 SPATS2 -1.3 1.57E-002 -1.7 7.04E-007 
155 SPIRE1 -1.3 1.43E-002 -1.4 8.63E-003 
156 SPTBN2 -2.5 3.48E-002 -1.5 1.74E-002 
157 SRPR -1.4 3.20E-003 -1.8 4.60E-010 
158 ST13 -1.5 2.76E-005 -1.5 1.19E-004 
159 ST13P3 -1.4 5.71E-003 -1.5 1.64E-003 
160 ST13P4 -1.6 6.68E-004 -1.6 2.13E-003 
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Continue: Commonly downregulated genes in AML3 and HL-60 cells following APE1 
knockdown. 
Gene AML 3 HL-60 
Fold 
Change 
P value Fold 
Change 
P value 
161 ST13P5 -1.5 4.52E-003 -1.5 4.52E-003 
162 STK32C -1.5 5.59E-003 -1.7 2.61E-003 
163 TBC1D4 -1.5 1.68E-002 -1.9 5.15E-005 
164 TEAD4 -1.4 2.81E-002 -23.5 3.69E-012 
165 TEX19 -4.1 2.13E-002 -2.8 4.04E-003 
166 THUMPD1 -1.2 4.82E-004 -1.2 1.56E-002 
167 TMEM14B -1.4 1.31E-003 -1.3 4.30E-002 
168 TMEM194A -1.4 3.34E-003 -1.4 1.05E-002 
169 TNNT1 -2.0 9.36E-006 -12.8 2.36E-037 
170 TOP1MT -1.3 3.61E-002 -1.4 4.24E-002 
171 TRAP1 -1.3 3.61E-002 -1.3 4.66E-002 
172 TRIM24 -1.5 4.14E-005 -1.3 4.40E-002 
173 TUBA1C -1.4 3.74E-004 -1.3 1.85E-002 
174 TWISTNB -1.6 5.05E-013 -1.3 1.27E-003 
175 UAP1L1 -1.3 2.12E-002 -1.6 2.07E-004 
176 UBFD1 -1.4 2.73E-005 -1.3 1.42E-003 
177 USMG5 -3.5 2.87E-011 -2.8 8.83E-008 
178 USP46 -1.5 2.64E-003 -1.3 4.18E-002 
179 VASH2 -1.6 6.33E-003 -1.7 3.33E-003 
180 VDAC2 -1.2 1.06E-002 -1.1 4.93E-002 
181 VEGFB -1.3 1.74E-002 -1.4 3.59E-003 
182 VPS4A -1.9 8.05E-008 -1.6 2.61E-004 
183 VWA9 -1.2 1.64E-002 -1.2 4.06E-002 
184 WNT10B -2.0 3.98E-005 -1.6 2.12E-003 
185 XPO6 -1.8 7.37E-010 -1.6 3.02E-007 
186 XRCC6 -1.2 1.80E-002 -1.2 1.03E-002 
187 YWHAQ -1.2 2.72E-003 -1.2 3.65E-003 
188 ZDHHC2 -1.9 1.49E-011 -1.3 1.43E-002 
189 ZFP1 -1.3 1.01E-002 -1.4 5.65E-003 
190 ZMAT5 -1.4 4.61E-002 -1.8 6.94E-005 
191 ZNF343 -1.5 3.23E-003 -1.4 5.44E-003 
 
 
 
 
 
 
 
 
238 
 
References 
 
Abbas, S., Lugthart, S., Kavelaars, F.G., Schelen, A., Koenders, J.E., Zeilemaker, A., van 
Putten, W.J., Rijneveld, A.W., Lowenberg, B. and Valk, P.J. (2010) 'Acquired mutations in 
the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: 
prevalence and prognostic value', Blood, 116(12), pp. 2122-6. 
Abbas, T. and Dutta, A. (2009) 'p21 in cancer: intricate networks and multiple activities', 
Nature reviews. Cancer, 9(6), pp. 400-414. 
Abbi, K.K., Rybka, W., Ehmann, W.C. and Claxton, D.F. (2015) 'Phase I/II study of 
clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute 
leukemia', Clin Lymphoma Myeloma Leuk, 15(1), pp. 41-6. 
Abbotts, R., Jewell, R., Nsengimana, J., Maloney, D.J., Simeonov, A., Seedhouse, C., Elliott, 
F., Laye, J., Walker, C., Jadhav, A., Grabowska, A., Ball, G., Patel, P.M., Newton-Bishop, J., 
Wilson, D.M., 3rd and Madhusudan, S. (2014) 'Targeting human apurinic/apyrimidinic 
endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells 
for personalized therapy', Oncotarget. 
Abbotts, R. and Madhusudan, S. (2010) 'Human AP endonuclease 1 (APE1): From 
mechanistic insights to druggable target in cancer', Cancer Treatment Reviews, 36(5), pp. 
425-435. 
Abdel-Fatah, T.M., Arora, A., Moseley, P.M., Perry, C., Rakha, E.A., Green, A.R., Chan, 
S.Y., Ellis, I.O. and Madhusudan, S. (2015) 'DNA repair prognostic index modelling reveals 
an essential role for base excision repair in influencing clinical outcomes in ER negative and 
triple negative breast cancers', Oncotarget, 6(26), pp. 21964-78. 
Abdel-Fatah, T.M., Perry, C., Moseley, P., Johnson, K., Arora, A., Chan, S., Ellis, I.O. and 
Madhusudan, S. (2014) 'Clinicopathological significance of human apurinic/apyrimidinic 
endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer', Breast 
Cancer Res Treat, 143(3), pp. 411-21. 
Agrawal, K. (2007) 'Daunorubicin', in  xPharm: The Comprehensive Pharmacology 
Reference. New York: Elsevier, pp. 1-4. 
239 
 
Akbari, M., Otterlei, M., Peña-Diaz, J., Aas, P.A., Kavli, B., Liabakk, N.B., Hagen, L., Imai, 
K., Durandy, A., Slupphaug, G. and Krokan, H.E. (2004) 'Repair of U/G and U/A in DNA by 
UNG2-associated repair complexes takes place predominantly by short-patch repair both in 
proliferating and growth-arrested cells', Nucleic Acids Research, 32(18), pp. 5486-5498. 
Al-Attar, A., Gossage, L., Fareed, K.R., Shehata, M., Mohammed, M., Zaitoun, A.M., 
Soomro, I., Lobo, D.N., Abbotts, R., Chan, S. and Madhusudan, S. (2010) 'Human 
apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-
oesophageal and pancreatico-biliary cancers', Br J Cancer, 102(4), pp. 704-9. 
Al-Safi, R.I., Odde, S., Shabaik, Y. and Neamati, N. (2012) 'Small-molecule inhibitors of 
APE1 DNA repair function: an overview', Curr Mol Pharmacol, 5(1), pp. 14-35. 
Alcalay, M., Meani, N., Gelmetti, V., Fantozzi, A., Fagioli, M., Orleth, A., Riganelli, D., 
Sebastiani, C., Cappelli, E., Casciari, C., Sciurpi, M.T., Mariano, A.R., Minardi, S.P., Luzi, 
L., Muller, H., Di Fiore, P.P., Frosina, G. and Pelicci, P.G. (2003) 'Acute myeloid leukemia 
fusion proteins deregulate genes involved in stem cell maintenance and DNA repair', J Clin 
Invest, 112(11), pp. 1751-61. 
Allan, J.M., Smith, A.G., Wheatley, K., Hills, R.K., Travis, L.B., Hill, D.A., Swirsky, D.M., 
Morgan, G.J. and Wild, C.P. (2004) 'Genetic variation in XPD predicts treatment outcome 
and risk of acute myeloid leukemia following chemotherapy', Blood, 104(13), pp. 3872-3877. 
Allan, J.M. and Travis, L.B. (2005) 'Mechanisms of therapy-related carcinogenesis', Nat Rev 
Cancer, 5(12), pp. 943-955. 
Aly, A. and Ganesan, S. (2011) 'BRCA1, PARP, and 53BP1: conditional synthetic lethality 
and synthetic viability', Journal of Molecular Cell Biology, 3(1), pp. 66-74. 
Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, 
C.D., Cazzola, M. and Vardiman, J.W. (2016) 'The 2016 revision to the World Health 
Organization classification of myeloid neoplasms and acute leukemia', Blood, 127(20), pp. 
2391-405. 
Baer, M.R., Stewart, C.C., Lawrence, D., Arthur, D.C., Byrd, J.C., Davey, F.R., Schiffer, 
C.A. and Bloomfield, C.D. (1997) 'Expression of the Neural Cell Adhesion Molecule CD56 Is 
240 
 
Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With 
t(8; 21)(q22; q22)', Blood, 90(4), pp. 1643-1648. 
Bagrintseva, K., Geisenhof, S., Kern, R., Eichenlaub, S., Reindl, C., Ellwart, J.W., 
Hiddemann, W. and Spiekermann, K. (2005) 'FLT3-ITD-TKD dual mutants associated with 
AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of 
Bcl-x(L)', Blood, 105(9), pp. 3679-3685. 
Bănescu, C., Duicu, C., Trifa, A.P. and Dobreanu, M. (2014) 'XRCC1 Arg194Trp and 
Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid 
leukemia', Leukemia & lymphoma, 55(2), pp. 365-370. 
Bapat, A., Fishel, M.L. and Kelley, M.R. (2009) 'Going ape as an approach to cancer 
therapeutics', Antioxid Redox Signal, 11(3), pp. 651-68. 
Bapat, A., Glass, L.S., Luo, M., Fishel, M.L., Long, E.C., Georgiadis, M.M. and Kelley, M.R. 
(2010) 'Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks 
proliferation and reduces viability of glioblastoma cells', J Pharmacol Exp Ther, 334(3), pp. 
988-98. 
Barakat, K.H., Gajewski, M.M. and Tuszynski, J.A. (2012) 'DNA polymerase beta (pol beta) 
inhibitors: a comprehensive overview', Drug Discov Today, 17(15-16), pp. 913-20. 
Barnes, T., Kim, W.C., Mantha, A.K., Kim, S.E., Izumi, T., Mitra, S. and Lee, C.H. (2009) 
'Identification of Apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that 
cleaves c-myc mRNA', Nucleic Acids Res, 37(12), pp. 3946-58. 
Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. and 
Sultan, C. (1976) 'Proposals for the classification of the acute leukaemias. French-American-
British (FAB) co-operative group', Br J Haematol, 33(4), pp. 451-8. 
Bennett, R.A.O., Wilson, D.M., Wong, D. and Demple, B. (1997) 'Interaction of human 
apurinic endonuclease and DNA polymerase β in the base excision repair pathway', 
Proceedings of the National Academy of Sciences of the United States of America, 94(14), pp. 
7166-7169. 
241 
 
Bhakat, K.K., Izumi, T., Yang, S.H., Hazra, T.K. and Mitra, S. (2003) 'Role of acetylated 
human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene', 
EMBO J, 22(23), pp. 6299-309. 
Bhakat, K.K., Mantha, A.K. and Mitra, S. (2009) 'Transcriptional regulatory functions of 
mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein', Antioxid 
Redox Signal, 11(3), pp. 621-38. 
Bhakat, K.K., Mokkapati, S.K., Boldogh, I., Hazra, T.K. and Mitra, S. (2006) 'Acetylation of 
human 8-oxoguanine-DNA glycosylase by p300 and its role in 8-oxoguanine repair in vivo', 
Mol Cell Biol, 26(5), pp. 1654-65. 
Bishop, J.F., Lowenthal, R.M., Joshua, D., Matthews, J.P., Todd, D., Cobcroft, R., Whiteside, 
M.G., Kronenberg, H., Ma, D., Dodds, A. and et al. (1990) 'Etoposide in acute 
nonlymphocytic leukemia. Australian Leukemia Study Group', Blood, 75(1), pp. 27-32. 
Bjoras, M., Luna, L., Johnsen, B., Hoff, E., Haug, T., Rognes, T. and Seeberg, E. (1997) 
'Opposite base-dependent reactions of a human base excision repair enzyme on DNA 
containing 7,8-dihydro-8-oxoguanine and abasic sites', Embo j, 16(20), pp. 6314-22. 
Boehrer, S., Ades, L., Tajeddine, N., Hofmann, W.K., Kriener, S., Bug, G., Ottmann, O.G., 
Ruthardt, M., Galluzzi, L., Fouassier, C., Tailler, M., Olaussen, K.A., Gardin, C., Eclache, V., 
de Botton, S., Thepot, S., Fenaux, P. and Kroemer, G. (2009) 'Suppression of the DNA 
damage response in acute myeloid leukemia versus myelodysplastic syndrome', Oncogene, 
28(22), pp. 2205-18. 
Boiteux, S. and Radicella, J.P. (2000) 'The human OGG1 gene: structure, functions, and its 
implication in the process of carcinogenesis', Arch Biochem Biophys, 377(1), pp. 1-8. 
Boultwood, J. (2013) 'CUX1 in leukemia: dosage matters', Blood, 121(6), pp. 869-871. 
Brandwein, J.M., Yang, L., Schimmer, A.D., Schuh, A.C., Gupta, V., Wells, R.A., Alibhai, 
S.M.H., Xu, W. and Minden, M.D. (2007) 'A phase II study of temozolomide therapy for 
poor-risk patients aged [ges]60 years with acute myeloid leukemia: low levels of MGMT 
predict for response', Leukemia, 21(4), pp. 821-824. 
242 
 
Branzei, D. and Foiani, M. (2008) 'Regulation of DNA repair throughout the cell cycle', Nat 
Rev Mol Cell Biol, 9(4), pp. 297-308. 
Buckley, S.A., Mawad, R., Gooley, T.A., Becker, P.S., Sandhu, V., Hendrie, P., Scott, B.L., 
Wood, B.L., Walter, R.B., Smith, K., Dean, C., Estey, E.H. and Pagel, J.M. (2015) 'A phase 
I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid 
leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age', British 
Journal of Haematology, 170(3), pp. 349-355. 
Bulgar, A.D., Snell, M., Donze, J.R., Kirkland, E.B., Li, L., Yang, S., Xu, Y., Gerson, S.L. 
and Liu, L. (2010) 'Targeting base excision repair suggests a new therapeutic strategy of 
fludarabine for the treatment of chronic lymphocytic leukemia', Leukemia, 24(10), pp. 1795-9. 
Bulgar, A.D., Weeks, L.D., Miao, Y., Yang, S., Xu, Y., Guo, C., Markowitz, S., Oleinick, N., 
Gerson, S.L. and Liu, L. (2012) 'Removal of uracil by uracil DNA glycosylase limits 
pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision 
repair', Cell Death Dis, 3, p. e252. 
Burkovics, P., Hajdú, I., Szukacsov, V., Unk, I. and Haracska, L. (2009) 'Role of PCNA-
dependent stimulation of 3′-phosphodiesterase and 3′–5′ exonuclease activities of 
human Ape2 in repair of oxidative DNA damage', Nucleic Acids Research, 37(13), pp. 4247-
4255. 
Burkovics, P., Szukacsov, V., Unk, I. and Haracska, L. (2006) 'Human Ape2 protein has a 
3′–5′ exonuclease activity that acts preferentially on mismatched base pairs', Nucleic 
Acids Research, 34(9), pp. 2508-2515. 
Burnett, A., Wetzler, M. and Lowenberg, B. (2011a) 'Therapeutic advances in acute myeloid 
leukemia', J Clin Oncol, 29(5), pp. 487-94. 
Burnett, A.K., Hills, R.K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N.H., Yin, J.A., 
Hunter, A., Goldstone, A.H. and Wheatley, K. (2011b) 'Identification of patients with acute 
myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of 
the MRC AML15 trial', J Clin Oncol, 29(4), pp. 369-77. 
243 
 
Burnett, A.K., Russell, N.H., Hills, R.K., Hunter, A.E., Kjeldsen, L., Yin, J., Gibson, B.E., 
Wheatley, K. and Milligan, D. (2013) 'Optimization of chemotherapy for younger patients 
with acute myeloid leukemia: results of the medical research council AML15 trial', J Clin 
Oncol, 31(27), pp. 3360-8. 
Burnett, A.K., Russell, N.H., Hills, R.K., Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M.-
F., Cahalin, P., Dennis, M., Friis, L., Thomas, I.F., Milligan, D. and Clark, R.E. (2015) 'A 
randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results 
from the UK NCRI AML17 trial in 1206 patients', Blood, 125(25), pp. 3878-3885. 
Busso, C.S., Iwakuma, T. and Izumi, T. (2009) 'Ubiquitination of mammalian AP 
endonuclease (APE1) regulated by the p53-MDM2 signaling pathway', Oncogene, 28(13), pp. 
1616-25. 
Busso, C.S., Wedgeworth, C.M. and Izumi, T. (2011) 'Ubiquitination of human AP-
endonuclease 1 (APE1) enhanced by T233E substitution and by CDK5', Nucleic Acids 
Research, 39(18), pp. 8017-8028. 
Caimi, P., Cooper, B., William, B.M., Campagnaro, E.L., Creger, R.J., Afable, M., Xu, Y., 
Pink, J., Dowlati, A., Lazarus, H.M., de Lima, M. and Gerson, S.L. (2014) 'Phase I Trial of 
the Base – Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in 
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies', 
Blood, 124(21), pp. 4688-4688. 
Campisi, J. and d'Adda di Fagagna, F. (2007) 'Cellular senescence: when bad things happen to 
good cells', Nat Rev Mol Cell Biol, 8(9), pp. 729-740. 
Cappelli, E., Taylor, R., Cevasco, M., Abbondandolo, A., Caldecott, K. and Frosina, G. 
(1997) 'Involvement of XRCC1 and DNA Ligase III Gene Products in DNA Base Excision 
Repair', Journal of Biological Chemistry, 272(38), pp. 23970-23975. 
Cardoso, A.A., Jiang, Y., Luo, M., Reed, A.M., Shahda, S., He, Y., Maitra, A., Kelley, M.R. 
and Fishel, M.L. (2012) 'APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-
1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival', PLoS One, 7(10), 
p. e47462. 
244 
 
Carter, R.J. and Parsons, J.L. (2016) 'Base excision repair: A pathway regulated by post-
translational modifications', Mol Cell Biol. 
Casorelli, I., Tenedini, E., Tagliafico, E., Blasi, M.F., Giuliani, A., Crescenzi, M., Pelosi, E., 
Testa, U., Peschle, C., Mele, L., Diverio, D., Breccia, M., Lo-Coco, F., Ferrari, S. and 
Bignami, M. (2006) 'Identification of a molecular signature for leukemic promyelocytes and 
their normal counterparts: Focus on DNA repair genes', Leukemia, 20(11), pp. 1978-88. 
Castilla, L.H. (2008) 'C/EBPalpha in leukemogenesis: a matter of being in the right place with 
the right signals', Cancer Cell, 13(4), pp. 289-91. 
Cavelier, C., Didier, C., Prade, N., Mansat-De Mas, V., Manenti, S., Recher, C., Demur, C. 
and Ducommun, B. (2009) 'Constitutive activation of the DNA damage signaling pathway in 
acute myeloid leukemia with complex karyotype: potential importance for checkpoint 
targeting therapy', Cancer Res, 69(22), pp. 8652-61. 
Cazzalini, O., Scovassi, A.I., Savio, M., Stivala, L.A. and Prosperi, E. (2010) 'Multiple roles 
of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response', Mutat Res, 704(1-3), 
pp. 12-20. 
Chattopadhyay, R., Das, S., Maiti, A.K., Boldogh, I., Xie, J., Hazra, T.K., Kohno, K., Mitra, 
S. and Bhakat, K.K. (2008) 'Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-
1-mediated activation of the multidrug resistance gene MDR1', Mol Cell Biol, 28(23), pp. 
7066-80. 
Chaturvedi, A., Araujo Cruz, M.M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., 
Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E.A., 
Jansen, E.E., Modlich, U., Li, Z., Sly, L.M., Geffers, R., Lindner, R., Manstein, D.J., 
Lehmann, U., Krauter, J., Ganser, A. and Heuser, M. (2013) 'Mutant IDH1 promotes 
leukemogenesis in vivo and can be specifically targeted in human AML', Blood, 122(16), pp. 
2877-2887. 
Chen, J., Odenike, O. and Rowley, J.D. (2010) 'Leukaemogenesis: more than mutant genes', 
Nat Rev Cancer, 10(1), pp. 23-36. 
245 
 
Chen, Z., Shojaee, S., Buchner, M., Geng, H., Lee, J.W., Klemm, L., Titz, B., Graeber, T.G., 
Park, E., Tan, Y.X., Satterthwaite, A., Paietta, E., Hunger, S.P., Willman, C.L., Melnick, A., 
Loh, M.L., Jung, J.U., Coligan, J.E., Bolland, S., Mak, T.W., Limnander, A., Jumaa, H., Reth, 
M., Weiss, A., Lowell, C.A. and Muschen, M. (2015) 'Signalling thresholds and negative B-
cell selection in acute lymphoblastic leukaemia', Nature, 521(7552), pp. 357-361. 
Cheng, X., Byrne, M., Brown, K.D., Konopleva, M.Y., Kornblau, S.M., Bennett, R.L. and 
May, W.S. (2015) 'PKR inhibits the DNA damage response, and is associated with poor 
survival in AML and accelerated leukemia in NHD13 mice', Blood, 126(13), pp. 1585-94. 
Chikamori, K., Grozav, A.G., Kozuki, T., Grabowski, D., Ganapathi, R. and Ganapathi, M.K. 
(2010) 'DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy', Curr 
Cancer Drug Targets, 10(7), pp. 758-71. 
Cho, E.K., Bang, S.M., Ahn, J.Y., Yoo, S.M., Park, P.W., Seo, Y.H., Shin, D.B. and Lee, J.H. 
(2003) 'Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute 
Myelogenous Leukemia', The Korean Journal of Internal Medicine, 18(1), pp. 13-20. 
Choi, S., Lee, Y.R., Park, M.S., Joo, H.K., Cho, E.J., Kim, H.S., Kim, C.S., Park, J.B., Irani, 
K. and Jeon, B.H. (2013) 'Histone deacetylases inhibitor trichostatin A modulates the 
extracellular release of APE1/Ref-1', Biochem Biophys Res Commun. 
Chou, K.-M., Kukhanova, M. and Cheng, Y.-C. (2000) 'A Novel Action of Human 
Apurinic/Apyrimidinic Endonuclease: EXCISION OF l-CONFIGURATION 
DEOXYRIBONUCLEOSIDE ANALOGS FROM THE 3′ TERMINI OF DNA', Journal of 
Biological Chemistry, 275(40), pp. 31009-31015. 
Chuang, M.K., Chiu, Y.C., Chou, W.C., Hou, H.A., Chuang, E.Y. and Tien, H.F. (2015) 'A 3-
microRNA scoring system for prognostication in de novo acute myeloid leukemia patients', 
Leukemia, 29(5), pp. 1051-1059. 
Cooke, M.S., Evans, M.D., Dizdaroglu, M. and Lunec, J. (2003) 'Oxidative DNA damage: 
mechanisms, mutation, and disease', The FASEB Journal, 17(10), pp. 1195-1214. 
Coombs, C.C., Tallman, M.S. and Levine, R.L. (2015) 'Molecular therapy for acute myeloid 
leukaemia', Nat Rev Clin Oncol. 
246 
 
Cornelissen, J.J. and Blaise, D. (2016) 'Hematopoietic stem cell transplantation for patients 
with AML in first complete remission', Blood, 127(1), pp. 62-70. 
Cornelissen, J.J., Gratwohl, A., Schlenk, R.F., Sierra, J., Bornhauser, M., Juliusson, G., Racil, 
Z., Rowe, J.M., Russell, N., Mohty, M., Lowenberg, B., Socie, G., Niederwieser, D. and 
Ossenkoppele, G.J. (2012) 'The European LeukemiaNet AML Working Party consensus 
statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted 
approach', Nat Rev Clin Oncol, 9(10), pp. 579-590. 
Cowell, I.G. and Austin, C.A. (2012) 'Mechanism of Generation of Therapy Related 
Leukemia in Response to Anti-Topoisomerase II Agents', International Journal of 
Environmental Research and Public Health, 9(6), pp. 2075-2091. 
Cowell, I.G., Tilby, M.J. and Austin, C.A. (2011) 'An overview of the visualisation and 
quantitation of low and high MW DNA adducts using the trapped in agarose DNA 
immunostaining (TARDIS) assay', Mutagenesis, 26(2), pp. 253-60. 
Cun, Y., Dai, N., Xiong, C., Li, M., Sui, J., Qian, C., Li, Z. and Wang, D. (2013) 'Silencing of 
APE1 enhances sensitivity of human hepatocellular carcinoma cells to radiotherapy in vitro 
and in a xenograft model', PLoS One, 8(2), p. e55313. 
Curtin, N.J. and Szabo, C. (2013) 'Therapeutic applications of PARP inhibitors: anticancer 
therapy and beyond', Mol Aspects Med, 34(6), pp. 1217-56. 
D'Andrea, A.D. (2010) 'Targeting DNA repair pathways in AML', Best Pract Res Clin 
Haematol, 23(4), pp. 469-73. 
Dantzer, F., Luna, L., Bjørås, M. and Seeberg, E. (2002) 'Human OGG1 undergoes serine 
phosphorylation and associates with the nuclear matrix and mitotic chromatin in vivo', 
Nucleic Acids Research, 30(11), pp. 2349-2357. 
Deisenroth, C., Thorner, A.R., Enomoto, T., Perou, C.M. and Zhang, Y. (2010) 
'Mitochondrial HEP27 Is a c-Myb Target Gene That Inhibits Mdm2 and Stabilizes p53', 
Molecular and Cellular Biology, 30(16), pp. 3981-3993. 
247 
 
Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, 
O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., 
Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., 
Vainchenker, W. and Bernard, O.A. (2009) 'Mutation in TET2 in myeloid cancers', N Engl J 
Med, 360(22), pp. 2289-301. 
Di Maso, V., Avellini, C., Croce, L.S., Rosso, N., Quadrifoglio, F., Cesaratto, L., Codarin, E., 
Bedogni, G., Beltrami, C.A., Tell, G. and Tiribelli, C. (2007) 'Subcellular localization of 
APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance', Mol Med, 
13(1-2), pp. 89-96. 
Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, 
H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., 
Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B. and Bloomfield, 
C.D. (2010) 'Diagnosis and management of acute myeloid leukemia in adults: 
recommendations from an international expert panel, on behalf of the European 
LeukemiaNet', Blood, 115(3), pp. 453-74. 
Döhner, H., Weisdorf, D.J. and Bloomfield, C.D. (2015) 'Acute Myeloid Leukemia', New 
England Journal of Medicine, 373(12), pp. 1136-1152. 
Dohner, K. and Dohner, H. (2008) 'Molecular characterization of acute myeloid leukemia', 
Haematologica, 93(7), pp. 976-82. 
Dombret, H. (2011) 'Gene mutation and AML pathogenesis', Blood, 118(20), pp. 5366-5367. 
Dombret, H., Seymour, J.F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J.H., Kumar, 
R., Cavenagh, J., Schuh, A.C., Candoni, A., Recher, C., Sandhu, I., Bernal del Castillo, T., 
Al-Ali, H.K., Martinelli, G., Falantes, J., Noppeney, R., Stone, R.M., Minden, M.D., 
McIntyre, H., Songer, S., Lucy, L.M., Beach, C.L. and Dohner, H. (2015) 'International phase 
3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed 
AML with >30% blasts', Blood, 126(3), pp. 291-9. 
Donley, N., Jaruga, P., Coskun, E., Dizdaroglu, M., McCullough, A.K. and Lloyd, R.S. 
(2015) 'Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1)', ACS 
Chemical Biology, 10(10), pp. 2334-2343. 
248 
 
Dorjsuren, D., Kim, D., Vyjayanti, V.N., Maloney, D.J., Jadhav, A., Wilson, D.M., 3rd and 
Simeonov, A. (2012) 'Diverse small molecule inhibitors of human apurinic/apyrimidinic 
endonuclease APE1 identified from a screen of a large public collection', PLoS One, 7(10), p. 
e47974. 
Drexler, H.G., Fombonne, S., Matsuo, Y., Hu, Z.B., Hamaguchi, H. and Uphoff, C.C. (2000) 
'p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for 
cell immortalization?', Leukemia, 14(1), pp. 198-206. 
Dyrkheeva, N.S., Lebedeva, N.A. and Lavrik, O.I. (2016) 'AP Endonuclease 1 as a Key 
Enzyme in Repair of Apurinic/Apyrimidinic Sites', Biochemistry (Mosc), 81(9), pp. 951-67. 
Egger, G., Liang, G., Aparicio, A. and Jones, P.A. (2004) 'Epigenetics in human disease and 
prospects for epigenetic therapy', Nature, 429(6990), pp. 457-63. 
Erba, H.P. (2007) 'Prognostic factors in elderly patients with AML and the implications for 
treatment', Hematology Am Soc Hematol Educ Program, pp. 420-8. 
Esposito, M.T. and So, C.W. (2014) 'DNA damage accumulation and repair defects in acute 
myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy 
resistance', Chromosoma, 123(6), pp. 545-61. 
Esposito, M.T., Zhao, L., Fung, T.K., Rane, J.K., Wilson, A., Martin, N., Gil, J., Leung, A.Y., 
Ashworth, A. and Eric So, C.W. (2015) 'Synthetic lethal targeting of oncogenic transcription 
factors in acute leukemia by PARP inhibitors', Nat Med, 21(12), pp. 1481-1490. 
Ewald, B., Sampath, D. and Plunkett, W. (2008) 'Nucleoside analogs: molecular mechanisms 
signaling cell death', Oncogene, 27(50), pp. 6522-6537. 
Falini, B. and Martelli, M.P. (2011) 'NPM1-mutated AML: targeting by disassembling', 
Blood, 118(11), pp. 2936-8. 
Fan, J., Li, L., Small, D. and Rassool, F. (2010) 'Cells expressing FLT3/ITD mutations exhibit 
elevated repair errors generated through alternative NHEJ pathways: implications for genomic 
instability and therapy', Blood, 116(24), pp. 5298-305. 
249 
 
Fantini, D., Moritz, E., Auvre, F., Amouroux, R., Campalans, A., Epe, B., Bravard, A. and 
Radicella, J.P. (2013) 'Rapid inactivation and proteasome-mediated degradation of OGG1 
contribute to the synergistic effect of hyperthermia on genotoxic treatments', DNA Repair 
(Amst), 12(3), pp. 227-37. 
Fantini, D., Vascotto, C., Deganuto, M., Bivi, N., Gustincich, S., Marcon, G., Quadrifoglio, 
F., Damante, G., Bhakat, K.K., Mitra, S. and Tell, G. (2008) 'APE1/Ref-1 regulates PTEN 
expression mediated by Egr-1', Free Radic Res, 42(1), pp. 20-9. 
Fantini, D., Vascotto, C., Marasco, D., D'Ambrosio, C., Romanello, M., Vitagliano, L., 
Pedone, C., Poletto, M., Cesaratto, L., Quadrifoglio, F., Scaloni, A., Radicella, J.P. and Tell, 
G. (2010) 'Critical lysine residues within the overlooked N-terminal domain of human APE1 
regulate its biological functions', Nucleic Acids Res, 38(22), pp. 8239-56. 
Feng, Z., Kochanek, S., Close, D., Wang, L., Srinivasan, A., Almehizia, A.A., Iyer, P., Xie, 
X.-Q., Johnston, P.A. and Gold, B. (2015) 'Design and activity of AP endonuclease-1 
inhibitors', Journal of Chemical Biology, 8(3), pp. 79-93. 
Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y.S., Bhagwat, 
N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z.X., Wolniak, K., Peeters, 
J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., 
Delwel, R., Valk, P.J.M., Thompson, C.B., Levine, R.L. and Melnick, A. (2010a) 'Leukemic 
IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, 
and Impair Hematopoietic Differentiation', Cancer Cell, 18(6), pp. 553-567. 
Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., 
Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., 
Greally, J.M., Valk, P.J., Lowenberg, B., Delwel, R. and Melnick, A. (2010b) 'DNA 
methylation signatures identify biologically distinct subtypes in acute myeloid leukemia', 
Cancer Cell, 17(1), pp. 13-27. 
Fischer, F., Baerenfaller, K. and Jiricny, J. (2007) '5-Fluorouracil Is Efficiently Removed 
From DNA by the Base Excision and Mismatch Repair Systems', Gastroenterology, 133(6), 
pp. 1858-1868. 
250 
 
Fishel, M.L., Colvin, E.S., Luo, M., Kelley, M.R. and Robertson, K.A. (2010) 'Inhibition of 
the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive 
response to retinoic acid-induced differentiation and apoptosis', Exp Hematol, 38(12), pp. 
1178-88. 
Fishel, M.L., He, Y., Reed, A.M., Chin-Sinex, H., Hutchins, G.D., Mendonca, M.S. and 
Kelley, M.R. (2008) 'Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 
blocks ovarian cancer cell and tumor growth', DNA Repair (Amst), 7(2), pp. 177-86. 
Fishel, M.L., He, Y., Smith, M.L. and Kelley, M.R. (2007) 'Manipulation of base excision 
repair to sensitize ovarian cancer cells to alkylating agent temozolomide', Clin Cancer Res, 
13(1), pp. 260-7. 
Fishel, M.L., Jiang, Y., Rajeshkumar, N.V., Scandura, G., Sinn, A.L., He, Y., Shen, C., Jones, 
D.R., Pollok, K.E., Ivan, M., Maitra, A. and Kelley, M.R. (2011) 'Impact of APE1/Ref-1 
redox inhibition on pancreatic tumor growth', Mol Cancer Ther, 10(9), pp. 1698-708. 
Fishel, M.L. and Kelley, M.R. (2007) 'The DNA base excision repair protein Ape1/Ref-1 as a 
therapeutic and chemopreventive target', Mol Aspects Med, 28(3-4), pp. 375-95. 
Fishel, M.L., Wu, X., Devlin, C.M., Logsdon, D.P., Jiang, Y., Luo, M., He, Y., Yu, Z., Tong, 
Y., Lipking, K.P., Maitra, A., Rajeshkumar, N.V., Scandura, G., Kelley, M.R. and Ivan, M. 
(2015) 'Apurinic/apyrimidinic endonuclease/redox factor-1 (APE1/Ref-1) redox function 
negatively regulates NRF2', J Biol Chem, 290(5), pp. 3057-68. 
Fitzgerald, M.E. and Drohat, A.C. (2008) 'Coordinating the Initial Steps of Base Excision 
Repair: APURINIC/APYRIMIDINIC ENDONUCLEASE 1 ACTIVELY STIMULATES 
THYMINE DNA GLYCOSYLASE BY DISRUPTING THE PRODUCT COMPLEX', The 
Journal of Biological Chemistry, 283(47), pp. 32680-32690. 
Fleckenstein, D.S., Uphoff, C.C., Drexler, H.G. and Quentmeier, H. (2002) 'Detection of p53 
gene mutations by single strand conformational polymorphism (SSCP) in human acute 
myeloid leukemia-derived cell lines', Leukemia Research, 26(2), pp. 207-214. 
Fojo, T. and Bates, S. (2013) 'Mechanisms of Resistance to PARP Inhibitors—Three and 
Counting', Cancer Discovery, 3(1), pp. 20-23. 
251 
 
Fordham, S.E., Matheson, E.C., Scott, K., Irving, J.A. and Allan, J.M. (2011) 'DNA mismatch 
repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs', 
Leukemia, 25(6), pp. 1046-9. 
Forster, V.J., Nahari, M.H., Martinez-Soria, N., Bradburn, A.K., Ptasinska, A., Assi, S.A., 
Fordham, S.E., McNeil, H., Bonifer, C., Heidenreich, O. and Allan, J.M. (2016) 'The 
leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype', Leukemia, 
30(1), pp. 251-254. 
Fortini, P. and Dogliotti, E. (2007) 'Base damage and single-strand break repair: mechanisms 
and functional significance of short- and long-patch repair subpathways', DNA Repair (Amst), 
6(4), pp. 398-409. 
Fortini, P., Parlanti, E., Sidorkina, O.M., Laval, J. and Dogliotti, E. (1999) 'The type of DNA 
glycosylase determines the base excision repair pathway in mammalian cells', J Biol Chem, 
274(21), pp. 15230-6. 
Fritz, G. (2000) 'Human APE/Ref-1 protein', Int J Biochem Cell Biol, 32(9), pp. 925-9. 
Fronza, G. and Gold, B. (2004) 'The biological effects of N3-methyladenine', J Cell Biochem, 
91(2), pp. 250-7. 
Fu, Z. and Tindall, D.J. (2008) 'FOXOs, cancer and regulation of apoptosis', Oncogene, 
27(16), pp. 2312-2319. 
Fung, H., Bennett, R.A. and Demple, B. (2001) 'Key role of a downstream specificity protein 
1 site in cell cycle-regulated transcription of the AP endonuclease gene APE1/APEX in 
NIH3T3 cells', J Biol Chem, 276(45), pp. 42011-7. 
Fung, H. and Demple, B. (2005) 'A vital role for Ape1/Ref1 protein in repairing spontaneous 
DNA damage in human cells', Mol Cell, 17(3), pp. 463-70. 
Fung, H. and Demple, B. (2011) 'Distinct roles of Ape1 protein in the repair of DNA damage 
induced by ionizing radiation or bleomycin', J Biol Chem, 286(7), pp. 4968-77. 
252 
 
Gaiddon, C., Moorthy, N.C. and Prives, C. (1999) 'Ref-1 regulates the transactivation and 
pro-apoptotic functions of p53 in vivo', Embo j, 18(20), pp. 5609-21. 
Gaidzik, V.I., Paschka, P., Späth, D., Habdank, M., Köhne, C.-H., Germing, U., von 
Lilienfeld-Toal, M., Held, G., Horst, H.-A., Haase, D., Bentz, M., Götze, K., Döhner, H., 
Schlenk, R.F., Bullinger, L. and Döhner, K. (2012) 'TET2 Mutations in Acute Myeloid 
Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML 
Study Group', Journal of Clinical Oncology, 30(12), pp. 1350-1357. 
Galmarini, C.M., Mackey, J.R. and Dumontet, C. (2001) 'Nucleoside analogues: mechanisms 
of drug resistance and reversal strategies', Leukemia, 15(6), pp. 875-90. 
Garzon, R., Volinia, S., Liu, C.G., Fernandez-Cymering, C., Palumbo, T., Pichiorri, F., 
Fabbri, M., Coombes, K., Alder, H., Nakamura, T., Flomenberg, N., Marcucci, G., Calin, 
G.A., Kornblau, S.M., Kantarjian, H., Bloomfield, C.D., Andreeff, M. and Croce, C.M. 
(2008) 'MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid 
leukemia', Blood, 111(6), pp. 3183-9. 
Gaymes, T.J., Mohamedali, A.M., Patterson, M., Matto, N., Smith, A., Kulasekararaj, A., 
Chelliah, R., Curtin, N., Farzaneh, F., Shall, S. and Mufti, G.J. (2013) 'Microsatellite 
instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity 
to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies', Haematologica, 98(9), 
pp. 1397-406. 
Gaymes, T.J., Shall, S., MacPherson, L.J., Twine, N.A., Lea, N.C., Farzaneh, F. and Mufti, 
G.J. (2009) 'Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid 
leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes', 
Haematologica, 94(5), pp. 638-646. 
Gencer, M., Dasdemir, S., Cakmakoglu, B., Cetinkaya, Y., Varlibas, F., Tireli, H., Kucukali, 
C.I., Ozkok, E. and Aydin, M. (2012) 'DNA repair genes in Parkinson's disease', Genet Test 
Mol Biomarkers, 16(6), pp. 504-7. 
'Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia',  (2013) 
New England Journal of Medicine, 368(22), pp. 2059-2074. 
253 
 
Gewirtz, D.A. (1999) 'A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin', Biochem 
Pharmacol, 57(7), pp. 727-41. 
Gmeiner, W.H., Yu, S., Pon, R.T., Pourquier, P. and Pommier, Y. (2003) 'Structural basis for 
topoisomerase I inhibition by nucleoside analogs', Nucleosides Nucleotides Nucleic Acids, 
22(5-8), pp. 653-8. 
Goto, M., Yamada, K., Katayama, K. and Tanaka, I. (1996) 'Inhibitory effect of E3330, a 
novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on 
activation of nuclear factor-kappa B', Mol Pharmacol, 49(5), pp. 860-73. 
Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., 
Wheatley, K., Harrison, C.J. and Burnett, A.K. (2010) 'Refinement of cytogenetic 
classification in acute myeloid leukemia: determination of prognostic significance of rare 
recurring chromosomal abnormalities among 5876 younger adult patients treated in the 
United Kingdom Medical Research Council trials', Blood, 116(3), pp. 354-65. 
Guo, Y., Chen, J., Zhao, T. and Fan, Z. (2008) 'Granzyme K degrades the redox/DNA repair 
enzyme Ape1 to trigger oxidative stress of target cells leading to cytotoxicity', Mol Immunol, 
45(8), pp. 2225-35. 
Gustafson, S.A., Lin, P., Chen, S.S., Chen, L., Abruzzo, L.V., Luthra, R., Medeiros, L.J. and 
Wang, S.A. (2009) 'Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares 
many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have 
a favorable outcome', Am J Clin Pathol, 131(5), pp. 647-55. 
Hadi, M.Z., Coleman, M.A., Fidelis, K., Mohrenweiser, H.W. and Wilson, D.M., 3rd (2000) 
'Functional characterization of Ape1 variants identified in the human population', Nucleic 
Acids Res, 28(20), pp. 3871-9. 
Hann, I.M., Stevens, R.F., Goldstone, A.H., Rees, J.K.H., Wheatley, K., Gray, R.G. and 
Burnett, A.K. (1997) 'Randomized Comparison of DAT Versus ADE as Induction 
Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of 
the Medical Research Council's 10th AML Trial (MRC AML10)', Blood, 89(7), pp. 2311-
2318. 
254 
 
Hardie, L.J., Briggs, J.A., Davidson, L.A., Allan, J.M., King, R.F., Williams, G.I. and Wild, 
C.P. (2000) 'The effect of hOGG1 and glutathione peroxidase I genotypes and 3p 
chromosomal loss on 8-hydroxydeoxyguanosine levels in lung cancer', Carcinogenesis, 21(2), 
pp. 167-72. 
Hartmann, L., Dutta, S., Opatz, S., Vosberg, S., Reiter, K., Leubolt, G., Metzeler, K.H., 
Herold, T., Bamopoulos, S.A., Braundl, K., Zellmeier, E., Ksienzyk, B., Konstandin, N.P., 
Schneider, S., Hopfner, K.P., Graf, A., Krebs, S., Blum, H., Middeke, J.M., Stolzel, F., 
Thiede, C., Wolf, S., Bohlander, S.K., Preiss, C., Chen-Wichmann, L., Wichmann, C., 
Sauerland, M.C., Buchner, T., Berdel, W.E., Wormann, B.J., Braess, J., Hiddemann, W., 
Spiekermann, K. and Greif, P.A. (2016) 'ZBTB7A mutations in acute myeloid leukaemia with 
t(8;21) translocation', Nat Commun, 7, p. 11733. 
Hegde, M.L., Izumi, T. and Mitra, S. (2012) 'Oxidized Base Damage and Single-Strand Break 
Repair in Mammalian Genomes: Role of Disordered Regions and Posttranslational 
Modifications in Early Enzymes', Progress in molecular biology and translational science, 
110, pp. 123-153. 
Hill, J.W. and Evans, M.K. (2007) 'A novel R229Q OGG1 polymorphism results in a 
thermolabile enzyme that sensitizes KG-1 leukemia cells to DNA damaging agents', Cancer 
Detect Prev, 31(3), pp. 237-43. 
Hill, J.W., Hazra, T.K., Izumi, T. and Mitra, S. (2001) 'Stimulation of human 8-oxoguanine-
DNA glycosylase by AP-endonuclease: potential coordination of the initial steps in base 
excision repair', Nucleic Acids Research, 29(2), pp. 430-438. 
Hills, R.K., Castaigne, S., Appelbaum, F.R., Delaunay, J., Petersdorf, S., Othus, M., Estey, 
E.H., Dombret, H., Chevret, S., Ifrah, N., Cahn, J.Y., Recher, C., Chilton, L., Moorman, A.V. 
and Burnett, A.K. (2014) 'Addition of gemtuzumab ozogamicin to induction chemotherapy in 
adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from 
randomised controlled trials', Lancet Oncol, 15(9), pp. 986-96. 
Hole, P.S., Darley, R.L. and Tonks, A. (2011) 'Do reactive oxygen species play a role in 
myeloid leukemias?', Blood, 117(22), pp. 5816-26. 
255 
 
Hong, J., Chen, Z., Peng, D., Zaika, A., Revetta, F., Washington, M.K., Belkhiri, A. and El-
Rifai, W. (2016) APE1-mediated DNA damage repair provides survival advantage for 
esophageal adenocarcinoma cells in response to acidic bile salts. 
Horton, T.M., Jenkins, G., Pati, D., Zhang, L., Dolan, M.E., Ribes-Zamora, A., Bertuch, A.A., 
Blaney, S.M., Delaney, S.L., Hegde, M. and Berg, S.L. (2009a) 'Poly(ADP-ribose) 
polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia 
cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase 
activity', Mol Cancer Ther, 8(8), pp. 2232-42. 
Horton, T.M., Jenkins, G., Pati, D., Zhang, L., Dolan, M.E., Ribes-Zamora, A., Bertuch, A.A., 
Blaney, S.M., Delaney, S.L., Hegde, M. and Berg, S.L. (2009b) 'Poly(ADP-ribose) 
polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia 
cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase 
activity', Molecular Cancer Therapeutics, 8(8), pp. 2232-2242. 
Hsieh, M.M., Hegde, V., Kelley, M.R. and Deutsch, W.A. (2001) 'Activation of APE/Ref-1 
redox activity is mediated by reactive oxygen species and PKC phosphorylation', Nucleic 
Acids Research, 29(14), pp. 3116-3122. 
Hu, J., de Souza-Pinto, N.C., Haraguchi, K., Hogue, B.A., Jaruga, P., Greenberg, M.M., 
Dizdaroglu, M. and Bohr, V.A. (2005a) 'Repair of formamidopyrimidines in DNA involves 
different glycosylases: role of the OGG1, NTH1, and NEIL1 enzymes', J Biol Chem, 280(49), 
pp. 40544-51. 
Hu, J., Imam, S.Z., Hashiguchi, K., de Souza-Pinto, N.C. and Bohr, V.A. (2005b) 
'Phosphorylation of human oxoguanine DNA glycosylase (α-OGG1) modulates its function', 
Nucleic Acids Research, 33(10), pp. 3271-3282. 
Huang, E., Qu, D., Zhang, Y., Venderova, K., Haque, M.E., Rousseaux, M.W.C., Slack, R.S., 
Woulfe, J.M. and Park, D.S. (2010) 'The role of Cdk5-mediated apurinic/apyrimidinic 
endonuclease 1 phosphorylation in neuronal death', Nat Cell Biol, 12(6), pp. 563-571. 
Huang, H., Stivers, J.T. and Greenberg, M.M. (2009) 'Competitive Inhibition of Uracil DNA 
Glycosylase by a Modified Nucleotide Whose Triphosphate is a Substrate for DNA 
Polymerase', Journal of the American Chemical Society, 131(4), pp. 1344-1345. 
256 
 
Hyun, J.W., Cheon, G.J., Kim, H.S., Lee, Y.S., Choi, E.Y., Yoon, B.H., Kim, J.S. and Chung, 
M.H. (2002) 'Radiation sensitivity depends on OGG1 activity status in human leukemia cell 
lines', Free Radic Biol Med, 32(3), pp. 212-20. 
Hyun, J.W., Choi, J.Y., Zeng, H.H., Lee, Y.S., Kim, H.S., Yoon, S.H. and Chung, M.H. 
(2000) 'Leukemic cell line, KG-1 has a functional loss of hOGG1 enzyme due to a point 
mutation and 8-hydroxydeoxyguanosine can kill KG-1', Oncogene, 19(39), pp. 4476-9. 
Jacobs, A.C., Calkins, M.J., Jadhav, A., Dorjsuren, D., Maloney, D., Simeonov, A., Jaruga, 
P., Dizdaroglu, M., McCullough, A.K. and Lloyd, R.S. (2013) 'Inhibition of DNA 
Glycosylases via Small Molecule Purine Analogs', PLoS ONE, 8(12), p. e81667. 
Jankowska, A.M., Gondek, L.P., Szpurka, H., Nearman, Z.P., Tiu, R.V. and Maciejewski, J.P. 
(2008) 'Base excision repair dysfunction in a subgroup of patients with myelodysplastic 
syndrome', Leukemia, 22(3), pp. 551-8. 
Jedinak, A., Dudhgaonkar, S., Kelley, M.R. and Sliva, D. (2011) 'Apurinic/Apyrimidinic 
endonuclease 1 regulates inflammatory response in macrophages', Anticancer Res, 31(2), pp. 
379-85. 
Jeon, B.H., Gupta, G., Park, Y.C., Qi, B., Haile, A., Khanday, F.A., Liu, Y.-X., Kim, J.-M., 
Ozaki, M. and White, A.R. (2004) 'Apurinic/apyrmidinic endonuclease 1 regulates endothelial 
NO production and vascular tone', Circulation research, 95(9), pp. 902-910. 
Jiang, A., Gao, H., Kelley, M.R. and Qiao, X. (2011) 'Inhibition of APE1/Ref-1 redox activity 
with APX3330 blocks retinal angiogenesis in vitro and in vivo', Vision Res, 51(1), pp. 93-100. 
Jiang, Y., Zhou, S., Sandusky, G.E., Kelley, M.R. and Fishel, M.L. (2010) 'Reduced 
expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic 
cancer cell survival, proliferation, and cell cycle progression', Cancer Invest, 28(9), pp. 885-
95. 
Jiemjit, A., Fandy, T.E., Carraway, H., Bailey, K.A., Baylin, S., Herman, J.G. and Gore, S.D. 
(2008) 'p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage', 
Oncogene, 27(25), pp. 3615-23. 
257 
 
Jin, C., Qin, T., Barton, M.C., Jelinek, J. and Issa, J.P. (2015) 'Minimal role of base excision 
repair in TET-induced global DNA demethylation in HEK293T cells', Epigenetics, 10(11), 
pp. 1006-13. 
Jongen-Lavrencic, M., Sun, S.M., Dijkstra, M.K., Valk, P.J. and Lowenberg, B. (2008) 
'MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid 
leukemia', Blood, 111(10), pp. 5078-85. 
Joslin, J.M., Fernald, A.A., Tennant, T.R., Davis, E.M., Kogan, S.C., Anastasi, J., Crispino, 
J.D. and Le Beau, M.M. (2007) 'Haploinsufficiency of EGR1, a candidate gene in the del(5q), 
leads to the development of myeloid disorders', Blood, 110(2), pp. 719-726. 
Juliana, F.M., Nara, H., Onoda, T., Rahman, M., Araki, A., Jin, L., Fujii, H., Tanaka, N., 
Hoshino, T. and Asao, H. (2012) 'Apurinic/apyrimidinic endonuclease1/redox factor-1 
(Ape1/Ref-1) is essential for IL-21-induced signal transduction through ERK1/2 pathway', 
Biochem Biophys Res Commun, 420(3), pp. 628-34. 
Kang, X., Lu, Z., Cui, C., Deng, M., Fan, Y., Dong, B., Han, X., Xie, F., Tyner, J.W., 
Coligan, J.E., Collins, R.H., Xiao, X., You, M.J. and Zhang, C.C. (2015) 'The ITIM-
containing receptor LAIR1 is essential for acute myeloid leukemia development', Nature cell 
biology, 17(5), pp. 665-677. 
Karahalil, B., Bohr, V.A. and Wilson, D.M., 3rd (2012) 'Impact of DNA polymorphisms in 
key DNA base excision repair proteins on cancer risk', Hum Exp Toxicol, 31(10), pp. 981-
1005. 
Kelley, M.R. and Fishel, M.L. (2008) 'DNA repair proteins as molecular targets for cancer 
therapeutics', Anticancer Agents Med Chem, 8(4), pp. 417-25. 
Kelley, M.R., Georgiadis, M.M. and Fishel, M.L. (2012) 'APE1/Ref-1 role in redox signaling: 
translational applications of targeting the redox function of the DNA repair/redox protein 
APE1/Ref-1', Curr Mol Pharmacol, 5(1), pp. 36-53. 
Kelley, M.R., Logsdon, D. and Fishel, M.L. (2014) 'Targeting DNA repair pathways for 
cancer treatment: what's new?', Future oncology (London, England), 10(7), pp. 1215-1237. 
258 
 
Kershaw, R.M. and Hodges, N.J. (2012) 'Repair of oxidative DNA damage is delayed in the 
Ser326Cys polymorphic variant of the base excision repair protein OGG1', Mutagenesis, 
27(4), pp. 501-510. 
Kim, W.C., Berquist, B.R., Chohan, M., Uy, C., Wilson, D.M., 3rd and Lee, C.H. (2011) 
'Characterization of the endoribonuclease active site of human apurinic/apyrimidinic 
endonuclease 1', J Mol Biol, 411(5), pp. 960-71. 
Kim, W.C., King, D. and Lee, C.H. (2010) 'RNA-cleaving properties of human 
apurinic/apyrimidinic endonuclease 1 (APE1)', Int J Biochem Mol Biol, 1(1), pp. 12-25. 
Kim, Y.J. and Wilson, D.M., 3rd (2012) 'Overview of base excision repair biochemistry', 
Curr Mol Pharmacol, 5(1), pp. 3-13. 
Klungland, A., Rosewell, I., Hollenbach, S., Larsen, E., Daly, G., Epe, B., Seeberg, E., 
Lindahl, T. and Barnes, D.E. (1999) 'Accumulation of premutagenic DNA lesions in mice 
defective in removal of oxidative base damage', Proc Natl Acad Sci U S A, 96(23), pp. 13300-
5. 
Kode, A., Mosialou, I., Manavalan, S.J., Rathinam, C.V., Friedman, R.A., Teruya-Feldstein, 
J., Bhagat, G., Berman, E. and Kousteni, S. (2016) 'FoxO1-dependent induction of acute 
myeloid leukemia by osteoblasts in mice', Leukemia, 30(1), pp. 1-13. 
Kojima, K., Konopleva, M., Samudio, I.J., Shikami, M., Cabreira-Hansen, M., McQueen, T., 
Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L.T. and Andreeff, M. (2005) 'MDM2 antagonists 
induce p53-dependent apoptosis in AML: implications for leukemia therapy', Blood, 106(9), 
pp. 3150-3159. 
Koreth, J., Schlenk, R., Kopecky, K.J., Honda, S., Sierra, J., Djulbegovic, B.J., Wadleigh, M., 
DeAngelo, D.J., Stone, R.M., Sakamaki, H., Appelbaum, F.R., Döhner, H., Antin, J.H., 
Soiffer, R.J. and Cutler, C. (2009) 'Allogeneic stem cell transplantation for acute myeloid 
leukemia in first complete remission: a systematic review and meta-analysis of prospective 
clinical trials', JAMA : the journal of the American Medical Association, 301(22), pp. 2349-
2361. 
259 
 
Krajinovic, M., Labuda, D., Mathonnet, G., Labuda, M., Moghrabi, A., Champagne, J. and 
Sinnett, D. (2002) 'Polymorphisms in genes encoding drugs and xenobiotic metabolizing 
enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic 
leukemia', Clin Cancer Res, 8(3), pp. 802-10. 
Krauth, M.T., Eder, C., Alpermann, T., Bacher, U., Nadarajah, N., Kern, W., Haferlach, C., 
Haferlach, T. and Schnittger, S. (2014) 'High number of additional genetic lesions in acute 
myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical 
outcome', Leukemia, 28(7), pp. 1449-1458. 
Krejci, O., Wunderlich, M., Geiger, H., Chou, F.-S., Schleimer, D., Jansen, M., Andreassen, 
P.R. and Mulloy, J.C. (2008) 'p53 signaling in response to increased DNA damage sensitizes 
AML1-ETO cells to stress-induced death', Blood, 111(4), pp. 2190-2199. 
Krokan, H.E. and Bjoras, M. (2013) 'Base excision repair', Cold Spring Harb Perspect Biol, 
5(4), p. a012583. 
Kuptsova, N., Kopecky, K.J., Godwin, J., Anderson, J., Hoque, A., Willman, C.L., Slovak, 
M.L. and Ambrosone, C.B. (2007) 'Polymorphisms in DNA repair genes and therapeutic 
outcomes of AML patients from SWOG clinical trials', Blood, 109(9), pp. 3936-44. 
Lam, W., Park, S.-Y., Leung, C.-H. and Cheng, Y.-C. (2006) 'Apurinic/Apyrimidinic 
Endonuclease-1 Protein Level Is Associated with the Cytotoxicity of l-Configuration 
Deoxycytidine Analogs (Troxacitabine and β-l-2′,3′-Dideoxy-2′,3′-didehydro-5-
fluorocytidine) but Not d-Configuration Deoxycytidine Analogs (Gemcitabine and β-d-
Arabinofuranosylcytosine)', Molecular Pharmacology, 69(5), pp. 1607-1614. 
Levis, M. (2013) 'Targeting IDH: the next big thing in AML', Blood, 122(16), pp. 2770-2771. 
Li, M. and Wilson, D.M. (2014) 'Human Apurinic/Apyrimidinic Endonuclease 1', 
Antioxidants & Redox Signaling, 20(4), pp. 678-707. 
Li, Y., Wang, H., Wang, X., Jin, W., Tan, Y., Fang, H., Chen, S., Chen, Z. and Wang, K. 
(2016) 'Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in 
t(8;21) acute myeloid leukemia', Blood, 127(2), pp. 233-242. 
260 
 
Liddiard, K., Hills, R., Burnett, A.K., Darley, R.L. and Tonks, A. (2010) 'OGG1 is a novel 
prognostic indicator in acute myeloid leukaemia', Oncogene, 29(13), pp. 2005-12. 
Lin, S., Zhang, J. and Mulloy, J.C. (2014) 'Tumor Suppressor FOXO1 Serves As a Critical 
Oncogenic Mediator in AML1-ETO Leukemia', Blood, 124(21), pp. 264-264. 
Liu, C., Yin, Q., Li, L., Zhuang, Y.Z., Zu, X. and Wang, Y. (2013) 'APE1 Asp148Glu gene 
polymorphism and bladder cancer risk: a meta-analysis', Mol Biol Rep, 40(1), pp. 171-6. 
Liu, L. and Gerson, S.L. (2004) 'Therapeutic impact of methoxyamine: blocking repair of 
abasic sites in the base excision repair pathway', Curr Opin Investig Drugs, 5(6), pp. 623-7. 
Livak, K.J. and Schmittgen, T.D. (2001) 'Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method', Methods, 25(4), pp. 402-8. 
Ludwig, D.L., MacInnes, M.A., Takiguchi, Y., Purtymun, P.E., Henrie, M., Flannery, M., 
Meneses, J., Pedersen, R.A. and Chen, D.J. (1998) 'A murine AP-endonuclease gene-targeted 
deficiency with post-implantation embryonic progression and ionizing radiation sensitivity', 
Mutat Res, 409(1), pp. 17-29. 
Luna, L., Rolseth, V., Hildrestrand, G.A., Otterlei, M., Dantzer, F., Bjoras, M. and Seeberg, 
E. (2005) 'Dynamic relocalization of hOGG1 during the cell cycle is disrupted in cells 
harbouring the hOGG1-Cys326 polymorphic variant', Nucleic Acids Res, 33(6), pp. 1813-24. 
Luo, M., Delaplane, S., Jiang, A., Reed, A., He, Y., Fishel, M., Nyland, R.L., 2nd, Borch, 
R.F., Qiao, X., Georgiadis, M.M. and Kelley, M.R. (2008) 'Role of the multifunctional DNA 
repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule 
inhibition of the redox function of Ape1', Antioxid Redox Signal, 10(11), pp. 1853-67. 
Luo, M., He, H., Kelley, M.R. and Georgiadis, M.M. (2010) 'Redox Regulation of DNA 
Repair: Implications for Human Health and Cancer Therapeutic Development', Antioxidants 
& Redox Signaling, 12(11), pp. 1247-1269. 
Luo, M. and Kelley, M.R. (2004) 'Inhibition of the human apurinic/apyrimidinic endonuclease 
(APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with 
lucanthone', Anticancer Res, 24(4), pp. 2127-34. 
261 
 
Luo, M., Zhang, J., He, H., Su, D., Chen, Q., Gross, M.L., Kelley, M.R. and Georgiadis, 
M.M. (2012) 'Characterization of the redox activity and disulfide bond formation in 
apurinic/apyrimidinic endonuclease', Biochemistry, 51(2), pp. 695-705. 
Mack, G.S. (2007) 'MicroRNA gets down to business', Nat Biotech, 25(6), pp. 631-638. 
Madhusudan, S., Smart, F., Shrimpton, P., Parsons, J.L., Gardiner, L., Houlbrook, S., Talbot, 
D.C., Hammonds, T., Freemont, P.A., Sternberg, M.J., Dianov, G.L. and Hickson, I.D. (2005) 
'Isolation of a small molecule inhibitor of DNA base excision repair', Nucleic Acids Res, 
33(15), pp. 4711-24. 
Manvilla, B.A., Wauchope, O., Seley-Radtke, K.L. and Drohat, A.C. (2011) 'NMR studies 
reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1', Biochemistry, 
50(48), pp. 10540-9. 
Marchitti, S.A., Orlicky, D.J. and Vasiliou, V. (2007) 'Expression and Initial Characterization 
of Human ALDH3B1', Biochemical and biophysical research communications, 356(3), pp. 
792-798. 
Marcucci, G., Haferlach, T. and Dohner, H. (2011a) 'Molecular genetics of adult acute 
myeloid leukemia: prognostic and therapeutic implications', J Clin Oncol, 29(5), pp. 475-86. 
Marcucci, G., Maharry, K., Radmacher, M.D., Mrozek, K., Vukosavljevic, T., Paschka, P., 
Whitman, S.P., Langer, C., Baldus, C.D., Liu, C.G., Ruppert, A.S., Powell, B.L., Carroll, A.J., 
Caligiuri, M.A., Kolitz, J.E., Larson, R.A. and Bloomfield, C.D. (2008) 'Prognostic 
significance of, and gene and microRNA expression signatures associated with, CEBPA 
mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular 
features: a Cancer and Leukemia Group B Study', J Clin Oncol, 26(31), pp. 5078-87. 
Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrozek, K., Margeson, D., Holland, 
K.B., Whitman, S.P., Becker, H., Schwind, S., Metzeler, K.H., Powell, B.L., Carter, T.H., 
Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. and 
Bloomfield, C.D. (2010) 'IDH1 and IDH2 gene mutations identify novel molecular subsets 
within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia 
Group B study', J Clin Oncol, 28(14), pp. 2348-55. 
262 
 
Marcucci, G., Mrózek, K., Radmacher, M.D., Garzon, R. and Bloomfield, C.D. (2011b) 'The 
prognostic and functional role of microRNAs in acute myeloid leukemia', Blood, 117(4), pp. 
1121-1129. 
Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, 
D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, 
V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., 
Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., 
Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., 
Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., 
Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., 
Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., 
Graubert, T.A., DiPersio, J.F., Wilson, R.K. and Ley, T.J. (2009) 'Recurring mutations found 
by sequencing an acute myeloid leukemia genome', N Engl J Med, 361(11), pp. 1058-66. 
Mariani, A., Bartoli, A., Atwal, M., Lee, K.C., Austin, C.A. and Rodriguez, R. (2015) 
'Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules', Journal 
of Medicinal Chemistry, 58(11), pp. 4851-4856. 
Masani, S., Han, L. and Yu, K. (2013) 'Apurinic/Apyrimidinic Endonuclease 1 Is the 
Essential Nuclease during Immunoglobulin Class Switch Recombination', Molecular and 
Cellular Biology, 33(7), pp. 1468-1473. 
Matsuda, A. and Sasaki, T. (2004) 'Antitumor activity of sugar-modified cytosine 
nucleosides', Cancer Sci, 95(2), pp. 105-11. 
Maynard, S., Hejl, A.M., Dinh, T.S., Keijzers, G., Hansen, A.M., Desler, C., Moreno-
Villanueva, M., Burkle, A., Rasmussen, L.J., Waldemar, G. and Bohr, V.A. (2015) 'Defective 
mitochondrial respiration, altered dNTP pools and reduced AP endonuclease 1 activity in 
peripheral blood mononuclear cells of Alzheimer's disease patients', Aging (Albany NY), 
7(10), pp. 793-815. 
McNeill, D.R., Lam, W., DeWeese, T.L., Cheng, Y.C. and Wilson, D.M., 3rd (2009) 
'Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators 
and antimetabolites', Mol Cancer Res, 7(6), pp. 897-906. 
263 
 
McNeill, D.R. and Wilson, D.M. (2007) 'A Dominant-Negative Form of the Major Human 
Abasic Endonuclease Enhances Cellular Sensitivity to Laboratory and Clinical DNA-
Damaging Agents', Molecular Cancer Research, 5(1), pp. 61-70. 
McNerney, M.E., Brown, C.D., Wang, X., Bartom, E.T., Karmakar, S., Bandlamudi, C., Yu, 
S., Ko, J., Sandall, B.P., Stricker, T., Anastasi, J., Grossman, R.L., Cunningham, J.M., Le 
Beau, M.M. and White, K.P. (2013) 'CUX1 is a haploinsufficient tumor suppressor gene on 
chromosome 7 frequently inactivated in acute myeloid leukemia', Blood, 121(6), pp. 975-83. 
Meira, L.B., Devaraj, S., Kisby, G.E., Burns, D.K., Daniel, R.L., Hammer, R.E., Grundy, S., 
Jialal, I. and Friedberg, E.C. (2001) 'Heterozygosity for the mouse Apex gene results in 
phenotypes associated with oxidative stress', Cancer Res, 61(14), pp. 5552-7. 
Meisenberg, C., Tait, P.S., Dianova, II, Wright, K., Edelmann, M.J., Ternette, N., Tasaki, T., 
Kessler, B.M., Parsons, J.L., Kwon, Y.T. and Dianov, G.L. (2012) 'Ubiquitin ligase UBR3 
regulates cellular levels of the essential DNA repair protein APE1 and is required for genome 
stability', Nucleic Acids Res, 40(2), pp. 701-11. 
Melissa, L.F., Carlo, V. and Mark, R.K. (2013) 'DNA Base Excision Repair Therapeutics', in  
DNA Repair and Cancer. CRC Press, pp. 233-287. 
Mendez, F., Goldman, J.D. and Bases, R.E. (2002) 'Abasic sites in DNA of HeLa cells 
induced by lucanthone', Cancer Invest, 20(7-8), pp. 983-91. 
Metzeler, K.H., Hummel, M., Bloomfield, C.D., Spiekermann, K., Braess, J., Sauerland, M.-
C., Heinecke, A., Radmacher, M., Marcucci, G., Whitman, S.P., Maharry, K., Paschka, P., 
Larson, R.A., Berdel, W.E., Büchner, T., Wörmann, B., Mansmann, U., Hiddemann, W., 
Bohlander, S.K. and Buske, C. (2008) 'An 86-probe-set gene-expression signature predicts 
survival in cytogenetically normal acute myeloid leukemia', Blood, 112(10), pp. 4193-4201. 
Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrózek, K., Margeson, D., Becker, H., 
Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., Wu, Y.-Z., Blum, W., Powell, B.L., 
Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., 
Caligiuri, M.A., Marcucci, G. and Bloomfield, C.D. (2011) 'TET2 Mutations Improve the 
New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and 
Leukemia Group B Study', Journal of Clinical Oncology, 29(10), pp. 1373-1381. 
264 
 
Michl, P., Ramjaun, A.R., Pardo, O.E., Warne, P.H., Wagner, M., Poulsom, R., D’Arrigo, C., 
Ryder, K., Menke, A., Gress, T. and Downward, J. (2005) 'CUTL1 is a target of TGFβ 
signaling that enhances cancer cell motility and invasiveness', Cancer Cell, 7(6), pp. 521-532. 
Mikhed, Y., Görlach, A., Knaus, U.G. and Daiber, A. (2015) 'Redox regulation of genome 
stability by effects on gene expression, epigenetic pathways and DNA damage/repair', Redox 
Biology, 5, pp. 275-289. 
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) 'Anthracyclines: 
molecular advances and pharmacologic developments in antitumor activity and 
cardiotoxicity', Pharmacol Rev, 56(2), pp. 185-229. 
Minowa, O., Arai, T., Hirano, M., Monden, Y., Nakai, S., Fukuda, M., Itoh, M., Takano, H., 
Hippou, Y., Aburatani, H., Masumura, K.-i., Nohmi, T., Nishimura, S. and Noda, T. (2000) 
'Mmh/Ogg1 Gene Inactivation Results in Accumulation of 8-Hydroxyguanine in Mice', 
Proceedings of the National Academy of Sciences of the United States of America, 97(8), pp. 
4156-4161. 
Mitchell, J., Smith, G.C. and Curtin, N.J. (2009) 'Poly(ADP-Ribose) polymerase-1 and DNA-
dependent protein kinase have equivalent roles in double strand break repair following 
ionizing radiation', Int J Radiat Oncol Biol Phys, 75(5), pp. 1520-7. 
Miyamoto, K., Nagakawa, J., Hishinuma, I., Hirota, K., Yasuda, M., Yamanaka, T., 
Katayama, K. and Yamatsu, I. (1992) 'Suppressive effects of E3330, a novel quinone 
derivative, on tumor necrosis factor-alpha generation from monocytes and macrophages', 
Agents Actions, 37(3-4), pp. 297-304. 
Mogilyansky, E. and Rigoutsos, I. (2013) 'The miR-17/92 cluster: a comprehensive update on 
its genomics, genetics, functions and increasingly important and numerous roles in health and 
disease', Cell Death Differ, 20(12), pp. 1603-1614. 
Mohammed, M.Z., Vyjayanti, V.N., Laughton, C.A., Dekker, L.V., Fischer, P.M., Wilson, 
D.M., 3rd, Abbotts, R., Shah, S., Patel, P.M., Hickson, I.D. and Madhusudan, S. (2011) 
'Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma 
cell lines', Br J Cancer, 104(4), pp. 653-63. 
265 
 
Mokkapati, S.K., Wiederhold, L., Hazra, T.K. and Mitra, S. (2004) 'Stimulation of DNA 
glycosylase activity of OGG1 by NEIL1: functional collaboration between two human DNA 
glycosylases', Biochemistry, 43(36), pp. 11596-604. 
Montalban-Bravo, G. and Garcia-Manero, G. (2014) 'Novel drugs for older patients with 
acute myeloid leukemia', Leukemia. 
Montaldi, A.P., Godoy, P.R.D.V. and Sakamoto-Hojo, E.T. (2015) 'APE1/REF-1 down-
regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell 
line', Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 793, pp. 19-29. 
Moor, N.A., Vasil'eva, I.A., Anarbaev, R.O., Antson, A.A. and Lavrik, O.I. (2015) 
'Quantitative characterization of protein-protein complexes involved in base excision DNA 
repair', Nucleic Acids Res, 43(12), pp. 6009-22. 
Mrozek, K. and Bloomfield, C.D. (2008) 'Clinical significance of the most common 
chromosome translocations in adult acute myeloid leukemia', J Natl Cancer Inst Monogr, 
(39), pp. 52-7. 
Nagakawa, J., Hishinuma, I., Hirota, K., Miyamoto, K., Yamanaka, T., Yamatsu, I. and 
Katayama, K. (1992) 'Protective effects of E3330, a novel quinone derivative, on 
galactosamine/tumor necrosis factor-alpha-induced hepatitis in mice', Eur J Pharmacol, 
229(1), pp. 63-7. 
Naidu, M.D., Agarwal, R., Pena, L.A., Cunha, L., Mezei, M., Shen, M., Wilson, D.M., 3rd, 
Liu, Y., Sanchez, Z., Chaudhary, P., Wilson, S.H. and Waring, M.J. (2011) 'Lucanthone and 
its derivative hycanthone inhibit apurinic endonuclease-1 (APE1) by direct protein binding', 
PLoS One, 6(9), p. e23679. 
Naidu, M.D., Mason, J.M., Pica, R.V., Fung, H. and PeÑA, L.A. (2010) 'Radiation Resistance 
in Glioma Cells Determined by DNA Damage Repair Activity of Ape1/Ref-1', Journal of 
Radiation Research, 51(4), pp. 393-404. 
Nakajima, H. and Kunimoto, H. (2014) 'TET2 as an epigenetic master regulator for normal 
and malignant hematopoiesis', Cancer Sci, 105(9), pp. 1093-9. 
266 
 
Narciso, L., Fortini, P., Pajalunga, D., Franchitto, A., Liu, P., Degan, P., Frechet, M., Demple, 
B., Crescenzi, M. and Dogliotti, E. (2007) 'Terminally differentiated muscle cells are 
defective in base excision DNA repair and hypersensitive to oxygen injury', Proc Natl Acad 
Sci U S A, 104(43), pp. 17010-5. 
Nieminuszczy, J., Schwab, R.A. and Niedzwiedz, W. (2016) 'The DNA fibre technique – 
tracking helicases at work', Methods, 108, pp. 92-98. 
Nishii, K., Usui, E., Katayama, N., Lorenzo, F.t., Nakase, K., Kobayashi, T., Miwa, H., 
Mizutani, M., Tanaka, I., Nasu, K., Dohy, H., Kyo, T., Taniwaki, M., Ueda, T., Kita, K. and 
Shiku, H. (2003) 'Characteristics of t(8;21) acute myeloid leukemia (AML) with additional 
chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of 
t(8;21) AML', Leukemia, 17(4), pp. 731-7. 
Nishioka, K., Ohtsubo, T., Oda, H., Fujiwara, T., Kang, D., Sugimachi, K. and Nakabeppu, Y. 
(1999) 'Expression and differential intracellular localization of two major forms of human 8-
oxoguanine DNA glycosylase encoded by alternatively spliced OGG1 mRNAs', Mol Biol 
Cell, 10(5), pp. 1637-52. 
Olipitz, W., Lind, K., Monsberger, N., Katschnig, A., Mangerich, A., Hofer, S., Schulz, E., 
Quehenberger, F., Schlembach, D., Robier, C., Woelfler, A., Zebisch, A. and Sill, H. (2014) 
'Base Excision Repair Glycosylase Activity Is Impaired in a Subgroup of Acute Myeloid 
Leukemia Resulting in Increased Levels of Oxidative Base Lesions', Blood, 124(21), pp. 860-
860. 
Orta, M.L., Hoglund, A., Calderon-Montano, J.M., Dominguez, I., Burgos-Moron, E., Visnes, 
T., Pastor, N., Strom, C., Lopez-lazaro, M. and Helleday, T. (2014) 'The PARP inhibitor 
Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions', Nucleic Acids Res, 
42(14), pp. 9108-20. 
Palii, S.S., Van Emburgh, B.O., Sankpal, U.T., Brown, K.D. and Robertson, K.D. (2008) 
'DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide 
DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B', Molecular 
and Cellular Biology, 28(2), pp. 752-771. 
267 
 
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., 
Potter, N.E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., 
Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D.R., Teague, J.W., Butler, 
A.P., Greaves, M.F., Ganser, A., Döhner, K., Schlenk, R.F., Döhner, H. and Campbell, P.J. 
(2016) 'Genomic Classification and Prognosis in Acute Myeloid Leukemia', New England 
Journal of Medicine, 374(23), pp. 2209-2221. 
Parsons, J.L. and Dianov, G.L. (2013) 'Co-ordination of base excision repair and genome 
stability', DNA Repair (Amst), 12(5), pp. 326-33. 
Parsons, R., Li, G.-M., Longley, M.J., Fang, W.-h., Papadopoulos, N., Jen, J., de la Chapelle, 
A., Kinzler, K.W., Vogelstein, B. and Modrich, P. (1993) 'Hypermutability and mismatch 
repair deficiency in RER+ tumor cells', Cell, 75(6), pp. 1227-1236. 
Peddi, S.R., Chattopadhyay, R., Naidu, C.V. and Izumi, T. (2006) 'The human 
apurinic/apyrimidinic endonuclease-1 suppresses activation of poly(adp-ribose) polymerase-1 
induced by DNA single strand breaks', Toxicology, 224(1-2), pp. 44-55. 
Pemmaraju, N., Kantarjian, H., Andreeff, M., Cortes, J. and Ravandi, F. (2014) 
'Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia', 
Expert Opin Investig Drugs, 23(7), pp. 943-54. 
Pendleton, M., Lindsey, R.H., Felix, C.A., Grimwade, D. and Osheroff, N. (2014) 
'Topoisomerase II and leukemia', Annals of the New York Academy of Sciences, 1310(1), pp. 
98-110. 
Petersdorf, S.H., Kopecky, K.J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, 
R.A., Erba, H.P., Stiff, P.J., Stuart, R.K., Walter, R.B., Tallman, M.S., Stenke, L. and 
Appelbaum, F.R. (2013) 'A phase 3 study of gemtuzumab ozogamicin during induction and 
postconsolidation therapy in younger patients with acute myeloid leukemia', Blood, 121(24), 
pp. 4854-60. 
Petrie, K., Zelent, A. and Waxman, S. (2009) 'Differentiation therapy of acute myeloid 
leukemia: past, present and future', Current Opinion in Hematology, 16(2), pp. 84-91. 
268 
 
Petruccelli, L.A., Pettersson, F., Del Rincon, S.V., Guilbert, C., Licht, J.D. and Miller, W.H., 
Jr. (2013) 'Expression of leukemia-associated fusion proteins increases sensitivity to histone 
deacetylase inhibitor-induced DNA damage and apoptosis', Mol Cancer Ther, 12(8), pp. 
1591-604. 
Pillinger, G., Abdul-Aziz, A., Zaitseva, L., Lawes, M., MacEwan, D.J., Bowles, K.M. and 
Rushworth, S.A. (2015) 'Targeting BTK for the treatment of FLT3-ITD mutated acute 
myeloid leukemia', Scientific Reports, 5, p. 12949. 
Pines, A., Bivi, N., Romanello, M., Damante, G., Kelley, M.R., Adamson, E.D., D'Andrea, P., 
Quadrifoglio, F., Moro, L. and Tell, G. (2005) 'Cross-regulation between Egr-1 and APE/Ref-
1 during early response to oxidative stress in the human osteoblastic HOBIT cell line: 
Evidence for an autoregulatory loop', Free Radical Research, 39(3), pp. 269-281. 
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, 
A., McHugh, P., Newell, D., Harris, A., Johnson, P., Steinfeldt, H., Dewji, R., Wang, D., 
Robson, L. and Calvert, H. (2008) 'Phase I Study Of The Poly(ADP-Ribose) Polymerase 
Inhibitor, AG014699, In Combination With Temozolomide in Patients with Advanced Solid 
Tumors', Clinical cancer research : an official journal of the American Association for 
Cancer Research, 14(23), pp. 7917-7923. 
Poggi, A., Pellegatta, F., Leone, B.E., Moretta, L. and Zocchi, M.R. (2000) 'Engagement of 
the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-
kappaB nuclear translocation in human myeloid leukemias', Eur J Immunol, 30(10), pp. 2751-
8. 
Poletto, M., Legrand, A.J., Fletcher, S.C. and Dianov, G.L. (2016) 'p53 coordinates base 
excision repair to prevent genomic instability', Nucleic Acids Research. 
Poletto, M., Lirussi, L., Wilson, D.M., 3rd and Tell, G. (2014) 'Nucleophosmin modulates 
stability, activity and nucleolar accumulation of base excision repair proteins', Mol Biol Cell. 
Poletto, M., Malfatti, M.C., Dorjsuren, D., Scognamiglio, P.L., Marasco, D., Vascotto, C., 
Jadhav, A., Maloney, D.J., Wilson, D.M., 3rd, Simeonov, A. and Tell, G. (2015) 'Inhibitors of 
the apurinic/apyrimidinic endonuclease 1 (APE1)/nucleophosmin (NPM1) interaction that 
display anti-tumor properties', Mol Carcinog. 
269 
 
Prakasha Gowda, A.S., Polizzi, J.M., Eckert, K.A. and Spratt, T.E. (2010) 'Incorporation of 
gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1', 
Biochemistry, 49(23), pp. 4833-40. 
Qian, C., Li, M., Sui, J., Ren, T., Li, Z., Zhang, L., Zhou, L., Cheng, Y. and Wang, D. (2014) 
'Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor', 
Drug Des Devel Ther, 8, pp. 485-96. 
Raffoul, J.J., Banerjee, S., Singh-Gupta, V., Knoll, Z.E., Fite, A., Zhang, H., Abrams, J., 
Sarkar, F.H. and Hillman, G.G. (2007) 'Down-regulation of apurinic/apyrimidinic 
endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer 
radiotherapy in vitro and in vivo', Cancer Res, 67(5), pp. 2141-9. 
Raffoul, J.J., Heydari, A.R. and Hillman, G.G. (2012) 'DNA Repair and Cancer Therapy: 
Targeting APE1/Ref-1 Using Dietary Agents', J Oncol, 2012, p. 370481. 
Rai, G., Vyjayanti, V.N., Dorjsuren, D., Simeonov, A., Jadhav, A., Wilson, D.M., 3rd and 
Maloney, D.J. (2012) 'Synthesis, biological evaluation, and structure-activity relationships of 
a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors', J Med Chem, 55(7), pp. 
3101-12. 
Rai, G., Vyjayanti, V.N., Dorjsuren, D., Simeonov, A., Jadhav, A., Wilson, D.M. and 
Maloney, D.J. (2010) 'Small Molecule Inhibitors of the Human Apurinic/apyrimidinic 
Endonuclease 1 (APE1)', in  Probe Reports from the NIH Molecular Libraries Program. 
Bethesda MD. 
Raia, G., Vaddadi N. Vyjayanti b, Dorjbal Dorjsurena, Anton Simeonova, Ajit Jadhava, 
David M. Wilsonb and Maloney, D.J. (2013) 'Small Molecule Inhibitors of the Human 
Apurinic/apyrimidinic Endonuclease 1 (APE1) 2010 Oct 29 [Updated 2013 Feb 28]', In: 
Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): 
National Center for Biotechnology Information (US); 2010-.  Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK133448/. 
Ramdzan, Z.M. and Nepveu, A. (2014) 'CUX1, a haploinsufficient tumour suppressor gene 
overexpressed in advanced cancers', Nat Rev Cancer, 14(10), pp. 673-682. 
270 
 
Ramdzan, Z.M., Pal, R., Kaur, S., Leduy, L., Berube, G., Davoudi, S., Vadnais, C. and 
Nepveu, A. (2015) 'The function of CUX1 in oxidative DNA damage repair is needed to 
prevent premature senescence of mouse embryo fibroblasts', Oncotarget, 6(6), pp. 3613-26. 
Ramdzan, Z.M., Vadnais, C., Pal, R., Vandal, G., Cadieux, C., Leduy, L., Davoudi, S., Hulea, 
L., Yao, L., Karnezis, A.N., Paquet, M., Dankort, D. and Nepveu, A. (2014) 'RAS 
transformation requires CUX1-dependent repair of oxidative DNA damage', PLoS Biol, 12(3), 
p. e1001807. 
Rao, D.D., Vorhies, J.S., Senzer, N. and Nemunaitis, J. (2009) 'siRNA vs. shRNA: 
Similarities and differences', Advanced Drug Delivery Reviews, 61(9), pp. 746-759. 
Rassool, F.V., Gaymes, T.J., Omidvar, N., Brady, N., Beurlet, S., Pla, M., Reboul, M., Lea, 
N., Chomienne, C., Thomas, N.S., Mufti, G.J. and Padua, R.A. (2007) 'Reactive oxygen 
species, DNA damage, and error-prone repair: a model for genomic instability with 
progression in myeloid leukemia?', Cancer Res, 67(18), pp. 8762-71. 
Reed, A.M., Fishel, M.L. and Kelley, M.R. (2009) 'Small-molecule inhibitors of proteins 
involved in base excision repair potentiate the anti-tumorigenic effect of existing 
chemotherapeutics and irradiation', Future oncology (London, England), 5(5), pp. 713-726. 
Renneville, A., Roumier, C., Biggio, V., Nibourel, O., Boissel, N., Fenaux, P. and 
Preudhomme, C. (2008) 'Cooperating gene mutations in acute myeloid leukemia: a review of 
the literature', Leukemia, 22(5), pp. 915-931. 
Ripka, S., Neesse, A., Riedel, J., Bug, E., Aigner, A., Poulsom, R., Fulda, S., Neoptolemos, J., 
Greenhalf, W., Barth, P., Gress, T.M. and Michl, P. (2010) 'CUX1: target of Akt signalling 
and mediator of resistance to apoptosis in pancreatic cancer', Gut, 59(8), pp. 1101-10. 
Robertson, K.A., Bullock, H.A., Xu, Y., Tritt, R., Zimmerman, E., Ulbright, T.M., Foster, 
R.S., Einhorn, L.H. and Kelley, M.R. (2001) 'Altered expression of Ape1/ref-1 in germ cell 
tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation', 
Cancer Res, 61(5), pp. 2220-5. 
Rohrabaugh, S.L., Hangoc, G., Kelley, M.R. and Broxmeyer, H.E. (2011) 'Mad2 
Haploinsufficiency Protects Hematopoietic Progenitor Cells Subjected to Cell Cycle Stress In 
271 
 
Vivo and to Inhibition of Redox Function of Ape1/Ref-1 In Vitro', Experimental hematology, 
39(4), pp. 415-423. 
Rollinson, S., Smith, A.G., Allan, J.M., Adamson, P.J., Scott, K., Skibola, C.F., Smith, M.T. 
and Morgan, G.J. (2007) 'RAD51 homologous recombination repair gene haplotypes and risk 
of acute myeloid leukaemia', Leuk Res, 31(2), pp. 169-74. 
Rosa, S., Fortini, P., Karran, P., Bignami, M. and Dogliotti, E. (1991) 'Processing in vitro of 
an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites 
formed in vivo', Nucleic Acids Research, 19(20), pp. 5569-5574. 
Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H. and Poirier, G.G. (2010) 'PARP 
inhibition: PARP1 and beyond', Nat Rev Cancer, 10(4), pp. 293-301. 
Rushworth, S.A., Murray, M.Y., Zaitseva, L., Bowles, K.M. and MacEwan, D.J. (2014) 
'Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid leukemia', 
Blood, 123(8), pp. 1229-1238. 
Russo, M.T., De Luca, G., Degan, P. and Bignami, M. (2007) 'Different DNA repair 
strategies to combat the threat from 8-oxoguanine', Mutat Res, 614(1-2), pp. 69-76. 
Russo, M.T., De Luca, G., Degan, P., Parlanti, E., Dogliotti, E., Barnes, D.E., Lindahl, T., 
Yang, H., Miller, J.H. and Bignami, M. (2004) 'Accumulation of the Oxidative Base Lesion 8-
Hydroxyguanine in DNA of Tumor-Prone Mice Defective in Both the Myh and Ogg1 DNA 
Glycosylases', Cancer Research, 64(13), pp. 4411-4414. 
Saitoh, T., Nitta, Y., Norjimaa, B., Omiya, C., Kamiya, A., Hatsumi, N., Shimizu, H., 
Ishizaki, T., Hoshino, T., Takada, S., Handa, H., Sakura, T., Yokohama, A., Tsukamoto, N. 
and Murakami, H. (2013) 'The Polymorphisms Of Base Excision Repair Genes Influence The 
Cytogenetic Risk Factors In Acute Myeloid Leukemia', Blood, 122(21), p. 1355. 
Saitoh, T., Shinmura, K., Yamaguchi, S., Tani, M., Seki, S., Murakami, H., Nojima, Y. and 
Yokota, J. (2001) 'Enhancement of OGG1 protein AP lyase activity by increase of APEX 
protein', Mutation Research/DNA Repair, 486(1), pp. 31-40. 
272 
 
Sakumi, K., Tominaga, Y., Furuichi, M., Xu, P., Tsuzuki, T., Sekiguchi, M. and Nakabeppu, 
Y. (2003) 'Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene 
disruption', Cancer Res, 63(5), pp. 902-5. 
Sallmyr, A., Fan, J., Datta, K., Kim, K.T., Grosu, D., Shapiro, P., Small, D. and Rassool, F. 
(2008a) 'Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, 
DNA damage, and misrepair: implications for poor prognosis in AML', Blood, 111(6), pp. 
3173-82. 
Sallmyr, A., Fan, J. and Rassool, F.V. (2008b) 'Genomic instability in myeloid malignancies: 
increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone 
repair', Cancer Lett, 270(1), pp. 1-9. 
Sander, J.D. and Joung, J.K. (2014) 'CRISPR-Cas systems for editing, regulating and 
targeting genomes', Nat Biotech, 32(4), pp. 347-355. 
Sandoval, A., Consoli, U. and Plunkett, W. (1996) 'Fludarabine-mediated inhibition of 
nucleotide excision repair induces apoptosis in quiescent human lymphocytes', Clin Cancer 
Res, 2(10), pp. 1731-41. 
Santos, M.A., Faryabi, R.B., Ergen, A.V., Day, A.M., Malhowski, A., Canela, A., Onozawa, 
M., Lee, J.E., Callen, E., Gutierrez-Martinez, P., Chen, H.T., Wong, N., Finkel, N., 
Deshpande, A., Sharrow, S., Rossi, D.J., Ito, K., Ge, K., Aplan, P.D., Armstrong, S.A. and 
Nussenzweig, A. (2014) 'DNA-damage-induced differentiation of leukaemic cells as an anti-
cancer barrier', Nature, 514(7520), pp. 107-11. 
Schanz, S., Castor, D., Fischer, F. and Jiricny, J. (2009) 'Interference of mismatch and base 
excision repair during the processing of adjacent U/G mispairs may play a key role in somatic 
hypermutation', Proceedings of the National Academy of Sciences of the United States of 
America, 106(14), pp. 5593-5598. 
Schild, L.J., Brookman, K.W., Thompson, L.H. and Wilson, D.M., 3rd (1999) 'Effects of 
Ape1 overexpression on cellular resistance to DNA-damaging and anticancer agents', Somat 
Cell Mol Genet, 25(5-6), pp. 253-62. 
273 
 
Schnerch, D., Yalcintepe, J., Schmidts, A., Becker, H., Follo, M., Engelhardt, M. and Wäsch, 
R. (2012) 'Cell cycle control in acute myeloid leukemia', American Journal of Cancer 
Research, 2(5), pp. 508-528. 
Schoofs, T., Berdel, W.E. and Muller-Tidow, C. (2014) 'Origins of aberrant DNA methylation 
in acute myeloid leukemia', Leukemia, 28(1), pp. 1-14. 
Schuermann, D., Weber, A.R. and Schär, P. (2016) 'Active DNA demethylation by DNA 
repair: Facts and uncertainties', DNA Repair. 
Scott, T.L., Rangaswamy, S., Wicker, C.A. and Izumi, T. (2014) 'Repair of Oxidative DNA 
Damage and Cancer: Recent Progress in DNA Base Excision Repair', Antioxidants & Redox 
Signaling, 20(4), pp. 708-726. 
Seedhouse, C., Faulkner, R., Ashraf, N., Das-Gupta, E. and Russell, N. (2004) 
'Polymorphisms in genes involved in homologous recombination repair interact to increase 
the risk of developing acute myeloid leukemia', Clin Cancer Res, 10(8), pp. 2675-80. 
Seedhouse, C.H., Hunter, H.M., Lloyd-Lewis, B., Massip, A.M., Pallis, M., Carter, G.I., 
Grundy, M., Shang, S. and Russell, N.H. (2006) 'DNA repair contributes to the drug-resistant 
phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications 
and is reversed by the FLT3 inhibitor PKC412', Leukemia, 20(12), pp. 2130-2136. 
Sengupta, S., Mantha, A.K., Mitra, S. and Bhakat, K.K. (2011) 'Human AP endonuclease 
(APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II 
loading in the drug-induced activation of multidrug resistance gene MDR1', Oncogene, 30(4), 
pp. 482-93. 
Sengupta, S., Mitra, S. and Bhakat, K.K. (2013) 'Dual regulatory roles of human AP-
endonuclease (APE1/Ref-1) in CDKN1A/p21 expression', PLoS One, 8(7), p. e68467. 
Shaheen, M., Allen, C., Nickoloff, J.A. and Hromas, R. (2011) 'Synthetic lethality: exploiting 
the addiction of cancer to DNA repair', Blood, 117(23), pp. 6074-82. 
She, M., Pan, I., Sun, L. and Yeung, S.C. (2005) 'Enhancement of manumycin A-induced 
apoptosis by methoxyamine in myeloid leukemia cells', Leukemia, 19(4), pp. 595-602. 
274 
 
Shen, W.H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolfi, P.P. and Yin, Y. (2007) 
'Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity', Cell, 128(1), pp. 
157-170. 
Sheng, Q., Zhang, Y., Wang, R., Zhang, J., Chen, B., Wang, J., Zhang, W. and Xin, X. (2012) 
'Prognostic significance of APE1 cytoplasmic localization in human epithelial ovarian cancer', 
Med Oncol, 29(2), pp. 1265-71. 
Shrivastav, N., Li, D. and Essigmann, J.M. (2010) 'Chemical biology of mutagenesis and 
DNA repair: cellular responses to DNA alkylation', Carcinogenesis, 31(1), pp. 59-70. 
Sidorenko, V.S., Nevinsky, G.A. and Zharkov, D.O. (2007) 'Mechanism of interaction 
between human 8-oxoguanine-DNA glycosylase and AP endonuclease', DNA Repair (Amst), 
6(3), pp. 317-28. 
Simeonov, A., Kulkarni, A., Dorjsuren, D., Jadhav, A., Shen, M., McNeill, D.R., Austin, C.P. 
and Wilson, D.M., 3rd (2009) 'Identification and characterization of inhibitors of human 
apurinic/apyrimidinic endonuclease APE1', PLoS One, 4(6), p. e5740. 
Simonelli, V., Camerini, S., Mazzei, F., Van Loon, B., Allione, A., D'Errico, M., Barone, F., 
Minoprio, A., Ricceri, F., Guarrera, S., Russo, A., Dalhus, B., Crescenzi, M., Hübscher, U., 
Bjørås, M., Matullo, G. and Dogliotti, E. (2013) 'Genotype–phenotype analysis of S326C 
OGG1 polymorphism: a risk factor for oxidative pathologies', Free Radical Biology and 
Medicine, 63, pp. 401-409. 
Singh-Gupta, V., Joiner, M.C., Runyan, L., Yunker, C.K., Sarkar, F.H., Miller, S., Gadgeel, 
S.M., Konski, A.A. and Hillman, G.G. (2011) 'Soy isoflavones augment radiation effect by 
inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer', J Thorac Oncol, 
6(4), pp. 688-98. 
Small, D. (2006) 'FLT3 mutations: biology and treatment', Hematology Am Soc Hematol Educ 
Program, pp. 178-84. 
Speina, E., Ciesla, J.M., Graziewicz, M.A., Laval, J., Kazimierczuk, Z. and Tudek, B. (2005) 
'Inhibition of DNA repair glycosylases by base analogs and tryptophan pyrolysate, Trp-P-1', 
Acta Biochim Pol, 52(1), pp. 167-78. 
275 
 
Srinivasan, A., Wang, L., Cline, C.J., Xie, Z., Sobol, R.W., Xie, X.Q. and Gold, B. (2012) 
'Identification and characterization of human apurinic/apyrimidinic endonuclease-1 
inhibitors', Biochemistry, 51(31), pp. 6246-59. 
Stanczyk, M., Sliwinski, T., Cuchra, M., Zubowska, M., Bielecka-Kowalska, A., Kowalski, 
M., Szemraj, J., Mlynarski, W. and Majsterek, I. (2011) 'The association of polymorphisms in 
DNA base excision repair genes XRCC1, OGG1 and MUTYH with the risk of childhood 
acute lymphoblastic leukemia', Mol Biol Rep, 38(1), pp. 445-51. 
Stanczyk, M., Sliwinski, T., Trelinska, J., Cuchra, M., Markiewicz, L., Dziki, L., Bieniek, A., 
Bielecka-Kowalska, A., Kowalski, M., Pastorczak, A., Szemraj, J., Mlynarski, W. and 
Majsterek, I. (2012) 'Role of base-excision repair in the treatment of childhood acute 
lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate', Mutat Res, 
741(1-2), pp. 13-21. 
Stein, E.M., Altman, J.K., Collins, R., DeAngelo, D.J., Fathi, A.T., Flinn, I., Frankel, A., 
Levine, R.L., Medeiros, B.C., Patel, M., Pollyea, D.A., Roboz, G.J., Stone, R.M., Swords, 
R.T., Tallman, M.S., Agresta, S., Fan, B., Yang, H., Yen, K. and de Botton, S. (2014) 'AG-
221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic 
Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation 
Positive Advanced Hematologic Malignancies', Blood, 124(21), pp. 115-115. 
Stoddart, A., Fernald, A.A., Wang, J., Davis, E.M., Karrison, T., Anastasi, J. and Le Beau, 
M.M. (2014) 'Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to 
induce acute myeloid leukemia in mice', Blood, 123(7), pp. 1069-78. 
Strom, C.E., Johansson, F., Uhlen, M., Szigyarto, C.A., Erixon, K. and Helleday, T. (2011) 
'Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP 
inhibition traps a single-strand intermediate', Nucleic Acids Res, 39(8), pp. 3166-75. 
Sudhakar, J., Khetan, V., Madhusudan, S. and Krishnakumar, S. (2014) 'Dysregulation of 
human apurinic/apyrimidinic endonuclease 1 (APE1) expression in advanced retinoblastoma', 
Br J Ophthalmol, 98(3), pp. 402-7. 
276 
 
Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Ishikawa, F., Takaku, 
F., Yazaki, Y. and Hirai, H. (1992) 'Frequent mutations in the p53 gene in human myeloid 
leukemia cell lines', Blood, 79(9), pp. 2378-83. 
Sultana, R., Abdel-Fatah, T., Abbotts, R., Hawkes, C., Albarakati, N., Seedhouse, C., Ball, G., 
Chan, S., Rakha, E.A., Ellis, I.O. and Madhusudan, S. (2013) 'Targeting XRCC1 deficiency in 
breast cancer for personalized therapy', Cancer Res, 73(5), pp. 1621-34. 
Sultana, R., McNeill, D.R., Abbotts, R., Mohammed, M.Z., Zdzienicka, M.Z., Qutob, H., 
Seedhouse, C., Laughton, C.A., Fischer, P.M., Patel, P.M., Wilson, D.M., 3rd and 
Madhusudan, S. (2012) 'Synthetic lethal targeting of DNA double-strand break repair 
deficient cells by human apurinic/apyrimidinic endonuclease inhibitors', Int J Cancer, 
131(10), pp. 2433-44. 
Sung, J.S. and Demple, B. (2006) 'Roles of base excision repair subpathways in correcting 
oxidized abasic sites in DNA', Febs j, 273(8), pp. 1620-9. 
Sutcliffe, T., Fu, L., Abraham, J., Vaziri, H. and Benchimol, S. (1998) 'A Functional Wild-
Type p53 Gene Is Expressed in Human Acute Myeloid Leukemia Cell Lines', Blood, 92(8), 
pp. 2977-2979. 
Swords, R., Freeman, C. and Giles, F. (2012) 'Targeting the FMS-like tyrosine kinase 3 in 
acute myeloid leukemia', Leukemia, 26(10), pp. 2176-85. 
Sykes, Stephen M., Lane, Steven W., Bullinger, L., Kalaitzidis, D., Yusuf, R., Saez, B., 
Ferraro, F., Mercier, F., Singh, H., Brumme, Kristina M., Acharya, Sanket S., Scholl, C., 
Tothova, Z., Attar, Eyal C., Fröhling, S., DePinho, Ronald A., Gilliland, D.G., Armstrong, 
Scott A. and Scadden, David T. (2011) 'AKT/FOXO Signaling Enforces Reversible 
Differentiation Blockade in Myeloid Leukemias', Cell, 146(5), pp. 697-708. 
Takacova, S., Slany, R., Bartkova, J., Stranecky, V., Dolezel, P., Luzna, P., Bartek, J. and 
Divoky, V. (2012) 'DNA damage response and inflammatory signaling limit the MLL-ENL-
induced leukemogenesis in vivo', Cancer Cell, 21(4), pp. 517-31. 
Tang, J.-L., Hou, H.-A., Chen, C.-Y., Liu, C.-Y., Chou, W.-C., Tseng, M.-H., Huang, C.-F., 
Lee, F.-Y., Liu, M.-C., Yao, M., Huang, S.-Y., Ko, B.-S., Hsu, S.-C., Wu, S.-J., Tsay, W., 
277 
 
Chen, Y.-C., Lin, L.-I. and Tien, H.-F. (2009) 'AML1/RUNX1 mutations in 470 adult patients 
with de novo acute myeloid leukemia: prognostic implication and interaction with other gene 
alterations', Blood, 114(26), pp. 5352-5361. 
Tell, G., Damante, G., Caldwell, D. and Kelley, M.R. (2005) 'The intracellular localization of 
APE1/Ref-1: more than a passive phenomenon?', Antioxid Redox Signal, 7(3-4), pp. 367-84. 
Tell, G., Fantini, D. and Quadrifoglio, F. (2010a) 'Understanding different functions of 
mammalian AP endonuclease (APE1) as a promising tool for cancer treatment', Cell Mol Life 
Sci, 67(21), pp. 3589-608. 
Tell, G., Quadrifoglio, F., Tiribelli, C. and Kelley, M.R. (2009) 'The many functions of 
APE1/Ref-1: not only a DNA repair enzyme', Antioxid Redox Signal, 11(3), pp. 601-20. 
Tell, G. and Wilson, D.M., 3rd (2010) 'Targeting DNA repair proteins for cancer treatment', 
Cell Mol Life Sci, 67(21), pp. 3569-72. 
Tell, G., Wilson, D.M., 3rd and Lee, C.H. (2010b) 'Intrusion of a DNA repair protein in the 
RNome world: is this the beginning of a new era?', Mol Cell Biol, 30(2), pp. 366-71. 
Thakur, S., Sarkar, B., Cholia, R.P., Gautam, N., Dhiman, M. and Mantha, A.K. (2014) 
'APE1/Ref-1 as an emerging therapeutic target for various human diseases: phytochemical 
modulation of its functions', Exp Mol Med, 46, p. e106. 
The Cancer Genome Atlas Research, N. (2013) 'Genomic and Epigenomic Landscapes of 
Adult De Novo Acute Myeloid Leukemia', New England Journal of Medicine, 368(22), pp. 
2059-2074. 
Thol, F., Schlenk, R.F., Heuser, M. and Ganser, A. (2015) 'How I treat refractory and early 
relapsed acute myeloid leukemia', Blood, 126(3), pp. 319-327. 
Tilby, M.J., Styles, J.M. and Dean, C.J. (1987) 'Immunological detection of DNA damage 
caused by melphalan using monoclonal antibodies', Cancer Res, 47(6), pp. 1542-6. 
Tothova, Z., Kollipara, R., Huntly, B.J., Lee, B.H., Castrillon, D.H., Cullen, D.E., McDowell, 
E.P., Lazo-Kallanian, S., Williams, I.R., Sears, C., Armstrong, S.A., Passegue, E., DePinho, 
278 
 
R.A. and Gilliland, D.G. (2007) 'FoxOs are critical mediators of hematopoietic stem cell 
resistance to physiologic oxidative stress', Cell, 128(2), pp. 325-39. 
Trachootham, D., Lu, W., Ogasawara, M.A., Nilsa, R.D. and Huang, P. (2008) 'Redox 
regulation of cell survival', Antioxid Redox Signal, 10(8), pp. 1343-74. 
Tsuchimoto, D., Sakai, Y., Sakumi, K., Nishioka, K., Sasaki, M., Fujiwara, T. and 
Nakabeppu, Y. (2001) 'Human APE2 protein is mostly localized in the nuclei and to some 
extent in the mitochondria, while nuclear APE2 is partly associated with proliferating cell 
nuclear antigen', Nucleic Acids Research, 29(11), pp. 2349-2360. 
Udensi, U.K. and Tchounwou, P.B. (2014) 'Dual effect of oxidative stress on leukemia cancer 
induction and treatment', Journal of Experimental & Clinical Cancer Research : CR, 33, p. 
106. 
Uttara, B., Singh, A.V., Zamboni, P. and Mahajan, R.T. (2009) 'Oxidative Stress and 
Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant 
Therapeutic Options', Current Neuropharmacology, 7(1), pp. 65-74. 
Vardiman, J.W., Harris, N.L. and Brunning, R.D. (2002) 'The World Health Organization 
(WHO) classification of the myeloid neoplasms', Blood, 100(7), pp. 2292-2302. 
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, 
N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. and Bloomfield, C.D. (2009) 'The 
2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms 
and acute leukemia: rationale and important changes', Blood, 114(5), pp. 937-51. 
Vascotto, C., Cesaratto, L., Zeef, L.A., Deganuto, M., D'Ambrosio, C., Scaloni, A., 
Romanello, M., Damante, G., Taglialatela, G., Delneri, D., Kelley, M.R., Mitra, S., 
Quadrifoglio, F. and Tell, G. (2009a) 'Genome-wide analysis and proteomic studies reveal 
APE1/Ref-1 multifunctional role in mammalian cells', Proteomics, 9(4), pp. 1058-74. 
Vascotto, C., Fantini, D., Romanello, M., Cesaratto, L., Deganuto, M., Leonardi, A., 
Radicella, J.P., Kelley, M.R., D'Ambrosio, C., Scaloni, A., Quadrifoglio, F. and Tell, G. 
(2009b) 'APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA 
quality control process', Mol Cell Biol, 29(7), pp. 1834-54. 
279 
 
Vascotto, C., Lirussi, L., Poletto, M., Tiribelli, M., Damiani, D., Fabbro, D., Damante, G., 
Demple, B., Colombo, E. and Tell, G. (2013) 'Functional regulation of the 
apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology', 
Oncogene. 
Viale, A., De Franco, F., Orleth, A., Cambiaghi, V., Giuliani, V., Bossi, D., Ronchini, C., 
Ronzoni, S., Muradore, I., Monestiroli, S., Gobbi, A., Alcalay, M., Minucci, S. and Pelicci, 
P.G. (2009) 'Cell-cycle restriction limits DNA damage and maintains self-renewal of 
leukaemia stem cells', Nature, 457(7225), pp. 51-6. 
Vidal, A.E., Boiteux, S., Hickson, I.D. and Radicella, J.P. (2001) 'XRCC1 coordinates the 
initial and late stages of DNA abasic site repair through protein-protein interactions', Embo j, 
20(22), pp. 6530-9. 
Voso, M.T., Fabiani, E., D'Alo, F., Guidi, F., Di Ruscio, A., Sica, S., Pagano, L., Greco, M., 
Hohaus, S. and Leone, G. (2007) 'Increased risk of acute myeloid leukaemia due to 
polymorphisms in detoxification and DNA repair enzymes', Annals of Oncology, 18(9), pp. 
1523-1528. 
Walker, R.A. and Marcucci, G. (2015) 'Genetics and Classification of Acute Myeloid 
Leukemia', in Andreeff, M. (ed.) Targeted Therapy of Acute Myeloid Leukemia. New York, 
NY: Springer New York, pp. 1-25. 
Wallace, S.S., Murphy, D.L. and Sweasy, J.B. (2012) 'Base excision repair and cancer', 
Cancer Lett, 327(1-2), pp. 73-89. 
Wander, S.A., Levis, M.J. and Fathi, A.T. (2014) 'The evolving role of FLT3 inhibitors in 
acute myeloid leukemia: quizartinib and beyond', Therapeutic Advances in Hematology, 5(3), 
pp. 65-77. 
Wang, D., Luo, M. and Kelley, M.R. (2004) 'Human apurinic endonuclease 1 (APE1) 
expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma 
to DNA damaging agents using silencing RNA APE1 expression inhibition', Mol Cancer 
Ther, 3(6), pp. 679-86. 
280 
 
Wang, D., Xiang, D.B., Yang, X.Q., Chen, L.S., Li, M.X., Zhong, Z.Y. and Zhang, Y.S. 
(2009a) 'APE1 overexpression is associated with cisplatin resistance in non-small cell lung 
cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells', Lung 
Cancer, 66(3), pp. 298-304. 
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, 
K., Kernytsky, A., Liu, W., Gliser, C., Yang, H., Gross, S., Artin, E., Saada, V., Mylonas, E., 
Quivoron, C., Popovici-Muller, J., Saunders, J.O., Salituro, F.G., Yan, S., Murray, S., Wei, 
W., Gao, Y., Dang, L., Dorsch, M., Agresta, S., Schenkein, D.P., Biller, S.A., Su, S.M., de 
Botton, S. and Yen, K.E. (2013a) 'Targeted inhibition of mutant IDH2 in leukemia cells 
induces cellular differentiation', Science, 340(6132), pp. 622-6. 
Wang, L., Hamard, P.J. and Nimer, S.D. (2015) 'PARP inhibitors: a treatment option for 
AML?', Nat Med, 21(12), pp. 1393-4. 
Wang, M., Qin, C., Zhu, J., Yuan, L., Fu, G., Zhang, Z. and Yin, C. (2010) 'Genetic variants 
of XRCC1, APE1, and ADPRT genes and risk of bladder cancer', DNA Cell Biol, 29(6), pp. 
303-11. 
Wang, Y., Liu, L., Wu, C., Bulgar, A., Somoza, E., Zhu, W. and Gerson, S.L. (2009b) 'Direct 
detection and quantification of abasic sites for in vivo studies of DNA damage and repair', 
Nuclear Medicine and Biology, 36(8), pp. 975-983. 
Wang, Y.T., Tzeng, D.W., Wang, C.Y., Hong, J.Y. and Yang, J.L. (2013b) 'APE1/Ref-1 
prevents oxidative inactivation of ERK for G1-to-S progression following lead acetate 
exposure', Toxicology, 305, pp. 120-9. 
Wang, Z.Y. and Chen, Z. (2008) 'Acute promyelocytic leukemia: from highly fatal to highly 
curable', Blood, 111(5), pp. 2505-15. 
Ward, P.S., Cross, J.R., Lu, C., Weigert, O., Abel-Wahab, O., Levine, R.L., Weinstock, D.M., 
Sharp, K.A. and Thompson, C.B. (2012) 'Identification of additional IDH mutations 
associated with oncometabolite R(-)-2-hydroxyglutarate production', Oncogene, 31(19), pp. 
2491-2498. 
281 
 
Weber, A.R., Krawczyk, C., Robertson, A.B., Kusnierczyk, A., Vagbo, C.B., Schuermann, 
D., Klungland, A. and Schar, P. (2016) 'Biochemical reconstitution of TET1-TDG-BER-
dependent active DNA demethylation reveals a highly coordinated mechanism', Nat Commun, 
7. 
Webersinke, G., Kranewitter, W., Deutschbauer, S., Zach, O., Hasenschwandtner, S., 
Wiesinger, K., Erdel, M., Marschon, R., Bohm, A. and Tschurtschenthaler, G. (2014) 'Switch 
of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or 
secondary AML[quest]', Blood Cancer Journal, 4, p. e221. 
Weil, M.K. and Chen, A. (2011) 'PARP Inhibitor Treatment in Ovarian and Breast Cancer', 
Current problems in cancer, 35(1), pp. 7-50. 
Whitehead, K.A., Langer, R. and Anderson, D.G. (2009) 'Knocking down barriers: advances 
in siRNA delivery', Nat Rev Drug Discov, 8(2), pp. 129-138. 
Wiederhold, L., Leppard, J.B., Kedar, P., Karimi-Busheri, F., Rasouli-Nia, A., Weinfeld, M., 
Tomkinson, A.E., Izumi, T., Prasad, R., Wilson, S.H., Mitra, S. and Hazra, T.K. (2004) 'AP 
Endonuclease-Independent DNA Base Excision Repair in Human Cells', Molecular Cell, 
15(2), pp. 209-220. 
Wilson, D.M., 3rd and Simeonov, A. (2010) 'Small molecule inhibitors of DNA repair 
nuclease activities of APE1', Cell Mol Life Sci, 67(21), pp. 3621-31. 
Wirtz, S., Nagel, G., Eshkind, L., Neurath, M.F., Samson, L.D. and Kaina, B. (2010) 'Both 
base excision repair and O(6)-methylguanine-DNA methyltransferase protect against 
methylation-induced colon carcinogenesis', Carcinogenesis, 31(12), pp. 2111-2117. 
Wolf, D. and Rotter, V. (1985) 'Major deletions in the gene encoding the p53 tumor antigen 
cause lack of p53 expression in HL-60 cells', Proc Natl Acad Sci U S A, 82(3), pp. 790-4. 
Wong, C.C., Martincorena, I., Rust, A.G., Rashid, M., Alifrangis, C., Alexandrov, L.B., 
Tiffen, J.C., Kober, C., Chronic Myeloid Disorders Working Group of the International 
Cancer Genome, C., Green, A.R., Massie, C.E., Nangalia, J., Lempidaki, S., Dohner, H., 
Dohner, K., Bray, S.J., McDermott, U., Papaemmanuil, E., Campbell, P.J. and Adams, D.J. 
(2014) 'Inactivating CUX1 mutations promote tumorigenesis', Nat Genet, 46(1), pp. 33-38. 
282 
 
Woo, J., Park, H., Sung, S.H., Moon, B.I., Suh, H. and Lim, W. (2014) 'Prognostic Value of 
Human Apurinic/Apyrimidinic Endonuclease 1 (APE1) Expression in Breast Cancer', PLoS 
One, 9(6), p. e99528. 
Wouters, B.J. and Delwel, R. (2016) 'Epigenetics and approaches to targeted epigenetic 
therapy in acute myeloid leukemia', Blood, 127(1), pp. 42-52. 
Xanthoudakis, S., Smeyne, R.J., Wallace, J.D. and Curran, T. (1996) 'The redox/DNA repair 
protein, Ref-1, is essential for early embryonic development in mice', Proc Natl Acad Sci U S 
A, 93(17), pp. 8919-23. 
Xie, J.Y., Li, M.X., Xiang, D.B., Mou, J.H., Qing, Y., Zeng, L.L., Yang, Z.Z., Guan, W. and 
Wang, D. (2010) 'Elevated expression of APE1/Ref-1 and its regulation on IL-6 and IL-8 in 
bone marrow stromal cells of multiple myeloma', Clin Lymphoma Myeloma Leuk, 10(5), pp. 
385-93. 
Xie, Y., Yang, H., Miller, J.H., Shih, D.M., Hicks, G.G., Xie, J. and Shiu, R.P. (2008) 'Cells 
deficient in oxidative DNA damage repair genes Myh and Ogg1 are sensitive to oxidants with 
increased G2/M arrest and multinucleation', Carcinogenesis, 29(4), pp. 722-8. 
Yacoub, A., Kelley, M.R. and Deutsch, W.A. (1997) 'The DNA repair activity of human 
redox/repair protein APE/Ref-1 is inactivated by phosphorylation', Cancer Res, 57(24), pp. 
5457-9. 
Yamamori, T., DeRicco, J., Naqvi, A., Hoffman, T.A., Mattagajasingh, I., Kasuno, K., Jung, 
S.B., Kim, C.S. and Irani, K. (2010) 'SIRT1 deacetylates APE1 and regulates cellular base 
excision repair', Nucleic Acids Res, 38(3), pp. 832-45. 
Yan, L., Bulgar, A., Miao, Y., Mahajan, V., Donze, J.R., Gerson, S.L. and Liu, L. (2007) 
'Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic 
site repair coupled with targeting topoisomerase IIalpha', Clin Cancer Res, 13(5), pp. 1532-9. 
Yan, T., Seo, Y., Schupp, J.E., Zeng, X., Desai, A.B. and Kinsella, T.J. (2006) 
'Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle 
kinetics and enhancing senescence', Molecular Cancer Therapeutics, 5(4), pp. 893-902. 
283 
 
Yang, Z.Z., Chen, X.H. and Wang, D. (2007) 'Experimental study enhancing the 
chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing 
RNA expression vector', Clin Lymphoma Myeloma, 7(4), pp. 296-304. 
Yeung, P.L., Denissova, N.G., Nasello, C., Hakhverdyan, Z., Chen, J.D. and Brenneman, 
M.A. (2012) 'Promyelocytic leukemia nuclear bodies support a late step in DNA double-
strand break repair by homologous recombination', Journal of Cellular Biochemistry, 113(5), 
pp. 1787-1799. 
Zaky, A., Mohammad, B., Moftah, M., Kandeel, K.M. and Bassiouny, A.R. (2013) 
'Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced 
neuroinflammation', BMC Neurosci, 14, p. 26. 
Zhang, J., Luo, M., Marasco, D., Logsdon, D., Lafavers, K.A., Chen, Q., Reed, A., Kelley, 
M.R., Gross, M.L. and Georgiadis, M.M. (2013) 'Inhibition of Apurinic/Apyrimidinic 
Endonuclease I's Redox Activity Revisited', Biochemistry, 52(17), pp. 2955-66. 
Zhang, J., Stevens, M.F. and Bradshaw, T.D. (2012) 'Temozolomide: mechanisms of action, 
repair and resistance', Curr Mol Pharmacol, 5(1), pp. 102-14. 
Zhao, J., Gao, F., Zhang, Y., Wei, K., Liu, Y. and Deng, X. (2008) 'Bcl2 inhibits abasic site 
repair by down-regulating APE1 endonuclease activity', J Biol Chem, 283(15), pp. 9925-32. 
Zhenchuk, A., Lotfi, K., Juliusson, G. and Albertioni, F. (2009) 'Mechanisms of anti-cancer 
action and pharmacology of clofarabine', Biochemical Pharmacology, 78(11), pp. 1351-1359. 
Zheng, Z.H., Du, W., Li, Y.J., Gao, M.Q., Huang, A.M. and Liu, J.F. (2015) 'Lentiviral-
mediated short hairpin RNA silencing of APE1 suppresses hepatocellular carcinoma 
proliferation and migration: A potential therapeutic target for hepatoma treatment', Oncol 
Rep, 34(1), pp. 95-102. 
Zhou, F.-L., Zhang, W.-G., Wei, Y.-C., Meng, S., Bai, G.-G., Wang, B.-Y., Yang, H.-Y., 
Tian, W., Meng, X., Zhang, H. and Chen, S.-P. (2010) 'Involvement of Oxidative Stress in the 
Relapse of Acute Myeloid Leukemia', The Journal of Biological Chemistry, 285(20), pp. 
15010-15015. 
284 
 
Zhou, F., Shen, Q. and Claret, F.X. (2013) 'Novel roles of reactive oxygen species in the 
pathogenesis of acute myeloid leukemia', Journal of Leukocyte Biology, 94(3), pp. 423-429. 
Zhou, X., Zhuang, Z., Wang, W., He, L., Wu, H., Cao, Y., Pan, F., Zhao, J., Hu, Z., Sekhar, 
C. and Guo, Z. (2016) 'OGG1 is essential in oxidative stress induced DNA demethylation', 
Cell Signal, 28(9), pp. 1163-1171. 
Zhu, H. (2014) 'Targeting forkhead box transcription factors FOXM1 and FOXO in leukemia 
(Review)', Oncol Rep, 32(4), pp. 1327-34. 
Zhu, R., Wu, Y., Lu, F.-j., Wang, A.-h., Tang, J.-y., Zhao, J.-c., Chen, C. and Xia, Z.-l. (2008) 
'Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in 
China: A case-control analysis', European Journal of Oncology, 13(3), pp. 187-192. 
Zhu, W., Wu, C., Li, Y., Somoza, E., Liu, L., Gerson, S. and Wang, Y. (2012) 'In vivo 
Quantification of Abasic Sites for Efficacious Evaluation of DNA Targeted Chemotherapies', 
Journal of Cancer Science & Therapy, 2012. 
Zocchi, M.R., Pellegatta, F., Pierri, I., Gobbi, M. and Poggi, A. (2001) 'Leukocyte-associated 
Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent 
proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells', Eur J 
Immunol, 31(12), pp. 3667-75. 
Zou, G.M., Luo, M.H., Reed, A., Kelley, M.R. and Yoder, M.C. (2007) 'Ape1 regulates 
hematopoietic differentiation of embryonic stem cells through its redox functional domain', 
Blood, 109(5), pp. 1917-22. 
Zou, G.M. and Maitra, A. (2008) 'Small-molecule inhibitor of the AP endonuclease 1/REF-1 
E3330 inhibits pancreatic cancer cell growth and migration', Mol Cancer Ther, 7(7), pp. 
2012-21. 
 
 
 
 
